WO2010039939A1 - Janus kinase inhibitors for treatment of dry eye and other eye related diseases - Google Patents

Janus kinase inhibitors for treatment of dry eye and other eye related diseases Download PDF

Info

Publication number
WO2010039939A1
WO2010039939A1 PCT/US2009/059203 US2009059203W WO2010039939A1 WO 2010039939 A1 WO2010039939 A1 WO 2010039939A1 US 2009059203 W US2009059203 W US 2009059203W WO 2010039939 A1 WO2010039939 A1 WO 2010039939A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
haloalkyl
independently selected
alkynyl
alkenyl
Prior art date
Application number
PCT/US2009/059203
Other languages
French (fr)
Inventor
Paul A. Friedman
Jordan S. Fridman
Monica E. Luchi
William V. Williams
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010039939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI200931388A priority Critical patent/SI2349260T1/en
Priority to ES09737257.7T priority patent/ES2564203T3/en
Priority to PL09737257T priority patent/PL2349260T3/en
Priority to RS20160064A priority patent/RS54651B1/en
Priority to EP09737257.7A priority patent/EP2349260B1/en
Application filed by Incyte Corporation filed Critical Incyte Corporation
Priority to JP2011530218A priority patent/JP2012504639A/en
Priority to CA2738520A priority patent/CA2738520C/en
Priority to DK09737257.7T priority patent/DK2349260T3/en
Publication of WO2010039939A1 publication Critical patent/WO2010039939A1/en
Priority to HK12101002.0A priority patent/HK1160607A1/en
Priority to SM201600080T priority patent/SMT201600080B/en
Priority to HRP20160330TT priority patent/HRP20160330T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention provides methods, kits, and compositions for the treatment of dry eye and other eye related diseases using compounds which inhibit one or more of the Janus kinases (JAKs).
  • JKs Janus kinases
  • Dry eye syndrome (DES, also known as keratoconjunctivitis sicca) is one of the most common problems treated by eye physicians.
  • a recent official report of the Dry Eye Workshop (DEWS) defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface.”
  • DES affects up to 10% of the population between the ages of 20 to 45 years, with this percentage increasing with age.
  • a wide variety of artificial tear products are available, these products provide only transitory relief of symptoms. As such, there is a need for agents, compositions and therapeutic methods to treat dry eye. This invention addresses this need and others.
  • the present invention provides, inter alia, a method of treating a dry eye disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent.
  • the agent used in the methods of the present invention is a compound which can inhibit the activity of one or more Janus kinases (JAKs).
  • the Janus kinase family of protein tyrosine kinases, as well as the Signal Transducers and Activators of Transcription (STATs), are engaged in the signaling of a wide range of cytokines.
  • STATs Signal Transducers and Activators of Transcription
  • cytokine receptors do not have intrinsic tyrosine kinase activity, and thus require receptor-associated kinases to propagate a phosphorylation cascade.
  • JAKs fulfill this function. Cytokines bind to their receptors, causing receptor dimerization, and this enables JAKs to phosphorylate each other as well as specific tyrosine motifs within the cytokine receptors. STATs that recognize these phosphotyrosine motifs are recruited to the receptor, and are then themselves activated by a JAK-dependent tyrosine phosphorylation event. Upon activation, STATs dissociate from the receptors, dimerize, and translocate to the nucleus to bind to specific DNA sites and alter transcription (Scott, M. J., C. J. Godshall, et al. (2002). "Jaks, STATs, Cytokines, and Sepsis.” Clin Diagn Lab Immunol 9(6): 1153-9).
  • JAKl also known as Janus kinase- 1
  • JAK2 also known as Janus kinase-2
  • JAK3 also known as Janus kinase, leukocyte
  • JAKL L-JAK and Janus kinase-3
  • TYK2 also known as protein-tyrosine kinase 2
  • JAK proteins range in size from 120 to 140 kDa and comprise seven conserved JAK homology (JH) domains; one of these is a functional catalytic kinase domain, and another is a pseudokinase domain potentially serving a regulatory function and/or serving as a docking site for STATs (Scott, Godshall et al. 2002, supra).
  • JH JAK homology
  • JAK3 is reported to be preferentially expressed in natural killer (NK) cells and not resting T cells, suggesting a role in lymphoid activation (Kawamura, M., D. W. Mc Vicar, et al. (1994). "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.” Proc NatlAcadSci O S A 91(14): 6374-8).
  • cytokine-stimulated immune and inflammatory responses contribute to normal host defense, they also play roles in the pathogenesis of diseases: pathologies such as severe combined immunodeficiency (SCID) arise from hypoactivity and suppression of the immune system, and a hyperactive or inappropriate immune / inflammatory response contributes to the pathology of autoimmune diseases such as rheumatoid and psoriatic arthritis, asthma and systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, type I diabetes mellitus, myasthenia gravis, thyroiditis, immunoglobulin nephropathies, myocarditis as well as illnesses such as scleroderma and osteoarthritis (Ortmann, R. A., T. Cheng, et al. (2000). "Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.” Arthritis Res 2(1): 16-32).
  • SCID severe combined immuno
  • JAK3 Janus kinase 3
  • GVHD graft versus host disease
  • JAK3 inhibitor WHI-P- 154 prevented these effects arresting the DCs at an immature level, suggesting that immunosuppressive therapies targeting the tyrosine kinase JAK3 may also affect the function of myeloid cells (Saemann, M. D., C. Diakos, et al. (2003). "Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3.” Am J Transplant 3(11): 1341-9). In the mouse model system, JAK3 was also shown to be an important molecular target for treatment of autoimmune insulin-dependent (type 1) diabetes mellitus.
  • JAK3 inhibitor JANEX- 1 exhibited potent immunomodulatory activity and delayed the onset of diabetes in the NOD mouse model of autoimmune type 1 diabetes (Cetkovic-Cvrlje, M., A. L. Dragt, et al. (2003). "Targeting JAK3 with JANEX-I for prevention of autoimmune type 1 diabetes in NOD mice.” Clin Immunol 106(3): 213-25). Deficiencies in expression of JAK family members are associated with disease states. Jakl-/- mice are runted at birth, fail to nurse, and die perinatally (Rodig, S. J., M. A. Meraz, et al. (1998).
  • Jak2-/- mouse embryos are anemic and die around day 12.5 postcoitum due to the absence of definitive erythropoiesis.
  • JAK2- deficient fibroblasts do not respond to IFN gamma, although responses to IFNalpha/beta and IL-6 are unaffected.
  • JAK2 functions in signal transduction of a specific group of cytokine receptors required in definitive erythropoiesis (Neubauer, H., A. Cumano, et al. (1998).
  • JAK3 appears to play a role in normal development and function of B and T lymphocytes. Mutations of JAK3 are reported to be responsible for autosomal recessive severe combined immunodeficiency (SCID) in humans (Candotti, F., S. A. Oakes, et al. (1997). "Structural and functional basis for JAK3 -deficient severe combined immunodeficiency.” Blood 90(10): 3996- 4003).
  • the present invention provides, inter alia, a method of treating dry eye disorders comprising administering to a patient a JAK inhibitor.
  • the present invention provides a method of treating conjunctivitis, uveitis, chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or ulceris; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a JAK inhibitor.
  • the agent is administered postoperatively to the patient.
  • the present invention provides an ophthalmic insert comprising a JAK inhibitor.
  • the present invention provides a kit for treating a dry eye disorder comprising a pharmaceutical composition or ophthalmic composition comprising a JAK inhibitor and instructions comprising a direction to administer the JAK inhibitor to a patient in need of treatment of a dry eye disorder.
  • the present invention provides, inter alia, a method of treating a dry eye disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent.
  • JAKs to which the agent can bind and inhibit includes any member of the JAK family.
  • the JAK is JAKl, JAK2, JAK3 or TYK2.
  • the JAK is JAKl.
  • the agent is selective for JAKl.
  • the JAK is JAKl or JAK2.
  • the JAK is JAK2.
  • the JAK is JAK3.
  • the agent is selective.
  • the agent is a selective inhibitor of JAKl or JAK2 over JAK3 and/or TYK2.
  • the agent is a selective inhibitor of JAK2 (e.g., over JAKl, JAK3 and TYK2).
  • Selectivity can be at least about 5-fold, 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold or at least about 1000-fold. Selectivity can be measured by methods routine in the art. In some embodiments, selectivity can be tested at the Km of each enzyme. In some embodiments, selectivity of the agent for JAK2 over JAK3 can be determined by the cellular ATP concentration.
  • the agents for use in the method of the invention include the JAK inhibitors in U.S. Patent Publ. No. US 20070135461, published June 14, 2007 (Appl. Ser. No. 11/637,545, filed December 12, 2006); U.S. Patent Publ. No. US 20060106020, published May 18, 2006 (Appl. Ser. No. 11/115,702 filed April 27, 2005); U.S. Patent Publ. No. US 20060183906, published August 17, 2006 (Appl. Ser. No. 11/313,394, filed December 21, 2005); U.S. Patent Publ. No. US 20070149506, published June 28, 2007 (Appl. Ser. No. 11/524,641, filed September 21, 2006); U.S. Patent Publ. No.
  • dry eye disorder is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface.” Lemp, “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92 April 2007, which is incorporated herein by reference in its entirety. Dry eye is also sometimes referred to as keratoconjunctivitis sicca.
  • the treatment of the dry eye disorder involves ameliorating a particular symptom of dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface.
  • dry eye can be classified into two different classes: aqueous tear-deficient dry eye and evaporative dry eye, which in turn encompass various subclasses.
  • the dry eye disorder is aqueous tear-deficient dry eye (ADDE).
  • the dry eye disorder is evaporative dry eye.
  • the dry eye disorder is selected from any of the subclasses of ADDE or evaporative dry eye disorder, or appropriate combinations thereof.
  • the various classes and subclasses are not mutually exclusive. Hence, dry eye can occur via different mechanism in different subclasses or a dry eye disease state originating in one subclass can lead to events that cause dry eye by a mechanism in another subclass.
  • the first class of dry eye is also known as tear deficient dry eye and lacrimal tear deficiency.
  • ADDE aqueous tear-deficient dry eye
  • dry eye is believed to be due to a failure of lacrimal tear secretion. While not wishing to be bound by any theory, it is believed that dryness results from reduced lacrimal tear secretion and volume, causing tear hyperosmolarity. Tear film hyperosmolarity can cause hyperosmolarity of the ocular surface epithelial cells, stimulating inflammatory events involving various kinases and signaling pathways.
  • the eye disorder is SSDE.
  • dry eye disorder is non- Sjogren syndrome dry eye.
  • activated T-cells can infiltrate the lacrimal glands, causing cell death of acinar and ductular cells and hyposecretion of tears.
  • the effects of locally released cytokines or circulating antibodies can amplify the effects of hyposecretion.
  • the two major forms of SSDE are primary and secondary forms. Primary SS can occur in combination with dry mouth (xerostomia).
  • Secondary SSDE occurs with the symptoms of primary SSDE together with an autoimmune connective disease such as rheumatoid arthritis (RA), systemic lupus erythematosis, polyarteritis nodosa, Wegener's granulomatosis, systemic sclerosis, primary bilary sclerosis, or mixed connective tissue disease. Diagnostic criteria for each of these connective diseases is known in the art. Further, primary SSDE may be associated with systemic manifestations of disease which may involve the lungs, kdneys, liver, blood vessels and joints.
  • RA rheumatoid arthritis
  • NSSDE the systemic autoimmune characteristics of Sjogren syndrome dry eye are excluded.
  • Forms of NSSDE include primary lacrimal gland deficiencies (including age-related dry eye, congenital alacrima, and familial dysautonomia), secondary lacrimal deficiencies (including inflammatory infiltration of the lacrimal gland by sarcoid granulomata, lymphomatous cells, and AIDS related T-cells; that associated with graft vs.
  • lacrimal gland ablation or lacrimal gland denervation including that caused by cicatrizing conjunctivitis including trachoma, cicatricial pemphigoid and mucous membrane pemphigoid, erythema multiforme, and chemical or thermal burns), and reflex hyposecretion (including reflex sensory block, such as that associated with contact lens wear, diabetes mellitus, and neurotrophic keratitis, and reflex motor block, including that associated with VII cranial nerve damage, multiple neuromatosis, and exposure to systemic drugs such as antihistamines, beta blockers, antispasmodics, diuretics, tricyclic antidepressants, selective serotonin reuptake inhibitors, and other psychotropic drugs).
  • reflex sensory block such as that associated with contact lens wear, diabetes mellitus, and neurotrophic keratitis
  • reflex motor block including that associated with VII cranial nerve damage, multiple neuromatosis, and exposure to systemic drugs such as antihistamine
  • the second major class of dry eye disorder is evaporative dry eye, which is caused by excessive water loss from the exposed ocular surface in the presence of normal lacrimal secretory function.
  • Intrinsic causes of evaporative dry eye include Meibomian gland dysfunction (MGD) (including that caused by a reduced number of glands due to congenital deficiency acquired-MGD; MGD associated with dystichiasis, dystichiasis lymphedema syndrome, and metaplasia; hypersecretory MGD associated with Meibomian seborrhea, hypersecretory MGD associated with retinoid therapy, primary and secondary obstructive MGD, focal or diffuse obstructive MGD, simple or cicatricial obstructive MGD, atrophic or inflammatory obstructive MGD; Simple MGD primary or secondary to anterior blepharitis, acne rosacea, seborrhoeic dermatitis, ectrodactyly syndrome, Turner
  • Extrinsic causes of evaporative dry eye include ocular surface disorders (including xerophthalmia caused by vitamin A deficiency; and that associated with topical drugs and preservatives such as topical anesthesia and benzalkonium chloride), contact lens wear, ocular surface disease (including allergic eye disease), allergic conjunctivitis (including aseasonal allergic conjunctivitis, vernal keratoconjunctivitis, and atopic keratoconjunctivitis), and the use of antihistamines.
  • ocular surface disorders including xerophthalmia caused by vitamin A deficiency; and that associated with topical drugs and preservatives such as topical anesthesia and benzalkonium chloride
  • contact lens wear ocular surface disease (including allergic eye disease), allergic conjunctivitis (including aseasonal allergic conjunctivitis, vernal keratoconjunctivitis, and atopic keratoconjunctiv
  • Patients in need of treatment of a dry eye disorder can be identified by a variety of diagnostic methods known in the art, including the diagnostic methods summarized in Bron, et al., "Methodologies to Diagnose and Monitor Dry Eye Disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop (2007)", The Ocular Surface, 5(2), 108-152 (April 2007), which is hereby incorporated herein by reference in its entirety.
  • symptom questionnaires e.g., Begley, et al., "Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye", Cornea, 2002:21 :664-70
  • staining of the ocular surface to check for surface damage e.g., Rose Bengal or fluorescein staining or other staining method such as those techniques summarized in Barr et al., "Corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: baseline prevalence and repeatability of detection", Cornea 1999;18(l):34-46; Lemp, "Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes", CLAO J 1995;21(4):221-31; Nichols, et al., "The repeatability of clinical measurements of dry eye", Cornea 2004;23:272-85; Bron, et al., "Grad
  • Ocular Protection Index to assess ocular surface protection and risk of ocular surface damage (e.g., Ousler et al., “Factors that influence the inter-blink interval (IBI) as measured by the ocular protection index (OPI)", (Poster presentation) ARVO 2002; Nally et al., "Ocular discomfort and tear film break-up time in dry eye patients: A correlation", Invest Ophthalmol Vis Sci 2000;41 :4: 1436; Abelson et al., “Alternate reference values for tear film break-up time in normal and dry eye populations", La
  • the present invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or ulceris; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof.
  • the agent is administered preoperatively to a patient about to undergo a procedure selected from corneal transplant, LASIK, photorefractive keratectomy, and LASEK. In some embodiments, the agent suppresses or lessens inflammation or pain during and after the procedure. In some embodiments, the agent is administered about 1 day to about 2 days prior to the procedure. In some embodiments, the agent is administered postoperatively to a patient who has undergone a procedure selected from corneal transplant, LASIK, photorefractive keratectomy, and LASEK. In some embodiments, inhibiting loss of visual acuity means lessening the loss of visual acuity.
  • the postoperative or preoperative treatment lessens the amount of scarring and fibrous deposits following the procedure.
  • inhibiting loss of visual acuity means that the patient retains visual acuity.
  • inhibiting transplant rejection means that the agent is immunosuppressive, thereby preventing total rejection of the corneal transplant.
  • one or more additional therapeutic agents can be used in combination with the agent in the methods of the present invention.
  • the one or more additional therapeutic agents can be administered to a patient simultaneously or sequentially.
  • the amount of additional therapeutic agent, when administered in a compositions is from about 0.01% to 5% by weight, from about 0.1% to 2% by weight, or from 0.5% to 50% by weight.
  • the additional therapeutic agent is fluocinolone acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcon).
  • the additional therapeutic agent is cyclosporine (Restasis®).
  • the additional therapeutic agent is a corticosteroid.
  • the corticosteroid is triaminolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
  • the additional therapeutic agent is selected from DehydrexTM (Holies Labs), Civamide (Opko), sodium hyaluonate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST- 603, Sirion Therapeutics), ARGlOl(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycline (ALTY-0501, Alacrity), minocycline, iDestrinTM (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI 1901, Lantibio), CFlOl (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[
  • the additional therapeutic agent is an anti- angiogenic agent, cholinergic agonist, TRP- 1 receptor modulator, a calcium channel blocker, a mucin secretagogue, MUCl stimulant, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, another JAK inhibitor, Bcr-Abl kinase inhibitor, Flt-3 kinase inhibitor, RAF kinase inhibitor, and FAK kinase inhibitor such as, for example, those described in WO 2006/056399.
  • the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline).
  • the additional therapeutic agent(s) are demulcent eye drops (also known as "artificial tears"), which include, but are not limited to, compositions containing polyvinylalcohol, hydroxypropyl methylcellulose, glycerin, polyethylene glycol (e.g. PEG400), or carboxymethyl cellulose. Artificial tears can help in the treatment dry eye by compensating for reduced moistening and lubricating capacity of the tear film.
  • the additional therapeutic agent is a mucolytic drug, such as N- acetyl-cysteine, which can interact with the mucoproteins and, therefore, to decrease the viscosity of the tear film.
  • the additional therapeutic agent includes an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and non-steroidal antiinflammatories, and anti-allergic agents.
  • suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomomycin; colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; ampho
  • Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, EP2005/009967, EP2005/010408, and U.S. Ser. No. 60/578,491.
  • Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.
  • Example suitable PvAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.
  • Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402.
  • the agents can be administered in the form of pharmaceutical compositions.
  • These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
  • topical including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery
  • pulmonary e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal
  • oral or parenteral e.g., by inhalation or in
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
  • Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • the agent is administered as an ophthalmic composition.
  • the methods comprise administration of the agent and an ophthalmically acceptable carrier.
  • the ophthalmic composition is a liquid composition, semisolid composition, insert, film, microparticles or nanooparticles.
  • the ophthalmic composition is a liquid composition. In some embodiments, the ophthalmic composition is a semi-solid composition. In some embodiments, the ophthalmic composition is an topical composition.
  • the topical compositions include, but are not limited to liquid and semi-solid compositions.
  • the ophthalmic composition is a topical composition.
  • the topical composition comprises aqueous solution, an aqueous suspension, an ointment or a gel.
  • the ophthalmic composition is topically applied to the front of the eye, under the upper eyelid, on the lower eyelid and in the cul-de- sac. In some embodiments, the ophthalmic composition is sterilized.
  • the sterilization can be accomplished by known techniques like sterilizing filtration of the solution or by heating of the solution in the ampoule ready for use.
  • the ophthalmic compositions of the invention can further contain pharmaceutical excipients suitable for the preparation of ophthalmic formulations. Examples of such excipients are preserving agents, buffering agents, chelating agents, antioxidant agents and salts for regulating the osmotic pressure.
  • the term "ophthalmically acceptable carrier” refers to any material that can contain and release the agent and that is compatible with the eye.
  • the ophthalmically acceptable carrier is water or an aqueous solution or suspension, but also includes oils such as those used to make ointments and polymer matrices such as used in ocular inserts.
  • the composition may be an aqueous suspension comprising the agent.
  • Liquid ophthalmic compositions, including both ointments and suspensions may have a viscosity that is suited for the selected route of administration. In some embodiments, the ophthalmic composition has a viscosity in the range of from about 1,000 to about 30,000 centipoise.
  • the liquid composition further comprises a polymer.
  • polymers may be used to improve the bioavailability, raise viscosity, or reduce drainage from the eye for a liquid formulation.
  • the polymers include, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety.
  • the polymer is sodium hyaluronase, chitosan, a cyclodextrin (e.g., hydroxypropyl ⁇ - cyclodextrin), polygalactoronic acid, xyloglucan, xanthan gum, gellan gum, a thiomer, a poly(ortho ester) (e.g., as described in Einmahl, Adv. Drug. Deliv. Rev. 53:45-73 (2001), which is incorporated herein by reference in its entirety), or a tamarind seed polysaccharide (e.g., as described in Ghelardi, et al., Antimicrob. Agents Chemother. 48:3396-3401 (2004), which is incorporated herein by reference in its entirety).
  • a cyclodextrin e.g., hydroxypropyl ⁇ - cyclodextrin
  • polygalactoronic acid e.g., hydroxypropyl ⁇ -
  • the ophthalmic compositions may further comprise one or more of surfactants, adjuvants, buffers, antioxidants, tonicity adjusters, preservatives (e.g., EDTA, BAK (benzalkonium chloride), sodium chlorite, sodium perborate, polyquaterium-1), thickeners or viscosity modifiers (e.g., carboxymethyl cellulose, hydroxymethyl cellulose, polyvinyl alcohol, polyethylene glycol, glycol 400, propylene glycol hydroxymethyl cellulose, hydroxpropyl-guar, hyaluronic acid, and hydroxypropyl cellulose) and the like.
  • Additives in the formulation may include, but are not limited to, sodium chloride, sodium bicarbonate, sorbic acid, methyl paraben, propyl paraben, chlorhexidine, castor oil, and sodium perborate.
  • Aqueous ophthalmic compositions generally do not contain physiologically or ophthalmically harmful constituents.
  • purified or deionized water is used in the composition.
  • the pH may be adjusted by adding any physiologically and ophthalmically acceptable pH adjusting acids, bases or buffers to within the range of about 5.0 to 8.5.
  • Ophthalmically acceptable examples of acids include acetic, boric, citric, lactic, phosphoric, hydrochloric, and the like
  • bases include sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, tromethamine, trishydroxymethylamino-methane, and the like.
  • Salts and buffers include citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures of the aforementioned acids and bases.
  • the osmotic pressure of the ophthalmic composition may be from about 10 milliosmolar (mOsM) to about 400 mOsM, or from 260 to about 340 mOsM. In some embodiments, the osmotic pressure can be adjusted by using appropriate amounts of physiologically and ophthalmically acceptable salts or excipients.
  • sodium chloride may be used to approximate physiologic fluid. In other embodiments, the composition comprises sodium chloride ranging from about 0.01% to about 1% by weight, or from about 0.05% to about 0.45% by weight, based on the total weight of the composition.
  • Equivalent amounts of one or more salts made up of cations such as potassium, ammonium and the like and anions such as chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, bisulfate, sodium bisulfate, ammonium sulfate, and the like can also be used in addition to or instead of sodium chloride to achieve osmolalities within the above stated range.
  • a sugar such as mannitol, dextrose, sorbitol, glucose and the like can also be used to adjust osmolality.
  • the methods involve forming or supplying a depot of the agent in contact with the external surface of the eye.
  • a depot refers to a source of agent that is not rapidly removed by tears or other eye clearance mechanisms. This allows for continued, sustained high concentrations of agent be present in the fluid on the external surface of the eye by a single application. Without wishing to be bound by any theory, it is believed that absorption and penetration may be dependent on both the dissolved drug concentration and the contact duration of the external tissue with the drug containing fluid. As the drug is removed by clearance of the ocular fluid and/or absorption into the eye tissue, more drug is provided, e.g. dissolved, into the replenished ocular fluid from the depot.
  • the use of a depot may more easily facilitate loading of the ocular tissue for more insoluble agents.
  • the depot can remain for up to eight hours or more.
  • the ophthalmic depot forms includes, but is not limited to, aqueous polymeric suspensions, ointments, and solid inserts.
  • a semi-solid composition is a liquid formulation which increases in viscosity upon application to the eye, usually because of a polymer in the liquid formulation. This viscosity increase may be triggered by a change in temperature, pH, or electrolyte concentration.
  • the polymer include, but are not limited to, those described for semi-solid dosage forms in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety.
  • the polymer is celluloseacetophthalate, polyacrylic acid, gellan gum, hyaluronase, chitosan, salts of alginic acid (e.g., sodium alginate), or a block copolymer of ethylene oxide and propylene oxide (e.g., Pluronic®, BASF; poloxamer).
  • the polyacrylic acid is crosslinked acrylic acid (e.g., Carbopol®).
  • the semi-solid composition comprises a mixture of carbopol and a block copolymer of ethylene oxide and propylene oxide; a mixture of methyl cellulose and hydroxyethyl cellulose; or a mixture of polyethylene glycol and a block copolymer of ethylene oxide and propylene oxide.
  • the ophthalmic composition is an ointment or gel.
  • the ophthalmic composition is an oil-based delivery vehicle.
  • the composition comprises a petroleum or lanolin base to which is added the active ingredient, usually as 0.1 to 2%, and excipients. Common bases may include, but are not limited to, mineral oil, petrolatum and combinations thereof.
  • the ointment is applied as a ribbon onto the lower eyelid.
  • the ophthalmic composition is an ophthalmic insert.
  • the ophthalmic insert is biologically inert, soft, bio-erodible, viscoelastic, stable to sterilization after exposure to therapeutic agents, resistant to infections from air borne bacteria, bio- erodible, biocompatible, and/or viscoelastic.
  • the insert comprises an ophthalmically acceptable matrix, e.g., a polymer matrix.
  • the matrix is typically a polymer and the agent is generally dispersed therein or bonded to the polymer matrix.
  • the agent may slowly released from the matrix through dissolution or hydrolysis of the covalent bond.
  • the polymer is bioerodible (soluble) and the dissolution rate thereof can control the release rate of the agent dispersed therein.
  • the polymer matrix is a biodegradable polymer that breaks down such as by hydrolysis to thereby release the agent bonded thereto or dispersed therein.
  • the matrix and agent can be surrounded with an additional polymeric coating to further control release.
  • the insert comprises a biodegradable polymer such as polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacrylate, polyurethane, a nylon, or poly (dl-lactide-co-glycolide) (PLGA), or a copolymer of any of these.
  • the agent is dispersed into the matrix material or dispersed amongst the monomer composition used to make the matrix material prior to polymerization.
  • the amount of agent is from about 0.1 to about 50%, or from about 2 to about 20%.
  • the biodegradable or bioerodible polymer matrix is used so that the spent insert does not have to be removed. As the biodegradable or bioerodible polymer is degraded or dissolved, the agent is released.
  • the ophthalmic insert comprises a polymer, including, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety.
  • the insert comprises a polymer selected from polyvinylpyrrolidone (PVP), an acrylate or methacrylate polymer or copolymer (e.g., Eudragit® family of polymers from Rohm or Degussa), hydroxymethyl cellulose, polyacrylic acid, poly(amidoamine) dendrimers, poly(dimethyl siloxane), polyethylene oxide, poly(lactide-co-glycolide), poly(2- hydroxyethylmethacrylate), poly(vinyl alcohol), or poly(propylene fumarate).
  • the insert comprises Gelfoam® R.
  • the insert is a polyacrylic acid of 450 kDa- cysteine conjugante.
  • the ophthalmic composition is a ophthalmic film.
  • Polymers suitable for such films include, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008),
  • the film is a soft-contract lense, such as ones made from copolymers of N,N- diethylacrylamide and methacrylic acid crosslmked with ethyleneglycol dimethacrylate.
  • the insert comprises a core comprising the agent and an outer tube (see e.g., U.S. Patent Pub. No. 20040009222, which is incorporated herein by reference in its entirety).
  • the outer tube may be permeable, semi-permeable, or impermeable to the drug.
  • the drug core may include a polymer matrix which does not significantly affect the release rate of the drug.
  • the outer tube, the polymer matrix of the drug core, or both may be bioerodible.
  • the co-extruded product can be segmented into drug delivery devices.
  • the devices may be left uncoated so that their respective ends are open, or the devices may be coated with, for example, a layer that is permeable to the agent, semi-permeable to the agent, or bioerodible.
  • the agent and at least one polymer are admixed in powder form.
  • the insert is formed by forwarding a polymeric material to a first extrusion device, forwarding an agent to a second extrusion device, co- extruding a mass including the polymeric material and the agent, and forming the mass into at least one co-extruded drug delivery device which comprises a core including the agent and an outer layer including the polymeric material.
  • the agent forwarded to the second extrusion device is in admixture with at least one polymer.
  • the agent and the at least one polymer are admixed in powder form. In certain embodiments, this act includes forwarding more than one drug to the second extrusion device.
  • the polymeric material is one of impermeable, semi-permeable, or permeable to the agent.
  • the polymeric material may be bioerodible and/or radiation curable. In latter instances, the insert may be irradiated,
  • the insert is in a tubular form, and may be segmented into a plurality of shorter products.
  • the insert further comprises a coating of the plurality of shorter products with one or more layers including at least one of a layer that is permeable to the agent, a layer that is semi-permeable to the agent, and a layer that is bioerodible.
  • the polymeric material may include any biocompatible polymer, such as polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacrylate, polyurethane, a nylon, or poly (dl-lactide-co- glycolide) (PLGA), or a copolymer of any of these.
  • the insert comprises a therapeutically effective amount of at least one agent coated by or dispersed in a polymer matrix, wherein the agent is in granular or particulate form.
  • the agent is released from the formulation as drug from the granules dissolves into or within the matrix, diffuses through the matrix, and is released into the surrounding physiological fluid.
  • the rate of release is limited primarily by the rate of dissolution of the agent from the granules/particles into the matrix; the steps of diffusion through the matrix and dispersion into the surrounding fluid are primarily not release-rate-limiting.
  • the polymer matrix is non-bioerodible, while in other embodiments it is bioerodible.
  • Exemplary non-bioerodible polymer matrices can be formed from polyurethane, polysilicone, poly(ethylene-co-vinyl acetate) (EVA), polyvinyl alcohol, and derivatives and copolymers thereof.
  • Exemplary bioerodible polymer matrices can be formed from polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate, and derivatives and copolymers thereof.
  • the insert comprises a collagenous material.
  • the insert may be a soluble ophthalmic drug insert (SODI, e.g., a polymeric oval film that can be introduced in the upper conjuctival sac for drug delivery; an elliptical insert such as OCUSERT® (Pilocarpine ocular therapeutic system, developed by Alza Corporation) which is made of ethylene vinyl acetate; OCUFIT® (developed by Escalon Ophthalmics Inc., Skillman, NS), which is a rod shaped silicone elastomer; Lacrisert®, a rod shaped insert made of cellulose; New Ophthalmic Drug Delivery Systems (NODS), made of poly (vinyl alcohol); and the inserts described in Fabrizio, Advanced Drug Delivery Reviews 16: 95 -106, 1998, which is incorporated herein by reference in its entirety.
  • SODI soluble ophthalmic drug insert
  • OCUFIT® developed by Escalon Ophthalmics Inc., Skillman, NS
  • the insert can be placed, depending on the location and the mechanism used to hold the insert in position, by either the patient or the doctor.
  • the insert comprises collagen, gelatin, or a polymer, wherein the polymer is selected from polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacralate, polyurethane, a nylon, poly(dl-lactide-co-glycolide) (PLGA), or a copolymer of any of the aforementioned.
  • the insert is implanted under the upper eyelid.
  • the insert is implanted in the posterior segment of the eye, in the chroidal space, or in the sclera. In some embodiments, the insert is implanted intravitreally or sub-retinally. In some embodiments, the insert is injected sub-retinally.
  • the insert provides a sustained release of the agent to the vitreous of the eye.
  • sustained release means that the composition releases the agent over an extended period of time in a controlled fashion.
  • the insert releases the agent at a rate such that the aqueous agent concentration remains less than the vitreous agent concentration during the release.
  • the aqueous agent concentration is from about 0.002 ⁇ g/mL to about 0.01 ⁇ g/mL, or from about 0.01 ⁇ g/mL to about 0.05 ⁇ g/mL, or less than about 0.05 ⁇ g/mL.
  • the agent is released at a rate of about 1 ⁇ g/day to about 50 ⁇ g/day, or from about 1 ⁇ g/day to about 10 ⁇ g/day.
  • the insert further comprises an additional therapeutic agent, as detailed above, e.g., fluocinolone acetonide (such as that found in the ophthalmic insert Retisert®).
  • the ophthalmic compositon comprises microspheres or nanoparticles.
  • the microspheres comprise gelatin.
  • the microspheres are injected to the posterior segment of the eye, in the chroidal space, in the sclera, intravitreally or sub- retinally.
  • the micospheres or nanoparticles comprises a polymer including, but not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety.
  • the polymer is chitosan, a polycarboxylic acid such as polyacrylic acid, albumin particles, hyaluronic acid esters, polyitaconic acid, poly(butyl)cyanoacrylate, polycaprolactone, poly(isobutyl)caprolactone, poly(lactic acid-co-glycolic acid), or poly(lactic acid).
  • the microspheres or nanoparticles comprise solid lipid particles.
  • the ophthalmic composition comprises an ion-exchange resin.
  • the ion-exchange resin is an inorganic zeolite or synthetic organic resin.
  • the ion-exchange resin includes, but is not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety.
  • the ion- exhange resin is a partially neutralized polyacrylic acid.
  • the ophthalmic composition is an aqueous polymeric suspension.
  • the agent or a polymeric suspending agent is suspended in an aqueous medium (e.g., having the properties as described above).
  • the agent is suspended.
  • the agent is in solution.
  • the suspending agent serves to provide stability to the suspension, to increase the residence time of the dosage form on the eye, or to enhance the sustained release of the drug in terms of both longer release times and a more uniform release curve.
  • polymeric suspending agents include, but are not limited to, dextrans, polyethylene glycols, polyvinylpyrolidone, polysaccharide gels, Gelrite®, cellulosic polymers like hydroxypropyl methylcellulose, and carboxy-containing polymers such as polymers or copolymers of acrylic acid, as well as other polymeric demulcents.
  • the polymeric suspending agent is a water swellable, water insoluble polymer, especially a crosslinked carboxy-containing polymer.
  • the polymeric suspending agent comprises from at least about 90% to about 99.9%, or from about 95% to about 99.9%, by weight based on the total weight of monomers present, of one or more carboxy-containing monoethylenically unsaturated monomers.
  • the carboxy-containing monoethylenically unsaturated monomer includes acrylic acid, methacrylic acid, ethacrylic acid, methylacrylic acid (crotonic acid), cis- ⁇ -methylcrotonic acid (angelic acid), trans- ⁇ -methylcrotonic acid (tiglic acid), ⁇ -butylcrotonic acid, ⁇ -phenylacrylic acid, ⁇ -benzylacrylic acid, ⁇ -cyclohexylacrylic acid, phenylacrylic acid (cinnamic acid), coumaric acid (o-hydroxycinnamic acid), and umbellic acid (p-hydroxycoumaric acid).
  • the polymers may be crosslinked by a polyfunctional crosslinking agent (e.g., a difunctional crosslinking agent).
  • a polyfunctional crosslinking agent e.g., a difunctional crosslinking agent
  • the amount of crosslinking should be sufficient to form insoluble polymer particles, but not so great as to unduly interfere with sustained release of the agent.
  • the polymers are only lightly crosslinked.
  • the crosslinking agent is contained in an amount of from about 0.01% to about 5%, or from about 0.1% to about 5.0%, or from about 0.2% to about 1%, based on the total weight of monomers present.
  • the crosslinked polymers may be made from a carboxy-containing monoethylenically unsaturated monomer or monomers as the sole monoethylenically unsaturated monomer present, together with a crosslinking agent or agents.
  • the polymers are ones in which up to about 40%, and preferably from about 0% to about 20% by weight, of the carboxy-containing monoethylenically unsaturated monomer or monomers has been replaced by one or more non-carboxyl-containing monoethylenically unsaturated monomer or monomers containing only physiologically and ophthalmically innocuous substituents, including acrylic and methacrylic acid esters such as methyl methacrylate, ethyl acrylate, butyl acrylate, 2-ethylhexylacrylate, octyl methacrylate, 2-hydroxyethylmethacrylate, 3-hydroxypropylacrylate, and the like, vinyl acetate, N- vinylpyrrolidon
  • the polymers include polycarbophil (Noveon AA-I), Carbopol®, and DuraSite®.
  • the crosslinked polymers are prepared by suspension or emulsion polymerizing the monomers, using conventional free radical polymerization catalysts, to a dry particle size of not more than about 50 ⁇ m in equivalent spherical diameter. In some embodiments, the average dry particle size is from about 1 to about 30 ⁇ m, or from about 3 to about 20 ⁇ m in equivalent spherical diameter.
  • the polymer particles are obtained by mechanically milling larger polymer particles.
  • such polymers will have a molecular weight from about 250,000 to about 4,000,000, and from 3,000,000,000 to 4,000,000,000.
  • the particles of crosslinked polymer are monodisperse, meaning that they have a particle size distribution such that at least about 80%, about 90% or about 95%, of the particles fall within a ⁇ m band of major particle size distribution.
  • the monodisperse particle size means that there is no more than about 20%, about 10%, or about 5% particles of a size below 1 ⁇ m.
  • the aqueous polymeric suspension comprises from about 0.05 to about 1%, from about 0.1 to about 0.5%, or from about 0.1 to about 0.5%, of the agent and from about 0.1 to about 10%, from about 0.5 to about 6.5%, from about 0.5 to about 2.0%, from about 0.5% to about 1.2%, from about 0.6 to about 0.9%, or from about 0.6 to about 0.8% of a polymeric suspending agent.
  • a polymeric suspending agent can be used with the total amount falling within the stated ranges.
  • the amount of insoluble lightly crosslinked polymer particles, the pH, and the osmotic pressure can be correlated with each other and with the degree of crosslinking to give a composition having a viscosity in the range of from about 500 to about 100,000 centipoise, and preferably from about 1,000 to about 30,000 or about 1,000 to about 10,000 centipoise, as measured at room temperature (about 25° C.) using a Brookfield Digital LVT Viscometer equipped with a number 25 spindle and a 13R small sample adapter at 12 rpm.
  • the viscosity is from about 10 to about 400 centipoise, from about 10 to about 200 centipoises or from about 10 to about 25 centipoise.
  • the aqueous polymeric suspensions may be formulated so that they retain the same or substantially the same viscosity in the eye that they had prior to administration to the eye. In some embodiments, they may be formulated so that there is increased gelation upon contact with tear fluid. For instance, when a formulation containing DuraSite® or other similar polyacrylic acid-type polymer is administered to the eye at a pH of less than about 6.7, the polymer may swell upon contact with tear fluid since it has a higher pH (around 7). This gelation or increase in gelation may lead to entrapment of the suspended particles, thereby extending the residence time of the composition in the eye. In some embodiments, the agent is released slowly as the suspended particles dissolve over time.
  • this delivery route increases patient comfort and increased agent contact time with the eye tissues, thereby increasing the extent of drug absorption and duration of action of the formulation in the eye.
  • the agents contained in these drug delivery systems will be released from the gels at rates that depend on such factors as the drug itself and its physical form, the extent of drug loading and the pH of the system, as well as on any drug delivery adjuvants, such as ion exchange resins compatible with the ocular surface, which may also be present.
  • the treating comprises administering a pharmaceutical composition to the patient, the composition comprising the agent and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is an oral dosage form.
  • the pharmaceutical compositions comprise, as the active ingredient, one or more of the agents above in combination with one or more pharmaceutically acceptable carriers (excipients).
  • the agent is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the agent can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the agent is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the agent is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the agent.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the agent can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the agent actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the agent is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the agent When referring to these preformulation compositions as homogeneous, the agent is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the agent.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • liquid forms in which the agent and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • compositions administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like.
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
  • the compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered.
  • Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the agent preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of the agents can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of an agent in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the agents can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
  • Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • compositions can further include one or more additional pharmaceutical agents, examples of which are listed hereinabove.
  • the term "individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:
  • preventing the disease for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;
  • inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
  • the agent is selected from a compound of Formula I:
  • a 1 and A 2 are independently selected from C and N;
  • T, U, and V are independently selected from O, S, N, CR 5 , and NR 6 ; wherein the 5-membered ring formed by A 1 , A 2 , U, T, and V is aromatic;
  • X is N or CR 4 ;
  • Y is Ci_ 8 alkylene, C 2 _ 8 alkenylene, C 2 _ 8 alkynylene, (CR 11 R 12 V(C 340 eye loalkylene)- (CR u R 12 ) q , (CR 11 R 12 ) p -(arylene)-(CR 11 R 12 ) q , (CR u R 12 ) p -(Ci_i 0 heterocycloalkylene)-(CR u R 12 ) q , (CR 11 R 12 ) p -(heteroarylene)-(CR 11 R 12 ) q , (CR 11 R 12 ⁇ O(CR 11 R 12 ), !
  • W is Ci_8 alkylenyl, C 2 _ 8 alkenylenyl, C 2 _ 8 alkynylenyl, O, S, C(O), C(0)NR c' , C(O)O, OC(O), 0C(0)NR c' , NR C' , NR c C(0)NR d' , S(O), S(O)NR C' , S(O) 2 , or S(O) 2 NR 0' ;
  • Q is H, halo, CN, NO 2 , Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, d_ 8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein the Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Ci_ 8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Q -4 haloalkyl, halosulfanyl, C ⁇ hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 2 , CN, NO 2 , OR 3' , SR 3'
  • Cy 1 and Cy 2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, Ci_ 4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, CN, NO 2 , OR 3" , SR 3" , C(0)R b” , C(0)NR c" R d ' , C(O)OR 3" , 0C(0)R b" , 0C(0)NR c" R d " , NR C “ R d " , NR C “ C(0)R b “ , NR C ' C(O)OR 3 ' , NR c" S(0)R b" , NR c" S(0) 2 R b” , S
  • R 1 , R 2 , R 3 , and R 4 are independently selected from H, halo, alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, C ⁇ haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR c C(0)0R 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , and S(O) 2 NR 9 R 10 ;
  • R 5 is H, halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, Ci_ 4 haloalkyl, halosulfanyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 , OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR 9 C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , or S(O) 2 NR 9 R 10 ;
  • R 6 is H, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, OR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , or S(O) 2 NR 9 R 10 ;
  • R 7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
  • R 8 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
  • R 9 and R 10 are independently selected from H, d.io alkyl, Ci -6 haloalkyl, C 2 _ 6 alkenyl, C 2 -6 alkynyl, Ci -6 alkylcarbonyl, arylcarbonyl, Ci -6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R 9 and R 10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
  • R 11 and R 12 are independently selected from H and -E 1 -E 2 -E 3 -E 4 ;
  • D 1 and E 1 are independently absent or independently selected from Ci -6 alkylene, C 2 _6 alkenylene, C 2 _6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci -6 alkylene, C 2 _6 alkenylene, C 2 _6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO 2 , N 3 , SCN, OH, Ci -6 alkyl, Ci -6 haloalkyl, C 2-8 alkoxyalkyl, d_ 6 alkoxy, d_ 6 haloalkoxy, amino, Ci_6 alkylamino, and C 2 _ 8 dialkylamino;
  • D and E are independently absent or independently selected from Ci_6 alkylene, C 2 _6 alkenylene, C 2 _ 6 alkynylene, (Ci -6 alkylene) r -O-( Ci_ 6 alkylene) s , (Ci -6 alkylene) r -S-(Ci_ 6 alkylene) s , (Ci -6 alkylene) r -NR e -(Ci_ 6 alkylene) s , (Ci -6 alkylene) r -CO-(Ci_ 6 alkylene) s , (Ci -6 alkylene) r -COO-(Ci_ 6 alkylene) s , (Ci -6 alkylene) r -CONR e -(Ci_6 alkylene) s , (Ci -6 alkylene) r -S0-(Ci_6 alkylene) s , (Ci -6 alkylene) r -
  • D 3 and E 3 are independently absent or independently selected from Ci_ 6 alkylene, C 2 _ 6 alkenylene, C 2 _ 6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C 2 _6 alkenylene, C 2 _6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO 2 , N 3 , SCN, OH, Ci -6 alkyl, Ci -6 haloalkyl, C 2-8 alkoxyalkyl, d_ 6 alkoxy, d_ 6 haloalkoxy, amino, Ci_6 alkylamino, and C 2 _ 8 dialkylamino;
  • R a is H, Cy 1 , -(Ci -6 alkyO-Cy 1 , Ci_ 6 alkyl, Ci_6 haloalkyl, C 2 - 6 alkenyl, C 2 _ 6 alkynyl, wherein the Ci_ 6 alkyl, Ci_ 6 haloalkyl, C 2 _ 6 alkenyl, or C 2 _ 6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -6 alkyl, Ci_ 6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  • R b is H, Cy 1 , -(Ci -6 alky ⁇ -Cy 1 , Ci -6 alkyl, Ci -6 haloalkyl, C 2 . 6 alkenyl, C 2 _ 6 alkynyl, wherein the Ci_6 alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, or C 2 _6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -6 alkyl, Q_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  • R a and R a are independently selected from H, Ci_6 alkyl, d_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Q_6 alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -6 alkyl, Ci_ 6 haloalkyl, halosul
  • R b and R b are independently selected from H, d_6 alkyl, d_6 haloalkyl, C 2 _6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci_6 alkyl, d_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -6 alkyl, Ci_ 6 haloalkyl, Ci
  • R c and R d are independently selected from H, Cy 1 , -(Ci -6 alkyfj-Cy 1 , d_ 10 alkyl, Ci -6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, wherein the Ci.io alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, or C 2 _6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy 1 , -(Ci -6 alkyfj-Cy 1 , OH, CN, amino, halo, Ci -6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently
  • R c and R d are independently selected from H, Ci.io alkyl, Ci_6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci.io alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_
  • R c and R d are independently selected from H, Ci -I0 alkyl, Ci_ 6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci -I0 alkyl, d_6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, Ci_ 6 haloalkyl, ha
  • R e and R f are independently selected from H and Ci_6 alkyl
  • R 1 Is H 1 CN 1 OrNO 2 ; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1.
  • the compound of Formula I is not selected from:
  • the moiety formed by T, U, V, A 1 , and A 2 is not a l,2,4-oxadiazol-3- yl ring. In some embodiments, the moiety formed by T, U, V, A 1 , and A 2 , is not an oxadiazole ring, wherein the moiety formed by T, U, V, A 1 , and A 2 is not the following moiety:
  • Y is other than (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 ) q .
  • the 5-membered ring formed by A 1 , A 2 , U, T, and V is other than pyrrolyl.
  • R 1 , R 2 , and R 3 are each H, n is 1, and the moiety formed by A 1 , A 2 , U, T, V, and -(Y) n -Z has the formula:
  • Y is other than (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 ) q or (CR 11 R 12 ) p C(O)(CR 11 R 12 ) q .
  • R 1 , R 2 , and R 3 are each H, n is 0, and the moiety formed by A 1 , A 2 , U, T, V, and -(Y) n -Z has the formula:
  • Z is other than CN, halo, or Ci_ 4 alkyl.
  • R 1 , R 2 , and R 3 are each H, n is 1, and the moiety formed by A 1 , A 2 , U, T, V, and -(Y) n -Z has the formula:
  • Y is other than (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 ) q or (CR 11 R 12 ) p C(O)(CR 11 R 12 ) q .
  • R 1 , R 2 , and R 3 are each H, n is 1, and the moiety formed by A 1 , A 2 , U, T, V, and -(Y) n -Z has the formula:
  • Y is other than (CR 11 R 12 ) p NR c (CR 11 R 12 ) q .
  • Z is H, halo, CN, NO 2 , Ci_ 8 alkyl, C 2 -8 alkenyl, C 2 -8 alkynyl, Ci_ 8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein the Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Ci_ 8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R
  • Cy 1 and Cy 2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_ 4 alkyl, C 2 ⁇ alkenyl, C 2 ⁇ alkynyl, Ci -4 haloalkyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, CN, NO 2 , 0R a " , SR a " , C(0)R b “ , C(0)NR c “ R d “ , C(O)OR 3" , 0C(0)R b” , 0C(0)NR c" R d" , NR c" R d" , NR c" C(0)R b" , NR c" C(0)0R a" , NR c" S(O)R b" , NR c” S(0) 2 R b” , S(O
  • R 1 , R 2 , R 3 , and R 4 are independently selected from H, halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, Ci -4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR c C(0)0R 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , and S(O) 2 NR 9 R 10 ;
  • R 5 is H, halo, C M alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, Ci_ 4 haloalkyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 , OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR 9 C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , or S(O) 2 NR 9 R 10 ;
  • R 6 is H, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, OR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , or S(O) 2 NR 9 R 10 ;
  • R 7 is H, Ci_ 6 alkyl, Ci_ 6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
  • R 8 is H, Ci_ 6 alkyl, Ci_ 6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
  • R 9 and R 10 are independently selected from H, Ci.io alkyl, d_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, d_6 alkylcarbonyl, arylcarbonyl, Ci_6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkylalkyl and heterocycloalkylalkyl; or R 9 and R 10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
  • R 11 and R 12 are independently selected from H, halo, OH, CN, Ci_ 4 alkyl, Ci_ 4 haloalkyl, C 2 ⁇ alkenyl, C 2 _ 4 alkynyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
  • R a , R a , and R a are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Cue alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, Ci_ 6 haloalky
  • R b , R b and R b are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci_ 6 alkyl, Ci_ 6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, d_ 6 haloalky
  • R c and R d are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the d.io alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_
  • R c and R d are independently selected from H, d- 1 0 alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci 40 alkyl, Ci_ 6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_
  • R c and R d are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the d.io alkyl, Ci_6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_ 6 alkyl, Ci_ 6 haloalkyl,
  • X is N.
  • X is CR 4 .
  • X is N or CR 4 .
  • a 1 is C.
  • a 1 is N.
  • a 2 is C.
  • A is N.
  • At least one of A 1 , A 2 , U, T, and V is N.
  • the 5-membered ring formed by A 1 , A 2 , U, T, and V is pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or oxadiazolyl.
  • the 5-membered ring formed by A 1 , A 2 , U, T, and V is selected from:
  • c and c ' designate the two sites of attachment of the fused 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring.
  • the 5-membered ring formed by A , A , U, T, and V is selected from:
  • c and c ' designate the two sites of attachment of the fused 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring.
  • the 5-membered ring formed by A 1 , A 2 , U, T, and V is selected from: wherein: a designates the site of attachment of moiety -(Y) n -Z; b designates the site of attachment to the core moiety:
  • the 5-membered ring formed by A 1 , A 2 , U, T, and V is selected from:
  • the 5-membered ring formed by A , A , U, T, and V is selected from:
  • the 5-membered ring formed by A 1 , A 2 , U, T, and V is selected from:
  • the 5-membered ring formed by A , A , U, T, and V is selected from
  • n 0.
  • n 1
  • n is 1 and Y is Ci_g alkylene, C 2 -8 alkenylene, (CR 11 R 12 ) p C(O)(CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)O(CR 11 R 12 ) q , (CR 11 R ⁇ ) P OC(O)(CR 11 R 12 ), ! , wherein the Ci_ 8 alkylene or C 2 - 8 alkenylene, is optionally substituted with 1, 2, or 3 halo, OH, CN, amino, Ci_ 4 alkylamino, or C 2 -8 dialkylamino.
  • n 1 and Y is Ci -8 alkylene, (CR 11 R 12 ⁇ C(O)(CR 11 R 12 ⁇ , (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)O(CR 11 R 12 ) q , wherein the Ci -8 alkylene is optionally substituted with 1, 2, or 3 halo, OH, CN, amino, C ⁇ alkylamino, or C 2 _ 8 dialkylamino.
  • n is 1 and Y is Ci_ 8 alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino, alkylamino, or C 2 -8 dialkylamino.
  • n is 1 and Y is ethylene optionally substituted with 1 , 2, or 3 halo, OH, CN, amino, Ci_ 4 alkylamino, or C 2 - 8 dialkylamino.
  • n is 1 and Y is (CR 11 R 12 ⁇ C(O)(CR 11 R 12 ⁇ (CR 11 R 12 ⁇ C(O)NR 0 - (CR 11 R 12 ) ⁇ or (CR 11 R 12 ⁇ C(O)O(CR 11 R 12 ) ⁇
  • Y is Ci_ 8 alkylene, C 2 _ 8 alkenylene, C 2 _ 8 alkynylene, (CR 11 R 1 ⁇ p -(C 340 cycloalkylene)-(CR u R 12 ) q , (CR 11 R 12 ) p -(arylene)-(CR 11 R 12 ) q , (CR 11 R 12 ) p -(C 1 . 10 heterocycloalkylene)- (CR u R 12 ) q , (CR 11 R 12 ) p -(heteroarylene)-(CR 11 R 12 ) q , (CR 11 R 12 ⁇ O(CR 11 R 12 ), !
  • Ci_g alkylene, C 2 - 8 alkenylene, C 2 - 8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene is optionally substituted with 1 , 2, or 3 substituents independently selected from -D 1 -D 2 -D 3 -D 4 .
  • Y is Ci_g alkylene, C 2 - 8 alkenylene, C 2 - 8 alkynylene, (CR 11 R 12 ⁇ -(C 340 cycloalkylene)-(CR u R 12 ) q , (CR 11 R 12 ) p -(arylene)-(CR 11 R 12 ) q , (CR u R 12 ) p -(Ci_io heterocycloalkylene)- (CR u R 12 ) q , (CR 11 R 12 ) p -(heteroarylene)-(CR 11 R 12 ) q , (CR 11 R 12 ) p O(CR 11 R 12 ) q , or (CR 11 R 12 ⁇ S(CR 11 R 12 ) ⁇ wherein the Ci_ 8 alkylene, C 2 - 8 alkenylene, C 2 - 8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene,
  • Y is Ci_ 8 alkylene, C 2 - 8 alkenylene, C 2 - 8 alkynylene, or (CR U R 12 ) P -(C 3 _ io cycloalkylene)-(CR u R 12 ) q , wherein the Ci_ 8 alkylene, C 2 - 8 alkenylene, C 2 - 8 alkynylene, or cycloalkylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D 1 - D 2 -D 3 -D 4 .
  • Y is Ci_ 8 alkylene, C 2 - 8 alkenylene, C 2 - 8 alkynylene, or (CR U R 12 ) P -(C 3 _ io cycloalkylene)-(CR u R 12 ) q , wherein the Ci_ 8 alkylene, C 2 _ 8 alkenylene, C 2 _ 8 alkynylene, or cycloalkylene, is optionally substituted with 1 , 2, or 3 substituents independently selected from D 4 .
  • Y is Ci_ 8 alkylene, C 2 _ 8 alkenylene, or C 2 _ 8 alkynylene, each optionally substituted with 1, 2, or 3 substituents independently selected from -D 1 -D 2 -D 3 -D 4 .
  • Y is Ci_ 8 alkylene optionally substituted with 1, 2, or 3 substituents independently selected from -D 1 -D 2 -D 3 -D 4 .
  • Y is Ci_ 8 alkylene optionally substituted with 1, 2, or 3 substituents independently selected from D 4 .
  • Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, (CR 11 R 12 ⁇ O- (CR u R 12 ) q , (CR 11 R 1 ⁇ p S(CR 11 R 12 ) ⁇ (CR 11 R 12 ) p C(O)(CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)O(CR 11 R 12 ) q , (CR 11 R 12 ) p OC(O)(CR 11 R 12 ) q , (CR 11 R 12 ) p OC(O)NR c (CR 11 R 12 ) q , (CR 1 'R ⁇ p NR ⁇ CR 11 R 12 V (CR 11 R 12 ) p NR c C(O)NR d (CR 11 R 12 ) q , (CR 11 R 12 )
  • Y is Ci_ 8 alkylene, C 2 _ 8 alkenylene, C 2 _ 8 alkynylene, (CR 11 R 1 ⁇ p -(C 340 cycloalkylene)-(CR u R 12 ) q , (CR 11 R 12 ) p -(arylene)-(CR 11 R 12 ) q , (CR u R 12 ) p -(Ci_io heterocycloalkylene)- (CR u R 12 ) q , (CR 11 R 12 ) p -(heteroarylene)-(CR 11 R 12 ) q , (CR 11 R 12 ) p O(CR 11 R 12 ) q , (CR 11 R 12 ) p S(CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)(CR 11 R 12 ) q , (CR 11 R 12 ) p C(O)NR c (CR 11 R 12 )
  • alkenylene, C 2 _ 8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene is optionally substituted with 1 , 2, or 3 substituents independently selected from halo, OH, CN, amino, Ci_ 4 alkylamino, and C 2 _ 8 dialkylamino.
  • n is 1 and Y is Q_ 8 alkylene optionally substituted with 1, 2, or 3 substituents independently selected from D 4 .
  • n is 1 and Y is Ci_g alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino, Q -4 alkylamino, or C 2 _g dialkylamino.
  • n is 1 and Y is Ci_g alkylene optionally substituted with cyano.
  • p is O.
  • p is 1.
  • p is 2.
  • q is O.
  • q is 1.
  • q is 2.
  • one of p and q is 0 and the other of p and q is 1, 2, or 3.
  • Z is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , SR a , C(0)R b , C(0)NR c R d , C(0)0R a , 0C(0)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R a , S(O)R b , S(O)NR c R d ,
  • Z is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, d_ 4 haloalkyl, C M hydroxyalkyl, C ⁇ cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , SR a , C(0)R b , C(0)NR c R d , C(0)0R a , 0C(0)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R a , S(O)R b , S(O)NR c R d , S(O) 2 R
  • Z is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci -4 haloalkyl, halosulfanyl, Ci -4 hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , SR a , C(0)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR d , NR c C(O)OR a , S(O)R b , S(O)NR c R d ,
  • Z is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci -4 haloalkyl, d_ 4 hydroxyalkyl, d_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , SR a , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(0)R b , NR c C(0)NR c R d , NR c C(0)0R a , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O)
  • Z is phenyl or 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, d_ 4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , SR a , C(O)R b , C(0)NR c R d , C(O)OR 3 , 0C(0)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R 3 , S(O)R b , S(O)NR c R d , S(O) 2
  • Z is phenyl or 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, C M hydroxyalkyl, C ⁇ cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , SR 3 , C(0)R b , C(0)NR c R d , C(O)OR 3 , 0C(0)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R 3 , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R
  • Z is phenyl optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, halosulfanyl, Ci -4 hydroxyalkyl, Ci -4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , SR 3 , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R 3 , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(0) 2 R b , NR
  • Z is phenyl optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, Ci -4 hydroxyalkyl, d_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , SR 3 , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R 3 , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O)R
  • Z is cycloalkyl or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci -4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , SR 3 , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R 3 , S(O)R b , S(O)NR c R d , S(O) 2 R b ,
  • Z is cycloalkyl or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci -4 haloalkyl, Ci -4 hydroxyalkyl, Ci -4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , SR 3 , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR c R d , NR c C(0)0R 3 , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R
  • Z is Ci_ 8 alkyl, C 2 -8 alkenyl, or C 2 -8 alkynyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q -4 alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, Ci -4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci -4 cyanoalkyl, Cy 1 , CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(0)R b , NR c C(0)NR c R d , NR c C(0)0R a , S(O)R b , S(O)NR c
  • Z is Ci_ 8 alkyl, C 2 _ 8 alkenyl, or C 2 _ 8 alkynyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 ⁇ alkynyl, C ⁇ haloalkyl, C ⁇ hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , SR a , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(0)R b , NR c C(0)NR c R d , NR c C(0)0R a , S(O)R b , S(O)NR c R d ,
  • Z is Ci_g alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci -4 alkyl, Ci_ 4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci -4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , C(0)NR c R d , C(O)OR 3 , NR c R d , NR c C(0)R b , and S(O) 2 R b .
  • Z is Ci_g alkyl, C 2 _g alkenyl, C 2 _g alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci -4 alkyl, Ci_ 4 haloalkyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , 0R a , C(0)NR c R d , C(O)OR 3 , NR c R d , NR c C(0)R b , and S(O) 2 R b .
  • Z is Ci_g alkyl, C 2 _g alkenyl, C 2 _g alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_ 4 alkyl, Ci_ 4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , C(0)NR c R d , C(O)OR 3 , NR c R d , NR c C(0)R b , and S(O) 2 R b .
  • Z is Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Q -4 alkyl, Q -4 haloalkyl, C x-4 hydroxyalkyl, C x-4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , C(0)NR c R d , C(O)OR 3 , NR c R d , NR c C(0)R b , and S(O) 2 R b .
  • Z is substituted with at least one substituent comprising at least one CN group.
  • Z is Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each substituted with at least one CN or Ci_ 4 cyanoalkyl and optionally substituted with 1, 2, 3, 4, or 5 further substituents selected from halo, Ci_ 4 alkyl, C 2 ⁇ alkenyl, C 2 _ 4 alkynyl, Ci -4 haloalkyl, halosulfanyl, Ci_ 4 hydroxyalkyl, Ci -4 cyanoalkyl, Cy 1 , CN, NO 2 , OR 3 , SR 3 , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(0)R b , NR c
  • Z is Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each substituted with at least one CN or Ci_ 4 cyanoalkyl and optionally substituted with 1, 2, 3, 4, or 5 further substituents selected from halo, Ci_ 4 alkyl, C 2 ⁇ alkenyl, C 2 _ 4 alkynyl, C ⁇ haloalkyl, C ⁇ hydroxyalkyl, Ci_ 4 cyanoalkyl, Cy 1 , CN, NO 2 , OR a , SR a , C(O)R b , C(0)NR c R d , C(O)OR 3 , OC(O)R b , 0C(0)NR c R d , NR c R d , NR c C(O)R b , NR c C(0)NR
  • X is N.
  • a 1 is C.
  • a 2 is N.
  • T is N.
  • U and V are independently CR 5 .
  • the -(Y) n -Z moiety is taken together with i) A 2 to which the moiety is attached, ii) R 5 or R 6 of either T or V, and iii) the C or N atom to which the R 5 or R 6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A 1 , A 2 , U, T, and V, wherein the 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W) m -Q.
  • the -(Y) n -Z moiety is taken together with i) A 2 to which the moiety is attached, ii) R 5 or R 6 of either T or V, and iii) the C or N atom to which the R 5 or R 6 of either T or V is attached to form a 4- to 8-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A 1 , A 2 , U, T, and V, wherein the 4- to 8-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W) m -Q.
  • the -(Y) n -Z moiety is taken together with i) A 2 to which the moiety is attached, ii) R 5 or R 6 of either T or V, and iii) the C or N atom to which the R 5 or R 6 of either T or V is attached to form a 6-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5- membered ring formed by A 1 , A 2 , U, T, and V, wherein the 6-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , Ci_ 8 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Ci_ 8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl where
  • Cy 1 and Cy 2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, Ci -4 hydroxyalkyl, Ci -4 cyanoalkyl, CN, NO 2 , 0R a" , SR a" , C(0)R b" , C(0)NR c" R d" , C(0)0R a" , 0C(0)R b” , 0C(0)NR c" R d" , NR c" R d" , NR c" C(0)R b" , NR c" C(0)0R a" , S(O)R b” , S(O)NR c" R d" , S(O)R
  • Cy 1 and Cy 2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, CN, NO 2 , OR a , SR a" , C(O)R b" , C(O)NR c" R d" , C(O)OR 3" , OC(O)R b" , 0C(0)NR c" R d" , NR c" R d" , NR c" C(0)R b" , NR c" C(0)0R a" , S(O)R b” , S(O)NR c" R d” , S(O) 2 R b" , and S(O) 2 NR
  • Cy 1 and Cy 2 are independently selected from cycloalkyl and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_ 4 alkyl, C 2 - 4 alkenyl, C 2 ⁇ alkynyl, Ci_ 4 haloalkyl, CN, NO 2 , 0R a" , SR a" , C(O)R b" , C(0)NR c" R d” , C(O)OR 3" , OC(O)R b” , 0C(0)NR c" R d" , NR c" R d" , NR c" C(0)R b" , NR c" C(0)0R a" , S(O)R b” , S(O)NR c" R d” , S(O) 2 R b" , and S(O) 2 NR c" R d” .
  • Cy 1 and Cy 2 are independently selected from cycloalkyl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci -4 alkyl, C 2 ⁇ alkenyl, C 2 _ 4 alkynyl, C ⁇ haloalkyl, CN, NO 2 , 0R a" , SR a" , C(O)R b" , C(0)NR c" R d” , C(O)OR a" , OC(O)R b" , 0C(0)NR c" R d" , NR c" R d" , NR c" C(0)R b" , NR c" C(0)0R a" , S(O)R b” , S(O)NR c" R d" , S(O) 2 R b" , and S(O) 2 NR c" R d” .
  • R 1 , R 2 , R 3 , and R 4 are independently selected from H, halo, Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR c C(0)0R 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , and S(O) 2 NR 9 R 10 .
  • R 1 , R 2 , R 3 , and R 4 are independently selected from H, halo, and Q_ 4 alkyl.
  • R 1 , R 2 , R 3 , and R 4 are each H.
  • R 1 is H, halo, or Ci_ 4 alkyl.
  • R 5 is H, halo, Ci_ 4 alkyl, C 2 ⁇ alkenyl, C 2 ⁇ alkynyl, Q ⁇ haloalkyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 , OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR 9 C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , or S(O) 2 NR 9 R 10 .
  • R 5 is H, halo, Ci_ 4 alkyl, C ⁇ haloalkyl, halosulfanyl, CN, or NR 9 R 10 .
  • R 5 is H, halo, Ci_ 4 alkyl, Ci -4 haloalkyl, CN, or NR 9 R 10 .
  • R 5 is H.
  • R 6 is H or Ci -4 alkyl.
  • R 6 is H.
  • R 11 and R 12 are independently selected from H, halo, OH, CN, Q -4 alkyl, Q -4 haloalkyl, halosulfanyl, SCN, C 2 ⁇ alkenyl, C 2 _ 4 alkynyl, C w hydroxyalkyl, Ci_ 4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.
  • R 11 and R 12 are independently selected from H, halo, OH, CN, Ci -4 alkyl, Ci -4 haloalkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, Ci_ 4 hydroxyalkyl, d_ 4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.
  • the agent is selected from compounds of Formula Ia or Ib:
  • the agent is selected from compounds of Formula Ic:
  • the agent is selected from compounds of Formula Id or Ie:
  • the agent is selected from compounds of Formula Ie:
  • the agent is selected from compounds of Formula Ih:
  • the agent is selected from compounds of Formula Ik:
  • the agent is selected from compounds of Formula H:
  • the agent is selected from compounds of Formula Im:
  • the agent is selected from compounds of Formula In:
  • the agent is selected from:
  • the agent is selected from 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile and pharmaceutically acceptable salts thereof.
  • the agent is selected from (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)-lH-pyrazol-l-yl]propanenitrile and pharmaceutically acceptable salts thereof.
  • the agent is selected from 3-[3-Methyl-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol- 4-yl]benzonitrile and pharmaceutically acceptable salts thereof.
  • the agent is selected from N-phenyl-4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-l,3-thiazol-2-amine and pharmaceutically acceptable salts thereof.
  • the agent is selected from compounds of Formula II:
  • L a is SO 2 or CO
  • R la is Ci_6 alkyl, C 3 _ 7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR 2a R 3a , or OR 4 , wherein the alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_ 4 alkyl;
  • R a and R a are independently selected from H, C ⁇ alkyl, and phenyl;
  • R 4a is Ci_6 alkyl, phenyl, or benzyl.
  • R la when L a is SO 2 , then R la is other than 0R 4a . In some embodiments, when L a is SO 2 , then R la is Ci_ 6 alkyl, C 3 _ 7 cycloalkyl, phenyl, 5- or 6- membered heteroaryl, or NR a R a , wherein the alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from F and Ci_ 4 alkyl.
  • R la is C 3 _ 7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR 2a R 3a , or OR 4a , wherein the cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from CN and Ci_ 4 alkyl.
  • L a is SO 2 .
  • L a is CO
  • R la is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, 2- methylprop- 1 -yl, 1 -methylprop- 1 -yl, each optionally substituted with 1 , 2, or 3 F.
  • R la is Ci_ 4 alkyl.
  • R la is ethyl
  • R la is C3_ 7 cycloalkyl optionally substituted by alkyl.
  • R la is phenyl optionally substituted with F, methyl, or CN.
  • R la is 5-membered heteroaryl selected from thienyl, pyrazolyl, pyrrolyl, 1,2,4-oxadiazolyl, and isoxazolyl, each optionally substituted with Ci_ 4 alkyl.
  • R la is pyridinyl
  • R la is NR 2a R 3a or 0R 4a .
  • L a is SO 2 and R la is Ci_6 alkyl.
  • the agent is selected from:
  • the agent is selected from ⁇ l-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-yl ⁇ acetonitrile and pharmaceutically acceptable salts thereof.
  • the agent is ⁇ l-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-lH-pyrazol-l-yl]azetidin-3-yl ⁇ acetonitrile phosphoric acid salt.
  • the agent is selected from compounds of Formula III:
  • R 5a and R 6a are independently selected from H, F, CN, OH, Ci_ 4 alkyl, benzyloxy, C 2 -8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein the alkyl is optionally substituted by 1, 2, or 3 substituents selected from F, OH, CN, and Ci_ 4 alkoxy, and wherein the 5-membered heteroaryl is optionally substituted with Ci_ 4 alkyl.
  • R 5a and R 6a when one of R 5a and R 6a is OH, then the other of R 5a and R 6a is other than CN or F.
  • one of R 5a and R 6a is H and the other is selected from H, F, CN, OH, Ci_ 4 alkyl, benzyloxy, C 2 -8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein the alkyl is optionally substituted by 1, 2, or 3 substituents selected from F, OH, CN, and Q -4 alkoxy, and wherein the 5-membered heteroaryl is optionally substituted with Ci_ 4 alkyl.
  • R 5a and R 6a are independently selected from H, F, CN, OH, and methyl.
  • R 5a and R 6a are independently selected from H and CN.
  • the agent is selected from:
  • the agent is selected from 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-l H-pyrazol- l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is selected from cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-l H-pyrazol- l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof.
  • the agent is selected from trans-3-(cyanomethyl)-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof.
  • the agent is selected from compounds of Formula IV:
  • D 1 is N, NO, or CR la ;
  • D z is N, NO, or CR I 1 b
  • D 3 is N, NO, or CR I 1 c C ;.
  • D 4 is N, NO or CR ld ;
  • Ring A is
  • X and Y are each, independently, N or CR 5 ;
  • Z 1 and Z 2 are each, independently, N, CR 6 , or NO; wherein at least one of Z 1 and Z 2 is other than CR 6 ;
  • D is O, S, or NR 8 ;
  • E is N or CR 9 ;
  • G is O, S, or NR 8 ;
  • J is N or CR 7 ;
  • R is -W 1 -W 2 - W 3 - W 4 ;
  • W 1 is absent, Q -6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, O, S, NR 11 , CO, COO, CONR 11 , SO, SO 2 , SONR 11 , SO 2 NR 11 , Or NR 11 CONR 12 , wherein the Ci_ 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl are each optionally substituted by 1, 2 or 3 halo, OH, Ci_ 4 alkoxy, Ci_ 4 haloalkoxy, amino, Ci_ 4 alkylamino or C 2 _8 dialkylamino;
  • R la , R lb , R lc and R ld are each, independently, H, halo,d_ 4 alkyl, C 24 alkenyl, C 2 _ 4 alkynyl, Q -4 haloalkyl, OH, Ci -4 alkoxy, Ci_ 4 haloalkoxy, CN, NO 2 , C(O)-(Ci 4 alkyl), C(O)OH, C(O)O-(Ci -4 alkyl), C(O)NH 2 , C(0)NH(Ci_ 4 alkyl), C(O)N(C 14 alkyl) 2 , S(O) 2 NH 2 , S(O) 2 NH(Ci 4 alkyl), S(O) 2 N(Ci 4 alkyl) 2 , S(O) 2 -(Ci 4 alkyl), NH 2 , NH(Ci 4 alkyl), Or N(Ci 4 alkyl) 2 ;
  • R 2 is H, OH, Ci_6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl;
  • R 2a is Ci_6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
  • R 3 , R 4 , R 5 , and R 6 are each, independently, H, Ci_6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, halo, Ci 4 haloalkyl, CN, NO 2 , OR 12 , SR 12 , C(O)R 13 , C(O)OR 12 , C(O)NR 14 R 15 , NR 14 R 15 , NR 14 CONHR 15 , NR 14 C(O)R 13 , NR 14 C(O)OR 12 , S(O)R 13 , S(O) 2 R 13 , S(O)NR 14 R 15 , SO 2 NR 14 R 15 ;
  • R 7 is H, Ci_6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, halo, Ci 4 haloalkyl, OH, Ci 4 alkoxy, Ci 4 haloalkoxy, CN, NO 2 , C(O)-(Ci 4 alkyl), C(O)OH, C(O)O-(Ci 4 alkyl), C(O)NH 2 , C(O)NH(Ci 4 alkyl), C(O)N(Ci_ 4 alkyl) 2 , S(O) 2 NH 2 , S(O) 2 NH(Ci_ 4 alkyl), S(O) 2 N(Ci_ 4 alkyl) 2 , S(O) 2 -(C 14 alkyl), NH 2 , NH(Ci_ 4 alkyl), or N(Ci_ 4 alkyl) 2 ;
  • R 8 is H, Ci -4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, OH or C 14 alkoxy;
  • R 9 is H, halo, C 14 alkyl, C 14 haloalkyl, C 24 alkenyl, C 24 alkynyl, OH, C 14 alkoxy or C 14 haloalkoxy;
  • R 10 and R 11 are each, independently, H, Q -6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, arylalkyl, cycloalkylalkyl, COR a , SOR a , or SO 2 R a wherein each of the Ci -6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl is optionally substituted by 1 , 2 or 3 substitutents sleeted from halo, C 14 alkyl, C 14 haloalkyl, OH, C 14 alkoxy, C 14 haloalkoxy, amino, Ci- 4 alkylamino, C 2 _g dialkylamino, aminocarbonyl, C 14 alkylaminocarbonyl, or C 2 _g dialkylamin
  • R 12 and R 13 are each, independently, H, Ci -6 alkyl, Ci -6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl;
  • R 14 and R 15 are each, independently, H, Ci -6 alkyl, Ci -6 haloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R 14 and R 15 together with the N atom to which they are attached form a heterocyclyl group;
  • R a is H, Ci -6 alkyl, Ci -6 haloalkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, aryl, cycloalkyl, arylalkyl, cycloalkylalkyl, heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, NH 2 , NH(Ci -6 alkyl), N(Ci -6 alkyl) 2 , NH(carbocyclyl), N(carbocyclyl) 2 , NH(carbocyclylalkyl) or N(carbocyclylalkyl) 2 ; with the proviso that when Ring A is:
  • Ring B is:
  • D 1 is CR la ;
  • D z is N or CR .
  • D 3 is CR lc ; and
  • D 4 is CR ld ; then W 1 is O, S, NR 11 , SO, SO 2 , SONR 11 , SO 2 NR u ,or NR 11 CONR 12 .
  • Ring A is
  • both X and Y are CR 5 .
  • both X and Y are N.
  • one of X and Y is N and the other is CR 5 .
  • X is CR 5 and Y is N.
  • X is N and Y is CR 5 .
  • R 2 is H.
  • R is H
  • X is CH
  • Y is CH
  • Ring A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Z 1 is NO or Z 2 is NO. In some embodiments, Z 1 is NO and Z 2 is CR 6 . In some embodiments, Z 2 is NO and Z 1 is CR 6 . In some embodiments, Ring A is
  • R a is Ci_6 alkyl. In some embodiments, R 2a is methyl. In some embodiments, at least one of X and Y is N. In some embodiments, Ring B is
  • G is O or S.
  • G is NR 8 .
  • G is NH
  • R is H, Q_ 6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or
  • R is H, Q_ 6 alkyl Or NR 10 R 11 .
  • R is O-W 2 -W 3 -W 4 , S-W 2 -W 3 -W 4 or NR U -W 2 -W 3 -W 4 .
  • Ring B is
  • D is S.
  • D is O.
  • D is NR 8 .
  • R is H, Ci_ 6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or
  • R is H, Q_ 6 alkyl Or NR 10 R 11 .
  • R is (Ci -6 alkyl)-W 2 -W 3 -W 4 , O-W 2 -W 3 -W 4 , S-W 2 -W 3 -W 4 , NR U -W 2 - W 3 -W 4 , or -W 2 -W 3 -W 4 .
  • D is S or O and R is O-W 2 -W 3 -W 4 , S-W 2 -W 3 -W 4 or NR U -W 2 -W 3 -W 4 .
  • D is S and R is O-W 2 -W 3 -W 4 , S-W 2 -W 3 -W 4 or NR 11 -W 2 - W 3 - W 4 .
  • Ring B is
  • E is N.
  • R 7 is H.
  • R is H, Ci_ 6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or
  • R is H, Ci_ 6 alkyl or NR R .
  • E is CR 9 and R is O-W 2 -W 3 -W 4 , S-W 2 -W 3 -W 4 or NR 11 -W 2 - W 3 - W 4 .
  • Ring B is
  • R is H, Q -6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl. In some embodiments, R is H or Ci_ 6 alkyl.
  • R is (Ci -6 alkyl)-W 2 -W 3 -W 4 , CO-W 2 - W 3 -W 4 , COO-W 2 - W 3 -W 4 , CONR U -W 2 -W 3 -W 4 or SO 2 -W 2 -W 3 -W 4 .
  • Ring B is:
  • J is N. In some embodiments, J is CR 7 .
  • R is H, d_ 6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl. In some embodiments, R is H or Ci_ 6 alkyl.
  • R is (C L6 alkyl)-W 2 -W 3 -W 4 , CO-W 2 - W 3 -W 4 , COO-W 2 - W 3 -W 4 , CONR U -W 2 -W 3 -W 4 or SO 2 -W 2 -W 3 -W 4 .
  • Ring B is (C L6 alkyl)-W 2 -W 3 -W 4 , CO-W 2 - W 3 -W 4 , COO-W 2 - W 3 -W 4 , CONR U -W 2 -W 3 -W 4 or SO 2 -W 2 -W 3 -W 4 .
  • Ring B is
  • R is cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, Ci_ 4 alkoxy, d_ 4 haloalkyl, Ci -4 haloalkoxy, COOH, COO-(Ci_ 4 alkyl), amino, Ci -4 alkylamino or C 2 -8 dialkylamino.
  • R is 5-, 6-, or 7-membered cycloalkyl or 5-, 6-, or 7-membered heterocycloalkyl, each optionally substituted by 1 or 2 halo, OH, CN, Ci_ 4 alkoxy, Ci_ 4 haloalkyl, or Ci_ 4 haloalkoxy.
  • D 1 is CR la
  • D 2 is CR lb
  • D 3 is CR lc
  • D 4 is CR ld .
  • D 2 is CR lb .
  • D 2 is CR lb and CR lb is H, Ci_ 4 alkyl or halo.
  • D 2 is CR lb and CR lb is H or halo.
  • D 2 is CR lb and CR lb is F, Cl, Br or I.
  • D 2 is CR lb ; CR lb is F, Cl, Br or I; D 1 is CH, D 3 is CH; and D 4 is CH.
  • D 2 is CF; D 1 is CH, D 3 is CH; and D 4 is CH.
  • At least one of D 1 , D 2 , D 3 , and D 4 is N.
  • At least one of D 1 , D 3 , and D 4 is N.
  • not more than 2 of D 1 , D 2 , D 3 , and D 4 are N.
  • At least one of D 1 , D 2 , D 3 , and D 4 is NO.
  • At least one of D 1 , D 3 , and D 4 is NO.
  • the agent is selected from compounds of Formula IVa:
  • R la , R lb , R lc and R ld are each, independently, H, Q -4 alkyl, C 2 - 4 alkenyl, C 2 _ 4 alkynyl, halo, Ci_ 4 haloalkyl, OH, Ci -4 alkoxy, Ci_ 4 haloalkoxy, CN, NO 2 , NH 2 , NH(Ci_ 4 alkyl), or N(Ci_ 4 alkyl) 2 .
  • R is other than H.
  • R is -W 1 -W 2 -W 3 -W 4 ; and W 1 is absent, Ci_ 6 alkyl, O, S, NR 11 , SO, or SO 2 .
  • R is -W 1 -W 2 - W 3 - W 4 ;
  • W 1 is absent or Ci_6 alkyl optionally substituted by 1, 2 or 3 halo, OH, Ci_ 4 alkoxy, Ci -4 haloalkoxy, amino, Ci_ 4 alkylamino or C 2 _g dialkylamino;
  • W 2 is absent; and W 3 is O, S, NR 10 , CO, or COO.
  • R is H, Ci_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, O-W 2 -W 3 -W 4 , S-W 2 - W 3 - W 4 , or NR 11 -W 2 - W 3 -W 4 , wherein the d_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl are each optionally substituted by 1, 2 or 3 halo, OH, Ci_ 4 alkoxy, Ci_ 4 haloalkoxy, amino, Ci_ 4 alkylamino or C 2 _ 8 dialkylamino.
  • R is W 4 .
  • R is -W 3 -W 4 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.

Description

JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE
RELATED DISEASES
FIELD OF THE INVENTION
The present invention provides methods, kits, and compositions for the treatment of dry eye and other eye related diseases using compounds which inhibit one or more of the Janus kinases (JAKs).
BACKGROUND OF THE INVENTION
Dry eye syndrome (DES, also known as keratoconjunctivitis sicca) is one of the most common problems treated by eye physicians. A recent official report of the Dry Eye Workshop (DEWS) defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface." DES affects up to 10% of the population between the ages of 20 to 45 years, with this percentage increasing with age. Although a wide variety of artificial tear products are available, these products provide only transitory relief of symptoms. As such, there is a need for agents, compositions and therapeutic methods to treat dry eye. This invention addresses this need and others.
SUMMARY OF THE INVENTION
The present invention provides, inter alia, a method of treating a dry eye disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent. In some embodiments, the agent used in the methods of the present invention is a compound which can inhibit the activity of one or more Janus kinases (JAKs). The Janus kinase family of protein tyrosine kinases, as well as the Signal Transducers and Activators of Transcription (STATs), are engaged in the signaling of a wide range of cytokines. Generally, cytokine receptors do not have intrinsic tyrosine kinase activity, and thus require receptor-associated kinases to propagate a phosphorylation cascade. JAKs fulfill this function. Cytokines bind to their receptors, causing receptor dimerization, and this enables JAKs to phosphorylate each other as well as specific tyrosine motifs within the cytokine receptors. STATs that recognize these phosphotyrosine motifs are recruited to the receptor, and are then themselves activated by a JAK-dependent tyrosine phosphorylation event. Upon activation, STATs dissociate from the receptors, dimerize, and translocate to the nucleus to bind to specific DNA sites and alter transcription (Scott, M. J., C. J. Godshall, et al. (2002). "Jaks, STATs, Cytokines, and Sepsis." Clin Diagn Lab Immunol 9(6): 1153-9).
The JAK family plays a role in the cytokine-dependent regulation of proliferation and function of cells involved in immune response. Currently, there are four known mammalian JAK family members: JAKl (also known as Janus kinase- 1), JAK2 (also known as Janus kinase-2), JAK3 (also known as Janus kinase, leukocyte; JAKL; L-JAK and Janus kinase-3) and TYK2 (also known as protein-tyrosine kinase 2). The JAK proteins range in size from 120 to 140 kDa and comprise seven conserved JAK homology (JH) domains; one of these is a functional catalytic kinase domain, and another is a pseudokinase domain potentially serving a regulatory function and/or serving as a docking site for STATs (Scott, Godshall et al. 2002, supra).
While JAKl, JAK2 and TYK2 are ubiquitously expressed, JAK3 is reported to be preferentially expressed in natural killer (NK) cells and not resting T cells, suggesting a role in lymphoid activation (Kawamura, M., D. W. Mc Vicar, et al. (1994). "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes." Proc NatlAcadSci O S A 91(14): 6374-8).
Not only do the cytokine-stimulated immune and inflammatory responses contribute to normal host defense, they also play roles in the pathogenesis of diseases: pathologies such as severe combined immunodeficiency (SCID) arise from hypoactivity and suppression of the immune system, and a hyperactive or inappropriate immune / inflammatory response contributes to the pathology of autoimmune diseases such as rheumatoid and psoriatic arthritis, asthma and systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, type I diabetes mellitus, myasthenia gravis, thyroiditis, immunoglobulin nephropathies, myocarditis as well as illnesses such as scleroderma and osteoarthritis (Ortmann, R. A., T. Cheng, et al. (2000). "Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation." Arthritis Res 2(1): 16-32).
Pharmacological targeting of Janus kinase 3 (JAK3) has been employed successfully to control allograft rejection and graft versus host disease (GVHD). In addition to its involvement in signaling of cytokine receptors, JAK3 is also engaged in the CD40 signaling pathway of peripheral blood monocytes. During CD40-induced maturation of myeloid dendritic cells (DCs), JAK3 activity is induced, and increases in costimulatory molecule expression, IL- 12 production, and potent allogeneic stimulatory capacity are observed. A rationally designed JAK3 inhibitor WHI-P- 154 prevented these effects arresting the DCs at an immature level, suggesting that immunosuppressive therapies targeting the tyrosine kinase JAK3 may also affect the function of myeloid cells (Saemann, M. D., C. Diakos, et al. (2003). "Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3." Am J Transplant 3(11): 1341-9). In the mouse model system, JAK3 was also shown to be an important molecular target for treatment of autoimmune insulin-dependent (type 1) diabetes mellitus. The rationally designed JAK3 inhibitor JANEX- 1 exhibited potent immunomodulatory activity and delayed the onset of diabetes in the NOD mouse model of autoimmune type 1 diabetes (Cetkovic-Cvrlje, M., A. L. Dragt, et al. (2003). "Targeting JAK3 with JANEX-I for prevention of autoimmune type 1 diabetes in NOD mice." Clin Immunol 106(3): 213-25). Deficiencies in expression of JAK family members are associated with disease states. Jakl-/- mice are runted at birth, fail to nurse, and die perinatally (Rodig, S. J., M. A. Meraz, et al. (1998). "Disruption of the Jakl gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine- induced biologic responses." Cell 93(3): 373-83). Jak2-/- mouse embryos are anemic and die around day 12.5 postcoitum due to the absence of definitive erythropoiesis. JAK2- deficient fibroblasts do not respond to IFN gamma, although responses to IFNalpha/beta and IL-6 are unaffected. JAK2 functions in signal transduction of a specific group of cytokine receptors required in definitive erythropoiesis (Neubauer, H., A. Cumano, et al. (1998). Cell 93(3): 397-409; Parganas, E., D. Wang, et al. (1998). Cell 93(3): 385-95.). JAK3 appears to play a role in normal development and function of B and T lymphocytes. Mutations of JAK3 are reported to be responsible for autosomal recessive severe combined immunodeficiency (SCID) in humans (Candotti, F., S. A. Oakes, et al. (1997). "Structural and functional basis for JAK3 -deficient severe combined immunodeficiency." Blood 90(10): 3996- 4003).
Consistent with the role of Janus kinases in inflammation and autoimmune disorders, the present invention provides, inter alia, a method of treating dry eye disorders comprising administering to a patient a JAK inhibitor. In a further aspect, the present invention provides a method of treating conjunctivitis, uveitis, chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or iritis; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a JAK inhibitor. In some embodiments, the agent is administered postoperatively to the patient. In a further aspect, the present invention provides an ophthalmic insert comprising a JAK inhibitor. In a still further aspect, the present invention provides a kit for treating a dry eye disorder comprising a pharmaceutical composition or ophthalmic composition comprising a JAK inhibitor and instructions comprising a direction to administer the JAK inhibitor to a patient in need of treatment of a dry eye disorder.
DETAILED DESCRIPTION
The present invention provides, inter alia, a method of treating a dry eye disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent. JAKs to which the agent can bind and inhibit includes any member of the JAK family. In some embodiments, the JAK is JAKl, JAK2, JAK3 or TYK2. In some embodiments, the JAK is JAKl. In some embodiments, the agent is selective for JAKl. In some embodiments, the JAK is JAKl or JAK2. In some embodiments, the JAK is JAK2. In some embodiments, the JAK is JAK3. In some embodiments, the agent is selective. By "selective" is meant that the compound inhibits a JAK with greater affinity or potency, respectively, compared to at least one other JAK. In some embodiments, the agent is a selective inhibitor of JAKl or JAK2 over JAK3 and/or TYK2. In some embodiments, the agent is a selective inhibitor of JAK2 (e.g., over JAKl, JAK3 and TYK2). Selectivity can be at least about 5-fold, 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold or at least about 1000-fold. Selectivity can be measured by methods routine in the art. In some embodiments, selectivity can be tested at the Km of each enzyme. In some embodiments, selectivity of the agent for JAK2 over JAK3 can be determined by the cellular ATP concentration.
In some embodiments, the agents for use in the method of the invention include the JAK inhibitors in U.S. Patent Publ. No. US 20070135461, published June 14, 2007 (Appl. Ser. No. 11/637,545, filed December 12, 2006); U.S. Patent Publ. No. US 20060106020, published May 18, 2006 (Appl. Ser. No. 11/115,702 filed April 27, 2005); U.S. Patent Publ. No. US 20060183906, published August 17, 2006 (Appl. Ser. No. 11/313,394, filed December 21, 2005); U.S. Patent Publ. No. US 20070149506, published June 28, 2007 (Appl. Ser. No. 11/524,641, filed September 21, 2006); U.S. Patent Publ. No. US 20080188500, published August 7, 2008 (Appl. Ser. No. 11/961,424, filed December 20, 2007); U.S. Prov. Appl. No. 61/035,662, filed March 11, 2008; U.S. Prov. Appl. No. 60/988,606, filed November 16, 2007; U.S. Patent Appl. Ser. No. 12/137,883, filed June 12, 2008; and U.S. Patent Appl. Ser. No. 12/137,892, filed June 12, 2008; U.S. Patent Appl. No. 12/138,082, filed June 12, 2008, each of which is incorporated herein by reference in its entirety.
As used herein, "dry eye disorder" is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface." Lemp, "The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92 April 2007, which is incorporated herein by reference in its entirety. Dry eye is also sometimes referred to as keratoconjunctivitis sicca. In some embodiments, the treatment of the dry eye disorder involves ameliorating a particular symptom of dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface.
As summarized in the DEWS report, dry eye can be classified into two different classes: aqueous tear-deficient dry eye and evaporative dry eye, which in turn encompass various subclasses. Accordingly, in some embodiments, the dry eye disorder is aqueous tear-deficient dry eye (ADDE). In further embodiments, the dry eye disorder is evaporative dry eye. In further embodiments, the dry eye disorder is selected from any of the subclasses of ADDE or evaporative dry eye disorder, or appropriate combinations thereof. As noted by the author of the DEWS report, however, the various classes and subclasses are not mutually exclusive. Hence, dry eye can occur via different mechanism in different subclasses or a dry eye disease state originating in one subclass can lead to events that cause dry eye by a mechanism in another subclass.
The first class of dry eye, aqueous tear-deficient dry eye (ADDE), is also known as tear deficient dry eye and lacrimal tear deficiency. In ADDE, dry eye is believed to be due to a failure of lacrimal tear secretion. While not wishing to be bound by any theory, it is believed that dryness results from reduced lacrimal tear secretion and volume, causing tear hyperosmolarity. Tear film hyperosmolarity can cause hyperosmolarity of the ocular surface epithelial cells, stimulating inflammatory events involving various kinases and signaling pathways.
Two subclasses of ADDE are Sjogren syndrome dry eye (SSDE), where the lacrimal glands are targeted by an autoimmune process, and non-Sjogren syndrome dry eye (NSSDE) . Accordingly, in some embodiments, the eye disorder is SSDE. In other embodiments, dry eye disorder is non- Sjogren syndrome dry eye. In SSDE, it is believed that activated T-cells can infiltrate the lacrimal glands, causing cell death of acinar and ductular cells and hyposecretion of tears. The effects of locally released cytokines or circulating antibodies can amplify the effects of hyposecretion. The two major forms of SSDE are primary and secondary forms. Primary SS can occur in combination with dry mouth (xerostomia). Secondary SSDE occurs with the symptoms of primary SSDE together with an autoimmune connective disease such as rheumatoid arthritis (RA), systemic lupus erythematosis, polyarteritis nodosa, Wegener's granulomatosis, systemic sclerosis, primary bilary sclerosis, or mixed connective tissue disease. Diagnostic criteria for each of these connective diseases is known in the art. Further, primary SSDE may be associated with systemic manifestations of disease which may involve the lungs, kdneys, liver, blood vessels and joints.
In NSSDE, the systemic autoimmune characteristics of Sjogren syndrome dry eye are excluded. Forms of NSSDE include primary lacrimal gland deficiencies (including age-related dry eye, congenital alacrima, and familial dysautonomia), secondary lacrimal deficiencies (including inflammatory infiltration of the lacrimal gland by sarcoid granulomata, lymphomatous cells, and AIDS related T-cells; that associated with graft vs. host disease; and that resulting from lacrimal gland ablation or lacrimal gland denervation), obstruction of the lacrimal gland ducts (including that caused by cicatrizing conjunctivitis including trachoma, cicatricial pemphigoid and mucous membrane pemphigoid, erythema multiforme, and chemical or thermal burns), and reflex hyposecretion (including reflex sensory block, such as that associated with contact lens wear, diabetes mellitus, and neurotrophic keratitis, and reflex motor block, including that associated with VII cranial nerve damage, multiple neuromatosis, and exposure to systemic drugs such as antihistamines, beta blockers, antispasmodics, diuretics, tricyclic antidepressants, selective serotonin reuptake inhibitors, and other psychotropic drugs).
The second major class of dry eye disorder is evaporative dry eye, which is caused by excessive water loss from the exposed ocular surface in the presence of normal lacrimal secretory function. Intrinsic causes of evaporative dry eye include Meibomian gland dysfunction (MGD) (including that caused by a reduced number of glands due to congenital deficiency acquired-MGD; MGD associated with dystichiasis, dystichiasis lymphedema syndrome, and metaplasia; hypersecretory MGD associated with Meibomian seborrhea, hypersecretory MGD associated with retinoid therapy, primary and secondary obstructive MGD, focal or diffuse obstructive MGD, simple or cicatricial obstructive MGD, atrophic or inflammatory obstructive MGD; Simple MGD primary or secondary to anterior blepharitis, acne rosacea, seborrhoeic dermatitis, ectrodactyly syndrome, Turner syndrome, systemic toxicity from 13-cis retinoic acid, polychlorinated biphenyls, and epinephrine; and cicatricial MGD primary or secondary to chemical burns, pemphigoid, acne rosacea, erythema multiforms, VKC and AKC), disorders of the lid aperture and lid/globe congruity or dynamic (such as that occurring with craniostenosis, endocrine and other forms of proptosis, myopia, and after plastic surgery on the lids), and low blink rate (including that caused by an extrapyramidal disorder such as Parkinson's disease). Extrinsic causes of evaporative dry eye include ocular surface disorders (including xerophthalmia caused by vitamin A deficiency; and that associated with topical drugs and preservatives such as topical anesthesia and benzalkonium chloride), contact lens wear, ocular surface disease (including allergic eye disease), allergic conjunctivitis (including aseasonal allergic conjunctivitis, vernal keratoconjunctivitis, and atopic keratoconjunctivitis), and the use of antihistamines.
Patients in need of treatment of a dry eye disorder can be identified by a variety of diagnostic methods known in the art, including the diagnostic methods summarized in Bron, et al., "Methodologies to Diagnose and Monitor Dry Eye Disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop (2007)", The Ocular Surface, 5(2), 108-152 (April 2007), which is hereby incorporated herein by reference in its entirety. These include, but are not limited to: (1) symptom questionnaires (e.g., Begley, et al., "Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye", Cornea, 2002:21 :664-70); (2) staining of the ocular surface to check for surface damage (e.g., Rose Bengal or fluorescein staining or other staining method such as those techniques summarized in Barr et al., "Corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: baseline prevalence and repeatability of detection", Cornea 1999;18(l):34-46; Lemp, "Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes", CLAO J 1995;21(4):221-31; Nichols, et al., "The repeatability of clinical measurements of dry eye", Cornea 2004;23:272-85; Bron, et al., "Grading of corneal and conjunctival staining in the context of other dry eye tests", Cornea 2003;22(7):640-50); (3) measurement of tear film break-up time to test for tear film stability (e.g., Abelson, et al., "Alternate reference values for tear film break-up time in normal and dry eye populations", Adv Exp Med Biol 2002;506,Part B: 1121-1125; Bron AJ, et al., "Grading of corneal and conjunctival staining in the context of other dry eye tests", Cornea 2003;22:640-50; Cho et al, "Review of the tear break-up time and a closer look at the tear break-up time of Hong Kong Chinese", Optom Vis Sci 1993;70(l):30-8; Craig et al. "Tear lipid layer structure and stability following expression of the meibomian glands. Ophthalmic Physiol Opt 1995, 15(6):569-74; Eliason, et al., "Staining of the conjunctiva and conjunctival tear film", Br J Ophthalmol 1990;74:519-22; Farrell et al., "A classification for dry eyes following comparison of tear thinning time with Schirmer tear test", Acta Ophthalmol (Copenh) 1992; 70(3):357-60; Johnson et al., "The effect of instilled fluorescein solution volume on the values and repeatability of TBUT measurements", Cornea 2005;24:811-7; Lemp et al., "Corneal desiccation despite normal tear volume", Ann Ophthalmol 1970;284:258-261; Lemp "Report of National Eye Institute/Industry Workshop on clinical trials in dry eyes", CLAO J 1995;21 :221-232; Madden et al. Comparative study of two non-invasive tear film stability techniques. Curr Eye Res 1994; 13(4):263-9; Marquardt et al., "Modification of tear film break-up time test for increased reliability" in Holly ed. The Preocular Tear Film in
Health, Disease and Contact Lens Wear. Lubbock, Texas: Dry Eye Institute, 1986:57-63; Mengher et al., "Non-invasive tear film break-up time: sensitivity and specificity", Acta Ophthalmol (Copenh) 1986; 64(4):441-4; Nichols et al., "The repeatability of clinical measurements of dry eye" Cornea 2004;23:272-85; Pflugfelder et al. "Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998; 17(l):38-56; Vitali et al. "The European Community Study Group on diagnostic criteria for Sjogren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjogren's syndrome." 1992; Ann Rheum Dis 53(10):637-47; Welch et al., "An approach to a more standardized method of evaluating tear film break-up time" Invest Ophthalmol Vis Sci 2003; 2485/B324.); (4) the Schirmer test (an estimation of tear flow stimulated reflexly by insertion of a filter paper into the conjunctival sac) (e.g., van Bijsterveld, "Diagnostic tests in the sicca syndrome" Arch Ophthalmol 1969;82: 10-14; Holly et al., "Lacrimation kinetics as determined by a novel technique", in HoIIy FJ (ed). The preocular tear film. Lubbock TX, Lubbock Dry Eye Institute, 1986, pp 76-88); (5) measurement of tear osmolality (e.g., Farris, "Tear osmolarity— a new gold standard?" Adv Exp Med Biol 350:495-503, 1994; Nelson et al., "Tear film osmolality determination: an evaluation of potential errors in measurement" Curr Eye Res Sep;5(9):677-81, 1986; Sullivan et al., "4th International Conference on the Lacrimal Gland, Tear Film & Ocular Surface and Dry Eye Syndromes, 11/20/04"; White et al., "Human basic tear fluid osmolality. I. Importance of sample collection strategy", Acta Ophthalmol (Copenh) Aug;71(4):524-9, 1993; (6) measurement of tear meniscus radius, height and cross sectional area to diagnose aqueous tear deficiency (e.g., Cermak et al, "Is complete androgen insensitivity syndrome associated with alterations in the meibomium gland and ocular surface", Cornea 2003;22:516-521; Farrell et al., "A clinical procedure to predict the value of temporary occlusion therapy in keratoconjunctivitis sicca" Ophthal Physiol Opt 2003;23: l-8; Glasson et al., "Differences in clinical parameters and tear film of tolerant and intolerant contact lens wearers", Invest Ophthalmol Vis Sci 2003;44:5116-5124; Mainstone et al., "Tear meniscus measurement in the diagnosis of dry eye", Curr Eye Res 1996; 15:653-661; Nichols et al., "The repeatability of clinical measurements of dry eye", Cornea 2004a; 23:272-285; Nichols et al., "The lack of association between signs and symptoms in patients with dry eye disease", Cornea 2004b; 23:762-770; Oguz et al., "The height and radius of the tear meniscus and methods for examining these parameters", Cornea 2000; 19:497-500; Yokoi et al., "Non-invasive methods of assessing the tear film", Exp Eye Res 2004;78:399-407); (7) tear film lipid layer interferometry to diagnose aqueous tear deficient dry eye (ATD) or precorneal lipid tear deficiency (Danjo et al., "Observation of precorneal tear film in patients with Sjogren's syndrome", Acta Ophthalmol Scand 1995;73:501-5; Doane, "An instrument for in vivo tear film interferometry", Optom Vis Sci 1989; 66: 383-8; Goto et al., "Computer-synthesis of an interference color chart of human tear lipid layer by a colorimetric approach" Jnvest Ophthalmol Vis Sci 2003;44:4693-7; Goto et al., "Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images", Arch Ophthalmol 2003; 121 : 173- 80; Goto E, et al., "Kinetic analysis of tear interference images in aqueous tear deficiency dry eye before and after punctal occlusion. Invest Ophthalmol Vis Sci 2003;44: 1897-905; Goto et al., "Color mapping of tear lipid layer thickness distribution from the image analysis in DR-I tear lipid layer interference images (ARVO abstract). ARVO 2004; Guillon, "Tear film photography and contact lens wear", J Br Contact Lens Assoc 1982;5:84-7; King-Smith et al., "Three interferometric methods for measuring the thickness of layers of the tear film", Optom Vis Sci 1999;76: 19-32; Korb, et al., "Increase in tear film lipid layer thickness following treatment of meibomian gland dysfunction", Adv Exp Med Biol 1994;350:293-8; Korb et al., "The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms", Optom Vis Sci 2005; 82: 594-601; Mathers et al., "Assessment of the tear film with tandem scanning confocal microscopy", Cornea 1997; 16: 162-8; Maruyama et al., "Effect of environmental conditions on tear dynamics in soft contact lens wearers", Invest Ophthalmol Vis Sci 2004;45(8):2563-8; Tiffany, "Refractive index of meibomian and other lipids", Curr Eye Res 1986;5:887-9; Tiffany et al., "Meniscometry using the Tearscope-plus (ARVO abstract). Invest Ophthalmol Vis Sci 2001;42, s37; Yokoi et al., "Correlation of tear lipid layer interference patterns with the diagnosis and severity of dry eye", Am J Ophthalmol 1996;122:818-24; Yokoi et al., "Assessment of meibomian gland function in dry eye using meibometry", Arch Ophthalmol 1999; 117:723-9); (8) Tear Stability Analyses System (TSAS) to diagnose tear instability (e.g., Goto et al., "Tear Film Stability Analysis System: Introducing a new application for videokeratography", Cornea 2004a; Nov;23(8):S65-S70; Goto et al., "Evaluation of the tear film stability after laser in situ keratomileusis using the tear film stability analysis system", Am J Ophthalmol 2004b Jan;137(l):l 16-20; Kojima et al., "A new noninvasive tear stability analysis system for the assessment of dry eyes" Invest Ophthalmol Vis Sci 2004;May;45(5):1369-74); (9) meibometry to assess Meibomian gland dysfunction (e.g., Chew et al., "An instrument for quantifying meibomian lipid on the lid margin: the Meibometer", Curr Eye Res 1993a;12:247-254; Chew et al., "The casual level of meibomian lipids in humans", Current Eye Research 1993b;12:255-259; Komuro et al., "Assessment of meibomian gland function by a newly developed laser meibometer", Adv Exp Med Biol 2002;506:517-520; Yokoi et al., "Assessment of meibomian gland function in dry eye using meibometry" Arch Ophthalmol 1999; 117:723-729); (10) meibography or meiboscopy to measure Meibomian gland dysfunction (e.g., Kaercher, "Ocular symptoms and signs in patients with ectodermal dysplasia symdromes", Grafes Arch Clin Exp Ophthalmol 2004;495-500; Jester et al., "In vivo biomcroscopy and photography of meibomian glands in a rabbit model of meibomian gland dysfunction", Invest Ophthalmol Vis Sci 1982;22:660-7; Mathers et al., "Video imaging of the meibomian gland", Arch Ophthalmol 1994;112:448-9; Pflugfelder, et al., "Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation", Cornea 1998;17(l):38-56; Robin et al., "In vivo transillumination biomicroscopy and photography of meibomian gland dysfunction. Ophthalmology 1985;92: 1423-6; Shimazaki et al., "Meibomian gland dysfunction in patients with Sjogren syndrome", Ophthalmology 1998; 105(8): 1485-8; Yokoi et al., "A newly developed video-meibography system featuring a newly designed probe", Jpn J Ophthalmol 2007; 51 : 53-6); (11) Brush Cytology Technique (e.g., Fukagawa et al., "Histological evaluation of brush cytology of rabbit conjunctiva", Nippon Ganka Gakkai Zasshi 1993;97: 1173-8; Fujihara et al., "Evaluation of human conjunctival epithelium by a combination of brush cytology and flow cytometry: an approach to the quantitative technique", Diagn Cytopathol 1997;17:456-60; Miyoshi et al., "Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage", Cornea 2001;20:743-7; Takano et al., "Inflammatory cells in brush cytology samples correlate with the severity of corneal lesions in atopic keratoconjunctivitis", Br J Ophthalmol 2004;88: 1504-5; Tsubota et al., "Brush cytology for the evaluation of dry-eye", Nippon Ganka Gakkai Zasshi 1990a ;94:224-30; Tsubota et al., "Conjunctival brush cytology", Acta Cytol 1990 b;34:233-5; Tsubota et al., "Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis"; Cornea 1991 ;10:525-31); (12) Flow cytometry in impression cytology to detect conjuctivial inflammation (e.g., Baudouin et al., "Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival Inflammation", Invest Ophthalmol Vis Sci 1997a;38:1458-1464; Bourcier et al., "Expression of CD40 and CD40 ligand in the human conjunctival epithelium", Invest Ophthalmol Vis Sci 2000;41 : 120-126; Brignole et al., "Expression of Fas antigen (CD95) in the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory conditions", Exp Eye Res 1998;67:687-697; Brignole et al., "Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes" Invest Ophthalmol Vis Sci 2000; 41 : 1356-1363; Brignole et al., "Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A", Invest Ophthalmol Vis Sci 2001;42:90-95; Brignole et al., "Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies", Exp Eye Res 2004;78:473-481; Fujihara et al., "Evaluation of human conjunctival epithelium by a combination of brush cytology and flow cytometry: an approach to the quantitative technique" Diagn Cytopathol 1997; 17:456-460; Pisella et al., "Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology 2000; 107: 1841-1849; Pisella, et al., "Conjunctival proinflammatory and proapoptotic effects of latanoprost, preserved timolol and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45: 1360-1368); (13) the Ferning test to diagnose the quality of tears (electrolyte concentration), KCS, and hyperosmolarity (e.g., Albach et al., "Diagnosis of keratoconjunctivitis sicca in rheumatoid arthritis. The value of various tests", Ophthalmologe 1994 Apr;91(2):229-34; Golding et al., "X-ray and scanning electron microscopic analysis of the structural composition of tear ferns", Cornea 1994 Jan;13(l):58-66; Norn, "Quantitative tear ferning. Clinical investigations", Acta Ophthalmol (Copenh) 1994 Jun;72(3):369-72; Pearce et al., "Spatial location studies on the chemical composition of human tear ferns", Ophthalmic Physiol Opt 2000;Jul;20(4):306-13; Pensyl et al., "The repeatability of tear mucus ferning grading", Optom Vis Sci 1998 Aug;75(8):600-4; Rolando, "Tear mucus ferning test in normal and keratoconjunctivitis sicca eyes. Chibret Int J Ophthalmol 1984;2(4):32-41; Rolando et al., "Tear mucus ferning test in keratoconjunctivitis sicca",in: Holly FJ, Lamberts DW, MacKeen DL (eds.): The preocular tear film in health, disease, and contact lens wear,. 1st Intern Tear Film Symposium. Lubbok (Texas, USA), Dry Eye Institute, 1986, 203-210; Rolando et al., "The effect of hyperosmolarity on tear mucus ferning", Fortschr Ophthalmol 1986;83:644-646; Rolando et al., "Tear mucus crystallization in children with cystic fibrosis", Ophthalmologica 1988;197(4):202-6); (14) Ocular Protection Index (OPI) to assess ocular surface protection and risk of ocular surface damage (e.g., Ousler et al., "Factors that influence the inter-blink interval (IBI) as measured by the ocular protection index (OPI)", (Poster presentation) ARVO 2002; Nally et al., "Ocular discomfort and tear film break-up time in dry eye patients: A correlation", Invest Ophthalmol Vis Sci 2000;41 :4: 1436; Abelson et al., "Alternate reference values for tear film break-up time in normal and dry eye populations", Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3 Part B", Adv Exp Med Biol 2002; 506:1121-1125; Abelson et al., "Dry eye syndrome: diagnosis, clinical trials, and pharmaceutical treatment — 'improving clinical trials'. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3 Part B", Adv Exp Med Biol 2002; 506: 1079-86); (15) fluorophotometry (fluorimetry) of tear flow to assess changes in tear flow in aqueous tear deficiency (ATD) (e.g., Gobbels et al., "Tear secretion in dry eyes as assessed by objective fluorophotometry. Ger J Ophthalmol 1992; 1 :350-353; Kuppens et al., "Basal tear turnover and topical timolol in glaucoma patients and healthy controls by Fluorophotometry", Invest Ophthalmol Vis Sci 1992; 33:3442-3448; Mishima, "Some physiological aspects of the precorneal tear film", Arch Ophthalmol 1965;73:233-241; Mishima S, "Determination of tear volume and tear flow", Invest Ophthalmol 1966; 5:264-275; Mathers et al., "Tear film and evaporation in patients with and without dry eye", Ophthalmology 1996; 103:664-669; Mathers et al., "Tear film changes associated with normal aging", Cornea 1996; 15:229-334; Mathers, "Evaporation from the ocular surface", Exp Eye Res 2004; 78:389-394; Van Best et al., "Measurement of basal tear turnover using a standardized protocol", Graefe 's Arch Clin Exp Ophthalmol 1995; 233:1-7; McNamara et al., "Fluorometry in contact lens research: The next step", Optom Vis Sci 1998; 75:316-322; Pearce, "An improved fluorophotometric method for tear turnover assessment", Optom Vis Sci 2001; 78:30-36), and combinations of these diagnostic tests, the disclosures of each reference are incorporated herein by reference in their entireties. These methods can also be used to assess the clinical efficacy of the agents of the invention in treating dry eye disorders.
In a further aspect, the present invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or iritis; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof. In some embodiments, the agent is administered preoperatively to a patient about to undergo a procedure selected from corneal transplant, LASIK, photorefractive keratectomy, and LASEK. In some embodiments, the agent suppresses or lessens inflammation or pain during and after the procedure. In some embodiments, the agent is administered about 1 day to about 2 days prior to the procedure. In some embodiments, the agent is administered postoperatively to a patient who has undergone a procedure selected from corneal transplant, LASIK, photorefractive keratectomy, and LASEK. In some embodiments, inhibiting loss of visual acuity means lessening the loss of visual acuity. In some embodiments, the postoperative or preoperative treatment lessens the amount of scarring and fibrous deposits following the procedure. In some embodiments, inhibiting loss of visual acuity means that the patient retains visual acuity. In some embodiments, inhibiting transplant rejection means that the agent is immunosuppressive, thereby preventing total rejection of the corneal transplant.
In some embodiments, one or more additional therapeutic agents, or other agents, can be used in combination with the agent in the methods of the present invention. The one or more additional therapeutic agents can be administered to a patient simultaneously or sequentially. In some embodiments, the amount of additional therapeutic agent, when administered in a compositions, is from about 0.01% to 5% by weight, from about 0.1% to 2% by weight, or from 0.5% to 50% by weight.
In some embodiments, the additional therapeutic agent is fluocinolone acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcon).
In some embodiments, the additional therapeutic agent is cyclosporine (Restasis®).
In some embodiments, the additional therapeutic agent is a corticosteroid. In some embodiments, the corticosteroid is triaminolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
In some embodiments, the additional therapeutic agent is selected from Dehydrex™ (Holies Labs), Civamide (Opko), sodium hyaluonate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST- 603, Sirion Therapeutics), ARGlOl(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI 1901, Lantibio), CFlOl (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-m ethyl-oxolane-2-carboxamide, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG 103 (Agentis), RX- 10045 (synthetic resolvin analog, Resolvyx), DYN 15 (Dyanmis Therapeutics), rivoglitazone (DEOl 1, Daiichi Sanko), TB4 (RegeneRx), OPH-Ol (Ophtalmis Monaco), PCSlOl (Pericor Science), REV 1-31 (Evolutec), Lacritin (Senju), rebamipide (Otsuka- Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University), pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), or thalidomide.
In some embodiments, the additional therapeutic agent is an anti- angiogenic agent, cholinergic agonist, TRP- 1 receptor modulator, a calcium channel blocker, a mucin secretagogue, MUCl stimulant, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, another JAK inhibitor, Bcr-Abl kinase inhibitor, Flt-3 kinase inhibitor, RAF kinase inhibitor, and FAK kinase inhibitor such as, for example, those described in WO 2006/056399. In some embodiments, the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline).
In some embodiments, the additional therapeutic agent(s) are demulcent eye drops (also known as "artificial tears"), which include, but are not limited to, compositions containing polyvinylalcohol, hydroxypropyl methylcellulose, glycerin, polyethylene glycol (e.g. PEG400), or carboxymethyl cellulose. Artificial tears can help in the treatment dry eye by compensating for reduced moistening and lubricating capacity of the tear film. In some embodiments, the additional therapeutic agent is a mucolytic drug, such as N- acetyl-cysteine, which can interact with the mucoproteins and, therefore, to decrease the viscosity of the tear film.
In some embodiments, the additional therapeutic agent includes an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and non-steroidal antiinflammatories, and anti-allergic agents. Examples of suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomomycin; colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; comolyn; lodoxamide; levocabastin; naphazoling; antazoline; pheniramimane; or azalide antibiotic. Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, EP2005/009967, EP2005/010408, and U.S. Ser. No. 60/578,491.
Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.
Example suitable PvAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.
Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402.
When employed as pharmaceuticals, the agents can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
In some embodiments, the agent is administered as an ophthalmic composition. Accordingly, in some embodiments, the methods comprise administration of the agent and an ophthalmically acceptable carrier. In some embodiments, the ophthalmic composition is a liquid composition, semisolid composition, insert, film, microparticles or nanooparticles.
In some embodiments, the ophthalmic composition is a liquid composition. In some embodiments, the ophthalmic composition is a semi-solid composition. In some embodiments, the ophthalmic composition is an topical composition. The topical compositions include, but are not limited to liquid and semi-solid compositions. In some embodiments, the ophthalmic composition is a topical composition. In some embodiments, the topical composition comprises aqueous solution, an aqueous suspension, an ointment or a gel. In some embodiments, the ophthalmic composition is topically applied to the front of the eye, under the upper eyelid, on the lower eyelid and in the cul-de- sac. In some embodiments, the ophthalmic composition is sterilized. The sterilization can be accomplished by known techniques like sterilizing filtration of the solution or by heating of the solution in the ampoule ready for use. The ophthalmic compositions of the invention can further contain pharmaceutical excipients suitable for the preparation of ophthalmic formulations. Examples of such excipients are preserving agents, buffering agents, chelating agents, antioxidant agents and salts for regulating the osmotic pressure.
As used herein, the term "ophthalmically acceptable carrier" refers to any material that can contain and release the agent and that is compatible with the eye. In some embodiments, the ophthalmically acceptable carrier is water or an aqueous solution or suspension, but also includes oils such as those used to make ointments and polymer matrices such as used in ocular inserts. In some embodiments, the composition may be an aqueous suspension comprising the agent. Liquid ophthalmic compositions, including both ointments and suspensions, may have a viscosity that is suited for the selected route of administration. In some embodiments, the ophthalmic composition has a viscosity in the range of from about 1,000 to about 30,000 centipoise.
In some embodiments, the liquid composition further comprises a polymer. These polymers may be used to improve the bioavailability, raise viscosity, or reduce drainage from the eye for a liquid formulation. In some embodiments, the polymers include, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety. In some embodiments, the polymer is sodium hyaluronase, chitosan, a cyclodextrin (e.g., hydroxypropyl β- cyclodextrin), polygalactoronic acid, xyloglucan, xanthan gum, gellan gum, a thiomer, a poly(ortho ester) (e.g., as described in Einmahl, Adv. Drug. Deliv. Rev. 53:45-73 (2001), which is incorporated herein by reference in its entirety), or a tamarind seed polysaccharide (e.g., as described in Ghelardi, et al., Antimicrob. Agents Chemother. 48:3396-3401 (2004), which is incorporated herein by reference in its entirety).
In some embodiments, the ophthalmic compositions may further comprise one or more of surfactants, adjuvants, buffers, antioxidants, tonicity adjusters, preservatives (e.g., EDTA, BAK (benzalkonium chloride), sodium chlorite, sodium perborate, polyquaterium-1), thickeners or viscosity modifiers (e.g., carboxymethyl cellulose, hydroxymethyl cellulose, polyvinyl alcohol, polyethylene glycol, glycol 400, propylene glycol hydroxymethyl cellulose, hydroxpropyl-guar, hyaluronic acid, and hydroxypropyl cellulose) and the like. Additives in the formulation may include, but are not limited to, sodium chloride, sodium bicarbonate, sorbic acid, methyl paraben, propyl paraben, chlorhexidine, castor oil, and sodium perborate.
Aqueous ophthalmic compositions (solutions or suspensions) generally do not contain physiologically or ophthalmically harmful constituents. In some embodiments, purified or deionized water is used in the composition. The pH may be adjusted by adding any physiologically and ophthalmically acceptable pH adjusting acids, bases or buffers to within the range of about 5.0 to 8.5. Ophthalmically acceptable examples of acids include acetic, boric, citric, lactic, phosphoric, hydrochloric, and the like, and examples of bases include sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, tromethamine, trishydroxymethylamino-methane, and the like. Salts and buffers include citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures of the aforementioned acids and bases.
In some embodiments, the osmotic pressure of the ophthalmic composition may be from about 10 milliosmolar (mOsM) to about 400 mOsM, or from 260 to about 340 mOsM. In some embodiments, the osmotic pressure can be adjusted by using appropriate amounts of physiologically and ophthalmically acceptable salts or excipients. In further embodiments, sodium chloride may be used to approximate physiologic fluid. In other embodiments, the composition comprises sodium chloride ranging from about 0.01% to about 1% by weight, or from about 0.05% to about 0.45% by weight, based on the total weight of the composition. Equivalent amounts of one or more salts made up of cations such as potassium, ammonium and the like and anions such as chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, bisulfate, sodium bisulfate, ammonium sulfate, and the like can also be used in addition to or instead of sodium chloride to achieve osmolalities within the above stated range. Similarly, a sugar such as mannitol, dextrose, sorbitol, glucose and the like can also be used to adjust osmolality.
In some embodiments, the methods involve forming or supplying a depot of the agent in contact with the external surface of the eye. A depot refers to a source of agent that is not rapidly removed by tears or other eye clearance mechanisms. This allows for continued, sustained high concentrations of agent be present in the fluid on the external surface of the eye by a single application. Without wishing to be bound by any theory, it is believed that absorption and penetration may be dependent on both the dissolved drug concentration and the contact duration of the external tissue with the drug containing fluid. As the drug is removed by clearance of the ocular fluid and/or absorption into the eye tissue, more drug is provided, e.g. dissolved, into the replenished ocular fluid from the depot. Accordingly, the use of a depot may more easily facilitate loading of the ocular tissue for more insoluble agents. In some embodiments, the depot can remain for up to eight hours or more. In some embodiments, the ophthalmic depot forms includes, but is not limited to, aqueous polymeric suspensions, ointments, and solid inserts.
In some embodiments, a semi-solid composition is a liquid formulation which increases in viscosity upon application to the eye, usually because of a polymer in the liquid formulation. This viscosity increase may be triggered by a change in temperature, pH, or electrolyte concentration. In some embodiments, the polymer include, but are not limited to, those described for semi-solid dosage forms in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety. In some embodiments, the polymer is celluloseacetophthalate, polyacrylic acid, gellan gum, hyaluronase, chitosan, salts of alginic acid (e.g., sodium alginate), or a block copolymer of ethylene oxide and propylene oxide (e.g., Pluronic®, BASF; poloxamer). In some embodiment, the polyacrylic acid is crosslinked acrylic acid (e.g., Carbopol®). In some embodiments, the semi-solid composition comprises a mixture of carbopol and a block copolymer of ethylene oxide and propylene oxide; a mixture of methyl cellulose and hydroxyethyl cellulose; or a mixture of polyethylene glycol and a block copolymer of ethylene oxide and propylene oxide.
In some embodiments, the ophthalmic composition is an ointment or gel. In some embodiment, the ophthalmic composition is an oil-based delivery vehicle. In some embodiments, the composition comprises a petroleum or lanolin base to which is added the active ingredient, usually as 0.1 to 2%, and excipients. Common bases may include, but are not limited to, mineral oil, petrolatum and combinations thereof. In some embodiments, the ointment is applied as a ribbon onto the lower eyelid.
In some embodiment, the ophthalmic composition is an ophthalmic insert. In some embodiments, the ophthalmic insert is biologically inert, soft, bio-erodible, viscoelastic, stable to sterilization after exposure to therapeutic agents, resistant to infections from air borne bacteria, bio- erodible, biocompatible, and/or viscoelastic. In some embodiments, the insert comprises an ophthalmically acceptable matrix, e.g., a polymer matrix. The matrix is typically a polymer and the agent is generally dispersed therein or bonded to the polymer matrix. In some embodiments, the agent may slowly released from the matrix through dissolution or hydrolysis of the covalent bond. In some embodiments, the polymer is bioerodible (soluble) and the dissolution rate thereof can control the release rate of the agent dispersed therein. In another form, the polymer matrix is a biodegradable polymer that breaks down such as by hydrolysis to thereby release the agent bonded thereto or dispersed therein. In further embodiments, the matrix and agent can be surrounded with an additional polymeric coating to further control release. In some embodiments, the insert comprises a biodegradable polymer such as polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacrylate, polyurethane, a nylon, or poly (dl-lactide-co-glycolide) (PLGA), or a copolymer of any of these. In some embodiments, the agent is dispersed into the matrix material or dispersed amongst the monomer composition used to make the matrix material prior to polymerization. In some embodiments, the amount of agent is from about 0.1 to about 50%, or from about 2 to about 20%. In further embodiments, the biodegradable or bioerodible polymer matrix is used so that the spent insert does not have to be removed. As the biodegradable or bioerodible polymer is degraded or dissolved, the agent is released.
In further embodiments, the ophthalmic insert comprises a polymer, including, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety. In some embodiments, the insert comprises a polymer selected from polyvinylpyrrolidone (PVP), an acrylate or methacrylate polymer or copolymer (e.g., Eudragit® family of polymers from Rohm or Degussa), hydroxymethyl cellulose, polyacrylic acid, poly(amidoamine) dendrimers, poly(dimethyl siloxane), polyethylene oxide, poly(lactide-co-glycolide), poly(2- hydroxyethylmethacrylate), poly(vinyl alcohol), or poly(propylene fumarate). In some embodiments, the insert comprises Gelfoam® R. In some embodiments, the insert is a polyacrylic acid of 450 kDa- cysteine conjugante.
In some embodiments, the ophthalmic composition is a ophthalmic film. Polymers suitable for such films include, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), In some embodiments, the film is a soft-contract lense, such as ones made from copolymers of N,N- diethylacrylamide and methacrylic acid crosslmked with ethyleneglycol dimethacrylate.
In some embodiments, the insert comprises a core comprising the agent and an outer tube (see e.g., U.S. Patent Pub. No. 20040009222, which is incorporated herein by reference in its entirety). In some embodiments, the outer tube may be permeable, semi-permeable, or impermeable to the drug. In some embodiments, the drug core may include a polymer matrix which does not significantly affect the release rate of the drug. In some embodiments, the outer tube, the polymer matrix of the drug core, or both may be bioerodible. In some embodiments, the co-extruded product can be segmented into drug delivery devices. In some embodiments, the devices may be left uncoated so that their respective ends are open, or the devices may be coated with, for example, a layer that is permeable to the agent, semi-permeable to the agent, or bioerodible. In certain embodiments, the agent and at least one polymer are admixed in powder form. In some embodiments, the insert is formed by forwarding a polymeric material to a first extrusion device, forwarding an agent to a second extrusion device, co- extruding a mass including the polymeric material and the agent, and forming the mass into at least one co-extruded drug delivery device which comprises a core including the agent and an outer layer including the polymeric material. In certain embodiments, the agent forwarded to the second extrusion device is in admixture with at least one polymer. In certain embodiments, the agent and the at least one polymer are admixed in powder form. In certain embodiments, this act includes forwarding more than one drug to the second extrusion device. In certain embodiments, the polymeric material is one of impermeable, semi-permeable, or permeable to the agent. The polymeric material may be bioerodible and/or radiation curable. In latter instances, the insert may be irradiated,
In certain embodiments, the insert is in a tubular form, and may be segmented into a plurality of shorter products. In certain embodiments, the insert further comprises a coating of the plurality of shorter products with one or more layers including at least one of a layer that is permeable to the agent, a layer that is semi-permeable to the agent, and a layer that is bioerodible. The polymeric material may include any biocompatible polymer, such as polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacrylate, polyurethane, a nylon, or poly (dl-lactide-co- glycolide) (PLGA), or a copolymer of any of these.
In some embodiments, the insert comprises a therapeutically effective amount of at least one agent coated by or dispersed in a polymer matrix, wherein the agent is in granular or particulate form. In some embodiments, the agent is released from the formulation as drug from the granules dissolves into or within the matrix, diffuses through the matrix, and is released into the surrounding physiological fluid. In some embodiments, the rate of release is limited primarily by the rate of dissolution of the agent from the granules/particles into the matrix; the steps of diffusion through the matrix and dispersion into the surrounding fluid are primarily not release-rate-limiting. In certain embodiments, the polymer matrix is non-bioerodible, while in other embodiments it is bioerodible. Exemplary non-bioerodible polymer matrices can be formed from polyurethane, polysilicone, poly(ethylene-co-vinyl acetate) (EVA), polyvinyl alcohol, and derivatives and copolymers thereof. Exemplary bioerodible polymer matrices can be formed from polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate, and derivatives and copolymers thereof.
In some embodiments, the insert comprises a collagenous material. In some embodiments, the insert may be a soluble ophthalmic drug insert (SODI, e.g., a polymeric oval film that can be introduced in the upper conjuctival sac for drug delivery; an elliptical insert such as OCUSERT® (Pilocarpine ocular therapeutic system, developed by Alza Corporation) which is made of ethylene vinyl acetate; OCUFIT® (developed by Escalon Ophthalmics Inc., Skillman, NS), which is a rod shaped silicone elastomer; Lacrisert®, a rod shaped insert made of cellulose; New Ophthalmic Drug Delivery Systems (NODS), made of poly (vinyl alcohol); and the inserts described in Fabrizio, Advanced Drug Delivery Reviews 16: 95 -106, 1998, which is incorporated herein by reference in its entirety. In further embodiments, the insert can be placed, depending on the location and the mechanism used to hold the insert in position, by either the patient or the doctor. In further embodiments, the insert comprises collagen, gelatin, or a polymer, wherein the polymer is selected from polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacralate, polyurethane, a nylon, poly(dl-lactide-co-glycolide) (PLGA), or a copolymer of any of the aforementioned. In some embodiments, the insert is implanted under the upper eyelid. In some embodiments, the insert is implanted in the posterior segment of the eye, in the chroidal space, or in the sclera. In some embodiments, the insert is implanted intravitreally or sub-retinally. In some embodiments, the insert is injected sub-retinally. Methods of administration and techniques for their preparation are set forth in Remington's Pharmaceutical Sciences, which is incorporated herein by reference in it entirety.
In other embodiments, the insert provides a sustained release of the agent to the vitreous of the eye. As used herein, "sustained release" means that the composition releases the agent over an extended period of time in a controlled fashion. In some embodiments, the insert releases the agent at a rate such that the aqueous agent concentration remains less than the vitreous agent concentration during the release. In some embodiments, the aqueous agent concentration is from about 0.002 μg/mL to about 0.01 μg/mL, or from about 0.01 μg/mL to about 0.05 μg/mL, or less than about 0.05 μg/mL. In some embodiments, the agent is released at a rate of about 1 μg/day to about 50 μg/day, or from about 1 μg/day to about 10 μg/day. In some embodiments, the insert further comprises an additional therapeutic agent, as detailed above, e.g., fluocinolone acetonide (such as that found in the ophthalmic insert Retisert®).
In some embodiments, the ophthalmic compositon comprises microspheres or nanoparticles. In some embodiment, the microspheres comprise gelatin. In some embodiments, the microspheres are injected to the posterior segment of the eye, in the chroidal space, in the sclera, intravitreally or sub- retinally. In some embodiments, the micospheres or nanoparticles comprises a polymer including, but not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety. In some embodiments, the polymer is chitosan, a polycarboxylic acid such as polyacrylic acid, albumin particles, hyaluronic acid esters, polyitaconic acid, poly(butyl)cyanoacrylate, polycaprolactone, poly(isobutyl)caprolactone, poly(lactic acid-co-glycolic acid), or poly(lactic acid). In some embodiments, the microspheres or nanoparticles comprise solid lipid particles.
In some embodiments, the ophthalmic composition comprises an ion-exchange resin. In some embodiments, the ion-exchange resin is an inorganic zeolite or synthetic organic resin. In some embodiments, the ion-exchange resin includes, but is not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety. In some embodiments, the ion- exhange resin is a partially neutralized polyacrylic acid.
In some embodiments, the ophthalmic composition is an aqueous polymeric suspension. In some embodiments, the agent or a polymeric suspending agent is suspended in an aqueous medium (e.g., having the properties as described above). In some embodiment, the agent is suspended. In some embodiments, the agent is in solution. In further embodiments, the suspending agent serves to provide stability to the suspension, to increase the residence time of the dosage form on the eye, or to enhance the sustained release of the drug in terms of both longer release times and a more uniform release curve. Examples of polymeric suspending agents include, but are not limited to, dextrans, polyethylene glycols, polyvinylpyrolidone, polysaccharide gels, Gelrite®, cellulosic polymers like hydroxypropyl methylcellulose, and carboxy-containing polymers such as polymers or copolymers of acrylic acid, as well as other polymeric demulcents. In some embodiments, the polymeric suspending agent is a water swellable, water insoluble polymer, especially a crosslinked carboxy-containing polymer. In some embodiments, the polymeric suspending agent comprises from at least about 90% to about 99.9%, or from about 95% to about 99.9%, by weight based on the total weight of monomers present, of one or more carboxy-containing monoethylenically unsaturated monomers. In some embodiments, the carboxy-containing monoethylenically unsaturated monomer includes acrylic acid, methacrylic acid, ethacrylic acid, methylacrylic acid (crotonic acid), cis- α-methylcrotonic acid (angelic acid), trans-α-methylcrotonic acid (tiglic acid), α-butylcrotonic acid, α-phenylacrylic acid, α-benzylacrylic acid, α-cyclohexylacrylic acid, phenylacrylic acid (cinnamic acid), coumaric acid (o-hydroxycinnamic acid), and umbellic acid (p-hydroxycoumaric acid). In some embodiments, the polymers may be crosslinked by a polyfunctional crosslinking agent (e.g., a difunctional crosslinking agent). In further embodiments, the amount of crosslinking should be sufficient to form insoluble polymer particles, but not so great as to unduly interfere with sustained release of the agent. In some embodiment, the polymers are only lightly crosslinked. In some embodiments, the crosslinking agent is contained in an amount of from about 0.01% to about 5%, or from about 0.1% to about 5.0%, or from about 0.2% to about 1%, based on the total weight of monomers present. In some embodiments, the crosslinking agents are nonpolyalkenyl polyether difunctional crosslinking monomers such as divinyl glycol, 2,3-dihydroxyhexa-l,5-diene, 2,5-dimethyl-l,5-hexadiene, divinylbenzene, N,N-diallylacrylamide, N,N-diallymethacrylamide; polyalkenyl polyether crosslinking agents containing two or more alkenyl ether groupings per molecule, e.g., alkenyl ether groupings containing terminal H2C=C<groups, prepared by etherifying a polyhydric alcohol containing at least four carbon atoms and at least three hydroxyl groups with an alkenyl halide such as allyl bromide or the like, e.g., polyallyl sucrose, polyallyl pentaerythritol, or the like; diolefinic non- hydrophilic macromeric crosslinking agents having molecular weights of from about 400 to about 8,000, such as insoluble diacrylates and polyacrylates and methacrylates of diols and polyols, diisocyanate hydroxyalkyl acrylate or methacrylate reaction products of isocyanate terminated prepolymers derived from polyester diols, polyether diols or polysiloxane diols with hydroxyalkylmethacrylates, and the like.
In some embodiments, the crosslinked polymers may be made from a carboxy-containing monoethylenically unsaturated monomer or monomers as the sole monoethylenically unsaturated monomer present, together with a crosslinking agent or agents. In some embodiments, the polymers are ones in which up to about 40%, and preferably from about 0% to about 20% by weight, of the carboxy-containing monoethylenically unsaturated monomer or monomers has been replaced by one or more non-carboxyl-containing monoethylenically unsaturated monomer or monomers containing only physiologically and ophthalmically innocuous substituents, including acrylic and methacrylic acid esters such as methyl methacrylate, ethyl acrylate, butyl acrylate, 2-ethylhexylacrylate, octyl methacrylate, 2-hydroxyethylmethacrylate, 3-hydroxypropylacrylate, and the like, vinyl acetate, N- vinylpyrrolidone, and the like (see Mueller et al. U.S. Pat. No. 4,548,990, the entire contents of which are incorporated herein by reference, for a more extensive listing of such additional monoethylenically unsaturated monomers). In some embodiments, the polymers include polycarbophil (Noveon AA-I), Carbopol®, and DuraSite®. In some embodiments, the crosslinked polymers are prepared by suspension or emulsion polymerizing the monomers, using conventional free radical polymerization catalysts, to a dry particle size of not more than about 50 μm in equivalent spherical diameter. In some embodiments, the average dry particle size is from about 1 to about 30 μm, or from about 3 to about 20 μm in equivalent spherical diameter. In some embodiments, the polymer particles are obtained by mechanically milling larger polymer particles. In further embodiments, such polymers will have a molecular weight from about 250,000 to about 4,000,000, and from 3,000,000,000 to 4,000,000,000. In other embodiments, the particles of crosslinked polymer are monodisperse, meaning that they have a particle size distribution such that at least about 80%, about 90% or about 95%, of the particles fall within a μm band of major particle size distribution. In further embodiments, the monodisperse particle size means that there is no more than about 20%, about 10%, or about 5% particles of a size below 1 μm. In some embodiments, the aqueous polymeric suspension comprises from about 0.05 to about 1%, from about 0.1 to about 0.5%, or from about 0.1 to about 0.5%, of the agent and from about 0.1 to about 10%, from about 0.5 to about 6.5%, from about 0.5 to about 2.0%, from about 0.5% to about 1.2%, from about 0.6 to about 0.9%, or from about 0.6 to about 0.8% of a polymeric suspending agent. Although referred to in the singular, it should be understood that one or more species of polymeric suspending agent can be used with the total amount falling within the stated ranges. In one embodiment, the amount of insoluble lightly crosslinked polymer particles, the pH, and the osmotic pressure can be correlated with each other and with the degree of crosslinking to give a composition having a viscosity in the range of from about 500 to about 100,000 centipoise, and preferably from about 1,000 to about 30,000 or about 1,000 to about 10,000 centipoise, as measured at room temperature (about 25° C.) using a Brookfield Digital LVT Viscometer equipped with a number 25 spindle and a 13R small sample adapter at 12 rpm. In some embodiments, the viscosity is from about 10 to about 400 centipoise, from about 10 to about 200 centipoises or from about 10 to about 25 centipoise.
In some embodiments, the aqueous polymeric suspensions may be formulated so that they retain the same or substantially the same viscosity in the eye that they had prior to administration to the eye. In some embodiments, they may be formulated so that there is increased gelation upon contact with tear fluid. For instance, when a formulation containing DuraSite® or other similar polyacrylic acid-type polymer is administered to the eye at a pH of less than about 6.7, the polymer may swell upon contact with tear fluid since it has a higher pH (around 7). This gelation or increase in gelation may lead to entrapment of the suspended particles, thereby extending the residence time of the composition in the eye. In some embodiments, the agent is released slowly as the suspended particles dissolve over time. In some embodiments, this delivery route increases patient comfort and increased agent contact time with the eye tissues, thereby increasing the extent of drug absorption and duration of action of the formulation in the eye. The agents contained in these drug delivery systems will be released from the gels at rates that depend on such factors as the drug itself and its physical form, the extent of drug loading and the pH of the system, as well as on any drug delivery adjuvants, such as ion exchange resins compatible with the ocular surface, which may also be present. In some embodiment, the treating comprises administering a pharmaceutical composition to the patient, the composition comprising the agent and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is an oral dosage form. In some embodiments, the pharmaceutical compositions comprise, as the active ingredient, one or more of the agents above in combination with one or more pharmaceutically acceptable carriers (excipients). In making the compositions of the invention, the agent is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, the agent can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the agent is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the agent is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the agent. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The agent can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the agent actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. For preparing solid compositions such as tablets, the agent is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the agent is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the agent.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the agent and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
The amount of agent or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like. The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the agent preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of the agents can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of an agent in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the agents can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
The compositions can further include one or more additional pharmaceutical agents, examples of which are listed hereinabove.
As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:
(1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;
(2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
JAK Inhibitors for Use as Agents in the Methods of the Invention
The next section details eleven different classes of agents for use in the methods of the invention. Some of the agents are defined generically in Formulas I-IX. The embodiments following each generic formula relate to the preceding generic formula.
In a first aspect, the agent is selected from a compound of Formula I:
Figure imgf000026_0001
I and pharmaceutically acceptable salt forms or prodrugs thereof, wherein:
A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR11R12V(C340 eye loalkylene)- (CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_i0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12^O(CR11R12),!, (CR11R12^S(CR11R12)^ (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)PNRC(CR11R12)<1, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R1^pS(O)2(CR11R12)^ or (CR11R12)pS(O)2NRc(CR11R12)q, wherein the Ci-8 alkylene, C2_8 alkenylene, C2_g alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_g alkyl, C2_g alkenyl, C2_g alkynyl, C^ haloalkyl, halosulfanyl, C^ hydroxyalkyl, Ci_4 cyanoalkyl, =C-R, =N-R', Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, C(=N0(Ci_6 alkyl)Rb, and S(0)2NRcRd, wherein the Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, alkyl, C2-4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(O)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein the 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(WV-Q;
W is Ci_8 alkylenyl, C2_8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(0)NRc', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NRC', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, d_8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein the Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Q-4 haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, OR3', SR3', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NRc C(0)0R3', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, OR3", SR3", C(0)Rb", C(0)NRc"Rd ', C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd ", NRC "Rd ", NRC "C(0)Rb ", NRC 'C(O)OR3 ', NRc"S(0)Rb", NRc"S(0)2Rb", S(O)Rb ', S(O)NRC "Rd ', S(O)2Rb", and S(0)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo,
Figure imgf000027_0001
alkyl, C2_4 alkenyl, C2^ alkynyl, C^ haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; R8 is H, Ci-6 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, d.io alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2-6 alkynyl, Ci-6 alkylcarbonyl, arylcarbonyl, Ci-6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from Ci-6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci-6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D and E are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci-6 alkylene)r-O-( Ci_6 alkylene)s, (Ci-6 alkylene)r-S-(Ci_6 alkylene)s, (Ci-6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-COO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CONRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SONRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReC0NRf-(Ci_6 alkylene)s, wherein each of the Ci_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D3 and E3 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D4 and E4 are independently selected from H, halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, C(=N0(Ci_6 alkyl)Rb, and S(0)2NRcRd, wherein the Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000028_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci_6 alkyl))Rb, and S(O)2NRcRd;
Ra is H, Cy1, -(Ci-6 alkyO-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2_6 alkynyl, wherein the Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, -(Ci-6 alkyφ-Cy1, Ci-6 alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2_6 alkynyl, wherein the Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Q_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, d_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci-6 alkyfj-Cy1, d_10 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein the Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci-I0 alkyl, d_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1.
In some embodiments, the compound of Formula I is not selected from:
4-[5-(2-isopropyl-5-methylcyclohexyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-(4-tert-butylphenoxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- cyclopentylethyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,6-difluorophenyl)-l,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(l-tert-butyl-3-methyl-lH-pyrazol-5-yl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(benzyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(3-fluorophenyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (phenoxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-methoxybenzyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(phenylthiomethyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(3-methylbutyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- benzyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,2-dimethylpropyl)-l,2-4-oxadiazol- 3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-methyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (formyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(furan-2-yl)-l,2-4-oxadiazol-3-yl]- 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-( 1 -methyl- 1 H-pyrrol-2-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 - b]pyridine; 4-[5-(sec-butyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopropyl-l,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; and pharmaceutically acceptable salts of any of the aforementioned.
In some embodiments, the moiety formed by T, U, V, A1, and A2, is not a l,2,4-oxadiazol-3- yl ring. In some embodiments, the moiety formed by T, U, V, A1, and A2, is not an oxadiazole ring, wherein the moiety formed by T, U, V, A1, and A2 is not the following moiety:
Figure imgf000031_0001
In some embodiments, when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000031_0002
then Y is other than (CR11R12)pC(O)NRc(CR11R12)q.
In some embodiments, when X is N, the 5-membered ring formed by A1, A2, U, T, and V is other than pyrrolyl.
In some embodiments, when X is CH, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000031_0003
then -(Y)n-Z is other than COOH.
In some embodiments, when X is CH or C-halo, R1, R2, and R3 are each H, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000031_0004
then Y is other than (CR11R12)pC(O)NRc(CR11R12)q or (CR11R12)pC(O)(CR11R12)q. In some embodiments, when X is CH or C-halo, R1, R2, and R3 are each H, n is 0, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000032_0001
then Z is other than CN, halo, or Ci_4 alkyl.
In some embodiments, when X is CH or C-halo, R1, R2, and R3 are each H, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000032_0002
then Y is other than (CR11R12)pC(O)NRc(CR11R12)q or (CR11R12)pC(O)(CR11R12)q.
In some embodiments, when X is CH or C-halo, R1, R2, and R3 are each H, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000032_0003
then Y is other than (CR11R12)pNRc(CR11R12)q.
In some embodiments, when X is CH or C-halo and R1, R2, and R3 are each H, then the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has a formula other than:
Figure imgf000032_0004
In some embodiments:
Z is H, halo, CN, NO2, Ci_8 alkyl, C2-8 alkenyl, C2-8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein the Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl,
Figure imgf000032_0005
hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd; Q is H, halo, CN, NO2, Ci_8 alkyl, C2_g alkenyl, C2-8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein the Ci_g alkyl, C2_g alkenyl, C2_g alkynyl, Ci_g haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, Ci_4 hydroxy- alkyl, ClΛ cyanoalkyl, Cy2, CN, NO2, 0Ra', SRa', C(O)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NRc C(0)0Ra', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc'S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2^ alkenyl, C2^ alkynyl, Ci-4 haloalkyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, 0Ra ", SRa ", C(0)Rb ", C(0)NRc "Rd ", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rb", NRc"C(0)0Ra", NRc"S(O)Rb", NRc"S(0)2Rb", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", and S(0)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, CM alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, Ci.io alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 alkylcarbonyl, arylcarbonyl, Ci_6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H, halo, OH, CN, Ci_4 alkyl, Ci_4 haloalkyl, C2^ alkenyl, C2_4 alkynyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Ra, Ra , and Ra are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Cue alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb, Rb and Rb are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 haloalkyl, d_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, d-10 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the Ci40 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein the d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; and or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl.
In some embodiments, X is N.
In some embodiments, X is CR4.
In some embodiments, X is N or CR4.
In some embodiments, A1 is C.
In some embodiments, A1 is N.
In some embodiments, A2 is C.
In some embodiments, A is N.
In some embodiments, at least one of A1, A2, U, T, and V is N.
In some embodiments, the 5-membered ring formed by A1, A2, U, T, and V is pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or oxadiazolyl.
In some embodiments, the 5-membered ring formed by A1, A2, U, T, and V is selected from:
Figure imgf000035_0001
wherein: a designates the site of attachment of moiety -(Y)n-Z; b designates the site of attachment to the core moiety:
Figure imgf000036_0001
c and c ' designate the two sites of attachment of the fused 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring.
In some embodiments, the 5-membered ring formed by A , A , U, T, and V is selected from:
Figure imgf000036_0002
wherein: a designates the site of attachment of moiety -(Y)n-Z; b designates the site of attachment to the core moiety:
Figure imgf000036_0003
c and c ' designate the two sites of attachment of the fused 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring.
In some embodiments, the 5-membered ring formed by A1, A2, U, T, and V is selected from:
Figure imgf000037_0001
wherein: a designates the site of attachment of moiety -(Y)n-Z; b designates the site of attachment to the core moiety:
Figure imgf000037_0002
: and c ' designate the two sites of attachment of the fused 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring.
In some embodiments, the 5-membered ring formed by A1, A2, U, T, and V is selected from:
Figure imgf000037_0003
wherein: a designates the site of attachment of moiety -(Y)n-Z; b designates the site of attachment to the core moiety:
Figure imgf000037_0004
In some embodiments, the 5-membered ring formed by A , A , U, T, and V is selected from:
Figure imgf000037_0005
wherein: a designates the site of attachment of moiety -(Y)n-Z; b designates the site of attachment to the core moiety:
Figure imgf000038_0001
In some embodiments, the 5-membered ring formed by A1, A2, U, T, and V is selected from:
Figure imgf000038_0002
wherein: a designates the site of attachment of moiety -(Y)n-Z; b designates the site of attachment to the core moiety:
Figure imgf000038_0003
In some embodiments, the 5-membered ring formed by A , A , U, T, and V is selected from
Figure imgf000038_0004
In some embodiments, n is 0.
In some embodiments, n is 1.
In some embodiments, n is 1 and Y is Ci_g alkylene, C2-8 alkenylene, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R^)POC(O)(CR11R12),!, wherein the Ci_8 alkylene or C2-8 alkenylene, is optionally substituted with 1, 2, or 3 halo, OH, CN, amino, Ci_4 alkylamino, or C2-8 dialkylamino.
In some embodiments, n is 1 and Y is Ci-8 alkylene, (CR11R12^C(O)(CR11R12^, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, wherein the Ci-8 alkylene is optionally substituted with 1, 2, or 3 halo, OH, CN, amino, C^ alkylamino, or C2_8 dialkylamino.
In some embodiments, n is 1 and Y is Ci_8 alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino,
Figure imgf000038_0005
alkylamino, or C2-8 dialkylamino. In some embodiments, n is 1 and Y is ethylene optionally substituted with 1 , 2, or 3 halo, OH, CN, amino, Ci_4 alkylamino, or C2-8 dialkylamino.
In some embodiments, n is 1 and Y is (CR11R12^C(O)(CR11R12^ (CR11R12^C(O)NR0- (CR11R12)^ or (CR11R12^C(O)O(CR11R12)^
In some embodiments, Y is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR11R1^p-(C340 cycloalkylene)-(CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CR11R12)p-(C1.10 heterocycloalkylene)- (CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12^O(CR11R12),!, or (CR11R12^S(CR11R12^, wherein the Ci_g alkylene, C2-8 alkenylene, C2-8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1 , 2, or 3 substituents independently selected from -D1-D2-D3-D4.
In some embodiments, Y is Ci_g alkylene, C2-8 alkenylene, C2-8 alkynylene, (CR11R12^-(C340 cycloalkylene)-(CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_io heterocycloalkylene)- (CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12)pO(CR11R12)q, or (CR11R12^S(CR11R12)^ wherein the Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1 , 2, or 3 substituents independently selected from D4.
In some embodiments, Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, or (CRUR12)P-(C3_ io cycloalkylene)-(CRuR12)q, wherein the Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, or cycloalkylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1- D2-D3-D4.
In some embodiments, Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, or (CRUR12)P-(C3_ io cycloalkylene)-(CRuR12)q, wherein the Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, or cycloalkylene, is optionally substituted with 1 , 2, or 3 substituents independently selected from D4.
In some embodiments, Y is Ci_8 alkylene, C2_8 alkenylene, or C2_8 alkynylene, each optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4.
In some embodiments, Y is Ci_8 alkylene optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4.
In some embodiments, Y is Ci_8 alkylene optionally substituted with 1, 2, or 3 substituents independently selected from D4.
In some embodiments, Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, (CR11R12^O- (CRuR12)q, (CR11R1^pS(CR11R12)^ (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR1 'R^pNR^CR11R12V (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R12)pS(O)2(CR11R12)q, or (CR11R12)pS(O)2NRc(CR11R12)q, wherein the Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, OH, CN, amino, Q-4 alkylamino, and C2-8 dialkylamino. In some embodiments, Y is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR11R1^p-(C340 cycloalkylene)-(CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_io heterocycloalkylene)- (CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12)pO(CR11R12)q, (CR11R12)pS(CR11R12)q, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)PNRC(CR11R12)<1, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R1^pS(O)2(CR11R12)^ or (CR11R12)pS(O)2NRc(CR11R12)q, wherein the d_8 alkylene, C2.8 alkenylene, C2_8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1 , 2, or 3 substituents independently selected from halo, OH, CN, amino, Ci_4 alkylamino, and C2_8 dialkylamino.
In some embodiments, n is 1 and Y is Q_8 alkylene optionally substituted with 1, 2, or 3 substituents independently selected from D4. In some embodiments, n is 1 and Y is Ci_g alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino, Q-4 alkylamino, or C2_g dialkylamino. In some embodiments, n is 1 and Y is Ci_g alkylene optionally substituted with cyano.
In some embodiments, p is O.
In some embodiments, p is 1.
In some embodiments, p is 2.
In some embodiments, q is O.
In some embodiments, q is 1.
In some embodiments, q is 2.
In some embodiments, one of p and q is 0 and the other of p and q is 1, 2, or 3.
In some embodiments, Z is H, halo, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Q-4 haloalkyl, halosulfanyl, Q-4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein the Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(O)2NRcRd.
In some embodiments, Z is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)ORa, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd. In some embodiments, Z is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, d_4 haloalkyl, CM hydroxyalkyl, d_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Q-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Q-4 haloalkyl, halosulfanyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl or 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl or 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, ClΛ hydroxyalkyl, Q-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, d_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is cycloalkyl or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, halosulfanyl, Ci-4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is cycloalkyl or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is Ci_g alkyl, C2_g alkenyl, or C2_g alkynyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is Ci_g alkyl, C2_g alkenyl, or C2_g alkynyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, d_4 haloalkyl, CM hydroxyalkyl, Cμ cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, halosulfanyl, Ci-4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, d_4 hydroxyalkyl, d_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is phenyl or 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, d_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl or 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, CM hydroxyalkyl, Cμ cyanoalkyl, Cy1, CN, NO2, OR3, SR3, C(0)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, OR3, SR3, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(0)2Rb, and S(0)2NRcRd.
In some embodiments, Z is phenyl optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, Ci-4 hydroxyalkyl, d_4 cyanoalkyl, Cy1, CN, NO2, OR3, SR3, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is cycloalkyl or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, OR3, SR3, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is cycloalkyl or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, OR3, SR3, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd. In some embodiments, Z is Ci_8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci-4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Cμ haloalkyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is Ci_g alkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, C(0)NRcRd, C(O)OR3, NRcRd, NRcC(0)Rb, and S(O)2Rb.
In some embodiments, Z is Ci_g alkyl, C2_g alkenyl, C2_g alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, Ci_4 haloalkyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, C(0)NRcRd, C(O)OR3, NRcRd, NRcC(0)Rb, and S(O)2Rb.
In some embodiments, Z is Ci_g alkyl, C2_g alkenyl, C2_g alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_4 alkyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, OR3, C(0)NRcRd, C(O)OR3, NRcRd, NRcC(0)Rb, and S(O)2Rb.
In some embodiments, Z is Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Q-4 alkyl, Q-4 haloalkyl, Cx-4 hydroxyalkyl, Cx-4 cyanoalkyl, Cy1, CN, NO2, OR3, C(0)NRcRd, C(O)OR3, NRcRd, NRcC(0)Rb, and S(O)2Rb.
In some embodiments, Z is substituted with at least one substituent comprising at least one CN group.
In some embodiments, Z is Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each substituted with at least one CN or Ci_4 cyanoalkyl and optionally substituted with 1, 2, 3, 4, or 5 further substituents selected from halo, Ci_4 alkyl, C2^ alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, OR3, SR3, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0R3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each substituted with at least one CN or Ci_4 cyanoalkyl and optionally substituted with 1, 2, 3, 4, or 5 further substituents selected from halo, Ci_4 alkyl, C2^ alkenyl, C2_4 alkynyl, Cμ haloalkyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, Z is cyclopentyl, which is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Q-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd. In some embodiments, Z is cyclopentyl.
In some embodiments, X is N. In some embodiments, A1 is C. In some embodiments, A2 is N. In some embodiments, T is N. In some embodiments, U and V are independently CR5.
In some embodiments, wherein the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein the 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q.
In some embodiments, wherein the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 8-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein the 4- to 8-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q.
In some embodiments, the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 6-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5- membered ring formed by A1, A2, U, T, and V, wherein the 6-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl wherein the Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, d_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted by 1 , 2 or 3 CN.
In some embodiments, Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, CN, NO2, 0Ra", SRa", C(0)Rb", C(0)NRc"Rd", C(0)0Ra", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rb", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", and S(0)2NRc"Rd". In some embodiments, Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, CN, NO2, ORa , SRa", C(O)Rb", C(O)NRc"Rd", C(O)OR3", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rb", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", and S(O)2NRc"Rd".
In some embodiments, Cy1 and Cy2 are independently selected from cycloalkyl and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2-4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, CN, NO2, 0Ra", SRa", C(O)Rb", C(0)NRc"Rd", C(O)OR3", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rb", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", and S(O)2NRc"Rd".
In some embodiments, Cy1 and Cy2 are independently selected from cycloalkyl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci-4 alkyl, C2^ alkenyl, C2_ 4 alkynyl, Cμ haloalkyl, CN, NO2, 0Ra", SRa", C(O)Rb", C(0)NRc"Rd", C(O)ORa", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rb", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", and S(O)2NRc"Rd".
In some embodiments, R1, R2, R3, and R4 are independently selected from H, halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10.
In some embodiments, R1, R2, R3, and R4 are independently selected from H, halo, and Q_4 alkyl.
In some embodiments, R1, R2, R3, and R4 are each H.
In some embodiments, R1 is H, halo, or Ci_4 alkyl.
In some embodiments, R5 is H, halo, Ci_4 alkyl, C2^ alkenyl, C2^ alkynyl, Q^ haloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10.
In some embodiments, R5 is H, halo, Ci_4 alkyl, C^ haloalkyl, halosulfanyl, CN, or NR9R10.
In some embodiments, R5 is H, halo, Ci_4 alkyl, Ci-4 haloalkyl, CN, or NR9R10.
In some embodiments, R5 is H.
In some embodiments, R6 is H or Ci-4 alkyl.
In some embodiments, R6 is H.
In some embodiments, R11 and R12 are independently selected from H, halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, d_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)ORa, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein the Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Q-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NR0CC=NRONR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(d_6 alkyl))Rb, and S(O)2NRcRd.
In some embodiments, R11 and R12 are independently selected from H, halo, OH, CN, Q-4 alkyl, Q-4 haloalkyl, halosulfanyl, SCN, C2^ alkenyl, C2_4 alkynyl, Cw hydroxyalkyl, Ci_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.
In some embodiments, R11 and R12 are independently selected from H, halo, OH, CN, Ci-4 alkyl, Ci-4 haloalkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 hydroxyalkyl, d_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.
In some embodiments, the agent is selected from compounds of Formula Ia or Ib:
Figure imgf000047_0001
Ia Ib and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Ic:
Figure imgf000047_0002
Ic and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Id or Ie:
Figure imgf000047_0003
and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Ie:
Figure imgf000048_0001
and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Ih:
Figure imgf000048_0002
Ih and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Ik:
Figure imgf000048_0003
Ik and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula H:
Figure imgf000048_0004
Il and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Im:
Figure imgf000049_0001
Im and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula In:
Figure imgf000049_0002
In and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from:
3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl]benzonitrile;
3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] acrylonitrile;
3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl]propanenitrile;
4-(4-phenyl- lH-imidazol- 1 -yl)- 1 H-pyrrolo [2,3 -b]pyridine;
[3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] -piperidin- 1 -yl-methanone;
[3-methyl-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-ylmethyl]-phenyl-amine;
3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] -cyclohexanol;
4- [ 1 -(3-methoxy- 1 -methyl-propyl)- 1 H-pyrazol-4-yl] - 1 H-pyrrolo [2,3 -b]pyridine;
4- [ 1 -( 1 -methyl-3 -pyrazol- 1 -yl-propyl)- 1 H-pyrazol-4-yl] - 1 H-pyrrolo[2,3 -b]pyridine; l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazole-4-carboxylic acid ethyl ester;
4-(3-methyl-4-phenyl-pyrazol- 1 -yl)- 1 H-pyrrolo [2,3 -b]pyridine;
4-(3-phenyl-pyrazol- 1-yl)- lH-pyrrolo[2,3-b]pyridine;
4-(4-bromo-imidazol- 1 -yl)- 1 H-pyrrolo [2,3 -b]pyridine;
4-(4-bromo-3-methyl-pyrazol-l-yl)-lH-pyrrolo[2,3-b]pyridine;
3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] -benzonitrile; 4- [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] -benzonitrile; 4-[4-(3-fluoro-phenyl)-3-methyl-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[4-(3,5-bis-trifluoromethyl-phenyl)-3-methyl-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[4-(3,5-difluoro-phenyl)-3-methyl-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine; {3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] -phenyl} -methanol; 4-(3-methyl-4-pyrimidin-5-yl-pyrazol-l-yl)-lH-pyrrolo[2,3-b]pyridine; 4-[3-methyl-4-(l -methyl- lH-indol-5-yl)-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine; 4-(3-methyl-4-thiophen-3-yl-pyrazol-l-yl)-l H-pyrrolo [2,3 -b]pyridine; N,N-dimethyl-4- [3 -methyl- 1 -(I H-pyrrolo [2,3 -b]pyridin-4-yl)-l H-pyrazol-4-yl] -benzene- sulfonamide;
N-{4-[3-methyl-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]-phenyl}-acetamide;
3-tert-butyl-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazole-4-carbonitrile;
4-bromo-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazole-3-carbonitrile;
4-(3-cyano-phenyl)-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazole-3-carbonitrile;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-3-trifluoromethyl-lH-pyrazol-4-yl]-propan-l-ol;
3 - [3 -methyl- 1 -( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol-4-yl] -prop-2-en- 1 -ol;
2-[4-bromo-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]-isoindole-l,3-dione;
4-[4-(2,6-dimethyl-phenyl)-3-methyl-pyrazol- 1 -yl]- 1 H-pyrrolo[2,3-b]pyridine;
3-[3-amino-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]-benzonitrile;
3-[3-benzylamino-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]-benzonitrile;
N-[4-(3-cyano-phenyl)-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]-acetamide;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-pyrazol-l-yl]-propan-l-ol;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-pyrazol-l-yl]-butan-l-ol;
4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-pyrazol-l-yl]-pentanenitrile;
4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-pyrazol-l-yl]-pentanoic acid amide;
4- [ 1 -(3 -imidazol- 1 -yl- 1 -methyl-propyl)- 1 H-pyrazol-4-yl] - 1 H-pyrrolo [2,3 -b]pyridine;
4-cyclopentyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-pyrazol-l-yl]-butyronitrile;
4-cyclopentyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-pyrazol-l-yl]-butyramide;
3-cyclopropyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-l-yl]-propionitrile;
4-(2-tert-butyl-l-methyl-lH-imidazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-(2-phenyl-lH-imidazol-5-yl)-lH-pyrrolo[2,3-b]pyridine;
4-(2-benzyl-lH-imidazol-5-yl)-lH-pyrrolo[2,3-b]pyridine;
4-[2-(l-phenylethyl)-lH-imidazol-5-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(2-phenyl-l,3-thiazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
N-methyl-N-propyl-4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-l,3-thiazol-2-amine;
N-phenyl-4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-l,3-thiazol-2-amine;
N-methyl-N-phenyl-4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-l,3-thiazol-2-amine; 4-(2-phenyl-l,3-thiazol-5-yl)-lH-pyrrolo[2,3-b]pyridine; ethyl 2-methyl-2-[4-(lH-pyrrolo [2,3 -b]pyridin-4-yl)-lH-pyrazol-l-yl]propanoate; 2-methyl-2- [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]propanoic acid; 2-methyl-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanamide; ethyl 3 -methyl-3 - [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]butanoate; 3 -methyl-3 - [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]butan- 1 -ol; 4-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]pentanenitrile; 4-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]pentanamide; 3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]butanenitrile; 3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanenitrile; 3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]hexanenitrile; 3-cyclopentyl-3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanenitrile; 3-cyclohexyl-3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanenitrile; 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanenitrile; 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile; 2-methyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile; 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanenitrile; 5-methyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]hexanenitrile; 3 -cyclohexyl-3-[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)-l H-pyrazol- l-yl]propanenitrile; 4-cyclopropyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanenitrile; 4-{l-[l-methylbutyl]-lH-pyrazol-4-yl}-7H-pyrrolo[2,3-d]pyrimidine; 4-methyl-4-[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yljpentanenitrile; 3- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]cyclopropylpropanenitrile; 4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanenitrile; 3 -methyl-3 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)-l H-pyrazol- l-yl]butanenitrile; 3-ethyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanenitrile; l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclopropylacetonitrile; 4-l-[(pyrrolidin-2-ylmethyl]-lH-pyrazol-4-yl-7H-pyrrolo[2,3-d]pyrimidine; 4-(l-[l-(methylsulfonyl)pyrrolidin-2-yl]methyl-lH-pyrazol-4-72yl)-7H-pyrrolo[2,3-d]- pyrimidine; ethyl 2-methyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanoate;
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]acrylonitrile;
3-cyclopentylidene-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3-(methyl[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]amino)propanenitrile;
3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]hexanenitrile;
3-cyclopentyl-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]propanenitrile;
5-methyl-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]hexanenitrile; 3 -pyridin-3 -yl-3 - [5-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 ,3 -thiazol-2-yl]propanenitrile;
3-(5-bromopyridin-3-yl)-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]propane- nitrile;
5-(2-cyano- 1 -[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 ,3-thiazol-2-yl]ethyl)nicotinonitrile;
3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]butanenitrile;
2-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]pentanenitrile;
4-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]heptanenitrile;
3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]pentanedinitrile;
3-cyclopentyl-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-oxazol-2-yl]propanenitrile;
3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-oxazol-2-yl]hexanenitrile;
5-(methylthio)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanenitrile;
5-(methylsulfinyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-pentanenitrile;
5-(methylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-pentanenitrile;
4,4,4-trifluoro-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-l-yl]-butyronitrile;
5,5-dimethyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-l-yl]-hexanenitrile;
4-[l-(2-methanesulfonyl-ethyl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
5,5,5-trifluoro-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-l-yl]-pentanenitrile;
3-(2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl)-cyclopentane- carbonitrile;
3 - [3 -(hydroxymethyl)cyclopentyl] -3 - [4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile; l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-indazole;
2-(lH-pyrrolo[2,3-b]pyridin-4-yl)-2H-indazole;
3-[3-(lH-pyrrolo[2,3-b]pyridin-4-yl)-l,2,4-oxadiazol-5-yl]benzonitrile;
4-(l-benzothien-2-yl)-lH-pyrrolo[2,3-b]pyridine;
4-fluoro-2-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]phenol ;
4-3 - [3 -(trifluoromethyl)phenyl] - 1 H-pyrazol- 1 -yl- 1 H-pyrrolo [2,3 -b]pyridine;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]benzonitrile;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]benzonitrile;
2-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]-l,3-benzoxazole; cyclohexyl[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]methanol;
4-[4-(l-phenylvinyl)-lH-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(l -benzyl- lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2-naphthylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(l -phenyl- lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
4-{l-[l-methylbutyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine ; 4-methyl-3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
2-(lH-pyrrolo[2,3-b]pyridin-4-yl)-4,5,6,7-tetrahydro-2H-indazole;
5-nitro-2-(lH-pyrrolo[2,3-b]pyridin-4-yl)-2H-indazole;
6-nitro-2-(lH-pyrrolo[2,3-b]pyridin-4-yl)-2H-indazole;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-imidazol-4-yl]benzonitrile;
4-[4-(3-methoxyphenyl)-lH-imidazol-l-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(5-phenyl-2-thienyl)-lH-pyrrolo[2,3-b]pyridine;
4- [3 -(4-fluorophenyl)- 1 H-pyrazol- 1 -yl] - 1 H-pyrrolo [2,3 -b]pyridine;
4-[3-(3-nitrophenyl)-lH-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine;
4- [3 -(4-chlorophenyl)- 1 H-pyrazol- 1 -yl] - 1 H-pyrrolo [2,3 -b]pyridine;
4- [3 -(4-methoxyphenyl)- 1 H-pyrazol- 1 -yl] - 1 H-pyrrolo [2,3 -b]pyridine;
4-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]benzonitrile;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]aniline;
4- [3 -(3-methoxyphenyl)- 1 H-pyrazol- 1 -yl] - 1 H-pyrrolo [2,3 -b]pyridine;
{3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]phenoxy}acetonitrile;
2-cyano-N-{3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]phenyl}acetamide;
3-cyano-N- {3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-3-yl]phenyl}benzamide;
4-[4-(4-nitrophenyl)-lH-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]aniline;
4-(4-phenyl- 1 H-pyrazol- 1 -yl)- 1 H-pyrrolo [2,3 -b]pyridine;
4-(4-pyridin-3-yl- 1 H-pyrazol- 1 -y I)- 1 H-pyrrolo [2,3 -b]pyridine;
2-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]benzonitrile;
{2-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]phenyl}acetonitrile;
4-[4-(3-nitrophenyl)-lH-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]aniline;
{3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]phenyl}acetonitrile;
4-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]benzonitrile;
3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]phenol; methyl 3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]benzoate;
{4-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]phenyl}acetonitrile;
2-cyano-N-{3-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]phenyl}acetamide;
4-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]phenol;
5-[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]nicotinonitrile;
{4- [ 1 -( 1 H-pyrrolo [2,3-b]pyridin-4-yl)- 1 H-pyrazol-4-yl]phenoxy } acetonitrile;
4-(4-cyclohex- 1 -en- 1 -yl- 1 H-pyrazol- 1 -yl)- 1 H-pyrrolo[2,3-b]pyridine;
4-[4-(4-methoxyphenyl)-lH-pyrazol-l-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(4-pyrimidin-4-yl-lH-pyrazol-l-yl)-lH-pyrrolo[2,3-b]pyridine; 3-{hydroxy[l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-4-yl]methyl}benzonitrile;
4-[4-(cyclohex- 1 -en- 1-ylmethyl)- lH-pyrazol- 1 -yl]- lH-pyrrolo[2,3-b]pyridine;
4-[l-(3,5-dimethoxybenzyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(l-phenylethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(cyclohexylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
3-{[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]methyl}benzonitrile;
2-{[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]methyl}benzonitrile;
4-{[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]methyl}benzonitrile; l-phenyl-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]ethanone;
3,3-dimethyl-l-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]butan-2-one;
4- { 1 - [(5-methylisoxazol-3 -yl)methyl] - 1 H-pyrazol-4-yl} - 1 H-pyrrolo [2,3 -b]pyridine;
4-[l-(tetrahydro-2H-pyran-2-ylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(l -cyclohex-2-en- 1 -yl- 1 H-pyrazol-4-yl)- lH-pyrrolo[2,3-b]pyridine;
4- [l-(l-ethylpropyl)-l H-pyrazol-4-yl] -1 H-pyrrolo [2,3 -b]pyridine;
4-(l-cyclohexyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
2- [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl] acetamide;
4'-{[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]methyl}biphenyl-2-carbonitrile;
4-[l-(2-nitrobenzyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-{l-[2,6-dichloro-4-(trifluoromethyl)phenyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-[l-(3-nitrobenzyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4- [ 1 -(2-bromobenzyl)- 1 H-pyrazol-4-yl] - 1 H-pyrrolo [2,3-b]pyridine;
N-phenyl-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanamide;
4-{l-[3-(trifluoromethoxy)benzyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-{l-[2-fluoro-5-(trifluoromethyl)benzyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-{l-[3-(trifluoromethyl)benzyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-[l-(pyridin-3-ylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-{l-[l-phenylbutyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
1 -phenyl-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)- lH-pyrazol- 1 -yl]propan- 1 -one;
4-[l-(2,6-dichlorobenzyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2,6-dimethylphenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-5-(trifluoromethyl)-benzonitrile;
4-[l-(4-bromo-3,5,6-trifluoropyridin-2-yl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(cyclopropylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2,5-dimethylphenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2-methylphenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2-methoxyphenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
3 - { 1 - [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} benzonitrile; 3-chloro-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
4-[l-(l-cyclohexylethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-fluoro-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
2-fluoro-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
3-fluoro-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
4-(l- {l-[3-(trifluoromethyl)phenyl]ethyl}-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-[l-(3,5-dimethylphenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
{4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]phenyl}acetonitrile;
4-[l-(l-methylhexyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(l -sec-butyl- lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-[l-(l-phenylpropyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(l - { 1 -[4-(methylsulfonyl)phenyl] ethyl} - lH-pyrazol-4-yl)- lH-pyrrolo[2,3-b]pyridine;
4- { 1 -[I -(3-fluoro-4-methoxyphenyl)ethyl]- lH-pyrazol-4-yl} - lH-pyrrolo[2,3-b]pyridine;
4-(l- {l-[2-(trifluoromethyl)phenyl]ethyl}-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-(l- {l-[3,5-bis(trifluoromethyl)phenyl]ethyl}-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-{l-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]ethyl}benzonitrile;
4-{l-[4-nitro-2-(trifluoromethyl)phenyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
3-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
4-[l-(2-chlorophenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
3-bromo-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile; ethyl 4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzoate;
4-{l-[2-chloro-6-nitro-4-(trifluoromethyl)phenyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]- pyridine;
4-(l- {l-[4-(trifluoromethyl)phenyl]ethyl}-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2,3-dihydro-lH-inden-l-yl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(l,2,3,4-tetrahydronaphthalen-l-yl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-(l - { 1 -[2-chloro-5-(trifluoromethyl)phenyl]ethyl} - lH-pyrazol-4-yl)- lH-pyrrolo[2,3-b]- pyridine;
4-{l-[l-(2,4-dichloro-5-fluorophenyl)ethyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-[l-(l-cyclopentylethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4- [ 1 -( 1 -methyl-3 -phenylpropyl)- 1 H-pyrazol-4-yl] - 1 H-pyrrolo [2,3 -b]pyridine;
4-[l-(l-cyclobutylethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
[2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-5-(trifluoromethyl)phenyl]- acetonitrile;
[5-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-2-(trifluoromethyl)phenyl]- acetonitrile; 4- { 1 -[pent-3-en- 1 -yl]- lH-pyrazol-4-yl} - lH-pyrrolo[2,3-b]pyridine;
2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
4- { 1 -[4-phenylbut-3-en- 1 -yl]- lH-pyrazol-4-yl} - lH-pyrrolo[2,3-b]pyridine;
6-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]hexanenitrile; ethyl 3-amino-2-{[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]methyl}-propanoate; ethyl 2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]propanoate;
4-[l-(l-propylbutyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]butanenitrile;
[3-chloro-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-5-(trifluoromethyl)phenyl]- acetonitrile;
5-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-2-(trifluoromethyl)-benzonitrile;
4-{l-[2-chloro-4-(trifluoromethyl)phenyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-2-(trifluoromethyl)-benzonitrile;
2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
3-chloro-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
4-amino-5,6-difluoro-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]isophthalonitrile;
1 - { [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]methyl} -cyclopropanecarbonitrile;
5-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]hexanenitrile;
2,2-dimethyl-6-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]hexanenitrile;
4-[l-(l-ethyl-2-methylpropyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
5-bromo-2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-4-(trifluoromethyl)-benzonitrile;
2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-3-(trifluoromethyl)-benzonitrile;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-4-(trifluoromethyl)benzamide;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclohexanone;
2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclohexanol;
4-(l- {[l-(methylsulfonyl)piperidin-4-yl]methyl}-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]- pyridine;
2-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclohexanecarbonitrile;
4-{l-[2-(trifluoromethyl)phenyl]-lH-pyrazol-4-yl}-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2,6-dichlorophenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
(4- { [4-(l H-pyrrolo[2,3-b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]methyl} eye lohexyl)methanol;
4- [l-(tetrahydrofuran-2-ylmethyl)-lH-pyrazol-4-yl]-l H-pyrrolo [2,3 -b]pyridine;
4-[l-(l-cyclopentylpropyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(tetrahydroruran-3-ylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
2-chloro-3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-3-(l,3-thiazol-5-yl)propanenitrile; l-benzyl-4- {[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]methyl}pyrrolidin-2-one;
3 -( 1 -methyl- 1 H-imidazol-5-yl)-3 - [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]- propanenitrile;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]-3-(3-thienyl)propanenitrile;
{ 1 -[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)- lH-pyrazol- 1 -yl]cyclopentyl} acetonitrile;
4-chloro-3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]phthalonitrile;
3-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]benzaldehyde;
4-[l-(2-methyl-4-nitrophenyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclopentanone;
4-[l-(3-furylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
4-[l-(2-furylmethyl)-lH-pyrazol-4-yl]-lH-pyrrolo[2,3-b]pyridine;
3-{2-cyano-l-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]ethyl}benzonitrile;
{3-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]phenyl}methanol;
4-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]pentan-2-one;
3 -(l-benzofuran-2-yl)-3 -[4-(I H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yljpropanenitrile;
3 -(3 -furyl)-3 - [4-( 1 H-pyrrolo [2,3 -b]pyridin-4-yl)- 1 H-pyrazol- 1 -yl]propanenitrile;
{3-methyl-4-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]phenyl} acetonitrile;
4-methyl-3-[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)-l H-pyrazol- l-yl]benzonitrile;
4-[l-(l-cyclopentylpropyl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
{ 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]cyclopentyl} acetonitrile;
3- {(2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}benzonitrile;
3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] -3 -(3 -thienyl)propanenitrile;
4-chloro-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]benzonitrile;
3 -(3 -furyl)-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]propanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanedinitrile;
3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]cyclopentyl} -propanenitrile;
{ 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- l-yl]cyclohexyl} acetonitrile;
{3-methyl-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]phenyl}methanol;
3-pyridin-4-yl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]propanenitrile; 3-pyridin-3-yl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3-[4-(methylthio)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3-(3-methoxyphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3-(4-methoxyphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
{3-methyl-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]phenyl} acetonitrile; 3-[4-(methylsulfinyl)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3 - [4-(methylsulfonyl)phenyl] -3 - [4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3-[3-(cyanomethoxy)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-(6-chloropyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
5-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}pyridine-2- carbonitrile;
3-(3,5-dimethylisoxazol-4-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]- propanenitrile;
3-(6-methoxypyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3-pyridin-2-yl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3-(6-bromopyridin-2-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
6-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}pyridine-2- carbonitrile;
4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]heptanedinitrile;
3-(5-bromopyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3 -[4-(7H-Pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]pentane- 1 ,5-diol
5-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}nicotinonitrile;
3-(2-methoxypyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3-[4-(cyanomethoxy)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-[2-(cyanomethoxy)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-(3,5-dibromophenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
5-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}isophthalonitrile;
3 - [6-(dimethylamino)pyridin-2-yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile; 3-(4-bromo-2-thienyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
5- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}thiophene-3- carbonitrile;
3-(5-bromo-2-fluorophenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-(3-nitrophenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3-(5-bromo-2-methoxyphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -4-methoxybenzo- nitrile;
3-(3-bromophenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -4-fluorobenzo- nitrile;
3-[5-bromo-2-(cyanomethoxy)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]propanenitrile;
3-(4-bromo-2-fiαryl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l-yl]propanenitrile;
4-(cyanomethoxy)-3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]- ethy 1 } b enzonitrile ;
3-(4-bromopyridin-2-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
2- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}isonicotinonitrile;
5- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -3-furonitrile;
3-[2-bromo-5-(cyanomethoxy)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]propanenitrile;
4-(cyanomethoxy)-2- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]- ethy 1 } b enzonitrile ;
3-pyrimidin-5-yl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3-(2-bromopyridin-4-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
4- {2-cyano- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}pyridine-2-carbo- nitrile;
3-(5-methoxypyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3-(3-chlorophenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]-3 - [3 -(trifluoromethyl)phenyl] - propanenitrile; 3-(3-phenoxyphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]-3 - [3 -(trifluoromethoxy)-phenyl] - propanenitrile; methyl 3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}benzoate;
3-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}benzoic acid;
3-[3-(lH-pyrazol-4-yl)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-(3-aminophenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-y I)- 1 H-pyrazol- 1 -yl] ethyl} pheny I)- acetamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl)- methanesulfonamide ;
4- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}thiophene-2- carbonitrile;
5- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}thiophene-2- carbonitrile;
3-[3-(morpholin-4-ylcarbonyl)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]propanenitrile;
N-(2-aminoethyl)-3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]- ethyl}benzamide;
3-(5-formyl-3-thienyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3- {2-cyano- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}-N-methylbenz- amide;
2-cyano-N-(3- {2-cyano- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}- phenyl)acetamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl- nicotinamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-y I)- 1 H-pyrazol- 1 -yl] ethyl} pheny I)-N'- isopropylurea; isopropyl (3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]ethyl} - phenyl)carbamate;
3-(5-phenylpyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3-(3,3'-bipyridin-5-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile; 3-(5-pyrimidin-5-ylpyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-[5-(l-methyl-lH-pyrazol-4-yl)pyridin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
3-(5-ethynylpyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
3-[5-(phenylthio)pyridin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3-(2-bromo-l,3-thiazol-5-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile; ethyl 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- l-yl]butanoate;
3-(5-morpholin-4-ylpyridin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3 -( 1 -methyl- 1 H-pyrazol-4-yl)-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
4-{l-[l-phenyl-2-(lH-l,2,4-triazol-l-yl)ethyl]-lH-pyrazol-4-yl}-7H-pyrrolo[2,3-d]- pyrimidine;
4-{l-[l-phenyl-2-(4H-l,2,4-triazol-4-yl)ethyl]-lH-pyrazol-4-yl}-7H-pyrrolo[2,3-d]- pyrimidine;
3-(3-pyridin-3-ylphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3 - [5-(phenylsulfinyl)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 - [5-(phenylsulfonyl)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 -[4-(7H-pyrro Io [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]pentan- 1 -ol; methyl 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentyl carbonate;
(lE)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanal oxime;
(lE)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanal O-methyloxime;
(lZ)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanal O-methyloxime;
4-[l -(4,4-dibromo- 1 -ethylbut-3-en- 1 -yl)- lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-[5-(l,3-thiazol-2-ylthio)pyridin- 3-yl]propanenitrile;
3-[5-(ethylthio)pyridin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
4-[l -(I -ethylbut-3-yn- 1 -yl)- lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine trifluoroacetate; 4- { 1 - [ 1 -methyl-2-( 1 H- 1 ,2,4-triazol- 1 -yl)ethyl] - 1 H-pyrazol-4-yl} -7H-pyrrolo [2,3 -d] - pyrimidine;
4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]pentan-2-one trifluoroacetate;
1 -phenyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]propan- 1 -one;
3-[5-(ethylsulfinyl)pyridin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
3 - [5-(ethylsulfonyl)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 - [5-(cyclohexylthio)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
1 -phenyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]propan- 1 -ol;
1 -phenyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]propan- 1 -ol;
3 - [3 -(ethylthio)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 - [3 -(ethylsulfinyl)phenyl] -3 - [4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 - [3 -(ethylsulfonyl)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 - [5-(cyclohexylsulfonyl)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]-pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]propanenitrile;
3 - [5-(cyclohexylsulfmyl)pyridin-3 -yl]-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]propanenitrile;
4-[l-(l-methyl-2-phenylethyl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4-{l-[l-methyl-2-(3-thienyl)ethyl]-lH-pyrazol-4-yl}-7H-pyrrolo[2,3-d]pyrimidine;
3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}benzonitrile;
4- { 1 -[2-( 1 H-imidazol- 1 -yl)- 1 -methylethyl]- 1 H-pyrazol-4-yl} -7H-pyrrolo[2,3-d]pyrimidine; 4- { 1 - [ 1 -methyl-2-(3 -methyl- 1 ,2,4-oxadiazol-5-yl)ethyl] - 1 H-pyrazol-4-yl} -7H-pyrrolo [2,3 -d] - pyrimidine;
3 - [3 -(methylsulfbnyl)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3-(3-pyridin-4-ylphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propane- nitrile;
4-[l -(I -ethylbut-3-en- 1 -yl)- 1 H-pyrazol-4-yl] -7H-pyrrolo [2,3 -d]pyrimidine;
4-[l-(l,3-dimethylbut-3-en-l-yl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
3 - [5-(isopropylthio)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile; 3 - [5-(isopropylsulfmyl)pyridin-3 -yl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]propanenitrile;
3 - [5-(isopropylsulfbnyl)pyridm-3 -yl]-^ - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]propanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-[5-(trifluoromethyl)pyridin-3-yl]- propanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-[5-(trifluoromethyl)pyridin-3-yl]- propanenitrile;
2- [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]-N- [3 -(trifluoromethyl)phenyl] - propanamide;
N-2-naphthyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanamide;
N-l-naphthyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanamide;
N-(3-cyanophenyl)-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanamide;
N-benzyl-2- [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]propanamide;
N-phenyl-2-[4-(7H-pyrrolo[2,3-d]-'pyrimidin-4-yl)-lH-pyrazol-l-yl]-'butanamide;
N-(4-phenoxyphenyl)-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanamide;
N-2-naphthyl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanamide;
N-(3-cyanophenyl)-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanamide;
N-biphenyl-4-yl-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanamide;
N-(biphenyl-4-ylmethyl)-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- butanamide;
N-(biphenyl-3-ylmethyl)-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- butanamide;
N-(4-cyanophenyl)-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]butanamide;
N- 1 -naphthyl-2- [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]butanamide;
5- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-phenylnicotin- amide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl)-3- (trifluoromethyl)benzamide;
N-(3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}phenyl)-3-(trifluoro- methyl)benzamide;
3 - [3 -(methylsulfbnyl)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3 - [3 -(methylsulfbnyl)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
N-(3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}phenyl)benzene- sulfonamide; 3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}-N-[3-(trifluoromethyl)- phenyl]benzamide;
3-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}-N,N-dimethyl- benzenesulfonamide;
3-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}-N,N-dimethyl- benzenesulfonamide;
N-benzyl-3 - {2-cyano- 1 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} - benzenesulfonamide;
N-benzyl-3- {2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}- benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-phenyl- benzamide;
3 - {2-cyano- 1 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} -N- [3 -(trifluoro- methyl)phenyl]benzamide;
N-(3-cyanophenyl)-3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}- benzamide;
N-benzyl-3- {[4-(7H-pyrrolo-'[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}benzamide;
N- 1 -naphthyl-3- {[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]methyl}benzamide;
N-2-naphthyl-3- {[4-(7H-pyrrolo[2,3-d]-'pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}benzamide;
N-(3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}phenyl)-2-naphthamide;
N-(3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}phenyl)-l-naphthamide;
2-phenyl-N-(3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}phenyl)- acetamide;
3-chloro-N-(3- {[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}phenyl)- benzamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl)-2- naphthamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl)- 1 - naphthamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] -ethyl} phenyl)-2- phenylacetamide;
3-cyano-N-(3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} - phenyl)benzamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl)- benzamide;
N-(3- {2-cyano- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] ethyl} phenyl)-4- (trifluoromethyl)benzamide; N-(3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}phenyl)-N'- phenylurea;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-[4-(trifluoro- methyl)phenyl]benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-(4-methyl- phenyl)benzamide;
N-(4-cyanophenyl)-3- {2-cyano- l-[4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)- lH-pyrazol- 1-yl]- ethyl}benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-2-naphthyl- benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N- 1-naphthyl- benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl) - lH-pyrazol- 1 -yl] ethyl} -N,N-dimethyl- benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-pyridin-3-yl- benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-methyl-N- phenylbenzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-cyclohexyl- benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-(4-phenoxy- phenyl)benzamide;
N-(3-cyanophenyl)-3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]- ethyl}benzamide;
N-biphenyl-4-yl-3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d ]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]- ethyl}benzamide;
N-(4-chlorophenyl)-3- {2-cyano- l-[4-(7H-pyrrolo [2, 3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- ethyl}benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(3,4-dimethyl- phenyl)benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(3-methoxy- phenyl)benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(4-methoxy- phenyl)benzamide;
3- {2-cyano- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}-N-isoxazol-3-yl- benzamide; 3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-methyl-N- phenylbenzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-propyl- benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-phenyl- benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-2-naphthyl- benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-cyclopropyl- benzenesulfonamide;
3-[3-(piperidin- 1 -ylsulfonyl)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl]propanenitrile;
3 - [3 -(morpholin-4-ylsulfonyl)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]propanenitrile;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-(4-methyl- phenyl)benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(3,4-dimethyl- phenyl)benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(3-methoxy- phenyl)benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(4-methoxy- phenyl)benzenesulfonamide;
3-{2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}-N-(3,5- dimethoxyphenyl)benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-[4-(dimethyl- amino)phenyl]benzamide;
3 - [3 -(benzylsulfonyl)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3-[3-(benzylthio)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- propanenitrile;
4-{[(3- {2-cyano-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}phenyl)- sulfonyl]methyl}benzonitrile;
3- {2-cyano- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]ethyl}-N-methyl- benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N- 1-naphthyl- benzenesulfonamide; N-biphenyl-4-yl-3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} - benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-[4-(trifluoro- methoxy)phenyl]benzamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(2-methoxy- phenyl)benzamide;
3 - [3 -(benzyloxy)phenyl] -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-cyclohexyl- benzenesulfonamide;
3-[3-(3,4-dihydroisoquinolin-2(lH)-ylsulfonyl)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)- 1 H-p yrazol- 1 -yl]propanenitrile;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] ethyl} -N-(2-methoxy- ethyl)benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N,N-diethyl- benzenesulfonamide;
3-{3-[(4-ethylpiperazin-l-yl)sulfonyl]phenyl}-3-[ 4-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
N- 1 ,3 -benzodioxol-5-yl-3 - {2-cyano- 1 - [4-(7H-pyrrol o [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl] ethyl} benzenesulfonamide;
3-{3-[(3-methoxybenzyl)sulfonyl]phenyl}-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
3-{3-[(4-methoxybenzyl)sulfonyl]phenyl}-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
3-{3-[(2,6-dimethylmorpholin-4-yl)sulfonyl]phenyl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]propanenitrile;
3-{3-[(4-oxopiperidin-l-yl)sulfonyl]phenyl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
3 - [3 -(isopropylsulfonyl)phenyl]-3 - [4-(7H-pyrrolo [ 2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3-{3-[(cyclohexylmethyl)sulfonyl]phenyl}-3-[4-(7H -pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
3-[3-(octahydroisoquinolin-2(lH)-ylsulfonyl)phenyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)- 1 H-pyrazol- 1 -yl]propanenitrile;
3-{3-[(2-phenylethyl)-sulfonyl]phenyl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol- l-yl]propanenitrile cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclohexylacetonitrile; cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexylmethylthiocyanate;
N-S-f^is^-^^TH-pyrroloP^-dlpyrimidin^-y^-lH-pyrazol-l-yllcyclohexylmethy^thio]- 4H- 1 ,2,4-triazol-3-ylpyrimidin-2-amine;
N-5-[(cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexylmethyl)thio]- 4H- 1 ,2,4-triazol-3-ylpyrimidin-2-amine;
3-cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexylpropanenitrile;
5-[(2-cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexylethyl)thio]-4H- l,2,4-triazol-3-amine;
4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yljcyclohexylideneacetonitrile; cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexanecarbonitrile;
2-[(cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexylmethyl)sulfinyl]- benzonitrile;
2-[(cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexylmethyl)sulfonyl]- benzonitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]cyclohexylacetonitrile;
5-({cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexyl}thio)-lH-l,2,4- triazol-3-amine;
N-{5-[({cis-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclohexyl}methyl)- thio]-4H- 1 ,2 ,4-triazol-3-yl}methanesulfonamide;
[cis-4-[4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]- 1 -(1H- 1 ,2,4-triazol- 1 -yl)cyclo- hexyl] acetonitrile;
3-[3-(piperazin- 1 -ylsulfonyl)phenyl]-3-[4-(7H-pyr rolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl]propanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-[3-(thiomorpholin-4-ylsulfonyl)- phenyljpropanenitrile;
3-{3-[(4-hydroxypiperidin-l-yl)sulfonyl]phenyl}-3 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol -l-yl]propanenitrile;
3 - [3 -(isobutylsulfonyl)phenyl] -3 - [4-(7H-pyrrolo [2 ,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - propanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol -l-yl]-3-{3-[(tetrahydro-2H-pyran-4- ylmethyl)sul fonyl]phenyl}propanenitrile;
3-{3-[(2-methoxyethyl)sulfonyl]phenyl}-3-[4-(7H-p yrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
3-{3-[(3-fiαrylmethyl)sulfonyl]phenyl}-3-[4-(7H-py rrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol- 1 -yl]propanenitrile;
3 - {3 - [( 1 , 1 -dioxidothiomorpholin-4-yl)sulfonyl]phe nyl} -3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4- yl)- 1 H-p yrazol- 1 -yl]propanenitrile; 3- {3-[(4-acetylpiperazin- 1 -yl)sulfonyl]phenyl} -3- [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- IH- pyrazol- 1 -yl]propanenitrile;
3-{3-[(pyridin-4-ylmethyl)sulfonyl]phenyl}-3-[4-( 7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]propanenitrile;
4-[l -(I -phenylbut-3-yn- 1 -yl)- lH-pyrazol-4-yl]-7H- pyrrolo[2,3-d]pyrimidine;
4-(l- {l-[3-(morpholin-4-ylsulfonyl)phenyl]but-3-yn-l-yl}-lH-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidine;
3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]but-3-yn- 1 -yljbenzonitrile;
3- { 1 -[4-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)- lH-pyrazol- 1 -yl]but-3-yn- 1 -yljbenzaldehyde; methyl 3 -(3 -cyanophenyl)-3-[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)-l H-pyrazol- 1-yl]- propanoate;
N,N-dimethyl-3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)- 1 H-pyrazol- 1 -yl]but-3-yn- 1 -yl} - benzenesulfonamide;
3- {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl} -N-[4-(dimethyl- amino)phenyl]benzenesulfonamide;
3- {3-methoxy- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-y I)- 1 H-pyrazol- 1 -yl]propyl} -NN- dimethylbenzenesulfonamide;
N-phenyl-3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl )- lH-pyrazol- 1 -yl]but-3-yn- 1 -yl} - benzamide;
4- [ 1 -(3 -methoxy- 1 -phenylpropyl)- 1 H-pyrazol-4-yl] - 7H-pyrrolo [2,3 -d]pyrimidine;
N-[4-(dimethylamino)phenyl]-3- { 1 -[4-(7H-pyrrolo[2 ,3-d]-pyrimidin-4-yl)- lH-pyrazol- 1 - yl]but-3-yn- 1 -yl}benzamide;
3- {3-hydroxy- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-y I)- 1 H-pyrazol- 1 -yl]propyl} -NN- dimethylbenzenesulfonamide;
3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]but-3-en- 1 -yl}benzonitrile;
4- { 1 -[I -(3-bromophenyl)but-3-en- 1 -yl]- 1 H-pyrazol-4-yl} -7H-pyrrolo[2,3-d]pyrimidine; 3-{4,4-difluoro-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)-lH-pyrazol-l-yl]but-3-en-l-yl}- benzonitrile;
4-(l - {4,4-difluoro- 1 -[3-(morpholin-4-ylsulfonyl)phenyl]but-3-en- 1 -yl} - lH-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidine;
4-(l - { 1 -[3-(ethylsulfonyl)phenyl]-4,4-difluorobut-3-en- 1 -yl} - lH-pyrazol-4-yl)-7H-pyrrolo- [2,3-d]pyrimidine;
4-(l- {l-[3-(benzyloxy)phenyl]-4,4-difluorobut-3-en-l-yl}-lH-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidine;
4-[l -(2-methoxy- 1 -phenylethyl)- lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4-(l- {4j4-difluoro-l-[3-(methylsulfonyl)phenyl]but-3-en-l-yl}-lH-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidine; 3-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]methyl}benzonitrile;
3- { 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -ylj-'butyljbenzonitrile; 4-(l- {l-[3-(ethylsulfonyl)phenyl]-4,4-difluorobutyl}-lH-pyrazol-4-yl)-7H-pyrrolo[2,3-d]- pyrimidine;
4-[l -(4,4-difluoro- 1 - {3-[(2-methoxyethyl)sulfonyl]phenyl} -but-3-en- 1 -yl)- 1 H-pyrazol-4-yl] - 7H-pyrrolo[2,3-d]pyrimidine;
4-[l-(l-cyclopentylbut-3-en-l-yl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4-[l-(l-methylbut-3-en-l-yl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4-[l-(l-cyclopentyl-2-cyclopropylethyl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4-[l-(l-cyclopentylbut-3-yn-l-yl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4-[l-(l-cyclopentylbutyl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
4- [ 1 -( 1 -cyclopentyl-4,4-difluorobut-3 -en- 1 -yl)- 1 H-pyrazol-4-yl] -7H-pyrrolo [2,3 -d] - pyrimidine;
4- { 1 -[4,4-difluoro- 1 -(tetrahydrofuran-3-yl)but-3-en- 1 -yl]- 1 H-pyrazol-4-yl} -7H-pyrrolo[2,3- d]pyrimidine;
4-(l-(5,5-difluoropent-4-en-2-yl)-lH-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine; 4-[l-(l- cyclopropyl-4,4-difluorobut-3 -en- l-yl)-l H-pyrazol-4-yl] -7H-pyrrolo [2,3 -d]pyrimidine;
4-[l-(l-cyclopentyl-4,4-difluorobutyl)-lH-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine;
3-(l -methylcyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]propane- nitrile;
4,4-dimethyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]pentanenitrile;
1 - {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}cyclopropane- carbonitrile;
N-[(l - {2-cyano- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]ethyl}cyclopentyl)- methyl]benzamide;
3- { 1 -[(benzyloxy)methyl]cyclopentyl} -3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl]propanenitrile;
3-[l-(methylsulfonyl)pyrrolidin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]propanenitrile;
N'-cyano-4-(cyanomethyl)-4-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]- piperidine- 1 -carboximidamide;
4-{l-[2,2,2-trifluoro-l-(lH-imidazol-2-ylmethyl)ethyl]-lH-pyrazol-4-yl}-7H-pyrrolo[2,3- d]pyrimidine;
4-(l -2,2,2-trifluoro- 1 -[(4-methyl- 1 ,3-thiazol-2-yl)methyl] ethyl- 1 H-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidine;
4- { 1 -[I -(trifluoromethyl)but-3-yn- 1 -yl]- 1 H-pyrazol-4-yl} -7H-pyrrolo[2,3-d]pyrimidine; 4- { 1 -[I -(trifluoromethyl)but-3-en- 1 -yl]- 1 H-pyrazol-4-yl} -7H-pyrrolo[2,3-d]pyrimidine; 4-{l-[l-(trifluoromethyl)butyl]-lH-pyrazol-4-yl}-7H-pyrrolo[2,3-d]pyrimidine;
4- { 1 -[4,4-difluoro- 1 -(trifluoromethyl)but-3-en- 1 -yl]- lH-pyrazol-4-yl} -7H-pyrrolo[2,3-d]- pyrimidine;
4- { 1 -[4,4-difluoro- 1 -(trifluoromethyl)butyl]- lH-pyrazol-4-yl} -7H-pyrrolo[2,3-d]pyrimidine;
3-pyridin-4-yl-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]propanenitrile;
4-{2-cyano-l-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]ethyl}pyridine-2- carbonitrile; and
3-pyridin-2-yl-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l,3-thiazol-2-yl]propanenitrile; and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is selected from (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)-lH-pyrazol-l-yl]propanenitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is selected from 3-[3-Methyl-l-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol- 4-yl]benzonitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is selected from N-phenyl-4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-l,3-thiazol-2-amine and pharmaceutically acceptable salts thereof.
In a second aspect, the agent is selected from compounds of Formula II:
R1 a N
Figure imgf000071_0001
II and pharmaceutically acceptable salts thereof, wherein:
La is SO2 or CO;
Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4, wherein the alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R a and R a are independently selected from H, C^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl.
In some embodiments, when La is SO2, then Rla is other than 0R4a. In some embodiments, when La is SO2, then Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6- membered heteroaryl, or NR aR a, wherein the alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from F and Ci_4 alkyl.
In some embodiments, when La is CO, then Rlais C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein the cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from CN and Ci_4 alkyl.
In some embodiments, La is SO2.
In some embodiments, La is CO.
In some embodiments, Rla is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, 2- methylprop- 1 -yl, 1 -methylprop- 1 -yl, each optionally substituted with 1 , 2, or 3 F.
In some embodiments, Rla is Ci_4 alkyl.
In some embodiments, Rla is ethyl.
In some embodiments, Rla is C3_7 cycloalkyl optionally substituted by
Figure imgf000072_0001
alkyl.
In some embodiments, Rla is phenyl optionally substituted with F, methyl, or CN.
In some embodiments, Rla is 5-membered heteroaryl selected from thienyl, pyrazolyl, pyrrolyl, 1,2,4-oxadiazolyl, and isoxazolyl, each optionally substituted with Ci_4 alkyl.
In some embodiments, Rla is pyridinyl.
In some embodiments, Rla is NR2aR3a or 0R4a.
In some embodiments, La is SO2 and Rla is Ci_6 alkyl.
In some embodiments, the agent is selected from:
{ 1 -(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -y 1] azetidin-3 - yljacetonitrile;
1 -(cyclopropylsulfonyl)-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] azetidin-3 - ylacetonitrile;
1 -[(1 -methylcyclopropy^carbonyl-S-^-^H-pyrroloP^-dJpyrimidm^-yl)- lH-pyrazol- 1 - yl] azetidin-3 -ylacetonitrile;
1 -[(1 -methylcyclopropyl)sulfonyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl] azetidin-3 -ylacetonitrile;
1 -(methylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] azetidin-3 - yljacetonitrile;
{ 1 -(phenylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] azetidin-3 - yljacetonitrile;
{ 1 -(isopropylsulfonyl)-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] azetidin-3 - yljacetonitrile;
{ 1 -(propylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl] azetidin-3 - yljacetonitrile; {l-(butylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- yl} acetonitrile;
{ 1 -(tert-butylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin-3- yl} acetonitrile;
3-(cyanomethyl)-N,N-dimethyl-3-[4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1- yl]azetidine- 1 -sulfonamide;
{l-[(l-methyl-lH-pyrazol-3-yl)sulfonyl]-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol- 1 -yl]az etidin-3-yl} acetonitrile;
{3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazo l-l-yl]-l-[(3,3,3- trifluoropropyl)sulfonyl]azetidin-3-yl} acetonitrile;
{ 1 -(isobutylsulfonyl)-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] azetidin-3 - yl} acetonitrile;
{l-(sec-butylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- yl} acetonitrile;
{l-[(5-methyl-2-thienyl)sulfonyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]azetidin-3-yl} acetonitrile;
{ 1 -[(4-fluorophenyl)sulfonyl]-3-[4-(7H-pyrrolo[2, 3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]azetidin-3-yl} acetonitrile;
{ 1 -[(3-fluorophenyl)sulfonyl]-3-[4-(7H-pyrrolo[2, 3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]azetidin-3-yl} acetonitrile;
{ 1 -[(2-fluorophenyl)sulfonyl]-3-[4-(7H-pyrrolo[2, 3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]azetidin-3-yl} acetonitrile;
{ 1 -(pyridin-3 -ylsulfonyl)-3-[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -y 1] azetidin-3 - yl} acetonitrile;
{ 1 -(pyridin-2-ylsulfonyl)-3 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -y 1] azetidin-3 - yl} acetonitrile;
{ 1 -(cyclopropylcarbonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin- 3-yl} acetonitrile;
1 -[(1 -methylcyclopropyl)carbonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl] azetidin-3 -ylacetonitrile;
{l-benzoyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- yl} acetonitrile;
{ 1 -[(6-methylpyridin-2-yl)carbonyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yljazetid in-3-yl} acetonitrile;
{ 1 -(pyridin-3-ylcarbonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin- 3-yl} acetonitrile; { 1 -(3-methylbenzoyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin-3- yl} acetonitrile;
{ 1 -(4-methylbenzoyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin-3- yl} acetonitrile;
3-({3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-l- yl} carbonyl)benzonitrile;
[3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazo l-l-yl]-l-(2-thienylcarbonyl)azetidin-3- yl]acetonitrile;
[3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] - 1 -( 1 H-pyrrol-2- ylcarbonyl)azetidin-3 -yl] acetonitrile;
{l-(lH-indol-2-ylcarbonyl)-3-[4-(7H-pyrrolo[2,3-d ]pyrimidin-4-yl)-lH-pyrazol-l- yl]azetidin-3-yl} acetonitrile;
{ 1 -(isoxazol-5-ylcarbonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin- 3-yl} acetonitrile;
{l-(lH-pyrazol-3-ylcarbonyl)-3-[4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)-l H-pyrazol- 1- yl]azetidin-3-yl} acetonitrile; isobutyl 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidine- 1 -carboxylate; phenyl 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidine- 1 - carboxylate; benzyl 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidine- 1 - carboxylate;
3 -(cyanomethyl)-N-phenyl-3-[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)-l H-pyrazol- 1- yl]azetidine- 1 -carboxamide; and pharmaceutically acceptable salts of any of the aforementioned.
In some embodiments, the agent is selected from {l-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-yl}acetonitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is {l-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-lH-pyrazol-l-yl]azetidin-3-yl}acetonitrile phosphoric acid salt.
In a third aspect, the agent is selected from compounds of Formula III:
Figure imgf000075_0001
III and pharmaceutically acceptable salts thereof, wherein:
R5a and R6a are independently selected from H, F, CN, OH, Ci_4 alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein the alkyl is optionally substituted by 1, 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein the 5-membered heteroaryl is optionally substituted with Ci_4 alkyl.
In some embodiments, when one of R5a and R6a is OH, then the other of R5a and R6a is other than CN or F.
In some embodiments, one of R5a and R6a is H and the other is selected from H, F, CN, OH, Ci_4 alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein the alkyl is optionally substituted by 1, 2, or 3 substituents selected from F, OH, CN, and Q-4 alkoxy, and wherein the 5-membered heteroaryl is optionally substituted with Ci_4 alkyl.
In some embodiments, R5a and R6a are independently selected from H, F, CN, OH, and methyl.
In some embodiments, R5a and R6a are independently selected from H and CN.
In some embodiments, the agent is selected from:
3-(cyanomethyl)-N,N-dimethyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl] cyclobutanesulfonamide ;
3-isoxazol-3-yl-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl] cyclobuty lacetonitrile ;
{3-(3-methyl- 1 ,2,4-oxadiazol-5-yl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidn-4-yl)- 1 H-pyrazol- 1 - yl]cyclobutyl} acetonitrile;
{3 -(3 -tert-butyl- 1 ,2,4-oxadiazol-5-yl)- 1 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl]cyclobutyl} acetonitrile; l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutylacetonitrile;
3-(hydroxymethyl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl] cyclobuty lacetonitrile ;
3-(fluoromethyl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl] cyclobuty lacetonitrile ; 3-(difluoromethyl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl] cyclobuty lacetonitrile ;
2,2'- [1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]cyclobutane- 1 ,3- diyl] diacetonitrile;
3-(cyanomethyl)- 1 -methyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yljcyclobutanecarbonitrile;
3-(cyanomethyl)- 1 -(methoxymethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yljcyclobutanecarbonitrile;
3-(cyanomethyl)- 1 -(fluoromethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yljcyclobutanecarbonitrile;
1 ,3-bis(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yljcyclobutanecarbonitrile;
3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutanecarbonitrile;
3,3-bis(hydroxymethyl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 - yl] cyclobuty lacetonitrile ;
3,3-bis(fluoromethyl)-l-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]pyrimidin- 4-yl)- 1 H-pyrazol- 1 -yl]cyclobutylacetonitrile;
2,2',2"-[l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutane-l,3,3- triyl]triacetonitrile;
3-hydroxy-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutylacetonitrile;
3-fluoro- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl] cyclobuty lacetonitrile;
3 -methyl- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]cyclobutylacetonitrile;
3, 3 -dimethyl- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-y I)- 1 H-pyrazol- 1 -yl]cyclobutylacetonitrile;
3-(benzyloxy)- 1 -[4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl] cyclobuty lacetonitrile ; and pharmaceutically acceptable salts of any of the aforementioned.
In some embodiments, the agent is selected from 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-l H-pyrazol- l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is selected from cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-l H-pyrazol- l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof. In some embodiments, the agent is selected from trans-3-(cyanomethyl)-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof.
In a fourth aspect, the agent is selected from compounds of Formula IV:
Figure imgf000077_0001
I or pharmaceutically acceptable salt or prodrug thereof, wherein: D1 is N, NO, or CRla;
Dz is N, NO, or CR I1b
D3 is N, NO, or CR I1cC;. D4 is N, NO or CRld; Ring A is
Figure imgf000077_0002
X and Y are each, independently, N or CR5;
Z1 and Z2 are each, independently, N, CR6, or NO; wherein at least one of Z1 and Z2 is other than CR6;
Ring B is
Figure imgf000077_0003
D is O, S, or NR8; E is N or CR9;
G is O, S, or NR8;
J is N or CR7;
R is -W1 -W2- W3- W4;
W1 is absent, Q-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, O, S, NR11, CO, COO, CONR11, SO, SO2, SONR11, SO2NR11, Or NR11CONR12, wherein the Ci_6 alkyl, C2.6 alkenyl, C2.6 alkynyl are each optionally substituted by 1, 2 or 3 halo, OH, Ci_4 alkoxy, Ci_4 haloalkoxy, amino, Ci_4 alkylamino or C2_8 dialkylamino;
W is absent, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the Q_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by one or more halo, CN, NO2, OH, =NH, =N0H, =NO-(Ci_ 4 alkyl), Ci_4 haloalkyl, Ci4 alkoxy, Ci_4 haloalkoxy, amino, Ci4 alkylamino or C2_g dialkylamino;
W3 is absent, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, O, S, NR10, =N-, =N-0-, =N-0-( Ci_4 alkyl), 0-( d_4 alkyl), S-(Ci-4 alkyl), NR10-( d_4 alkyl), (d_4 alkyl)-O-( d_4 alkyl), (d_4 alkyl)-S-(d_4 alkyl), (Ci_4 alkyl)-NR10-( Ci_4 alkyl), CO, COO, C(0)-(d_4 alkyl), C(0)0-(d_4 alkyl), C(O)-(Ci4 alkyl)- C(O), NR10C(O)-(d_4 alkyl), C(O)NR10-(d_4 alkyl), NR10C(O)O-(d_4 alkyl), NR10C(O)O, CONR10, SO, SO2, SONR10, SO2NR10, Or NR10CONR11, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl are each optionally substituted by 1, 2 or 3 halo, OH, CN, Ci-4 alkoxy, Ci_4 haloalkoxy, amino, Ci_4 alkylamino or C2_g dialkylamino;
W4 is H, NR10R11, CN, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, Q-4 alkoxy, =NH, =N0H, =N0-(d_4 alkyl), Ci-4 haloalkyl, Ci-4 haloalkoxy, COOH, COO-(CL4 alkyl), amino, Ci-4 alkylamino or C2_8 dialkylamino;
Rla, Rlb, Rlc and Rld are each, independently, H, halo,d_4 alkyl, C24 alkenyl, C2_4 alkynyl, Q-4 haloalkyl, OH, Ci-4 alkoxy, Ci_4 haloalkoxy, CN, NO2, C(O)-(Ci4 alkyl), C(O)OH, C(O)O-(Ci-4 alkyl), C(O)NH2, C(0)NH(Ci_4 alkyl), C(O)N(C14 alkyl)2, S(O)2NH2, S(O)2NH(Ci4 alkyl), S(O)2N(Ci4 alkyl)2, S(O)2-(Ci4 alkyl), NH2, NH(Ci4 alkyl), Or N(Ci4 alkyl)2;
R2 is H, OH, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl;
R2a is Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
R3, R4, R5, and R6 are each, independently, H, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, halo, Ci4 haloalkyl, CN, NO2, OR12, SR12, C(O)R13, C(O)OR12, C(O)NR14R15, NR14R15, NR14CONHR15, NR14C(O)R13, NR14C(O)OR12, S(O)R13, S(O)2R13, S(O)NR14R15, SO2NR14R15;
R7 is H, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, halo, Ci4 haloalkyl, OH, Ci4 alkoxy, Ci4 haloalkoxy, CN, NO2, C(O)-(Ci4 alkyl), C(O)OH, C(O)O-(Ci4 alkyl), C(O)NH2, C(O)NH(Ci4 alkyl), C(O)N(Ci_4 alkyl)2, S(O)2NH2, S(O)2NH(Ci_4 alkyl), S(O)2N(Ci_4 alkyl)2, S(O)2-(C14 alkyl), NH2, NH(Ci_4 alkyl), or N(Ci_4 alkyl)2;
R8 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, OH or C14 alkoxy;
R9 is H, halo, C14 alkyl, C14 haloalkyl, C24 alkenyl, C24 alkynyl, OH, C14 alkoxy or C14 haloalkoxy;
R10 and R11 are each, independently, H, Q-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, cycloalkylalkyl, CORa, SORa, or SO2Ra wherein each of the Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl is optionally substituted by 1 , 2 or 3 substitutents sleeted from halo, C14 alkyl, C14 haloalkyl, OH, C14 alkoxy, C14 haloalkoxy, amino, Ci- 4 alkylamino, C2_g dialkylamino, aminocarbonyl, C14 alkylaminocarbonyl, or C2_g dialkylaminocarbonyl, CN and NO2; or R10 and R11 together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by 1, 2 or 3 substitutents sleeted from halo, C14 alkyl, C14 haloalkyl, OH, C14 alkoxy, C14 haloalkoxy, amino, C14 alkylamino, C2_g dialkylamino, aminocarbonyl, C14 alkylaminocarbonyl, or C2_g dialkylaminocarbonyl;
R12 and R13 are each, independently, H, Ci-6 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl;
R14 and R15 are each, independently, H, Ci-6 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R14 and R15 together with the N atom to which they are attached form a heterocyclyl group;
Ra is H, Ci-6 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, cycloalkylalkyl, heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, NH2, NH(Ci-6 alkyl), N(Ci-6 alkyl)2, NH(carbocyclyl), N(carbocyclyl)2, NH(carbocyclylalkyl) or N(carbocyclylalkyl)2; with the proviso that when Ring A is:
Ring B is:
Figure imgf000079_0001
D1 is CRla;
Dz is N or CR . I1bD;. D3 is CRlc; and D4 is CRld; then W1 is O, S, NR11, SO, SO2, SONR11, SO2NRu,or NR11CONR12. According to some embodiments, Ring A is
Figure imgf000080_0001
In some embodiments, both X and Y are CR5.
In some embodiments, both X and Y are N.
In some embodiments, one of X and Y is N and the other is CR5.
In some embodiments, X is CR5 and Y is N.
In some embodiments, X is N and Y is CR5.
In some embodiments, R2 is H.
In some embodiments, R is H, X is CH and Y is CH.
In some embodiments, Ring A is
Figure imgf000080_0002
In some embodiments, Z1 is NO or Z2 is NO. In some embodiments, Z1 is NO and Z2 is CR6. In some embodiments, Z2 is NO and Z1 is CR6. In some embodiments, Ring A is
Figure imgf000080_0003
In some embodiments, R a is Ci_6 alkyl. In some embodiments, R2a is methyl. In some embodiments, at least one of X and Y is N. In some embodiments, Ring B is
Figure imgf000081_0001
In some embodiments, G is O or S.
In some embodiments, G is NR8.
In some embodiments, G is NH.
In some embodiments, R is H, Q_6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or
NR10R11
In some embodiments, R is H, Q_6 alkyl Or NR10R11.
In some embodiments, R is O-W2-W3-W4 , S-W2-W3-W4 or NRU-W2-W3-W4.
In some embodiments, Ring B is
Figure imgf000081_0002
In some embodiments, D is S.
In some embodiments, D is O.
In some embodiments, D is NR8.
In some embodiments, R is H, Ci_6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or
In some embodiments, R is H, Q_6 alkyl Or NR10R11.
In some embodiments, R is (Ci-6 alkyl)-W2-W3-W4, O-W2-W3-W4 , S-W2-W3-W4 , NRU-W2- W3-W4, or -W2-W3-W4.
In some embodiments, D is S or O and R is O-W2-W3-W4 , S-W2-W3-W4 or NRU-W2-W3-W4.
In some embodiments, D is S and R is O-W2-W3-W4 , S-W2-W3-W4 or NR11 -W2- W3- W4.
In some embodiments, Ring B is
Figure imgf000081_0003
In some embodiments, E is N.
In some embodiments, R7 is H.
In some embodiments, R is H, Ci_6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or
NR10R11
In some embodiments, R is H, Ci_6 alkyl or NR R . In some embodiments, E is CR9 and R is O-W2-W3-W4 , S-W2-W3-W4 or NR11 -W2- W3- W4. In some embodiments, Ring B is
Figure imgf000082_0001
In some embodiments, R is H, Q-6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl. In some embodiments, R is H or Ci_6 alkyl.
In some embodiments, R is (Ci-6 alkyl)-W2-W3-W4, CO-W2- W3-W4 , COO-W2- W3-W4, CONRU-W2-W3-W4 or SO2-W2-W3-W4. In some embodiments, Ring B is:
Figure imgf000082_0002
In some embodiments, J is N. In some embodiments, J is CR7.
In some embodiments, R is H, d_6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl. In some embodiments, R is H or Ci_6 alkyl.
In some embodiments, R is (CL6 alkyl)-W2-W3-W4, CO-W2- W3-W4 , COO-W2- W3-W4, CONRU-W2-W3-W4 or SO2-W2-W3-W4. In some embodiments, Ring B is
Figure imgf000082_0003
In some embodiments, R is Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, Ci_4 alkoxy, =NH, =N0H, =N0-(Ci_4 alkyl), Ci_4haloalkyl, Cμ haloalkoxy, COOH, COO-(d_4 alkyl), amino, Ci_4 alkylamino or C2-8 dialkylamino;
In some embodiments, R is cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, Ci_4 alkoxy, d_4haloalkyl, Ci-4 haloalkoxy, COOH, COO-(Ci_4 alkyl), amino, Ci-4 alkylamino or C2-8 dialkylamino.
In some embodiments, R is 5-, 6-, or 7-membered cycloalkyl or 5-, 6-, or 7-membered heterocycloalkyl, each optionally substituted by 1 or 2 halo, OH, CN, Ci_4 alkoxy, Ci_4haloalkyl, or Ci_4 haloalkoxy. In some embodiments, D1 is CRla, D2 is CRlb, D3 is CRlc and D4 is CRld.
In some embodiments, D2 is CRlb.
In some embodiments, D2 is CRlb and CRlb is H, Ci_4 alkyl or halo.
In some embodiments, D2 is CRlb and CRlb is H or halo.
In some embodiments, D2 is CRlb and CRlb is F, Cl, Br or I.
In some embodiments, D2 is CRlb; CRlb is F, Cl, Br or I; D1 is CH, D3 is CH; and D4 is CH.
In some embodiments, D2 is CF; D1 is CH, D3 is CH; and D4 is CH.
In some embodiments, at least one of D1, D2, D3, and D4 is N.
In some embodiments, at least one of D1, D3, and D4 is N.
In some embodiments, not more than 2 of D1, D2, D3, and D4 are N.
In some embodiments, at least one of D1, D2, D3, and D4 is NO.
In some embodiments, at least one of D1, D3, and D4 is NO.
In some embodiments, the agent is selected from compounds of Formula IVa:
Figure imgf000083_0001
IVa and pharmaceutically acceptable salts thereof.
In some embodiments, Rla, Rlb, Rlc and Rld are each, independently, H, Q-4 alkyl, C2-4 alkenyl, C2_4 alkynyl, halo, Ci_4 haloalkyl, OH, Ci-4 alkoxy, Ci_4 haloalkoxy, CN, NO2, NH2, NH(Ci_4 alkyl), or N(Ci_4 alkyl)2.
In some embodiments, R is other than H.
In some embodiments, R is -W1-W2-W3-W4; and W1 is absent, Ci_6 alkyl, O, S, NR11, SO, or SO2.
In some embodiments, R is -W1-W2-W3-W4; and W1 is absent, and W2 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, each optionally substituted by 1, 2, 3 or 4 halo, CN, NO2, OH, =NH, =N0H, =NO-(Ci_4 alkyl), C i_4 haloalkyl, Ci-4 alkoxy, Ci_4 haloalkoxy, amino, Ci_4 alkylamino or C2_8 dialkylamino.
In some embodiments:
R is -W1 -W2- W3- W4;
W1 is absent or Ci_6 alkyl optionally substituted by 1, 2 or 3 halo, OH, Ci_4 alkoxy, Ci-4 haloalkoxy, amino, Ci_4 alkylamino or C2_g dialkylamino;
W2 is absent; and W3 is O, S, NR10, CO, or COO.
In some embodiments, R is H, Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, O-W2-W3-W4 , S-W2- W3- W4 , or NR11 -W2- W3 -W4, wherein the d_6 alkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2 or 3 halo, OH, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino or C2_8 dialkylamino.
In some embodiments, R is W4.
In some embodiments, R is -W3-W4.
In some embodiments, R is -W2-W3-W4.
In some embodiments, R is -W1 -W4.
In some embodiments, R is -O-W2-W3-W4
In some embodiments, R is -S-W2-W3-W4
In some embodiments, R is -NR11 -W2- W3- W4.
In some embodiments, R is NR10R11.
In some embodiments, R is aryl, cycloalkyl, heteroaryl or heterocycloalkyl each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, d_4 alkoxy, =NH, =N0H, =NO-(Ci_4 alkyl), d_4 haloalkyl, C14 haloalkoxy, COOH, COO-(Ci_4 alkyl), amino, Ci_4 alkylamino or C2_g dialkylamino.
In some embodiments, W1 is O, S, NR11, CO, COO, CONR11, SO, SO2, SONR11, SO2NR11, or NR11CONR12.
In some embodiments, W1 is Ci_6 alkyl optionally substituted by one or more halo, CN, NO2, OH, =NH, =N0H, =NO-(Ci_4 alkyl), d_4 haloalkyl, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino or C2_g dialkylamino.
In some embodiments, W1 is absent.
In some embodiments, W2 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, each optionally substituted by one or more halo, CN, NO2, OH, =NH, =N0H, =N0-(d_4 alkyl), Ci-4 haloalkyl, Ci-4 alkoxy, Ci-4 haloalkoxy, amino, Ci-4 alkylamino or C2_8 dialkylamino.
In some embodiments, W is absent.
In some embodiments, W3 is O, S, NR10, =N-, =N-0-, =N-0-( Ci-4 alkyl), 0-( Ci-4 alkyl), S- (Ci-4 alkyl), NR10-( Ci-4 alkyl), (C14 alkyl)-O-( Ci-4 alkyl), (C14 alkyl)-S-(Ci_4 alkyl), (Ci-4 alkyl)-NR10-( C14 alkyl), CO, COO, C(O)-(C14 alkyl), C(O)O-(C14 alkyl), C(O)-(C14 alkyl)-C(O), NR10C(O)-(C14 alkyl),
Figure imgf000084_0001
SO2NR10, OrNR10CONR11.
In some embodiments, W is d_6 alkyl optionally substituted by 1, 2 or 3 halo, OH, CN, C14 alkoxy, C14 haloalkoxy, amino, C14 alkylamino or C2_g dialkylamino.
In some embodiments, W is absent.
In some embodiments, W4 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, C14 alkoxy, =NH, =N0H, =N0-(C14 alkyl), C14 haloalkyl, C14 haloalkoxy, COOH, COO-(C14 alkyl), amino, C14 alkylamino or C2_g dialkylamino. In some embodiments, W4 is Ci_6 alkyl optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, Ci_4 alkoxy, =NH, =N0H, =NO-(Ci_4 alkyl), d_4 haloalkyl, d_4haloalkoxy, COOH, COO-(d_4 alkyl), amino, Ci_4 alkylamino or C2-8 dialkylamino.
In some embodiments, W4 is H, NR10R11 or CN.
In some embodiments: Ring B is
Figure imgf000085_0001
R is H, Ci-6 alkyl, C2-6 alkenyl, C2_6 alkynyl, (Ci-6 alkyl)-W2-W3-W4, O-W2-W3-W4 , S-W2- W3- W4 , NRU-W2-W3-W4, or -W2-W3-W4, wherein the Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2 or 3 halo, OH, Ci_4 alkoxy, Ci_4 haloalkoxy, amino, Ci_4 alkylamino or C2-8 dialkylamino.
In some embodiments: Ring B is
Figure imgf000085_0002
R is S-W2-W3-W4, S(O)-W2- W3-W4 or S(O)2- W2- W3-W4.
In some embodiments: Ring B is
Figure imgf000085_0003
D is NR8; and
R is S-W2-W3-W4, S(O)-W2- W3-W4 or S(O)2- W2- W3-W4.
In some embodiments: Ring B is
Figure imgf000086_0001
E is N; and
R is H, (d.6 alkyl)-W2-W3-W4, (C2_6 alkenyl)-W2-W3-W4 or (C2.6 alkynyl)-W2-W3-W4.
In some embodiments: Ring B is
Figure imgf000086_0002
R7 is H; and
R is Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, d_4 alkoxy, =NH, =N0H, =NO-(CM alkyl), CXΛ haloalkyl,
Figure imgf000086_0003
COOH, COO-(Ci_4 alkyl), amino, Ci_4 alkylamino or C2-8 dialkylamino.
In some embodiments: Ring B is
Figure imgf000086_0004
R7 is H; and
R is cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, OH, CN, Ci_4 alkoxy, Q-4 haloalkyl, C^ haloalkoxy, COOH, C00-(Ci_4 alkyl), amino, Ci_4 alkylamino or C2-8 dialkylamino.
In some embodiments, the agent is selected from compounds of Formula IVb:
Figure imgf000086_0005
IVb and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula IVc:
Figure imgf000087_0001
IVc and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula IVd:
Figure imgf000087_0002
IVd and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula IVe:
Figure imgf000087_0003
IVe and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula IVf:
Figure imgf000088_0001
IVf and pharmaceutically acceptable salts thereof
In some embodiments, the agent is selected from compounds of Formula IVg:
Figure imgf000088_0002
IVg and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from:
9-Fluoro-2-piperidin-l-ylbenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-(tert-Butylamino)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-Fluoro-2-[(3-methoxypropyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-Fluoro-2-(4-methylpiperazin- 1 -yl)benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-(Dimethylamino)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-(Benzylamino)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-Anilino-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-Fluoro-2,6-dihydro-7H-benzo[h]pyrazolo[4,3-f]isoquinolin-7-one;
9-Fluoro-2-piperidin-l-ylbenzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
2-tert-Butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]quinoline;
2-tert-Butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]quinoline 7-oxide;
2-tert-Butyl-9-fluoro-7-methoxy-3H-benzo[f]imidazo[4,5-h]phthalazin-3-ol trifluoroacetic acid;
2-tert-Butyl-9-fluoro-7-methoxy-3H-l,3,5,6-tetraaza-cyclopenta[l]phenanthrene;
2-tert-Butyl-9-fluoro-3,6-dihydro-l,3,5,6-tetraaza-cyclopenta[l]phenanthren-7-one;
2-tert-Butyl-9-fluoro-3H-benzo[f]imidazo[4,5-h]phthalazine-3,7-diol;
2-tert-Butyl-9-fluoro-7-methoxy-3H-benzo[f]imidazo[4,5-h]quinazolin-5-amine;
5-Amino-2-tert-butyl-9-fluoro-3H-benzo[f]imidazo[4,5-h]quinazolin-7-ol; 2-tert-Butyl-9-fluoro-7-methoxy-3H-benzo[f]imidazo[4,5-h]quinazoline;
2-tert-Butyl-9-fluoro-3H-benzo[f]imidazo[4,5-h]quinazolin-7-ol;
2-tert-Butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-3-ol;
2-tert-Butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinoline;
2-tert-Butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinoline 6-oxide;
9-Fluoro-2-[hydroxy(pyridin-3-yl)methyl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-Fluoro-2-[4-(lH-imidazol-4-ylcarbonyl)piperazin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
2-Ethyl-9-fluoro-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]quinazolin-7-one; trans-2-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2- yl)cyclopropanecarboxamide; l-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2- yl)cyclopropanecarboxylic acid;
2-[2-(dimethylamino)- 1 , 1 -dimethylethyl]-9-fluoro-3,6-dihydro-7H-benzo[f]imidazo[4,5- h]quinazolin-7-one;
4-ethyl-4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2- yl)hexanenitrile;
4-ethyl-4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2- yl)hexanamide;
2-(4-amino- 1 , 1 -dimethylbutyl)-9-fluoro-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]quinazolin-7- one; benzyl [l-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-l- methylethyl]carbamate ; benzyl [2-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-2- methylpropyl]carbamate;
[2-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-2- methylpropoxy]acetonitrile;
2-(l -amino- l-methylethyl)-9-fluoro-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]quinazolin-7-one;
4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)butanenitrile;
N-[l-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-l- methy lethy 1] acetamide ; benzyl 4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)piperidine- 1 -carboxylate;
3-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)propanenitrile;
N-[2-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-2- methylpropyl]urea; 4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-4- methylpentanenitrile;
2-(l-acetylpiperidin-4-yl)-9-fluoro-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]quinazolin-7-one;
9-fluoro-2-(trans-4-hydroxycyclohexyl)-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]quinazolin-7- one;
9-fluoro-2-(cis-4-hydroxycyclohexyl)-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]quinazolin-7- one;
3-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]quinazolin-2-yl)-3- methylbutanenitrile;
2-(Ethylthio)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-(Ethylsulfinyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-(Ethylsulfonyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(9-Fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-4- hydroxybutanamide;
9-Fluoro-2-[(2-hydroxycyclohexyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
2-[(3,5-Dimethyl-lH-pyrazol-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-Fluoro-2-{[(5-hydroxy-lH-pyrazol-3-yl)methyl]thio}-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-Fluoro-2-[(2,3,5,6-tetrafluoropyridin-4-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-[(2,6-Diamino-3,5-difluoropyridin-4-yl)thio]-9-fluoro-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(2-Amino-3,5,6-trifluoropyridin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-(benzylthio)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one ;
2-(benzylsulfinyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-(benzylsulfonyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
3-{[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]methyl}benzonitrile ;
9-fluoro-2-[(2-methoxyethyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-[(2-oxotetrahydrofiαran-3-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ;
2-{2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]ethyl}- 1 H-isoindole- 1 ,3(2H)-dione; 9-fluoro-2-[(pyridin-3-ylmethyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
2-[(l-ethylpropyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(l-ethylpropyl)sulfinyl]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
2-[(l-ethylpropyl)sulfonyl]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
2-[(3,5-dimethoxybenzyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one; ethyl [(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]acetate;
9-fluoro-2-(isopropylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one ;
[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]acetic acid ;
9-fluoro-2-[(l-phenylethyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one ;
[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]acetonitrile;
[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)sulfinyl] acetonitrile;
2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-N- phenylpropanamide;
9-fluoro-2-[(3-hydroxypropyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-[(3,3,3-trifluoro-2-oxopropyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one; ethyl 4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]butanoate;
2-[(2-aminoethyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(cyclohexylmethyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one ;
2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]acetamide ;
2-(cyclohexylthio)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(2,2-dimethoxyethyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one ;
2-[(3,3-dimethyl-2-oxobutyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ; ethyl 2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]propanoate ;
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]butanenitrile; ethyl 2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]butanoate; 2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-4-hydroxy- N,N-dimethylbutanamide ; methyl 3-{[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]methyl}benzoate ;
9-fluoro-2-[(tetrahydro-2H-pyran-2-ylmethyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ;
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]butanoic acid;
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]butanamide;
9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl thiocyanate;
2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]propanenitrile;
9-fluoro-2-[(2-hydroxy-2-methylpropyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-[(3-hydroxy-2,2-dimethylpropyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-[(2-oxocyclopentyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
2-[(l,3-dioxolan-2-ylmethyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
N-ethyl-2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-4- hydroxybutanamide;
9-fluoro-2-[(2-hydroxyethyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(piperidin-4-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]propanenitrile ;
9-fluoro-2-[(3-oxocyclohex- 1 -en- 1 -yl)thio]-3,6-dihydro-7H-phenanthro[9, 10-d]imidazol-7- one ;
9-fluoro-2-(pyridin-4-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(lH-pyrazol-4-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-[(2-hydroxy-2-methylpropyl)sulfinyl]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)sulfinyl]propanenitrile ;
9-fluoro-2-[(2-hydroxy-3,3-dimethylbutyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ;
9-fluoro-2-[(2-oxopropyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one ; 9-fluoro-2-(pyridin-4-ylsulfinyl)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one ;
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)sulfinyl]butanenitrile ;
9-fluoro-2-(pyrimidin-5-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one; ethyl 4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-3- oxobutanoate;
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-2- methylpropanenitrile ;
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)sulfinyl]-2- methylpropanenitrile ;
9-fluoro-2-[(2-hydroxypropyl)thio]-3,3a,6,l lb-tetrahydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ;
9-fluoro-2-(isoxazol-4-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]propanamide;
2-[(3,5-dichloropyridin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-[(4,6-dimethoxy-l,3,5-triazin-2-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-(pyrimidin-2-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one ;
2-[(2,2-dimethylpropyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one ;
9-fluoro-2-(isobutylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(2,2-dimethylpropyl)sulfinyl]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one ;
2-(cyclohexylsulfinyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(pyrazin-2-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-[(3-fluoropyridin-4-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
2-[(6-chloropyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
2-[(2,6-dimethoxypyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-[(2,6-dichloropyridin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ;
2-[(6-chloropyridazin-3-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one; 2-[(3-amino-6-bromopyrazin-2-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-(quinolin-4-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(6-chloropyrazin-2-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
2-[(2,6-dichloropyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-[(l-oxidopyridin-4-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one ;
2-[(2,6-diaminopyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one ;
9-fluoro-2-[(l -methyl- lH-pyrazol-4-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]pyrazine-2- carbonitrile;
9-fluoro-2-[(2-methylpyrimidin-5-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-[(5-chloro-3-hydroxypyridazin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-[(3,5-dichloropyridazin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-[(l-oxidopyridin-2-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2-[(lH-tetrazol-5-ylmethyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one trifluoroacetate;
9-fluoro-2-[(6-hydroxypyridin-3-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
2-[(2-amino-6-chloropyridin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one trifluoroacetate;
2-[(6-aminopyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
2-[(6-aminopyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
9-fluoro-2-(pyridin-3-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate;
9-fluoro-2-(phenylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate; 2-[(2-chloropyrimidin-4-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
9-fluoro-2-(lH-tetrazol-5-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(5-bromopyridin-3-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one trifluoroacetate;
2-[(3-aminophenyl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate;
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]pyridine-2- carbonitrile;
9-fluoro-2-[(5-methoxypyridin-3-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one trifluoroacetate;
2-[(2-aminopyrimidin-4-yl)tliio]-9-fluoro-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoquinolin- 7-one;
5-[(9-fluoro-7-oxo-6,7-diliydro-3H-benzo[li]imidazo[4,5-f]isoquinolin-2-yl)tliio]-N-(2- hydroxyethyl)nicotinamide trifluoroacetate (salt); methyl 4-chloro-5-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoqumolin-2- yl)thio]pyridine-2-carboxylate;
9-fluoro-2-[(6-fluoropyridin-3-yl)tliio]-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoquinolin-7- one trifluoroacetate;
2-[(6-aminopyridin-3-yl)tliio]-9-fluoro-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoquinolin-7- one trifluoroacetate;
9-fluoro-2-[(6-methoxypyridin-3-yl)thio]-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoqumolin- 7-one trifluoroacetate;
9-fluoro-2-[(2-fluoropyridin-4-yl)tliio]-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2-(quinolin-3-ylthio)-3,6-dihydro-7H-benzo[li]imidazo[4,5-f]isoqumolin-7-one trifluoroacetate;
5-[(9-fluoro-7-oxo-6,7-diliydro-3H-benzo[li]imidazo[4,5-f]isoquinolin-2-yl)tliio]nicotinamide trifluoroacetate;
2-[(2-aminopyridin-4-yl)tliio]-9-fluoro-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2-[(2-methoxypyridin-4-yl)thio]-3,6-diliydro-7H-benzo[li]imidazo[4,5-f]isoqumolin- 7-one;
9-fluoro-2- {[5-(morpholin-4-ylcarbonyl)pyridin-3-yl]tliio}-3,6-diliydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate;
5-[(9-fluoro-7-oxo-6,7-diliydro-3H-benzo[li]imidazo[4,5-f]isoquinolin-2-yl)tliio]-N-[2- (tetrahydro-2H-pyran-4-yl)ethyl]nicotinamide; 9-fluoro-2-({5-[(4-methylpiperazin-l-yl)carbonyl]pyridin-3-yl}thio)-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-({2-[(2-morpholin-4-ylethyl)amino]pyridin-4-yl}thio)-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-{[2-(dimethylamino)pyridin-4-yl]thio}-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-({2-[(2-hydroxyethyl)amino]pyridin-4-yl}thio)-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one; methyl 4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]pyridine-2-carboxylate;
9-fluoro-2-(isoquinolin-4-ylthio)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate;
9-fluoro-2-({6-[(2-hydroxyethyl)amino]pyridin-3-yl}thio)-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate;
9-fluoro-2-({6-[(2-morpholin-4-ylethyl)amino]pyridin-3-yl}thio)-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate;
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]benzamide;
2-[(5-aminopyridin-3-yl)thio]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2- {[4-(lH-imidazol-l-yl)phenyl]thio}-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one trifluoroacetate;
9-fluoro-2-[(3-hydroxyphenyl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one trifluoroacetate (salt);
4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-N-(2- hydroxyethyl)benzamide trifluoroacetate (salt);
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]-N-(2- hydroxyethyl)benzamide trifluoroacetate (salt);
3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]benzonitrile trifluoroacetate;
9-fluoro-2-[(5-morpholin-4-ylpyridin-3-yl)thio]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one trifluoroacetate;
{3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]phenoxy} acetonitrile trifluoroacetate;
N-{3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoqumolin-2- yl)thio]phenyl}methanesulfonamide trifluoroacetate;
2-cyano-N- {3-[(9-fluoro-7-oxo-6,7-diliydro-3H-benzo[li]imidazo[4,5-f]isoquinolin-2- yl)thio]phenyl} acetamide trifluoroacetate; N'-{3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]phenyl}- N,N-dimethylsulfamide;
N-{3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]phenyl}ethanesulfonamide;
2-(dimethylamino)-N-{3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5- f]isoquinolin-2-yl)thio]phenyl} acetamide trifluoroacetate;
N-ethyl-N'-{3-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2- yl)thio]phenyl}urea trifluoroacetate;
2-tert-butyl- 10-fluorobenzo[c]imidazo [ 1 ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
10-Fluoro-2-(4-hydroxycyclohexyl)benzo[c]imidazo[ 1 ,2-a]- 1 ,6-naphthyridin-8(7H)-one; trans-4-(10-Fluoro-8-oxo-7,8-dihydrobenzo[c]imidazo[l,2-a]-l,6-naphthyridin-2- yl)cyclohexyl (dimethylamino) acetate;
10-fluoro-2-(l -methylcyclopropyl)benzo[c]imidazo[ 1 ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
2-cyclopropyl- 10-fluorobenzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
2-cyclobutyl- 10-fluorobenzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
2-ethyl-10-fluorobenzo[c]imidazo[l,2-a]-l,6-naphthyridin-8(7H)-one; ethyl 2-ethyl-2-(10-fluoro-8-oxo-7,8-dihydrobenzo[c]imidazo[l,2-a]-l,6-naphthyridin-2- yl)butanoate;
2-[l -ethyl- l-(hydroxymethyl)propyl]- 10-fluorobenzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin- 8(7H)-one;
2-( 1 -ethylpropyl)- 10-fluorobenzo[c]imidazo[ 1 ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
10-fluoro-2-(4-oxocyclohexyl)benzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
10-fluoro-2-methylbenzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
10-fluoro-2-(cis-4-methoxycyclohexyl)benzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
10-fluoro-2-(trans-4-methoxycyclohexyl)benzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)- one;
10-fluoro-2- [4-(hydroxyimino)cyclohexyl]benzo[c]imidazo[ 1 ,2-a] - 1 ,6-naphthyridin-8(7H)- one ;
2-(l -acetylpiperidin-4-yl)- 10-fluorobenzo[c]imidazo[l ,2-a]- 1 ,6-naphthyridin-8(7H)-one;
2-amino-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(4-hydroxypiperidin-l-yl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lS)-l-(hydroxymethyl)-3-methylbutyl]amino}benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lR)-2-hydroxy-l-phenylethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
(2S)-2-[(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)amino]-4- methoxy-N-methylbutanamide; 9-fluoro-2-(4-oxopiperidin-l-yl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lR)-l-(hydroxymethyl)-3-methylbu1yl]amino}benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-(3-hydroxypiperidin-l-yl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lS)-2-hydroxy-l-phenylethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-(3-hydroxypyrrolidin-l-yl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(l-hydroxy-4-oxocyclohexyl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-[4-(ethoxyimino)piperidin-l-yl]-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- [4-(hydroxyimino)piperidin- 1 -yl]benzo [h] [ 1 ,3 Jthiazolo [5,4-f]isoquinolin-7(6H)- one;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)butanenitrile;
2-(l,4-dihydroxycyclohexyl)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-(l-acetyl-4-hydroxypiperidin-4-yl)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-(4-hydroxy- 1 -isobutyrylpiperidin-4-yl)benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-isonicotinoylbenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(l-oxidoisonicotinoyl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-phenylbenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-ethyl-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-morpholin-4-ylbenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(pyridin-3-ylmethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(3-morpholin-4-ylpropyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[(3-methoxybenzyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lR)-l-(3-methoxyphenyl)ethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2- {[(1 S)- 1 -(3-methoxyphenyl)ethyl]amino}benzo[h] [ 1 ,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[(3-hydroxypropyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(2-hydroxyethyl)(methyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2- {[2-(4-hydroxyphenyl)ethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one; 9-fluoro-2-[(2-methoxy-l-methylethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
N,N-diethyl-l-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2- yl)piperidine-3-carboxamide;
9-fluoro-2-[(3-phenylpropyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lR)-l-(4-methoxyphenyl)ethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2- {[(lS)-l-(4-methoxyphenyl)ethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-(pyridin-3-ylamino)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(4-pyridin-2-ylpiperazin-l-yl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one ;
9-fluoro-2-{[3-(lH-imidazol-l-yl)propyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[(2-morpholin-4-ylethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(2-methoxyethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one ;
9-fluoro-2-[(tetrahydroilιran-2-ylmethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[(2-pyridin-2-ylethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[2-(lH-imidazol-4-yl)ethyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[4-(2-hydroxyethyl)piperazin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
2-{[3-(dimethylamino)propyl]amino}-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-(4-hydroxy-4-pyridin-2-ylpiperidin-l-yl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
2-[bis(2-methoxyethyl)amino]-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)acetonitrile;
2-{benzyl[2-(dimethylamino)ethyl]amino}-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2- {[3-(trifluoromethyl)phenyl]amino}benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[(2-methoxyphenyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(propylamino)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(isopropylamino)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one ;
3-[(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2- yl)amino]benzonitrile; 9-fluoro-2-[(3-hydroxyphenyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(trans-4-hydroxy-4-pyridin-2-ylcyclohexyl)amino]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[cis-4-hydroxy-3-(liydroxymethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[trans-4-hydroxy-3-(hydroxymethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[(2-hydroxyethyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(4-hydroxybenzyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[4-(hydroxymethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[3-(hydroxymethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2- [(2-hydroxy- 1 -methylethyl)amino]benzo [h] [ 1 ,3 ]thiazolo [5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[(2S)-2-(hydroxymethyl)pyrrolidin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[(2R)-2-(hydroxymethyl)pyrrolidin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
2-(4-acetylpiperazin- 1 -yl)-9-fluorobenzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-piperazin- 1 -ylbenzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)-one ;
2-{4-[(dimethylamino)acetyl]piperazin-l-yl}-9-fluorobenzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2- [4-(2-hydroxyethyl)piperidin- 1 -yl]benzo [h] [ 1 ,3 ]thiazolo [5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2- {4-[(2R)-2-hydroxypropyl]piperazin-l-yl}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
2-[(2,3-dihydroxypropyl)amino]-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperazine-l- carboxamide; methyl 4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperazine- 1 -carboxylate; ethyl 4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperazine-l- carboxylate;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperazine-l- carbaldehyde; 9-fluoro-2-[4-(lH-tetrazol-5-ylacetyl)piperazin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-(pyridin-2-ylamino)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(pyridin-4-ylamino)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(3R,4R)-3-methoxy-4-(methylamino)pyrrolidin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[(3S,4R)-3-methoxy-4-(methylamino)pyrrolidin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one; benzyl (3R,4R)-3-[(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2- yl)(methyl)amino]-4-methoxypyrrolidine- 1 -carboxylate;
2-(l-ethyl-l-hydroxypropyl)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(hydroxymethyl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-(ethoxymethyl)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
3-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)propanenitrile;
[l-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperidin-4- yl]acetonitrile; l-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperidine-4- carbonitrile;
3-[(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2- yl)methoxy]propanenitrile;
9-fluoro-2- {4-[2-(lH-l,2,4-triazol-l-yl)ethyl]piperidin-l-yl}benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2- [4-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)piperidin- 1 -yl]benzo [h] [ 1 ,3 ]thiazolo [5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[4-(lH-imidazol-l-ylmethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
3-[l-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperidin-4- yl]propanenitrile ;
9-fluoro-2- {4-[2-(lH-imidazol- 1 -yl)ethyl]piperidin- 1 -yl}benzo[h] [1 ,3]thiazolo[5,4- f]isoquinolin-7(6H)-one ;
2- {4-[(diethylamino)methyl]piperidin- 1 -yl} -9-fluorobenzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one ;
9-fluoro-2-(pyridin-3-ylmethyl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(pyridin-2-ylmethyl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(l-oxidopyridin-3-yl)methyl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(pyridin-4-ylmethyl)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one; 9-fluoro-2-[hydroxy(6-methoxypyridin-3-yl)methyl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[3-hydroxy-l-(pyridin-4-ylmethyl)piperidin-3-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
2-(l-acetyl-3-hydroxypiperidin-3-yl)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[(4-hydroxypiperidin- 1 -yl)methyl]benzo[h] [ 1 ,3]thiazolo[5,4-f]isoquinorin-7(6H)- one;
2-[(4-acetylpiperazin- 1 -yl)carbonyl]-9-fluorobenzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[3-hydroxy-l-(methylsulfonyl)piperidin-3-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-(l -hydroxy- 1 -pyridin-3-ylethyl)benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-(l -hydroxy- 1 -pyridin-4-ylethyl)benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[l -hydroxy- 1 -(I -oxidopyridin-3-yl)ethyl]benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[l -hydroxy- 1 -(I -oxidopyridin-4-yl)ethyl]benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
2- {4-[(dimethylamino)methyl]piperidin- 1 -yl} -9-fluorobenzo[h] [1 ,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-( yridine-3-yloxy)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(pyridin-4-ylthio)benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(trans-4-hydroxycyclohexyl)amino]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-(4-pyrazin-2-ylpiperazin- 1 -yl)benzo[h] [1 ,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)-N- methylpiperazine- 1 -carboxamide;
9-fluoro-2- [4-( 1 H-pyrazol-3-ylcarbonyl)piperazin- 1 -yljbenzo [h] [ 1 ,3 Jthiazolo [5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2- [4-( 1 H-pyrazol-4-ylcarbonyl)piperazin- 1 -yl]benzo [h] [ 1 ,3 ]thiazolo [5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[4-(lH-imidazol-2-ylcarbonyl)piperazin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
2-[4-(aminoacetyl)piperazin-l-yl]-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one; 2-[4-(azetidin-3-ylcarbonyl)piperazin-l-yl]-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
N-(tert-butyl)-4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2- yl)piperazine- 1 -carboxamide;
9-fluoro-2- {4-[(2S)-2-hydroxypropyl]piperazin-l-yl}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
3-[4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperazin-l-yl]- 3-oxopropanenitrile;
9-fluoro-2-[4-(methylsulfonyl)piperazin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)-N,N- dimethylpiperazine- 1 -carboxamide; l-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperidine-4- carboxylic acid;
9-fluoro-2- {4-hydroxy-4-[(methylamino)methyl]piperidin- 1 -yl}benzo[h] [1 ,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-[4-hydroxy-4-(lH- 1 ,2,4-triazol- 1 -ylmethyl)piperidin- 1 - yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[4-hydroxy-4-(hydroxymethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4- f]isoquinolin-7(6H)-one;
9-fluoro-2-piperidin-3-ylbenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
2-(l-acetylpiperidin-3-yl)-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[l-(methylsulfonyl)piperidin-3-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[l-(pyridin-4-ylmethyl)piperidin-3-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
3-[3-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]thiazolo[5,4-f]isoquinolin-2-yl)piperidin-l-yl]- 3-oxopropanenitrile;
9-fluoro-2- {l-[(2S)-2-hydroxypropyl]piperidin-3-yl}benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
2-{l-[(dimethylamino)acetyl]piperidin-3-yl}-9-fluorobenzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[4-(morpholin-4-ylmethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[4-(2-morpholin-4-ylethyl)piperidin-l-yl]benzo[h][l,3]thiazolo[5,4-f]isoquinolin- 7(6H)-one;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]oxazolo[5,4-f]isoquinolin-2-yl)butanenitrile; 9-fluoro-2- [3 -( 1 H- 1 ,2,4-triazol- 1 -yl)propyl]benzo [h] [ 1 ,3 ] oxazolo [5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2- {[(lR)-l-phenylethyl]amino}benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[(lS)-l-phenylethyl]amino}benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(2-methoxybenzyl)amino]benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(4-methoxybenzyl)amino]benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[(3-methoxybenzyl)amino]benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(4-oxopiperidin-l-yl)benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-(4-hydroxypiperidin-l-yl)benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[l-(methylsulfonyl)piperidin-4-yl]amino}benzo[h][l,3]oxazolo[5,4-f]isoquinolin- 7(6H)-one;
2-[(l-acetylpiperidin-4-yl)amino]-9-fluorobenzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2-[hydroxy(pyridin-3-yl)methyl]benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
2-(4-acetylpiperazin-l-yl)-9-fluorobenzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
4-(9-fluoro-7-oxo-6,7-dihydrobenzo[h][l,3]oxazolo[5,4-f]isoquinolin-2-yl)piperazine-l- carboxamide;
2-[(4-acetylpiperazin- 1 -yl)methyl]-9-fluorobenzo[h] [1 ,3]oxazolo[5,4-f]isoquinolin-7(6H)- one;
9-fluoro-2-[(trans-4-hydroxycyclohexyl)amino]benzo[h][l,3]oxazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-(pyridin-3-yloxy)benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
2-[(l-acetylpiperidin-3-yl)amino]-9-fluorobenzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)-one;
9-fluoro-2- {[l-(methylsulfonyl)piperidin-3-yl]amino}benzo[h][l,3]oxazolo[5,4-f]isoquinolin- 7(6H)-one;
9-fluoro-2-[4-(l,3-thiazol-2-yl)piperazin-l-yl]benzo[h][l,3]oxazolo[5,4-f]isoquinolin-7(6H)- one;
2-(trans-4-Hydroxycyclohexyl)imidazo[l,2-a]pyrido[4,3-c]-l,6-naphthyridin-8(7H)-one;
2-(cis-4-Hydroxycyclohexyl)imidazo[l,2-a]pyrido[4,3-c]-l,6-naphthyridin-8(7H)-one;
4-(8-Oxo-7,8-dihydroimidazo[l ,2-a]pyrido[4,3-c]- 1 ,6-naphthyridin-2-yl)piperidine- 1 - carbaldehyde;
2-Piperidin-4-ylimidazo[l,2-a]pyrido[4,3-c]-l,6-naphthyridin-8(7H)-one;
2-[l-(Cyclopropylmethyl)piperidin-4-yl]imidazo[l,2-a]pyrido[4,3-c]-l,6-naphthyridin-8(7H)- one;
2-[l-(Propyl)piperidin-4-yl]imidazo[l,2-a]pyrido[4,3-c]-l,6-naphthyridin-8(7H)-one;
2-tert-Butylimidazo[l,2-a]pyrido[4,3-c]-l,6-naphthyridin-8(7H)-one;
2-(4-Hydroxypiperidin-l-yl)-l,9-dihydro-8H-imidazo[4,5-f]-2,8-phenanthrolin-8-one;
2-(4-hydroxypiperidin-l-yl)[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one; 2-(isopropylamino)[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-[(3-methoxypropyl)amino][l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(lR)-l-(hydroxymethyl)-3-methylbutyl]amino} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin- 8(9H)-one;
2-{[l-(methylsulfonyl)piperidin-4-yl]oxy} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(lR)-l-(hydroxymethyl)butyl]amino} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(lR)-l-(hydroxymethyl)propyl]amino} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2- { [( 1 R)- 1 -(hydroxymethyl)-2-methylpropyl] amino } [ 1 ,3 Jthiazolo [4,5-f] -2,9-phenanthrolin- 8(9H)-one;
2-{[(lR,2R)-2-hydroxycyclohexyl]amino} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(lR,2R)-2-hydroxycyclopentyl]amino} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(lR)-l-(hydroxymethyl)-2,2-dimethylpropyl]amino} [l,3]thiazolo[4,5-f]-2,9- phenanthrolin-8(9H)-one;
2-(4- {[3-(2-oxopyrrolidin-l-yl)propyl]amino}piperidin-l-yl)[l,3]thiazolo[4,5-f]-2,9- phenanthrolin-8(9H)-one;
2-{[(lS,2S)-l-(hydroxymethyl)-2-methylbu1yl]amino} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin- 8(9H)-one;
2-{4-[(3-morpholin-4-ylpropyl)amino]piperidin-l-yl} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin- 8(9H)-one;
2-(dimethylamino)-N-[l-(8-oxo-8,9-dihydro[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-2- yl)piperidin-4-yl] acetamide;
2-(4-hydroxypiperidin-l-yl)[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-(propylamino)[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-(4-acetylpiperazin-l-yl)[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-piperazin-l-yl[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{4-[(2S)-2-hydroxypropyl]piperazin-l-yl} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-[4-(lH-imidazol-5-ylacetyl)piperazin-l-yl][l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)- one;
2-{4-[(2R)-2-hydroxypropyl]piperazin-l-yl} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)- one;
2-[4-(2-hydroxyethyl)piperazin-l-yl][l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(2R)-2-amino-3,3-dimethylbutyl]oxy} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-{[(lS)-l-(hydroxymethyl)-2,2-dimethylpropyl]amino} [l,3]thiazolo[4,5-f]-2,9- phenanthrolin-8(9H)-one;
N-[l-(8-oxo-8,9-dihydro[l,3]thiazolo[4,5-f]-2,9-phenanthrolin-2-yl)piperidin-4-yl]-3-pyridin- 3 -ylpropanamide; 2-[4-(2-morpholin-4-ylethoxy)piperidin-l-yl][l,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)- one;
2-{4-[(2-morpholin-4-ylethoxy)methyl]piperidin-l-yl} [l,3]thiazolo[4,5-f]-2,9-phenanthrolin- 8(9H)-one;
2-(4-{methyl[3-(2-oxopyrrolidin-l-yl)propyl]amino}piperidin-l-yl)[l,3]thiazolo[4,5-f]-2,9- phenanthrolin-8(9H)-one;
2-[4-(morpholin-4-ylmethyl)piperidin- 1 -yl] [1 ,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-[4-(2-morpholin-4-ylethyl)piperidin- 1 -yl] [1 ,3]thiazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-(4-hydroxypiperidin-l-yl)[l,3]oxazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-(4-oxopiperidin-l-yl)[l,3]oxazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
2-(4-hydroxy-4-methylpiperidin-l-yl)[l,3]oxazolo[4,5-f]-2,9-phenanthrolin-8(9H)-one;
9-fluoro-2-(pyridin-4-ylmethoxy)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-[(pyridin-3-ylmethyl)amino]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
9-fluoro-2-(3-piperidin- 1 -ylpropoxy)- 1 ,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2-[(3-morpholin-4-ylpropyl)amino]-l,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-4-hydroxy-4-[(2-morpholin-4-ylethoxy)methyl]piperidin- 1 -yl- 1 ,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(pyridin-3-yloxy)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-isopropoxy-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(pyridin-3-ylmethoxy)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(4-oxopyridin-l(4H)-yl)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2-[(cis-4-hydroxycyclohexyl)oxy]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-[(trans-4-hydroxycyclohexyl)oxy]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-(pyridin-2-ylmethoxy)-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-[(trans-4-hydroxycyclohexyl)amino]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
9-fluoro-2-[(pyridin-4-ylmethyl)amino]-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
9-fluoro-2-[(l-oxidopyridin-2-yl)methoxy]-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one; 9-fluoro-2- [( 1 -oxidopyridin-3 -yl)methoxy] -3 ,6-dihydro-7H-benzo [h]imidazo [4,5- f]isoquinolin-7-one;
9-fluoro-2-[(lR,3R)-3-hydroxycyclohexyl]oxy-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one; cis- and trans^-fluoro^-P-hydroxycyclohexylloxy-Sjό-dihydro^H-benzofhlimidazo^S- f]isoquinolin-7-one;
9-fluoro-2-[l-(methylsulfonyl)piperidin-4-yl]oxy-3,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-[(l-acetylpiperidin-4-yl)oxy]-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin- 7-one;
3-4-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)oxy]piperidin- 1 -yl-3-oxopropanenitrile;
9-fluoro-2-[(trans-4-hydroxycyclohexyl)(methyl)amino]-3,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-(3-morpholin-4-ylpropoxy)-l,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7- one;
9-fluoro-2-[3-(2-oxopyrrolidin- 1 -yl)propyl] amino- 1 ,6-dihydro-7H-benzo[h]imidazo[4,5- f]isoquinolin-7-one;
2-(4- { [bis(2-methoxyethyl)amino]methyl}piperidin- 1 -yl)-9-fluoro- 1 ,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2- {4-[(2-morpholin-4-ylethoxy)methyl]piperidin- 1 -yl} - 1 ,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
2-[(cyclopropylmethyl)(3-morpholin-4-ylpropyl)amino]- 9-fluoro-l,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-4-hydroxy-4-[(3-piperidin- 1 -ylpropoxy)methyl]piperidin- 1-yl- 1 ,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
9-fluoro-2-4-hydroxy-4-[(3-morpholin-4-ylpropoxy)methyl]piperidin- 1 -yl- 1 ,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
10-fluoro-2- [4-(hydroxyimino)cyclohexyl]benzo[c]imidazo [ 1 ,2-a]- 1 ,6-naphthyridin-8(7H)- one;
9-fluoro-2-4-[(2-morpholin-4-ylethoxy)imino]piperidin-l-yl-l,6-dihydro-7H- benzo[h]imidazo[4,5-f]isoquinolin-7-one;
4-ethyl-4-(9-fluoro-7-hydroxy-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)hexanenitrile;
4-ethyl-4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)hexanoic acid;
4-ethyl-4-(9-fluoro-7-hydroxy-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)hexanamide; methyl 2-(9-fluoro-7-hydroxy-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)-2- methylpropanoate;
2-(9-fluoro-7-hydroxy-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)-2-methylpropanoic acid;
9-fluoro-2-(2-hydroxy- 1 , 1 -dimethylethyl)-3H-benzo[f]imidazo[4,5-h]phthalazin-7-ol;
4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)-4- methylpentanenitrile;
(2E)-4-(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)-4- methylpent-2-enenitrile;
9-fluoro-2-[4-(methylthio)phenyl]-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]phthalazin-7-one;
9-fluoro-2-[4-(methylsulfinyl)phenyl]-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]phthalazin-7- one;
4-(9-fluoro-7-hydroxy-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)-4-methylpentanamide;
3-(9-fluoro-7-hydroxy-3H-benzo[f]imidazo[4,5-h]phthalazin-2-yl)propanenitrile;
9-fluoro-2-(2-pyridin-2-ylethyl)-3H-benzo[f]imidazo[4,5-h]phthalazin-7-ol;
9-fluoro-2-(pyridin-4-ylmethyl)-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]phthalazin-7-one;
9-fluoro-2-(pyridin-3-ylmethyl)-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]phthalazin-7-one;
2-[4-(benzyloxy)cyclohexyl]-9-fluoro-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]phthalazin-7- one;
9-fluoro-2-(4-hydroxycyclohexyl)-3,6-dihydro-7H-benzo[f]imidazo[4,5-h]phthalazin-7-one; methyl 2-(9-fluoro-7-hydroxybenzo[f][l,3]oxazolo[5,4-h]phthalazin-2-yl)-2- methylpropanoate; benzyl [4-(9-fluoro-7-hydroxybenzo[f][l,3]oxazolo[5,4-h]phthalazin-2-yl)-4- methylpentyl]carbamate;
2-(4-amino- 1 , 1 -dimethylbutyl)-9-fluorobenzo[f] [1 ,3]oxazolo[5,4-h]phthalazin-7-ol;
2-(9-fluoro-7-hydroxybenzo[f][l,3]oxazolo[5,4-h]phthalazin-2-yl)-2-methylpropanoic acid;
2-tert-butyl-l,9-dihydro-8H-imidazo[4,5-f]-2,8-phenanthrolin-8-one;
2-tert-butyl-3,6-dihydro-7H-imidazo[4,5-f]-l,9-phenanthrolin-7-one;
2-cyclohexyl-l,9-dihydro-8H-imidazo[4,5-f]-2,8-phenanthrolin-8-one;
3-(8-oxo-8,9-dihydro-lH-imidazo[4,5-f]-2,8-phenanthrolin-2-yl)propanenitrile;
2-(trans-4-hydroxycyclohexyl)-l,9-dihydro-8H-imidazo[4,5-f]-2,8-phenanthrolin-8-one;
2-[l-(methylsulfonyl)piperidin-4-yl]-l,9-dihydro-8H-imidazo[4,5-f]-2,8-phenanthrolin-8-one;
3-oxo-3-[4-(8-oxo-8,9-dihydro-lH-imidazo[4,5-f]-2,8-phenanthrolin-2-yl)piperidin-l- yl]propanenitrile;
3-methyl-3-(8-oxo-8,9-dihydro-lH-imidazo[4,5-f]-2,8-phenanthrolin-2-yl)butanenitrile;
2-tert-butyl-l,9-dihydro-8H-imidazo[4,5-f]-2,7-phenanthrolin-8-one;
2-cyclohexyl-l,9-dihydro-8H-imidazo[4,5-f]-2,7-phenanthrolin-8-one;
2-cyclopentyl-l,9-dihydro-8H-imidazo[4,5-f]-2,7-phenanthrolin-8-one; 2-tert-butyl-l,9-dihydro-8H-imidazo[4,5-f]-2,8-phenanthrolin-8-one 5-oxide; and 3-methyl-3-(5-oxido-8-oxo-8,9-dihydro-lH-imidazo[4,5-f]-2,8-phenanthrolin-2- yl)butanenitrile; and pharmaceutically acceptable salts of any of the aforementioned.
In a fifth aspect, the agent is selected from compounds of Formula V:
Figure imgf000109_0001
V or pharmaceutically acceptable salt forms or prodrug thereof, wherein:
R1, R2, and R3 are each, independently, H, halo, Ci_4 alkyl, C2^ alkenyl, C2^ alkynyl, Q-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, or S(O)2NRcRd;
R4 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, S(O)2R9, SOR9, cycloalkyl, or heterocycloalkyl, wherein the Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, cycloalkyl, heterocycloalkyl are each optionally substituted with 1, 2 or 3 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rd, NRcC(0)0Ra, S(O)Rb, S(0)NRcRd, S(O)2Rb, and S(0)2NRcRd;
R5 is 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -L-(3-8 membered cycloalkyl), -L-(3-8 membered heterocycloalkyl), each substituted by one R6 and O, 1 or 2 R7;
L is Ci_4 alkylenyl, C2-4 alkenylenyl, C2-4 alkynylenyl, O, S, NR14, CO, COO, OCO, NR14C(O)O, CONR14, SO, SO2, SONR14, SO2NR14, Or NR14CONR14;
R6 is -W1-W2-W3-W4-W5-W6-R13;
W1 is absent, Ci_4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(d. 4 alkyl), Ci_4 haloalkyl, d^ alkoxy, Ci_4haloalkoxy, amino, Ci-4 alkylamino or C2_g dialkylamino;
W2 is absent, Ci-4 alkylenyl, C2-4 alkenylenyl, C2-4 alkynylenyl, O, S, NR12, CO, COO, OCO, C(S), C(S)NR12, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, Or NR12CONR12, wherein the Ci_4 alkylenyl, C2^ alkenylenyl, C2^ alkynylenyl, are each optionally substituted by 1, 2 or 3 halo, OH, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci-4 alkylamino or C2_g dialkylamino;
W3 is absent, Ci_4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the Ci_4 alkylenyl, C2_4 alkenylenyl, C2^ alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1 , 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(Ci_4 alkyl),
Figure imgf000110_0001
haloalkyl, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino or C2-8 dialkylamino;
W4 is absent, Ci-4 alkylenyl, C2-4 alkenylenyl, C2.4 alkynylenyl, O, S, NR12, CO, COO, OCO, - C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, OrNR12CONR12, wherein the d_4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, are each optionally substituted by 1 , 2 or 3 halo, CN, NO2, OH, =NH, =N0H,
Figure imgf000110_0002
alkyl), Ci-4 haloalkyl, d_4 alkoxy, C!_4haloalkoxy, amino, Cx-4 alkylamino or C2_g dialkylamino;
W5 is absent, CL4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the CL4 alkylenyl, C2_4 alkenylenyl, C2^ alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(Ci_4 alkyl), Ci-4 haloalkyl, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino or C2_g dialkylamino;
W6 is absent, Ci-4 alkyl, C2-4 alkenyl, C2_4 alkynyl, O, S, NR12, CO, COO, OCO, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, Or NR12CONR12, wherein the Q-4 alkyl, C2_4 alkenyl, C2_4 alkynyl are each optionally substituted by 1, 2 or 3 CN, NO2, OH, =NH, =N0H, =NO- (Ci-4 alkyl), Ci_4 haloalkyl,
Figure imgf000110_0003
alkoxy, Ci_4haloalkoxy, amino, Ci-4 alkylamino or C2_g dialkylamino;
R7 is halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, CN, NO2, 0Ra , SR3", C(O)Rb", C(0)NRc"Rd", C(O)OR3", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0R3", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(Ci-6 alkyl)-CN, -(Cw alkyl)-NO2, - (Cw alkyl)-ORa", -(Ci-6 alkyl)-SRa", -(C1^ aUCyI)-C(O)R13", -(d_6 alkyl)-C(O)NRc"Rd", -(Cw alkyl)- C(O)OR3", -(CLS aUCyI)-OC(O)R13", -(Cw alkyl)-OC(O)NRc"Rd", -(d_6 alkyl)-NRc"Rd", -(Cwalkyl)- NRc"C(0)Rd", -(CLS aUCyI)-NR01 C(O)OR3", -(d_6 alkyl)-S(O)Rb", -(d_6 alkyl)-S(O)NRc"Rd", -(CL6 alkyl)-S(O)2Rb", or -(d_6 alkyl)-S(O)2NRc"Rd";
R9 is Ci-4 alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted with 1, 2, or 3 substituents selected from halo, CL4 alkyl, C2^ alkenyl, C2^ alkynyl, CL4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR3', SR3', C(O)Rb', C(0)NRc Rd', C(O)OR3', OC(O)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(0)Rd', NRc C(0)0R3', S(O)Rb', S(0)NRc Rd', S(O)2Rb', and S(0)2NRc'Rd';
R12 and R14 are each, independently, H or CL6 alkyl optionally substituted by 1, 2 or 3 substituents selected from OH, CN, NO2, amino, (Ci-4 alkyl)amino, (C2_g dialkyl)amino, CL6 haloalkyl, CL6 acyl, CL6 acyloxy, CL6 acylamino, -(CL6 alkyl)-CN, and -(CL6 aUcyl)-NO2;
R13 is halo, CL6 alkyl, C2_6 alkenyl, C2_6 alkynyl, CL6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, CN, NO2, OR3 , SR3", C(O)Rb", C(0)NRc"Rd", C(O)OR3", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0R3", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(CL6 alkyl)-CN, -(d_6 alkyl)-NO2, - (Ci-6 alkyl)-ORa", -(Ci-6 alkyl)-SRa",
-(Ci_6 alkyl)-C(O)Rb", -(Cw alkyl)-C(O)NRc"Rd", -(Cw alkyl)-C(O)ORa", -(d_6 alkyl)-OC(O)Rb", -(d_6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl)-NRc"Rd", -(d_6 alkyl)-NRc"C(O)Rd", -(Cw alkyl)-NRc"C(O)ORa", -(Ci-6 alkyl)- S(O)Rb", -(CLS aIlCyI)-S(O)NR01R11", -(CL6 alkyl)-S(O)2Rb", or -(CL6 alkyl)-S(O)2NRc"Rd", wherein each of the CL6 alkyl, C2_6 alkenyl, C2_6 alkynyl, CL6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from:
Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, 0Ra", SRa", C(O)Rb", C(0)NRc"Rd", C(O)ORa", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(O)Rd", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(Ci_6 alkyl)-CN, -(d_6 alkyl)-NO2, -(Ci-6 alkyl)-ORa", -(Ci_6 alkyl)-SRa", -(d_6 alkyl)-C(O)Rb", -(d_6 alkyl)-C(O)NRc"Rd", -(d_6 alkyl)-C(O)ORa", -(C L6 alkyl)-OC(O)Rb", -(d_6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl)-NRc"Rd",
-(d_6 alkyl)-NRc"C( 0O))RRdd"",, --((dd__66 aallkkyyll))--NNRRcc""CC((OO))OORRaa"",, --((CCii--66 aallkkyyll))-- SS((OO))FRb",
-(Ci_6 alkyl)-S(O)NRC Rd , -(d_6 alkyl)-S(O)2Rb , and -(d_6 alkyl)-S(O)2NRc Rd ;
Ra, Ra and Ra are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
Rb, Rb' and Rb" are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
Rc and Rd are each, independently, H, CL6 alkyl, CL6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
Rc and Rd are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group; and
Rc and Rd are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group.
In a sixth aspect, the agent is selected from the compounds of Formula VI:
Figure imgf000112_0001
VI or pharmaceutically acceptable salt forms or prodrugs thereof, wherein:
A is N or CR1;
R1, R2, and R3 are each, independently, H, halo, Ci_4 alkyl, C2^ alkenyl, C2^ alkynyl, Q-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rd, NRcC(0)0Ra, S(O)Rb, S(0)NRcRd, S(O)2Rb, or S(0)2NRcRd;
R4 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, S(O)2R9, SOR9, cycloalkyl, or heterocycloalkyl, wherein the Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, cycloalkyl, heterocycloalkyl are each optionally substituted with 1, 2 or 3 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(O)OR3, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rd, NRcC(0)0Ra, S(O)Rb, S(0)NRcRd, S(O)2Rb, and S(0)2NRcRd;
R5 is 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -L-(3-8 membered cycloalkyl), -L-(3-8 membered heterocycloalkyl), each substituted by one R6 and O, 1 or 2 R7;
L is Ci_4 alkylenyl, C2-4 alkenylenyl, C2-4 alkynylenyl, O, S, NR14, CO, COO, OCO, NR14C(O)O, CONR14, SO, SO2, SONR14, SO2NR14, Or NR14CONR14;
R6 is -W1-W2-W3-W4-W5-W6-R13;
W1 is absent, Ci_4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(d. 4 alkyl), Ci_4 haloalkyl, d^ alkoxy, Ci_4haloalkoxy, amino, Ci-4 alkylamino or C2_g dialkylamino;
W2 is absent, Ci-4 alkylenyl, C2-4 alkenylenyl, C2-4 alkynylenyl, O, S, NR12, CO, COO, OCO, C(S), C(S)NR12, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, Or NR12CONR12, wherein the Ci_4 alkylenyl, C2^ alkenylenyl, C2^ alkynylenyl, are each optionally substituted by 1, 2 or 3 halo, OH, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci-4 alkylamino or C2_g dialkylamino;
W3 is absent, Ci_4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the Q_4 alkylenyl, C2_4 alkenylenyl, C2^ alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1 , 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(Ci_4 alkyl), Ci-4 haloalkyl, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino or C2_g dialkylamino;
W4 is absent, Ci-4 alkylenyl, C2-4 alkenylenyl, C2.4 alkynylenyl, O, S, NR12, CO, COO, OCO, - C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, OrNR12CONR12, wherein the Ci-4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, are each optionally substituted by 1 , 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(Ci_4 alkyl), Q-4 haloalkyl, Ci_4 alkoxy, d_4haloalkoxy, amino, Ci_4 alkylamino or C2-8 dialkylamino;
W5 is absent, Ci_4 alkylenyl, C2^ alkenylenyl, C2_4 alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the Ci_4 alkylenyl, C2_4 alkenylenyl, C2^ alkynylenyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, CN, NO2, OH, =NH, =N0H, =N0-(Ci_4 alkyl), Q-4 haloalkyl, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino or C2_8 dialkylamino;
W6 is absent, Ci-4 alkyl, C2-4 alkenyl, C2_4 alkynyl, O, S, NR12, CO, COO, OCO, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, Or NR12CONR12, wherein the d_4 alkyl, C2_4 alkenyl, C2_4 alkynyl are each optionally substituted by 1, 2 or 3 CN, NO2, OH, =NH, =N0H, =NO- (Ci-4 alkyl), Ci_4 haloalkyl,
Figure imgf000113_0001
alkoxy, Ci_4haloalkoxy, amino, Ci-4 alkylamino or C2_g dialkylamino;
R7 is halo, Q_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, CN, NO2, 0Ra , SR3", C(0)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(O)Rd", NRc"C(0)0R3", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(C« alkyl)-CN, -(Ci-6 alkyl)-NO2, - (Ci_6 alkyl)-ORa", -(Ci_6 alkyl)-SR3", -(Cw alkyl)-C(O)Rb", -(Ci-6 alkyl)-C(O)NRc"Rd", -(Ci-6 alkyl)- C(O)OR3", -(d_6 alkyl)-0C(0)Rb", -(d_6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl) -NRc"Rd", -(Ci-6 alkyl)- NRc"C(0)Rd", -(Ci_6 alkyl)-NRc"C(O)ORa", -(Ci_6 alkyl)-S(O)Rb", -(Ci_6 alkyl)-S(O)NRc"Rd", -(Ci_6 alkyl)-S(O)2Rb", or -(d_6 alkyl)-S(O)2NRc"Rd";
R9 is Ci-4 alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted with 1, 2, or 3 substituents selected from halo, Ci_4 alkyl, C2^ alkenyl, C2^ alkynyl, Ci_4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, 0Ra', SRa', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rd', NRc C(0)0Ra', S(O)Rb', S(0)NRc Rd', S(O)2Rb', and S(0)2NRc'Rd';
R12 and R14 are each, independently, H or Ci_6 alkyl optionally substituted by 1, 2 or 3 substituents selected from OH, CN, NO2, amino, (Ci-4 alkyl)amino, (C2_8 dialkyl)amino, Ci_6 haloalkyl, Ci_6 acyl, Ci_6 acyloxy, Ci_6 acylamino, -(Ci-6 alkyl)-CN, and -(Ci-6 alkyl)-NO2;
R13 is halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, CN, NO2, 0Ra , SRa", C(0)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(O)Rd", NRc"C(0)0R3", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", S(O)2NRc"Rd", -(Ci-6 alkyl)-CN, -(Ci_6 alkyl)-NO2, - (d_6 alkyl)-0R3", -(d_6 alkyl)-SR3",
-(Ci_6 alkyl)-C(O)Rb", -(Ci_6 alkyl)-C(O)NRc"Rd", -(Ci_6 alkyl)-C(0)0R3", -(d_6 alkyl)-OC(O)Rb", -(d_6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl)-NRc"Rd", -(Ci_6 alkyl)-NRc"C(O)Rd", -(Ci_6 alkyl)-NRc"C(0)0R3", -(Ci-6 alkyl)- S(O)Rb", -(Ci_6 alkyl)-S(O)NRc"Rd", -(Ci_6 alkyl)-S(O)2Rb", or -(Ci_6 alkyl)-S(O)2NRc"Rd", wherein each of the Ci_6 alkyl, C2_6 alkenyl, C2-6 alkynyl, Q_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from:
Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, ORa", SRa", C(O)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(O)Rd", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(d_6 alkyl)-CN, -(d_6 alkyl)-NO2, -(Ci-6 alkyl)-ORa", -(d_6 alkyl)-SRa", -(Ci_6 alkyl)-C(O)Rb", -(Cw alkyl)-C(O)NRc"Rd", -(Cw alkyl)-C(O)ORa", -(C1-S alkyl)-OC(O)Rb", -(d_6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl)-NRc"Rd", -(Ci_6 alkyl)-NRc"C(O)Rd", -(Ci_6 alkyl)-NRc"C(O)ORa", -(Ci-6 alkyl)- S(O)Rb", -(d_6 alkyl)-S(O)NRc"Rd", -(d_6 alkyl)-S(O)2Rb", and -(d_6 alkyl)-S(O)2NRc"Rd";
Ra, Ra and Ra are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
R , R and R are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2 !_-66 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
Rc and Rd are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
Rc and Rd are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group; and
Rc and Rd are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group.
In some embodiments of the compounds of Formula V or VI, A is CR1.
In some embodiments of the compounds of Formula V or VI, A is N.
In some embodiments of the compounds of Formula V or VI, R1 is H.
In some embodiments of the compounds of Formula V or VI, R is H.
In some embodiments of the compounds of Formula V or VI, R3 is H.
In some embodiments of the compounds of Formula V or VI, R4 is H or Ci_4 alkyl.
In some embodiments of the compounds of Formula V or VI, R4 is methyl.
In some embodiments of the compounds of Formula V or VI, R5 is 3-8 membered heterocycloalkyl substituted by one R6 and O, 1 or 2 R7. In some embodiments of the compounds of Formula V or VI, R5 is 6-membered heterocycloalkyl substituted by one R6 and 0, 1 or 2 R7.
In some embodiments of the compounds of Formula V or VI, R5 is piperidinyl substituted by one R6 and 0, 1 or 2 R7.
In some embodiments of the compounds of Formula V or VI, R5 is piperidin-3-yl substituted by one R6 and 0, 1 or 2 R7.
In some further embodiments of the compounds of Formula V or VI, R6 is substituted on the piperidinyl N-atom.
In some embodiments of the compounds of Formula V or VI, R5 is -L-pyrrolidinyl; L is Ci_4 alkylenyl; and the pyrrolidinyl is substituted by one R6 and 0, 1 or 2 R7.
In some embodiments of the compounds of Formula V or VI, R5 is -L-pyrrolidin-2-yl; L is Ci_4 alkylenyl and the pyrrolidin-2-yl is substituted by one R6 and 0, 1 or 2 R7.
In some embodiments of the compounds of Formula V or VI, W is absent, Ci_4 alkylenyl, C2^ alkenylenyl, C2-4 alkynylenyl, O, S, NR12, CO, COO, OCO, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12, OrNR12CONR12, wherein the d_4 alkylenyl, C2_4 alkenylenyl, C2^ alkynylenyl, are each optionally substituted by 1 , 2 or 3 substituents independently selected from halo, OH, Ci_4 alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino, and C2_g dialkylamino.
In some embodiments of the compounds of Formula V or VI, W2 is SO2, CO, COO, C(S)NR12, or CONR12.
In some embodiments of the compounds of Formula V or VI, W2 is SO2, CO, COO, C(S)NH, CONH or -CON(CL4 alkyl)-.
In some embodiments of the compounds of Formula V or VI, W2 is SO2 or CO.
In some embodiments of the compounds of Formula V or VI, W3 is Q^ alkylenyl or cycloalkyl.
In some embodiments of the compounds of Formula V or VI, R13 is halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, CN, NO2, 0Ra", SRa", C(O)Rb", C(0)NRc"Rd", C(O)OR3", OC(O)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(O)2NRc"Rd", -(Ci_6 alkyl)-CN, -(Ci-6 alkyl)-NO2, -(Cw alkyl)-ORa", -(Ci_6 alkyl)-SRa", -(Ci- 6 alkyl)-C(O)Rb", -(CL6 alkyl)-C(O)NRc"Rd", -(CL6 alkyl)-C(O)ORa", -(d_6 alkyl)-OC(O)Rb", -(CL6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl)-NRc"Rd", -(Ci-6 alkyl)-NRc"C(O)Rd", -(d_6 alkyl)-NRc"C(O)ORa", - (d_6 alkyl)-S(O)Rb", -(d_6 alkyl)-S(O)NRc"Rd", -(Ci-6 alkyl)-S(O)2Rb", or -(d_6 alkyl)-S(O)2NRc"Rd".
In some embodiments of the compounds of Formula V or VI, R13 is CL6 alkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from: Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, OR3", SR3", C(O)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0R3", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(C1^ aIlCyI)-CN, -(d_6 alkyl)-NO2, -(d_6 alkyl)-0R3", -(C1^ aIlCyI)-SR3", -(d.6 alkyl)-C(O)Rb", -(Cw alkyl)-C(O)NRc"Rd", -(Cw alkyl)-C(0)0R3", -(d.6 alkyl)-OC(O)Rb", -(CL6 alkyl)-0C(0)NRc"Rd", -(CL6 alkyl)-NRc"Rd", -(d_6 alkyl)-NRc"C(O)Rd", -(Cw alkyl)-NRc"C(0)0R3", -(Ci-6 alkyl)- S(O)Rb", -(d_6 alkyl)-S(O)NRc"Rd", -(CL6 alkyl)-S(O)2Rb", and -(d_6 alkyl)-S(O)2NRc"Rd".
In some embodiments of the compounds of Formula V or VI, R13 is aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from:
CL6 alkyl, C2_6 alkenyl, C2_6 alkynyl, CL6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, OR3", SR3", C(0)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0R3", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", S(O)2NRc"Rd", -(CL6 alkyl)-CN, -(Ci-6 alkyl)-NO2, -(CL6 alkyl)-0R3", -(CL6 alkyl)-SR3", -(d_6 alkyl)-C(O)Rb", -(C L6 alkyl)-C(O)NRc"Rd", -(CL6 alkyl)-C(0)0R3", -(d_6 alkyl)-OC(O)Rb", -(C L6 alkyl)-0C(0)NRc"Rd", -(CL6 alkyl)-NRc"Rd", -(d_6 alkyl)-NRc"C(O)Rd", -(d_6 alkyl)-NRc"C(0)0R3", -(Ci-6 alkyl)- S(O)Rb", -(CL6 alkyl)-S(O)NRc"Rd", -(CL6 alkyl)-S(O)2Rb", and -(CL6 alkyl)-S(O)2NRc"Rd".
In some embodiments of the compounds of Formula V or VI, R13 is CL6 alkyl, CL6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from:
CL6 alkyl, C2_6 alkenyl, C2_6 alkynyl, CL6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, OR3", SR3", C(0)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0R3", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", S(O)2NRc"Rd", -(CL6 alkyl)-CN, -(CL6 alkyl)-NO2, -(CL6 alkyl)-0R3", -(CL6 alkyl)-SR3", -(d_6 alkyl)-C(O)Rb", -(C L6 alkyl)-C(O)NRc"Rd", -(CL6 alkyl)-C(0)0R3", -(d_6 alkyl)-OC(O)Rb", -(C L6 alkyl)-0C(0)NRc"Rd", -(CL6 alkyl)-NRc"Rd", -(d_6 alkyl)-NRc"C(O)Rd", -(d_6 alkyl)-NRc"C(0)0R3", -(Ci-6 alkyl)- S(O)Rb", -(CL6 alkyl)-S(O)NRc"Rd", -(CL6 alkyl)-S(O)2Rb", and -(d_6 alkyl)-S(O)2NRc"Rd".
In some embodiments of the compounds of Formula V or VI, R13 is CL6 alkyl, CL6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from Cw alkyl, Cw haloalkyl, aryl, heteroaryl, halo, CN, ORa", SRa", C(O)Rb", C(O)OR3", NRc"C(0)Rd", S(O)2Rb", and -(Ci-6 alkyl)-CN.
In some embodiments of the compounds of Formula V or VI, R13 is aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from Ci_6 alkyl, Ci_6 haloalkyl, aryl, heteroaryl, halo, CN, 0Ra", SRa", C(O)Rb", C(O)OR3", NRc"C(0)Rd", S(O)2Rb", and - (C1^ aUCyI)-CN.
In some embodiments of the compounds of Formula V or VI, R13 is Ci_6 alkyl, Q-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from Q-6 alkyl, Q-6 haloalkyl, aryl, heteroaryl, halo, CN, OH, Ci_4 alkoxy, Ci_4haloalkoxy, heteroaryloxy, aryloxy, -SCi-6 alkyl, -C(O)-Ci-6 alkyl, -C(O)OCi-6 alkyl, -S(O)2Ci-6 alkyl, -NHC(O)-Ci- 6 alkyl, and -(Cw alkyl)-CN.
In some embodiments of the compounds of Formula V or VI, R13 is aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from Ci_6 alkyl, Ci_6 haloalkyl, aryl, heteroaryl, halo, CN, OH,
Figure imgf000117_0001
alkoxy, Ci_4haloalkoxy, heteroaryloxy, aryloxy, -SCi_6 alkyl, -C(O)-Cw alkyl, -C(O)OCw alkyl, -S(O)2Cw alkyl, -NHC(O)-Cw alkyl, and -(Cw alkyl)-CN.
In some embodiments of the compounds of Formula V or VI, R13 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from d_6 alkyl, Ci_6 haloalkyl, aryl, heteroaryl, halo, CN, OH, Ci_4 alkoxy, Ci_4 haloalkoxy, heteroaryloxy, aryloxy, -SCL6 alkyl, -C(O)-CL6 alkyl, -C(O)OCL6 alkyl, -S(O)2CL6 alkyl, -NHC(O)-C1. 6 alkyl, and -(Cw alkyl)-CN.
In some embodiments of the compounds of Formula V or VI, R13 is arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from CL6 alkyl, CL6 haloalkyl, aryl, heteroaryl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkoxy, heteroaryloxy, aryloxy, -SCL6 alkyl, -C(O)-CL6 alkyl, -C(O)OCL6 alkyl, - S(O)2CL6 alkyl, -NHC(O)-CL6 alkyl, and -(Cw alkyl)-CN.
In some embodiments of the compounds of Formula V or VI, R13 is OH or CN.
In some embodiments of the compounds of Formula V or VI, W1 is absent, W2 is CO or SO2, W3 is Ci-4 alkyleneyl or cycloalkyl, W4 is absent, W5 is absent, W6 is absent, and R13 is CN or OH.
In some embodiments of the compounds of Formula V or VI, R6 is -W2-W3-R13.
In some embodiments of the compounds of Formula V or VI, R6 is -CO-CH2-CN.
In some embodiments of the compounds of Formula V or VI, R6 is -W2-R13.
In some embodiments of the compounds of Formula V or VI, R6 is R13.
In some embodiments of the compounds of Formula V or VI:
R6 is -W2 -R13; W2 is SO2, CO, COO, C(S)NR12, or CONR12; and
R13 is Ci_6 alkyl, d_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from:
Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, 0Ra", SRa", C(0)Rb", C(0)NRc"Rd", C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(C« alkyl)-CN, -(Ci-6 alkyl)-NO2, - (Ci_6 alkyl)-ORa", -(Ci_6 alkyl)-SRa", -(Cw alkyl)-C(O)Rb", -(d_6 alkyl)-C(O)NRc"Rd", -(d_6 alkyl)-C(O)ORa", -(d_6 alkyl)-OC(O)Rb",
-(Ci_6 alkyl)-0C(0)NRc Rd , -(Ci_6 alkyl)-NRc Rd , -(Ci_6 alkyl)-NRc C(0)Rd , -(d_6 alkyl)-NRc"C(0)0Ra", -(Ci-6 alkyl)-S(O)Rb", -(d_6 alkyl)-S(O)NRc"Rd", -(Ci_6 alkyl)-S(O)2Rb", and -(Ci_6 alkyl)-S(O)2NRc"Rd".
In some embodiments, the compounds of formula V have the structure of Formula Va:
Figure imgf000118_0001
wherein t is O, 1 or 2.
In some embodiments, the compounds of the invention have Formula Va, wherein:
W2 is SO2, CO, COO, C(S)NR12, or CONR12;
R13 is Ci_6 alkyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from:
Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halo, CN, NO2, 0Ra", SRa", C(0)Rb", C(0)NRc"Rd", C(0)0Ra", 0C(0)Rb", 0C(0)NRc"Rd", NRc"Rd", NRc"C(0)Rd", NRc"C(0)0Ra", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", S(0)2NRc"Rd", -(Ci-6 alkyl)-CN, -(d_6 alkyl)-NO2, - (Ci_6 alkyl)-ORa", -(Ci_6 alkyl)-SRa", -(Ci_6 alkyl)-C(O)Rb", -(Ci-6 alkyl)-C(O)NRc"Rd", -(Ci-6 alkyl)- C(0)0Ra", -(d_6 alkyl)-OC(O)Rb", -(d_6 alkyl)-OC(O)NRc"Rd", -(d_6 alkyl) -NRc"Rd", -(d_6alkyl)- NRc"C(0)Rd", -(d_6 alkyl)-NRc"C(O)ORa", -(d_6 alkyl)-S(O)Rb", -(d_6 alkyl)-S(O)NRc"Rd", -(Ci-6 alkyl)-S(O)2Rb", and -(d_6 alkyl)-S(O)2NRc"Rd"; and t is 0, 1 or 2.
In some embodiments, t is O.
In some embodiments, t is 1.
In some embodiments, t is 2.
In some embodiments, the compounds have the structure of Formula Vb:
Figure imgf000119_0001
Vb wherein tl is 0 or 1.
In some further embodiments, the compounds have Formula Vb wherein:
R13 is Ci_6 alkyl, d_6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from Ci_6 alkyl, Ci_6 haloalkyl, aryl, heteroaryl, halo, CN, ORa , SRa", C(O)Rb", C(O)OR3", NRc"C(O)Rd", S(O)2Rb", and -(d_6 alkyl)-CN;
W2 is SO2, CO, COO, C(S)NH, CONH or -CON(C1^ alkyl)-; and
R4 is Ci-4 alkyl, C2.4 alkenyl, C2.4 alkynyl, S(O)2R9, SOR9, cycloalkyl, or heterocycloalkyl, wherein the Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, cycloalkyl, heterocycloalkyl are each optionally substituted with 1, 2 or 3 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd.
In some embodiments, tl is O.
In some embodiments, tl is 1.
In some embodiments, the therapeutic agent is selected from:
3-{3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l-yl}-3-oxopropanenitrile;
3-{(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l-yl}-3- oxopropanenitrile;
N-methyl-N-[(3R,4R)-4-methyl-l-(phenylsulfonyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-(methoxyacetyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine; (3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]-N-phenylpiperidine-l- carboxamide;
(3R,4R)-N-benzyl-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- carboxamide;
(3R,4R)-N-ethyl-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- carboxamide;
(3R,4R)-N-isopropyl-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- carboxamide;
N-[(3R,4R)-l-isobutyryl-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3-b]pyridin-4- yl)-amine;
N-methyl-N-[(3R,4R)-4-methyl-l-(morpholin-4-ylcarbonyl)piperidin-3-yl]-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-acetyl-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3-b]pyridin-4-yl)- amine;
N-methyl-N-[(3R,4R)-4-methyl-l-(3-methylbutanoyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-benzoyl-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3-b]pyridin-4-yl)- amine;
(3R,4R)-N,N,4-trimethyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- carboxamide;
4-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl} carbonyl)benzonitrile;
N-[(3R,4R)-l-(cyclopropylcarbonyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-isonicotinoyl-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3-b]pyridin- 4-yl)-amine;
N- {(3R,4R)- 1 -[(1 -acetylpiperidin-4-yl)carbonyl]-4-methylpiperidin-3-yl} -N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
Phenyl (3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- carboxylate;
Methyl (3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- carboxylate;
N-methyl-N-[(3R,4R)-4-methyl-l-(trifluoroacetyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-(2-furoyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3-b]pyridin-4- yl)-amine; (3R,4R)-N-(4-cyanophenyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(3 -cyanophenyl)-4-methyl-3 - [methyl( 1 H-pyrrolo [2,3 -b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]-N-(2- phenylethyl)piperidine- 1 -carboxamide;
(3R,4R)-N-(2-rurylmethyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
N-methyl-N-[(3R,4R)-4-methyl-l-(propylsulfonyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-(isopropylsulfonyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
4-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl} sulfonyl)benzonitrile;
2-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl} sulfonyl)benzonitrile;
N-methyl-N-[(3R,4R)-4-methyl-l-(methylsulfonyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(trifluoromethyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-[(3R,4R)-4-methyl-l-(pyridin-3-ylsulfonyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
2-fluoro-5-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl} sulfonyl)benzonitrile;
N-methyl-N-[(3R,4R)-4-methyl-l-(3-pyridin-3-ylpropanoyl)piperidin-3-yl]-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-[(3R,4R)-4-methyl-l-(3,3,3-trifluoropropanoyl)piperidin-3-yl]-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-[(3R,4R)-4-methyl-l-(tetrahydrofuran-2-ylcarbonyl)piperidin-3-yl]-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
(2R)- 1 - {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 -yl} - 1 - oxopropan-2-ol;
(2S)- 1 - {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 -yl} - 1 - oxopropan-2-ol;
N-methyl-N-[(3R,4R)-4-methyl-l-(3-phenylpropanoyl)piperidin-3-yl]-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine; (3R,4R)-N-(4-cyanophenyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carbothioamide;
N-methyl-N-{(3R,4R)-4-methyl-l-[(5-methylisoxazol-4-yl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N- {(3R,4R)-4-methyl- 1 - [(I -methyl- 1 H-imidazol-4-yl)sulfonyl]piperidin-3-yl} -N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N- {(3R,4R)- 1 -[(3,5-dimethylisoxazol-4-yl)carbonyl]-4-methylpiperidin-3-yl} -N-methyl-N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]-N-2-thienylpiperidine-l- carboxamide;
N-[(3R,4R)-l-(isoxazol-5-ylcarbonyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(l,2-dimethyl-lH-imidazol-4-yl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl- N-(lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-[4-methyl-5-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidin- 1 -yl} sulfonyl)- 1 ,3-thiazol-2-yl]acetamide;
N- {(3R,4R)- 1 - [(2,4-dimethyl- 1 ,3-thiazol-5-yl)sulfonyl]-4-methylpiperidin-3-yl} -N-methyl- N-(lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N- {(3R,4R)-4-methyl- 1 -[(1 ,3,5-trimethyl- lH-pyrazol-4-yl)sulfonyl]piperidin-3- yl}-N-(lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N- {(3R,4R)- 1 -[(3,5-dimethylisoxazol-4-yl)sulfonyl]-4-methylpiperidin-3-yl} -N-methyl-N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(pyridin-4-ylmethyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(pyridin-3-ylmethyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(pyridin-2-ylmethyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
4-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl} sulfonyl)benzonitrile;
(3R,4R)-N-(4-cyanophenyl)-N,4-dimethyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(4-cyanophenyl)-N-ethyl-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]-N-l,3-thiazol-2- ylpiperidine- 1 -carboxamide; (3R,4R)-4-methyl-N-(3-methylisoxazol-5-yl)-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
3-chloro-4-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl} sulfonyl)benzonitrile;
(3R,4R)-4-methyl-N-(5-methylisoxazol-3-yl)-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-isoxazol-3-yl-4-methyl-3-[memyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
N-methyl-N-{(3R,4R)-4-methyl-l-[(5-pyridin-3-yl-2-thienyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
(3R,4R)-N-(3-cyano-2-thienyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-l,3-benzothiazol-2-yl-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
N-[(3R,4R)- 1 -(2,3-dihydro- lH-indol- 1 -ylcarbonyl)-4-methylpiperidin-3-yl]-N-methyl-N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(methylthio)acetyl]piperidin-3-yl}-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine;
(3R,4R)-N-(4,5-dihydro-l,3-thiazol-2-yl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]-N-(l,3-thiazol-2- ylmethyl)piperidine- 1 -carboxamide;
1 -( {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 - yl}carbonyl)piperidine-4-carbonitrile;
1 -( {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 - yl}carbonyl)piperidine-3-carbonitrile;
1 -( {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 - yl}carbonyl)pyrrolidine-3-carbonitrile;
(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]-N-(3- thienylmethyl)piperidine- 1 -carboxamide;
(3R,4R)-N-(2-benzothien-l-ylmethyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(l,3-benzothiazol-2-ylmethyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
N-[(3R,4R)-l-(3-rurylacetyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3- b]pyridin-4-yl)-amine; 3-(2- {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l-yl}-2- oxoethyl)- 1 ,3-thiazolidine-2,4-dione;
3-(2- {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l-yl}-2- oxoethyl)-l,3-benzothiazol-2(3H)-one;
(3R, 4R)-N-[5-(cyanomethyl)-4,5-dihydro,-l,3-thiazol-2-yl]-3-[methyl-(lH-pyrrolo[2,3- b]pyridin-4-yl)amino]-4-methyl-piperidine-l-carboxamide;
(3S)-l-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl}carbonyl)pyrrolidine-3-carbonitrile;
(3R)- 1 -( {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 - yl}carbonyl)pyrrolidine-3-carbonitrile;
1 -( {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 - yl}carbonyl)-4-phenylpiperidine-4-carbonitrile;
N-methyl-N-((3R,4R)-4-methyl- 1 - {[3-(trifluoromethyl)pyrrolidin- 1 -yl]carbonyl}piperidin-3- yl)-N-(lH-pyrrolo[2,3-b]pyridin-4-yl)-amine; l-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl}carbonyl)azetidine-3-carbonitrile;
4-methyl-l-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl}carbonyl)pyrrolidine-3-carbonitrile;
1 -( {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 - yl}carbonyl)pyrrolidine-3,4-dicarbonitrile;
3-methyl-l-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-l- yl}carbonyl)pyrrolidine-3-carbonitrile;
(3R,4R)-N-(2-cyanoethyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
4-methoxy-l-({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- l-yl}carbonyl)pyrrolidine-3-carbonitrile;
N-{(3R,4R)-l-[(2R)-2-aminopropanoyl]-4-methylpiperidin-3-yl}-N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-[(3R,4R)-l-(aminoacetyl)-4-methylpiperidin-3-yl]-N-methyl-N-(lH-pyrrolo[2,3-b]pyridin- 4-yl)-amine;
1 -(2- {(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin- 1 -yl} -2- oxoethyl)piperidine-4-carbonitrile;
N-methyl-N-[(3R,4R)-4-methyl-l-(l,3-thiazol-4-ylcarbonyl)piperidin-3-yl]-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine bis (trifluoroacetate);
4-(2-2S-{[methyl-(lH-pyrrolo[2,3-b]pyridin-4-yl)-amino]-methyl}-pyrrolidin-l-yl-sulfonyl)- benzonitrile trifluoroacetate; N- [( 1 -methanesulfonyl-2S-pyrrolidin-2-yl)-methyl] -N-methyl-N-( 1 H-pyrrolo [2,3 -b]pyridin- 4-yl)-amine trifluoroacetate;
3-((2S)-2-{[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]methyl}pyrrolidin-l-yl)-3- oxopropanenitrile trifluoroacetate;
Methyl 3-[({(3R,4R)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidine-l- yl} carbonyl)-amino]benzoate;
(3R,4R)-N-(4-trifluoromethoxyphenyl)-4-methyl-3-[methyl-(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(4-fluorophenyl)-4-methyl-3-[methyl-(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(3-fluorophenyl)-4-methyl-3-[methyl-(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(2-fluorophenyl)-4-methyl-3-[methyl-(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(4-trifluoromethylphenyl)-4-methyl-3-[methyl-(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-N-(2-methoxyphenyl)-4-methyl-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4- yl)amino]piperidine- 1 -carboxamide;
(3R,4R)-4-methyl-N-(4-methylphenyl)-3-[methyl(lH-pyrrolo[2,3-b]pyridin-4-yl)- amino]piperidine- 1 -carboxamide;
N-methyl-N-{(3R,4R)-4-methyl-l-[4-(pyridin-2-yloxy)phenyl]sulfonyl-piperidin-3-yl}-N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[4-(l,3-oxazol-5-yl)phenyl]sulfonyl-piperidin-3-yl}-N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[5-(l,3-oxazol-5-yl)thienyl]sulfonyl-piperidin-3-yl}-N- (lH-pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(6-phenoxy-pyridin-3-yl)sulfonyl]piperidin-3-yl}-(lH- pyrrolo[2,3-b]pyridin-4-yl)amine;
N-{(3R,4R)-l-[(2,6-dichlorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(4-fluorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(3-fluorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(2-fluorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine; N-{(3R,4R)-4-methyl-l-[4-(trifluoromethyl)phenyl]sulfonyl-piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-4-methyl-l-[3-(trifluoromethyl)phenyl]sulfonyl-piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-4-methyl-l-[2-(trifluoromethyl)phenyl]sulfonyl-piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(4-methoxyphenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(3-methoxyphenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(4-methylphenyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(3-methylphenyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-methyl-N-{(3R,4R)-4-methyl-l-[(2-methylphenyl)sulfonyl]piperidin-3-yl}-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(4-chlorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine;
N-{(3R,4R)-l-[(3-chlorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine; and
N-{(3R,4R)-l-[(2-chlorophenyl)sulfonyl]-4-methylpiperidin-3-yl}-N-methyl-N-(lH- pyrrolo[2,3-b]pyridin-4-yl)-amine, and pharmaceutically acceptable salts thereof.
In a seventh aspect, the agent is selected from compounds of Formula Vila, VIIb, and VIIc:
Figure imgf000126_0001
Vila VIIb VIIc and pharmaceutically acceptable salts thereof, wherein:
D1, D2, D3, D4, D5, D6 and D7 are, independently, CR1 or N;
E is O, S, SO, SO2, orNR2a;
G is N or CR2b;
Q1 and Q2 are each, independently, N or CR2c; W1 is absent, Ci_6 alkyl, C2* alkenyl, C2-6 alkynyl, O, S, NR3, CO, COO, CONR3, SO, SO2, SONR3, SO2NR3, or NR3CONR4, wherein the Ci-6 alkyl, C2_6 alkenyl or C2_6 alkynyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, OH, Ci_4 alkoxy, C14 haloalkoxy, amino, Ci_4 alkylamino and C2_8 dialkylamino;
W2 is absent, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, OH, =NH, =N0H, =N0-(C14 alkyl), -NR3C(O)O-(d_4 alkyl), NR3C(O)-(d_4 alkyl), - C(0)0-(Ci_4 alkyl), Ci_4haloalkyl, Ci_4cyanoalkyl, pentahalosulfanyl, C14hydroxylalkyl, Ci_4 alkylthio, Ci_4haloalkylthio, C14 alkoxy, Ci_4 haloalkoxy, amino, C14 alkylamino and C2_g dialkylamino;
W3 is absent, Ci-6 alkyl, C2* alkenyl, C2* alkynyl, O, S, NR3, =N-, =N-0-, =N-0-( C14 alkyl)-, 0-( Ci_4 alkyl), S-(C14 alkyl), NR3-( CM alkyl), (C14 alkyl)-O-( CM alkyl), (C14 alkyl)-S-(C14 alkyl), (C14 alkyl)-NR3-( C14 alkyl), CO, COO, C(O)-(C14 alkyl), C(O)O-(C14 alkyl), C(O)-(C14 alkyl)-C(O), NR3C(O)-(C14 alkyl), C(0)NR3-(C14 alkyl), NR3C(O)O-(C14 alkyl), NR3C(O)O, CONR3, SO, SO2, SONR3, SO2NR3, or NR3CONR4, wherein the Ci-6 alkyl, C2_6 alkenyl or C2_6 alkynyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, OH, CN, C14 alkoxy, C14 haloalkoxy, amino, C14 alkylamino and C2_g dialkylamino;
W4 is H, NR3R4, CN, Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein each of the Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, OH, CN, C14 alkoxy, =NH, =N0H, =NO-(C14 alkyl), C14haloalkyl, C14 haloalkoxy, pentahalosulfanyl, COOH, CONH2, COO-(C14 alkyl), amino, C14 alkylamino and C2_8 dialkylamino;
R1 is, independently, H, halo, C14 alkyl, C24 alkenyl, C24 alkynyl, C14 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, NRcC(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, NRcS(0)NRcRd, pentahalosulfanyl, S(O)2Rb, or S(O)2NRcRd;
R2a is H, C14 alkyl, C24 alkenyl, C24 alkynyl, OH, C14 alkoxy, C(O)Rb, C(0)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, or S(O)2NRcRd;
R2b and R2c are each, independently, H, halo, C14 alkyl, C24 alkenyl, C24 alkynyl, C14 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)ORa, OC(O)Rb, 0C(0)NRcRd, NRcC(O)NRcRd, NRcRd, NRcC(0)Rd, NRcC(0)0Ra, S(O)Rb, S(O)NRcRd, NRcS(0)NRcRd, S(O)2Rb, or S(O)2NRcRd;
R3 and R4 are each, independently, H, Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, cycloalkylalkyl, COORa , CORb , SORb', or SO2Rb' wherein each of the Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl is optionally substituted by 1 , 2 or 3 substituents selected from halo, C14 alkyl, C14 haloalkyl, OH, C14 alkoxy, C14 haloalkoxy, amino, Ci_4 alkylamino, C2-8 dialkylamino, aminocarbonyl, Ci_4 alkylaminocarbonyl, C2-8 dialkylaminocarbonyl, CN and NO2; or R3 and R4 together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by 1, 2 or 3 substituents selected from halo, Ci_4 alkyl, Ci_4 haloalkyl, OH, Ci_4 alkoxy, Ci_4 haloalkoxy, amino, Q_4 alkylamino, C2_8 dialkylamino, aminocarbonyl, Ci_4 alkylaminocarbonyl, and C2_8 dialkylaminocarbonyl;
Ra and Ra are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
Rb and Rb are each, independently, H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; and
Rc and Rd are each, independently, H, Ci_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
In some embodiments, when D7 is N, E is O or S, and G is N; then -W1-W2-W3-W4 is other than H.
In some embodiments, no more than two of D1, D2, and D3 are N.
In some embodiments, no more than three of D4, D5, D6, and D7 are N.
In some embodiments, no more than two of D4, D5, D6, and D7 are N.
In some embodiments, the compound has Formula 1 a.
In some embodiments, the compound has Formula Ib.
In some embodiments, the compound has Formula Ic.
In some embodiments, E is NR2a.
In some embodiments, E is NH or NOH.
In some embodiments, G is N.
In some embodiments, E is NH or NOH and G is N.
In some embodiments, E is NH and G is N.
In some embodiments, the compound has Formula Ia, E is NH or NOH, and G is N.
In some embodiments, Q1 is N and Q2 is CR2c.
In some embodiments, Q1 is CR2c and Q2 is N.
In some embodiments, each D1, D2, and D3 is CR1.
In some embodiments, each D1, D2, and D3 is CH.
In some embodiments, each D4, D5, D6, and D7 is CR1.
In some embodiments, each D4, D5, and D7 is CR1 and D6 is N.
In some embodiments, D4 and D7 are CH.
In some embodiments, D5 is CR1 and R1 is H or halo.
In some embodiments, D6 is CR1 and R1 is halo. In some embodiments, D6 is CF.
In some embodiments, D6 is N.
In some embodiments, D5 is CH or CF.
In some embodiments, -W1-W2-W3-W4 is Ci_6 alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, or 3 halo, Ci_4 alkyl, Q^haloalkyl, Ci_4haloalkylcarbonyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, -COOH, -COO-(Ci_4 alkyl), OH, Ci_4 alkoxy,
Figure imgf000129_0001
hydroxyalkyl, CN, cyanoalkyl, alkylthio, arylthio, haloalkylthio, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, aryloxy, cycloalkyloxy, arylalkyloxy, aminocarbonyl, aminocarbonylalkyl, cyanoalkylcarbonyl, formyl, alkylcarbonyl, amino, alkylamino, alkylcarbonylamino, alkyloxycarbonylamino, or dialkylamino optionally substituted by CN.
In some embodiments, -W1-W2-W3-W4 is Ci_6 alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heterocycloalkyl, or heterocycloalkylalkyl, each optionally substituted by 1, 2, or 3 halo, Ci_4 alkyl, Ci_4haloalkyl, Ci_4haloalkylcarbonyl, aryl, -COO-(Ci_4 alkyl), OH, Ci_4 alkoxy, Ci_4haloalkoxy, hydroxyalkyl, CN, cyanoalkyl, alkylthio, haloalkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyloxy, aminocarbonyl, aminocarbonylalkyl, cyanoalkylcarbonyl, formyl, alkylcarbonyl, alkyloxycarbonylamino, alkylcarbonylamino, or dialkylamino optionally substituted by CN.
In some embodiments, -W1-W2-W3-W4 is methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, biphenyl, benzyl, phenylethyl, phenylpropyl, cyclopropyl, cyclohexyl, cyclohexenyl, bicyclo[2.2.1]hept-2-enyl, cyclopentyl, pyridyl, pyrryl, imidazolyl, isoxazolyl, thiazolyl, quinolinyl, piperidinyl, tetrahydrofuranyl, pyrrolidinyl, benzo[l,3]dioxolyl, (piperidin-4-yl)methyl, (piperidin-3- yl)methyl, (tetrahydropyran-4-yl)-methyl, (tetrahydrothiopyran-4-yl)-methyl, each optionally substituted by 1, 2, or 3 halo, Ci_4 alkyl, Ci_4haloalkyl, Ci_4haloalkylcarbonyl, aryl, -COO-(Ci_4 alkyl), OH, Ci_4 alkoxy, Ci_4haloalkoxy, hydroxyalkyl, CN, cyanoalkyl, cyanoalkylcarbonyl, alkylthio, haloalkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyloxy, aminocarbonyl, aminocarbonylalkyl, cyanoalkylcarbonyl, formyl, alkylcarbonyl, alkyloxycarbonylamino, alkylcarbonylamino, or dialkylamino optionally substituted by CN.
In some embodiments, -W1-W2-W3-W4 is phenyl, pyrazyl, pyrindyl, pyrryl, indolyl, furyl, thienyl, or benzothienyl, each optionally substituted by 1, 2, 3, 4, or 5 halo, C^ alkyl, Ci_4 haloalkyl, aryl, OH, C^ alkoxy, hydroxyalkyl, CN, cyanoalkyl, alkylthio, haloalkylthio, alkylsulfinyl, alkylsulfonyl, cycloalkyl, heterocycloalkyl, cycloalkylakyl, heterocyclyoalkylalkyl, amino, dialkylamino, aminoalkyl, or aminosulfonyl.
In some embodiments, the agent is selected from compounds of Formula VIId or VIIe:
Figure imgf000130_0001
VIId VIIe and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIf or VIIg:
Figure imgf000130_0002
In some embodiments, the agent is selected from compounds of Formula VIIh or VIIi
Figure imgf000130_0003
and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIj or VIIk:
Figure imgf000130_0004
VIIj VIIk and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIl: W4
Figure imgf000131_0001
and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIm or VIIn:
Figure imgf000131_0002
VIIm VIIn and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIo or VIIp:
Figure imgf000131_0003
VIIo VIIp and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIq or VIIr:
Figure imgf000132_0001
VIIq VIIr and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from:
2-tert-butyl- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
2-cyclopropyl- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
2-cyclohexyl-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
10-fluoro-2-isobutyl-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
2-cyclopentyl- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [ 1 ]benzazepine;
10-fluoro-2-(tetrahydrofuran-3-yl)-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
2-cyclohex-3-en- 1 -yl- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
Trans ethyl (lR,S)-2-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclopropanecarboxylate;
2-bicyclo[2.2.1]hept-5-en-2-yl-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b] [ 1 ]benzazepine;
[(lS)-2-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclopropyl]methanol trifluoroacetate;
2-(l-ethylpentyl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
4-ethyl-4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)hexanenitrile;
2-cyclopentyl- 10, 11 -difluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
2-(l -ethylpentyl)- 10, 11 -difluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
3-[l-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclohexyl]propanenitrile;
4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)-4- methylpentanenitrile;
2-(l-ethylpropyl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
10-fluoro-2-[2-(methylthio)ethyl]-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
10-fluoro-2-[2-(methylsulfinyl)ethyl]-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepine;
2-[(benzyloxy)methyl]- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [ 1 ]benzazepine; Cis-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclohexyl]methanol;
Trans-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclohexyl]methanol;
Cis^^lO-fluoro-SjS-dihydroimidazo^jS-dlpyridoP^-blfllbenzazepin^-y^cyclohexanol;
Trans-4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)cyclohexanol;
Trans-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclohexyl] acetonitrile;
2-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2- yl)cyclohexyl] acetamide; tert-butyl 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidine- 1 -carboxylate;
10-fluoro-2-piperidin-4-yl-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [ 1 ]benzazepine;
3-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidin-l-yl]-3- oxopropanenitrile;
2-(l -acetylpiperidin-4-yl)- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
10-fluoro-2-[l-(methylsulfonyl)piperidin-4-yl]-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b][l]benzazepine;
[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidin-l- yl] acetonitrile; ethyl [4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidin-l- yl] acetate;
2-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidin-l- yljethanol;
3-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidin-l- yl]propan-l-ol;
4-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)piperidin-l- yl]butanenitrile;
10-fluoro-2-[3-methyl-5-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5- d]pyrido[2,3-b][l]benzazepine;
2-[3-(difluoromethyl)-5-methyl-lH-pyrazol-4-yl]-10-fluoro-3,8-dihydroimidazo[4,5- d]pyrido[2,3-b][l]benzazepine;
2-(3,5-dimethyl-lH-pyrazol-4-yl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b] [ 1 ]benzazepine;
2-(3,5-diethyl-lH-pyrazol-4-yl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b] [ 1 ]benzazepine; [4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)-5-methyl-3- (trifluoromethyl)- 1 H-pyrazol- 1 -yl] acetonitrile;
2-(2-chloro-6-methylphenyl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b] [ 1 Jbenzazepine trifluoroacetate;
2-(10-fluoro-l,8-dihydroimidazo[4,5-d]pyrido[2,3-b][l]benzazepin-2-yl)-3- methylbenzonitrile trifluoroacetate;
2-(2,6-dimethylphenyl)- 10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b] [1 ]benzazepine;
2-(3,5-dichloropyridin-4-yl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b] [ 1 ]benzazepine; and
2-(2,4-dimethylpyridin-3-yl)-10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3- b] [ 1 ]benzazepine; or pharmaceutically acceptable salt thereof.
In some embodiments, the agent is selected from:
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-ethylhexanenitrile;
2-[4-(hydroxymethyl)-cyclohexyl]-imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
[4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)cyclohexyl]methanol;
[4-(3-hydroxy-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)cyclohexyl] acetonitrile;
[4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)cyclohexyl]acetonitrile;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-methylbutanenitrile;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-ethylpentanenitrile;
[3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)cyclopentyl]methanol;
S^S^-dihydroimidazo^jS-dldipyridoP^-b^'^'-fjazepin^-y^cyclopentanecarbonitrile;
2-(3,5-dichloropyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine ;
2-(2-fluoro-6-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(6-chloro-2-fluoro-3-methylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2-fluoro-6-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2-chloro-6-fluoro-3-methylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-(2-chloro-6-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; 2-[2-chloro-5-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2,6-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,5-dichlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dibromopyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-bromophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-methylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-ethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,5-dimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-chloro-3-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,5-bis(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3-chloro-2,6-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,3-dichlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
3-[[4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- ylphenyl](ethyl)amino]propanenitrile;
2-(2-chloro-3,6-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-bromopyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-bromo-2,3-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[3-chloro-2-fluoro-5-(trifluoromethyl) phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-(2-chloropyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,3-dimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-fluoro-3-(trifluoromethyl) phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3-fluoro-2-methyl phenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-bromo-2-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-fluoro-5-(trifluoromethyl) phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2-fluoro-3-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-fluoro-5-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,3-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-quinolin-4-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-fluoro-2-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; 2-(5-bromo-2-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,5-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,5-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3,5-dimethyl-lH-pyrrol-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(4-methyl-lH-imidazol-5yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-dimethoxyphenol;
2-(2-pentafluoroethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-bromo-l,3-benzodioxol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-phenylpentanenitrile;
2-[2-fluoro-4-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(cyclohexylmethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
3-bromo-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxyphenol;
2-(2-fluoropyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-biphenyl-2-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; methyl-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzoate;
2-[2-(ethylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(lH-pyrrol-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-{4-[(trifluoromethyl)thio]phenyl}-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-naphthyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; tert-butyl[l-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-phenethyl] carbamate;
2-pyrrolidin-2-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chloro-6-methoxyquinolin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(l-acetylpyrrolidin-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(l,3-thiazol-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; l-acetyl-S^Sjδ-dihydroimidazo^jS-dldipyridoP^-b^'^'-flazepm^-y^pyrrolidm-S-ol;
N-[l-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)ethyl]acetamide; tert-butyl 2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4- hydroxypyrrolidine- 1 -carboxylate;
N-[4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenyl]acetamide;
2-[4-(difluoromethoxy)phenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(6-chloropyridin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
6-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2(methylthio)nicotinonitrile;
2-(3-fluoropyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; 2-(6-methoxypyridin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(6-bromopyridin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(6-bromopyridin-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(lH-imidazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-(methylthio)ethyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(piperidin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
3-[4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)piperidin-l-yl]-3- oxopropanenitrile;
3-[3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)piperidin-l-yl]-3- oxopropanenitrile;
3-[4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)piperidin-l-ylmethyl]-3- oxopropanenitrile;
3-[3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)piperidin-l-ylmethyl]-3- oxopropanenitrile;
2-[l-(trifluoroacetyl)piperidin-4-yl] 3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine bis(trifluoroacetate) ;
2-[l-(trifluoroacetyl)piperidin-3-yl] 3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-{[l-(trifluoroacetyl)piperidin-4-yl]methyl}- 3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-{[l-(trifluoroacetyl)piperidin-3-yl]methyl}- 3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(l-acetylpiperidin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)piperidine-l-carbaldehyde;
2-[(l-acetylpiperidin-4-yl)methyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[(l-acetylpiperidin-3-yl)methyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(l-methylpiperidin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
4-(3-hydroxy-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
2-pyridin-3-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-pyridin-3-ylimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-pyridin-2-ylimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-pyridin-4-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-pyridin-4-ylimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-piperidin-3-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; 2-[4-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[6-(trifluoromethyl)pyridine-3-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[3-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3,5-dimethylisoxazol-4-yl)imidazo [4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-[4-(methylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[4-(methylthio)phenyl]imidazo [4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-[4-(methylsulfonyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(lH-imidazol-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(l-methyl-lH-imidazol-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-phenyl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-phenylimidazo [4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-benzyl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-benzylimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-(2-phenethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-phenethyl)imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-piperidin-4-yl-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-piperidin-4-yl imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-(piperidin-4-ylmethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(piperidin-4-ylmethyl) imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-(piperidin-3-ylmethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(tetrahydro-2H-pyran-4-ylmethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(tetrahydro-2H-pyran-4-ylmethyl)imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-(tetrahydro-2H-thiopyran-4-ylmethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(tetrahydro-2H-thiopyran-4-ylmethyl)imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-3(8H)-ol;
2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-[3-(difluoromethyl)-5-methyl-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-[l-(4-methoxybenzyl)-3-methyl-5-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8- dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[l,5-dimethyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-[l-ethyl-5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5- d]dipyrido[2,3-b:4',3'-f]azepine;
2-[l-(cyclopropylmethyl)-5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8- dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; 2-[3-methyl-5-(pentafluoroethyl)-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-N,N,5-trimethyl-3- (trifluoromethyl)- 1 H-pyrazole- 1 -sulfonamide;
2-[3-[chloro(difluoro)methyl]-5-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4-yl]-3,8- dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[3-(difluoromethyl)-5-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4-yl]-3,8- dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3,5-dimethyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3-isobutyl-5-methyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3-ethyl-5-methyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3-butyl-5-methyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3,5-diethyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-cyclopropyl-3-methyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2-chloro-6-methylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-methylbenzonitrile;
2-(2,4-dimethyl-3-thienyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[4-methylsulfinyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[4-(ethylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-{4-[2-(5-methyl-2-furyl)propyl]phenyl}-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(l-benzothien-5-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine; l-(2,4-dimethyl-l,3-thiazol-5-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3-methyl-5-phenylisoxazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(4-chloro-l-methyl-lH-pyrazol-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(l,3,5-trimethyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-chloro-l,3-dimethyl-lH-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3,5-dimethylisoxazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[l-(2-methoxyethyl)-2,5-dimethyl-lH-pyrrol-3-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine; 2-(l-cyclopropyl-2,5-dimethyl-lH-pyrrol-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-[2,5-dimethoxy-4-(methylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(trifluoromethyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4-dimethoxy-3-methylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-(methylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-ethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,3,4,5,6-pentamethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chloro-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-methyl-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenol;
2-(2,5-dimethyl-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chloro-3,4-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,3-dimethyl-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichloro-3,4-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2,4-dichloro-3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6- methoxyphenol;
2-(2,4,5-trimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4-dichlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chloro-4-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4-dimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-(trifluoromethoxy)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-(difluoromethoxy)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-methoxypyridin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[4-fluoro-2-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4,6-trimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-chloro-3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxyphenol;
2-(3-methylpyridin-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-ethoxy-N,N-diethylaniline;
2-(2,5-dimethoxy-4-bromophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-isobutoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)pyridine-2-amine; 2-(lH-indol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-{2-[(trifluormethyl)thio]phenyl}-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
4-bromo-3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenol;
2-[2-chloro-4-(methylsulfonyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2,2-difluoro-l,3-benzodioxol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-dimethylphenol;
2-(2-chloro-4,6-dimethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3-chlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[3-fluoro-5-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3,5-dichlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(3-chloro-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(6-chloro-l,3-benzodioxol-5-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(4-chloro-2,6-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chloro-5,6-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichloro-3-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-chloro-6-fluoro-3-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2,4,6-trifluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3-chloro-4-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(4-fluoro-2-methylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4-dichloro-6-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichloro-3-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichloro-4-methylthiophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2,6-dichloro -4-(methylsulfinyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro -4-(methylsulfonyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2-chloro-6-fluoro-5-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(2-chloro-6-fluoro-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine; [3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenyl]methanol;
[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenyl]methanol;
3,5-dichloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenol
5-chloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)nicotinonitrile;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)pyridine-3,5-dicarbonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-6- methylbenzonitrile;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)nicotinonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,6-difluorobenzonitrile;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-fluoro-4- (trifluoromethyl)benzonitrile;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- 4-methoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5,6-dimethoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4,5- dimethoxyisophthalonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-5- methoxyisophthalonitrile;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2,5-dimethoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (methylsulfonyl)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-dimethoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-difluorobenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,4-difluorobenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-6- methoxybenzonitrile;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-fluorobenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-4- methoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-5- methoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (methylthio)isophthalonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (hydroxymethyl)isophthalonitrile; 2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (hydroxymethyl)benzonitrile;
[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenyl] acetonitrile;
5-(cyanomethyl)-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)isophthalonitrile;
5-(cyanomethyl)-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (methylsulfinyl)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)5- (methylsulfonyl)isophthalonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-hydroxybenzonitrile; l-[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-phenyl]- N,N-dimethylmethanamine;
2-[2,6-dichloro-4-(morpholin-4-ylmethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-[2,6-dichloro-4-(thiomorpholin-4-ylmethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepine;
2-[2,6-dichloro-4-(methoxymethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro-4-(ethylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2,6-dichloro-4-(isopropylthio)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro-4-(ethylsulfinyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro-4-(ethylsulfonyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro-4-(isopropylsulfinyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro-4-(isopropylsulfonyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (isopropylsulfonyl)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(ethylthio)isophthalonitrile;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (ethylthio)benzonitrile; 2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (isopropylthio)isophthalonitrile;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (isopropylthio)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (isopropylsulfinyl)isophthalonitrile;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (isopropylsulfinyl)benzo-nitrile;
2-[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy] acetonitrile;
2-[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy]propanenitrile;
5-(l-cyanoethoxy)-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)isophthalonitrile;
5-(l-cyanoethoxy)-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)benzonitrile;
5-(cyanomethoxy)-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)isophthalonitrile;
2-[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy]propanamide;
2-[3,5-dicyano-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy]propanamide;
5-(2-amino-l-methyl-2-oxoethoxy)-3-cyano-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:4',3'-f]azepin-2-yl)benzamide;
5-(2-amino-l-methyl-2-oxoehtoxy)-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- f]azepin-2-yl)isophthalamide;
2-[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy] acetamide;
2-[3,5-dicyano-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy] acetamide;
2-cyano-2-[3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)phenoxy]-N,N-dimethylacetamide;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)isophthalonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxybenzonitrile;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-l,3-benzodioxole-5- carbonitrile; 3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
3-fluoro-4-methyl-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)benzonitrile;
3-fluoro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
3-methoxy-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
5-fluoro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)benzonitrile;
3-chloro-6-methoxy-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2- yl)benzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-methoxyisophthalonitrile; tert-butyl [4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)pyridin-3- yljcarbamate; tert-butyl [4-(3-hydroxy-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)pyridin- 3-yl]carbamate;
2-(3,5-dimethylpyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'--f]azepine;
3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenol;
2-(2,6-dichloro-4-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichloro-4-ethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,6-dichloro-4-isopropoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
2-(3-methylpyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2-methylpyridin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,4-dimethylpyridin-3-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-chloro-2-ethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-chloro-2-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(5-bromo-2-ethoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-(2,3-difluoro-6-methoxyphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'- fjazepine;
3,5-dichloro-4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-N,N- dimethylaniline;
2-(2,6-dichloro-4-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- methoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-methoxyisophthalonitrile; 3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- ethoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-ethoxyisophthalonitrile;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- isopropoxybenzonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- isopropoxyisophthalonitrile;
2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (trifluoromethoxy)isophthalonitrile;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (trifluoromethyl)benzonitrile;
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- (dimethylamino)benzonitrile; and
3-chloro-2-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5- fluorobenzonitrile; and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from:
2-(3,5-dichloropyridin-4-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
2-(2,6-dichlorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
2-(2,6-difluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
2-(2-chloro-6-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
2-(2,6-dimethylphenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
4-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-2-yl)-4-ethylhexanenitrile;
2-[l-(4-methoxybenzyl)-5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]imidazo[4,5- d]dipyrido[2,3-b:3',4'-f]azepin-3(8H)-ol;
2-[l-(4-methoxybenzyl)-5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8- dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin- 3(8H)-ol;
2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-3,8-dihydroimidazo[4,5-d]dipyrido[2,3- b:3',4'-f]azepine;
2-(2,3-dimethylphenyl)imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-3(8H)-ol;
2-(2,3-dimethylphenyl)-l,8-dihydroitnidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine;
2-[2-(dimethylamino)-pyridin-3-yl]imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-3(8H)-ol;
3-(3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-2-yl)-N,N-dimethylpyridin-2- amine;
2-(2-cyano-6-fluorophenyl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine and pharmaceutically acceptable salts thereof.
In an eight aspect, the agent is selected from compounds of Formula VIII:
Figure imgf000147_0001
VIII
and pharmaceutically acceptable salts thereof; wherein:
Cya is selected from arylene, heteroarylene, cycloalkylene, and heterocycloalkylene, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, CC=NR^NR01R111, NR01CC=NR^NR01R111, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(0)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2.6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, C(=NR)NRclRdl, NR01CC=NRONR01R111, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl;
Cyb is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_ 6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NR02CC=NRONR02R112, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
L is a divalent moiety selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci-6 alkylene)p-(C3_io cycloalkylene)-( Ci_6 alkylene)q, (Ci-6 alkylene)p-(C3_io heterocycloalkylene)-( Ci_6 alkylene)q, (Ci_6 alkylene)p-(C6-io arylene)-( Ci_6 alkylene)q. (Ci_6 alkylene)p-(C3_io heteroarylene)-( Ci_6 alkylene)q, (Ci_6 alkylene)p-O-( Ci_6 alkylene)q, (Ci_6 alkylene)p-S-(Ci_6 alkylene)q, (Ci_6 alkylene)p- NRc3-(Ci_6 alkylene)q, (C« alkylene)p-C(O)-(Ci_6 alkylene)q, (Ci-6 alkylene)p-OC(O)-(Ci_6 alkylene)q, (d_6 alkylene)p-C(O)NRc3-(C1.6 alkylene)q, (Ci-6 alkylene)p-OC(O)NRc3-(C1.6 alkylene)q, (Ci-6 alkylene)p-SO-(Ci-6 alkylene)q, (Ci-6 alkylene)p-SO2-(Ci-6 alkylene)q, (CL6 alkylene)p-SONRc3-(C!.6 alkylene)q, (Cw alkylene)p-SO2NRc3-(d_6 alkylene)q, (Cw alkylene)p-NRc3CONRd3-(C1.6 alkylene)q, (d_6 alkylene)p-NRc3SONRd3-(C1.6 alkylene)q, and (C« alkylene)p-NRc3SO2NRd3-(C1.6 alkylene)q, wherein each of the Q_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, cycloalkylene, arylene, heterocycloalkylene, and heteroarylene is optionally substituted by 1 , 2 or 3 substituents independently selected from d_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, CN, NO2, SCN, OH, Ci_4 haloalkyl, halosulfanyl, Ci_4 alkoxy-Ci_4 alkyl, Ci_4alkoxy, Ci_4 haloalkoxy, amino, Ci_4 alkylamino, and C2_g dialkylamino; wherein L is oriented in either direction with respect to its attachment to Cya and Cyb;
Y1 is selected from CR3 and N;
Y2 is selected from CR4 and N;
Y3 is selected from CR5 and N; provided that at least one of Y1 and Y2 is other than N;
Z1 is selected from CR6 and N;
Z2 is selected from CR7 and N;
R1 is selected from H, Ci_6 alkyl, C(O)Ci_6 alkyl, and C(O)aryl;
R2, R3, R4, R5, R6, and R7 are independently selected from H, halo, Ci_6 alkyl, C2_6 alkenyl, C2.6 alkynyl, Cy1, Ci-6 haloalkyl, halosulfanyl, CN, NO2, 0Ra4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)OR34, OC(O)RM, OC(O)NRc4Rd4, C(=NRI)NRc4Rd4, NRc4C(=NRI)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, NRc4S(O)RM, NRc4S(O)2RM, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4; wherein the d_6 alkyl, C2.6 alkenyl, or C2.6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from CN, NO2, Cy1,
Figure imgf000148_0001
alkyl)-, 0Ra4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, OC(O)RM, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(O)ORa4, C(=NR')NRc4Rd4, NRc4C(=NR)NRc4Rd4, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4;
Cy, Cy1, and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, N3, 0Ra5, SRa5, C(0)Rb5, C(O)NRc5Rd5, C(O)OR35, 0C(0)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRI)NRc5Rd5, NRc5C(=NRI)NRc5Rd5, P(Rf5)2, P(ORe5)2, P(O)Re5Rf5, P(O)ORe5ORf5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, and S(O)2NRc5Rd5, wherein the Ci_6 alkyl, C2_6 alkenyl, and C2_6 alkynyl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci_6 haloalkyl, halosulfanyl, CN, NO2, N3, 0Ra5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)OR35, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, Q=NR^NR0V5, NR^C^NR^NR'V5, P(Rf5)2, P(ORe5)2, P(O)Re5Rf5, P(O)ORe5ORf5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, and S(O)2NRc5Rd5 ;
Ral, Ra2, and Ra4are independently selected from H, Cy2, -(Ci-6 alkyl)-Cy2, Ci-6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, and C(O)-Ci-7 hydrocarbyl, wherein the Ci_6 alkyl, C2_6 alkenyl, Ci_7 hydrocarbyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, Ci_6 alkoxy, CN, amino, alkylamino, dialkylamino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
Rbl, Rb2, and RM are independently selected from H, Cy2, -(Ci-6 alkyl)-Cy2, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, Ci_6 alkoxy, CN, amino, alkylamino, dialkylamino , halo, Ci-6 alkyl, Q_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
Rcl, Rc2, and Rc4 are independently selected from H, Cy2, -(Ci-6 alkyl)-Cy2, Ci_6 alkyl, Ci_6 haloalkyl, d_6 hydroxyalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, Ci_6 alkoxy, CN, amino, alkylamino, dialkylamino, halo, Ci_6 alkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
R , R , and Rd4 are independently selected from H, Cy2, -(Ci-6 alkyl)-Cy2, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, Ci_6 alkoxy, CN, amino, alkylamino, dialkylamino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl; or, one or more of Rcl and Rdl, Rc2 and Rd2, and Rc4 and Rd4 together with the N atom to which they are attached, optionally form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, d_6 alkoxy, CN, amino, alkylamino, dialkylamino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
Rc3 and Rd3 are independently selected from H, Cy2, -(Ci-6 alkyl)-Cy2, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, Ci_6 alkoxy, CN, amino, alkylamino, dialkylamino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
Ra5 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein the Ci- 6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 alkoxy, Ci_6 haloalkyl, and Ci_6haloalkoxy;
Rb5 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein the Ci- 6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 alkoxy, Ci_6 haloalkyl, and Ci_6haloalkoxy;
Rc5 and Rd5 are independently selected from H, Ci.io alkyl, d_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein the Ci.io alkyl, d_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 alkoxy, Ci_6 haloalkyl, and Ci_6haloalkoxy; or
Rc5 and Rd5 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 alkoxy, Q_6 haloalkyl, and Ci_6 haloalkoxy;
Re5 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, (Ci_6 alkoxy)-Ci_6 alkyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl;
Rβ is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl;
R1 is H, CN, NO2, C(O)NH2, or Ci-6 alkyl; p is O or 1 ; and q is O or 1.
In some embodiments, when Cya is a piperazine ring, R2 is other than halo.
In some embodiments, Y1 is N and Y2 is CR4.
In some embodiments, Y2 is N and Y1 is CR3.
In some embodiments, Y is N.
In some embodiments, Y3 is N.
In some embodiments, Y3 is CR5.
In some embodiments, at least one of Y1, Y2 and Y3 is N.
In some embodiments, both of Y1 and Y3 are N.
In some embodiments, both of Y2 and Y3 are N.
In some embodiments, Y1 is CR3, Y2 is CR4, and Y3 is CR5.
In some embodiments, Z1 is N. In some embodiments, Z1 is CR6.
In some embodiments, Z is N.
In some embodiments, Z2 is CR7.
In some embodiments, at least one of Z1 and Z2 is N.
In some embodiments, both of Z1 and Z2 are N.
In some embodiments, Z1 is CR6 and Z2 is CR7.
In some embodiments, Cya is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, CC=NR^NR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is aryl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(0)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, CC=NRONR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is aryl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(0)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is aryl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, CN, NO2, 0Ral, SRal, and NRclRdl.
In some embodiments, Cya is aryl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 and 0Ral. In some embodiments, Cya is phenyl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, CC=NR^NR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is heteroaryl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, CC=NR^NR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is cycloalkyl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, CC=NRONR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, CC=NR^NR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is heterocycloalkyl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, CC=NR^NR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cya is a substituted aryl or substituted heteroaryl ring according to Formula IA:
Figure imgf000153_0001
IA wherein:
R is selected from H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halo- sulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, CC=NRONR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, CU6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, CU6 haloalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, CC=NR^NR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl;
Q1, Q2 and Q3 are independently selected from CRQ and N;
RQ is independently selected from H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q_6 haloalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, or S(O)2NRclRdl; wherein the Q_6 alkyl, C2_6 alkenyl, and C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, CC=NRONR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; and the point of attachment on the right hand side of the ring of Formula IA is attached to L.
In some embodiments, Cya is a substituted aryl or substituted heteroaryl ring according to Formula IB:
Figure imgf000154_0001
wherein:
R is selected from H, halo, Q-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halo- sulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, CC=NRONR01R111, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl;
Q1, Q2 and Q3 are independently selected from CRQ and N;
RQ is independently selected from H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(O)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Q-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(O)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NRclRdl, C(=NR)NRclRdl, NRclC(=NR)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)ORal, NRclC(0)NRclRdl, NRclS(O)Rbl, NRclS(O)2Rbl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, and S(O)2NRclRdl; and the point of attachment on the right hand side of the ring of Formula IB is attached to L.
In some embodiments, R is selected from H, Ci_6 alkyl, halo and 0Ral.
In some embodiments, R is selected from Ci_6 alkyl, halo and 0Ral.
In some embodiments, R is selected from Ci_6 alkyl and 0Ral.
In some embodiments, R is selected from Ci_6 alkyl and halo.
In some embodiments, Q1 is N.
In some embodiments, Q1 is CRQ.
In some embodiments, Q2 is N.
In some embodiments, Q2 is CRQ. In some embodiments, Q3 is N. In some embodiments, Q3 is CRQ. In some embodiments, at least one of Q1, Q2 and Q3 is N.
In some embodiments, at least two of Q1, Q2 and Q3 is N.
In some embodiments, all of Q1, Q2 and Q3 are N.
In some embodiments, all of Q1, Q2 and Q3 are CRQ.
In some embodiments, RQ is independently selected from H, halo, Ci_6 alkyl, Ci_6 haloalkyl, ORal, halosulfanyl, Cy, NRclRdl, C(O)Rbl, and C(O)NRclRdl.
In some embodiments, Cya is a substituted aryl or substituted heteroaryl ring according to Formula IC:
Figure imgf000155_0001
and the point of attachment on the right hand side of the ring of Formula IC is attached to L.
In some embodiments, Cya is a substituted aryl or substituted heteroaryl ring according to Formula ID:
Figure imgf000155_0002
ID; and the point of attachment on the right hand side of the ring of Formula ID is attached to L.
In some embodiments, Cyb is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, d_6 alkyl, C2.6 alkenyl, C2.6 alkynyl, Cy, Cw haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR')NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, Cy, Q_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, and NRc2Rd2.
In some embodiments, Cyb is aryl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, CC=NR^NR02R112, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, or S(O)2NRc2Rd2; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR')NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is phenyl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, CC=NRONR02R112, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR')NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is heteroaryl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)OR32, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR')NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is cycloalkyl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, CC=NR^NR02R112, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR')NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is heterocycloalkyl, optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci-6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci-6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, CC=NRONR0V2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.
In some embodiments, Cyb is a substituted aryl or substituted heteroaryl ring according to Formula IE:
Figure imgf000157_0001
IE wherein: W1, W2 and W3 are independently selected from CRW and N; A1 and A2 are independently selected from CRW and N; or the group, A1=A2, is S, O, or NH; and each Rw is independently selected from H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, CC=NR^NR0V2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; provided that, when A1 and A2 are independently selected from CRW and N; then at least three of W1, W2, W3, A1 and A2 are CRW.
In some embodiments, Cyb is a substituted aryl or substituted heteroaryl ring according to
Formula IF:
Figure imgf000158_0001
IF wherein:
W1 and W2 are independently selected from CRW and N;
A1 and A2 are independently selected from CRW and N; or the group, A1=A2, is S, O, or NH; and each Rw is independently selected from H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo, Q_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Cy, Q_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NR)NRc2Rd2, NRc2C(=NR)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, or S(O)2NRc2Rd2. In some embodiments, Q1 is CRQ. In some embodiments, W1 is N. In some embodiments, W1 is CRW. In some embodiments, W2 is N. In some embodiments, W2 is CRW. In some embodiments, at least one of W1 and W2 is N. In some embodiments, both of W1 and W2 are N. In some embodiments, both of W1 and W2 are CRW. In some embodiments, A1 is N. In some embodiments, A1 is CRW. In some embodiments, A is N. In some embodiments, A2 is CRW. In some embodiments, at least one of W1 and W2 is N. In some embodiments, both of W1 and W2 are N. In some embodiments, both of W1 and W2 are CRW. In some embodiments, the group A1=A2 is S. In some embodiments, the group A1=A2 is O. In some embodiments, the group A1=A2 is NH.
In some embodiments, Rw is independently selected from H, halo, Q-6 alkyl, Q-6 haloalkyl, 0Ral, halosulfanyl, Cy, NRclRdl, C(O)Rbl, and C(O)NRclRdl.
In some embodiments, Cyb is a substituted aryl or substituted heteroaryl ring according to
Formula IG:
Figure imgf000159_0001
In some embodiments, L is a divalent moiety selected from Ci_6 alkylene, (Ci_6 alkylene)p-O-( Ci_6 alkylene)q, (Ci-6 alkylene)p-S-(Ci_6 alkylene)q, (Ci-6 alkylene)p-NRc3-(Ci_6 alkylene)q, (Ci-6 alkylene)p-C(O)-(Ci_6 alkylene)q, (Ci-6 alkylene)p-OC(O)-(Ci_6 alkylene)q, (Ci-6 alkylene)p-C(O)NRc3- (Ci-6 alkylene)q, (Ci-6 alkylene)p-OC(O)NRc3-(C1_6 alkylene)q, (Ci-6
Figure imgf000159_0002
alkylene)q, (Ci-6 alkylene)p-SO2-(Ci_6 alkylene)q, (Ci-6 alkylene)p-SONRc3-(Ci_6 alkylene)q, (Ci-6 alkylene)p-SO2NRc3- (Ci-6 alkylene)q, (Ci-6 alkylene)p-NRc3CONRd3-(Ci_6 alkylene)q, (Ci-6 alkylene)p-NRc3SONRd3-(Ci_6 alkylene)q, and (Ci-6 alkylene)p-NRc3SO2NRd3-(Ci_6 alkylene)q, wherein the Ci_6 alkylene is optionally substituted by 1, 2 or 3 substituents independently selected from Ci_4 alkyl, C2-A alkenyl, C2A alkynyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, CN, NO2, SCN, OH, Ci_4haloalkyl, halosulfanyl, d_4 alkoxy-Ci_4 alkyl, Ci_4alkoxy, Ci_4haloalkoxy, amino, Q-4 alkylamino, and C2_8 dialkylamino.
In some embodiments, L is a divalent moiety selected from (Ci-6 alkylene)p-C(O)NRc3-(Ci_6 alkylene)q and (Ci-6 alkylene)p-NRc3CONRd3-(Ci_6 alkylene)q, wherein the Ci_6 alkylene is optionally substituted by 1, 2 or 3 substituents independently selected from Ci_4 alkyl, C2_4 alkenyl, C2A alkynyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, CN, NO2, SCN, OH, Ci_4haloalkyl, halosulfanyl, Ci_4 alkoxy-Ci_4 alkyl, Ci_4alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino, and C2-8 dialkylamino.
In some embodiments,!, is a divalent moiety selected from (Ci-6 alkylene)p-C(O)NRc -(Ci-6 alkylene)q and (Ci-6 alkylene)p-NRc3CONRd3-(Ci_6 alkylene)q.
In some embodiments, L is a divalent moiety selected from C(O)NH, C(O)NH-(Ci_6 alkylene) and NHCONH.
In some embodiments, L is C(O)NH.
In some embodiments, L is C(O)NH-(Ci_6 alkylene).
In some embodiments, L is NHCONH.
In some embodiments, L is Ci_6 alkylene.
In some embodiments, L is (Ci-6 alkylene)p-(C3_io cycloalkylene)-( Ci_6 alkylene)q.
In some embodiments, L is (Ci_6 alkylene)p-(C3_ioheterocycloalkylene)-( Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-(C6-io arylene)-( Ci_6 alkylene)q.
In some embodiments, L is (Ci_6 alkylene)p-(C3_i0heteroarylene)-( Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-O-( Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-S-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-NRc3-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-C(0)-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-OC(O)-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-C(O)NRc -(Ci-6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-OC(O)NRc3-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-S0-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-SO2-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-SONRc -(Ci-6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-SO2NRc3-(Ci_6 alkylene)q.
In some embodiments, L is (Ci-6 alkylene)p-NRc3CONRd3-(Ci_6 alkylene)q. In some embodiments, L is (Ci_6 alkylene)p-NRc3SONRd3-(Ci_6 alkylene)q. In some embodiments, L is (Ci_6 alkylene)p-NRc3SO2NRd3-(Ci_6 alkylene)q In some embodiments, each of the Ci_6 alkylene, cycloalkylene, arylene, heterocycloalkylene, and heteroarylene in the above embodiments of L is optionally substituted by 1 , 2 or 3 substituents independently selected from Q-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, CN, NO2, SCN, OH, Ci_4haloalkyl, halosulfanyl, Ci_4 alkoxy-Ci_4 alkyl, Ci_4alkoxy, Ci_4haloalkoxy, amino, Ci_4 alkylamino, and C2_8 dialkylamino.
In some embodiments p is O.
In some embodiments p is 1.
In some embodiments q is 0.
In some embodiments q is 1.
In some embodiments p and q are both 0.
In some embodiments p and q are both 1.
In some embodiments, L is O.
In some embodiments, L is NRc3CONRd3.
In some embodiments, L is NRc3SO2NRd3.
In some embodiments p is 0.
In some embodiments p is 1.
In some embodiments q is 0.
In some embodiments q is 1.
In some embodiments p and q are both 0.
In some embodiments p and q are both 1.
In some embodiments p and q, when added together, total 1.
In some embodiments, R1 is selected from H, Ci_6 alkyl, or C(O)Ci_6 alkyl.
In some embodiments, R1 is H.
In some embodiments, R1 is Ci_6 alkyl.
In some embodiments, R1 is C(O)Ci_6 alkyl.
In some embodiments, R2, R3, R4, R5, R6, and R7 are independently selected from H, halo, Q-6 alkyl, Cy, Ci-6 haloalkyl, halosulfanyl, CN, NO2, ORa4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, OC(O)RM, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)RM, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, NRc4S(O)RM, NRc4S(O)2RM, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4; wherein the Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from CN, NO2, Cy, Cy-(Ci_6 alkyl)-, ORa4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, OC(O)RM, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)RM, NRc4C(O)ORa4, CC=NR^NR0V4, NRc4C(=NR)NRc4Rd4, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4.
In some embodiments, R2, R3, R4, R5, R6, and R7 are independently selected from H, halo, Q-6 alkyl, Cy, Ci-6 haloalkyl, halosulfanyl, CN, NO2, ORa4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, NRc4Rd4, NRc4C(O)RM, NRc4C(O)ORa4, NRc4S(O)2RM, S(O)RM, S(O)2RM, and S(O)2NRc4Rd4; wherein the Ci_6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from CN, NO2, Cy, Cy-(Ci-6 alkyl)-, ORa4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, OC(O)RM, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)RM, NRc4C(O)ORa4, C(=NR)NRc4Rd4, NRc4C(=NR)NRc4Rd4, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4.
In some embodiments, R2, R3, R4, R5, R6, and R7 are independently selected from H, halo, Q-6 alkyl, Cy, Q_6 haloalkyl, halosulfanyl, CN, NO2, 0Ra4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, NRc4Rd4, NRc4C(O)RM, NRc4S(O)2RM, S(O)2RM, and S(O)2NRc4Rd4; wherein the Q_6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from CN, NO2, Cy, Cy-(Q-6 alkyl)-, 0Ra4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, OC(O)RM, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(O)ORa4, C(=NR')NRc4Rd4, NRc4C(=NR)NRc4Rd4, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4.
In some embodiments, R2, R3, R4, R5, R6, and R7 are independently selected from H, halo, Q_6 alkyl, Cy, Ci-6 haloalkyl, halosulfanyl, CN, NO2, OCi-6 alkyl, SQ_6 alkyl, C(O)Ci-6 alkyl, NH2, NRc4C(O)Ci_6 alkyl, NRc4S(O)2Q_6 alkyl, S(O)2Ci-6 alkyl; wherein the Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from CN, NO2, Cy, Cy-(Q-6 alkyl)-, 0Ra4, SRa4, C(O)RM, C(O)NRc4Rd4, C(O)ORa4, OC(O)RM, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(O)ORa4, C(=NR')NRc4Rd4, NRc4C(=NR)NRc4Rd4, S(O)RM, S(O)NRc4Rd4, S(O)2RM, and S(O)2NRc4Rd4.
In some embodiments, at least one of R2, R3, R4, R5, R6, and R7 is H.
In some embodiments, at least two of R2, R3, R4, R5, R6, and R7 is H.
In some embodiments, at least three of R2, R3, R4, R5, R6, and R7 is H.
In some embodiments, at least four of R2, R3, R4, R5, R6, and R7 is H.
In some embodiments, at least one of R1 and R2 is H.
In some embodiments, R1 and R2 are both H.
In some embodiments, R is H.
In some embodiments, R is CN.
In some embodiments, R is C(O)NH2.
In some embodiments, R is Q_6 alkyl.
In some embodiments, R is H or Q-6 alkyl.
In some embodiments, the agent is selected from compounds of Formula Villa:
Figure imgf000162_0001
Villa and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIb:
Figure imgf000163_0001
VIIIb and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIc:
Figure imgf000163_0002
VIIIc and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIId:
Figure imgf000163_0003
VIIId and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIe:
Figure imgf000164_0001
VIIIe and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIf:
Figure imgf000164_0002
VIIIf and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIg:
Figure imgf000164_0003
VIIIg and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIh:
Figure imgf000164_0004
In some embodiments, the agent is selected from compounds of Formula Villi:
Figure imgf000165_0001
Villi and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIj :
Figure imgf000165_0002
VIIIj and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIk:
Figure imgf000165_0003
VIIIk and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula Villi:
Figure imgf000166_0001
Villi and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIm:
Figure imgf000166_0002
VIIIm and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIn:
Figure imgf000166_0003
VIIIn and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIo:
Figure imgf000166_0004
VIIIo and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIp:
Figure imgf000167_0001
VIIIp and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIq:
Figure imgf000167_0002
VIIIq and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIr:
Figure imgf000167_0003
VIIIr and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIs:
Figure imgf000168_0001
VIIIs and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIt:
Figure imgf000168_0002
and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from compounds of Formula VIIIu or VIIIv:
Figure imgf000168_0003
VIIIv
and pharmaceutically acceptable salts thereof.
In some embodiments, the agent is selected from:
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide;
3-(4-Methyl-lH-imidazol-l-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(tri- fluoromethyl)benzamide;
3-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoromethyl)- benzamide;
3-(4-formyl-lH-imidazol-l-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5- (trifluoromethyl)benzamide;
3-[4-(hydroxymethyl)-lH-imidazol-l-yl]-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)- phenyl]-5-(trifluoromethyl)benzamide;
3-4-[(methylamino)methyl]-lH-imidazol-l-yl-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7- yl)phenyl]-5-(trifluoromethyl)benzamide;
3-(4-methylpiperazin- 1 -yl)-N-[4-methyl-3-(9H-pyri mido[4,5-b]indol-7-yl)phenyl]-5- (trifluoromethyl)benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-3-(trifluoromethyl) benzamide;
4-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-3-(trifluoromethyl)- benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-N'-[3-(trifluoromethyl)phenyl]urea;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-N'-[3-(trifluoromethyl)phenyl]urea;
4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
4-chloro-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
4-cyano-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
2-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)- benzamide;
4-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)- benzamide;
2-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoromethyl)- benzamide;
3-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-2,5-bis(trifluoromethyl)benzamide;
3-chloro-2-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoromethyl)- benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3,5-bis(trifluoromethyl)benzamide; 4-methoxy-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)- benzamide;
3-methoxy-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-2-(trifluoromethyl)benzamide;
N-[4-fluoro-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide;
N-[3-(9H-pyrimido[4,5-b]-indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide;
3-chloro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(pentafluoro-λ(6)-sulfanyl)- benzamide;
N-[4-chloro-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-4-(trifluoromethyl)pyridine-2- carboxamide;
3-(lH-imidazol-l-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoro- methyl)benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(lH-l,2,4-triazol-l-yl)-5-(trifluoro- methyl)benzamide;
3- {4-[(dimethylamino)methyl]- lH-imidazol- 1 -yl} -N-[4-methyl-3-(9H-pyrimido[4,5-b]indol- 7-yl)phenyl]-5-(trifluoromethyl)benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-morpholin-4-yl-5-(trifluoromethyl)- benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-piperazin-l-yl-5-(trifluoromethyl)- benzamide;
3-(4-hydroxypiperidin-l-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5- (trifluoromethyl)benzamide;
3-(3-hydroxypiperidin-l-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5- (trifluoromethyl)benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-[(2-morpholin-4-ylethyl)amino]-5- (trifluoromethyl)benzamide;
3-[4-(2-hydroxyethyl)piperazin-l-yl]-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]- 5-(trifluoromethyl)benzamide;
3-{[3-(dimethylamino)propyl]amino}-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]- 5-(trifluoromethyl)benzamide;
3-(3-hydroxypyrrolidin-l-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5- (trifluoromethyl)benzamide;
3 - { [3 -( 1 H-imidazol- 1 -yl)-propyl] amino } -N- [4-methyl-3 -(9H-pyrimido [4,5-b]indol-7-yl)- phenyl]-5-(trifluoromethyl)benzamide; 3-(dimethylamino)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoro- methyl)benzamide;
3-[3-(dimethylamino)-pyrrolidin-l-yl]-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)- phenyl]-5-(trifluoromethyl)benzamide;
3-{[2-(dimethylamino)ethyl]amino}-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]- 5-(trifluoromethyl)benzamide;
4-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-3-(trifluoromethyl)- benzamide;
3-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-5-(trifluoromethyl)- benzamide;
3-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]benzamide;
N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-2,5-bis(trifluoromethyl)benzamide;
3-chloro-2-fluoro-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-6-yl)phenyl]-5-(trifluoromethyl)- benzamide;
4-methyl-3-(9H-pyrimido-[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
4-methyl-N-(3-methyl-phenyl)-3-(9H-pyrimido[4,5-b]indol-7-yl)benzamide;
4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethoxy)phenyl]benzamide;
N-(2,5-difluorobenzyl)-4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)benzamide;
4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)benzyl]benzamide;
4-methyl-N-(5-methyl-l,3-thiazol-2-yl)-3-(9H-pyrimido[4,5-b]indol-7-yl)benzamide;
4-chloro-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
4-methoxy-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl]- benzamide;
4-methyl-N-[3-(4-methyl-lH-imidazol-l-yl)-5-(trifluoromethyl)phenyl]-3-(9H-pyrimido[4,5- b]indol-7-yl)benzamide;
4-methyl-N-[(lR)-l-phenylethyl]-3-(9H-pyrimido[4,5-b]indol-7-yl)benzamide;
4-methyl-N-[(l S)- 1 -phenylethyl]-3-(9H-pyrimido[4,5-b]indol-7-yl)benzamide;
4-methyl-N-[3-(pentafluoro-λ(6)-sulfanyl)phenyl]-3-(9H-pyrimido[4,5-b]indol-7-yl)- benzamide;
4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)-N-[5-(trifluoromethyl)pyridin-3-yl]benzamide;
N-[3-(2-amino-9H-pyrimido[4,5-b]indol-7-yl)-4-methylphenyl]-3-(trifluoromethyl)- benzamide;
4-methyl-3-(9H-pyrido[2,3-b]indol-7-yl)-N-[3-(trifluoromethyl)phenyl]benzamide;
4-methyl-3-(9H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-N-[3-(trifluoromethyl)phenyl]- benzamide; N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7-yl)pyridin-3-yl]-3-(trifluoromethyl)benzamide;
3-fluoro-N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7-yl)pyridin-3-yl]-5- (trifluoromethyl)benzamide;
S-ClH-imidazol-l-y^-N-fό-methyl-S-Crø-pyrimidoμ^-blindol-T-y^pyridin-S-yll-S- (trifluoromethyl)benzamide;
N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7-yl)pyridin-3-yl]-3-(lH-l,2,4-triazol-l-yl)-5- (trifluoromethyl)benzamide;
3-(4-formyl-lH-imidazol-l-yl)-N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7-yl)pyridin-3-yl]- 5-(trifluoromethyl)benzamide;
3-[4-(hydroxymethyl)-lH-imidazol-l-yl]-N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7- yl)pyridin-3-yl]-5-(trifluoromethyl)benzamide;
3-[2-(dimethylamino)ethyl]amino-N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7-yl)pyridin-3- yl]-5-(trifluoromethyl)benzamide;
3-[3-(dimethylamino)propyl]amino-N-[6-methyl-5-(9H-pyrimido[4,5-b]indol-7-yl)pyridin-3- yl]-5-(trifluoromethyl)benzamide; and pharmaceutically acceptable salts thereof.
In a ninth aspect, the agent is selected from compounds of Formula IX:
Figure imgf000172_0001
IX and pharmaceutically acceptable salts forms thereof, wherein:
Ring A is aryl or heteroaryl;
L is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, (CR5R6)p-(C3_io cycloalkylene)-(CR5R6)q, (CR5R6)p-(arylene)-(CR5R6)q, (CR5R6)p-(Ci_io heterocycloalkylene)-(CR5R6)q, (CR5R6)P- (heteroarylene)-(CR5R6)q, (CR5R6)pO(CR5R6)q, (CR5R6)pS(CR5R6)q, (CR5R6)pC(O)(CR5R6)q, (CR5R6)pC(O)NRc(CR5R6)q, (CR5R6)pC(O)O(CR5R6)q, (CR5R6)pOC(O)(CR5R6)q, (CR5R6)pOC(O)NRc(CR5R6)q, (CR5R6)pNRc(CR5R6)q, (CR5R6)pNRcC(O)NRd(CR5R6)q, (CR5R6)pS(O)(CR5R6)q, (CR5R6)pS(O)NRc(CR5R6)q, (CR5R6)pS(O)2(CR5R6)q, or (CR5R6)pS(O)2NRc(CR5R6)q, wherein the Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd;
Q is H, Cy1, halo, Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, d_6 haloalkyl, CN, NO2, ORal, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(0)2Rbl, or S(0)2NRclRdl, wherein the C^6 alkyl, C2.6 alkenyl, C2.6 or alkynyl, are optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRclRdl;
X is H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, NO2, 0Ra, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, 0C(0)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, or S(0)2NRcRd;
Y is H, Cy2, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, NO2, 0Ral, SRal, C(0)Rbl, C(0)NRclRdl, C(0)0Ral, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2R", NRclS(0)2Rbl, or S(0)2NRclRdl, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, or Ci_6 haloalkyl, is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci- 6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(0)Rbl, C(0)NRclRdl, C(0)0Ral, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(0)2Rbl, and S(0)2NRclRdl;
R1, R2, R3, R4, R5, and R6 are independently selected from H, halo, Q-6 alkyl, C2_6 alkenyl, C2. 6 alkynyl, Ci_6 haloalkyl, CN, (CH2)mCN, NO2, 0Ra, (CH2)mORa, SRa, C(0)Rb, C(0)NRcRd, C(0)0Ra, NRcRd, (CH2)mNRcRd, NRcC(0)Rb, NRcS(0)2Rb, and S(0)2NRcRd;
Cy1 and Cy2 are independently selected from aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, d_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(0)Rbl, C(0)NRclRdl, C(0)0Ral, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(0)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(0)2NRclRdl, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl that is substituted on Cy1 or Cy2 is further optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(0)Rbl, C(0)NRclRdl, C(0)0Ral, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2R", NRclS(O)2Rbl, and S(O)2NRclRdl;
Ra, Rb, Rc, and Rd are independently selected from H, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 alkoxy, Ci_6haloalkyl, and Ci_6 haloalkoxy; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 alkoxy, Q_6 haloalkyl, and Ci_6 haloalkoxy;
Ral, Rbl, Rcl, and Rdl are independently selected from H, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein the Q_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from d_6 alkyl, halo, CN, 0Ra , SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NR8)NRc2Rd2, NRc2C(=NR8)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2,
S(O)2Rb2, NRc2S(O •))22IRb2, and S(O)2NRc2Rd2; or Rc and R i d . together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1 , 2, or 3 substituents independently selected from Ci-6 alkyl, halo, CN, 0Ra2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NR8)NRc2Rd2, NRc2C(=NR8)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, and S(O)2NRc2Rd2;
Ra2, Rb2, Rc2, and Rd2 are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein the Q_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 alkoxy, Q_6 haloalkyl, and Q_6 haloalkoxy; or Rc2 and Rd2 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 alkoxy, Q_6 haloalkyl, and Ci_6 haloalkoxy;
R8 is H, CN, and NO2; m is 0, 1, 2, or 3; n is 0 or 1; p is O, 1, 2, 3, 4, 5, or 6; and q is O, 1, 2, 3, 4, 5 or 6.
In some embodiments, A is aryl.
In some embodiments, A is phenyl.
In some embodiments, A is heteroaryl.
In some embodiments, A is pyrazolyl.
In some embodiments, A is pyridyl.
In some embodiments, L is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR5R6)p-(C3_i0 cycloalkylene)-(CR5R6)q, (CR5R6)p-(arylene)-(CR5R6)q, (CR5R6)p-(Ci_io heterocycloalkylene)- (CR5R6)q, (CR5R6)p-(heteroarylene)-(CR5R6)q, (CR5R6)pO(CR5R6)q, (CR5R6)pS(CR5R6)q, wherein the Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1 , 2, or 3 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, L is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR5R6)p-(C3_i0 cycloalkylene)-(CR5R6)q, (CR5R6)p-(arylene)-(CR5R6)q, (CR5R6)p-(Ci_io heterocycloalkylene)- (CR5R% (CR5R6)p-(heteroarylene)-(CR5R6)q, wherein the Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, L is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR5R6)p-(C3_io cycloalkylene)-(CR5R6)q, (CR5R6)p-(Ci_io heterocycloalkylene)-(CR5R6)q, wherein the Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, cycloalkylene, or heterocycloalkylene, is optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, L is Ci_8 alkylene or (CR5R6)p-(Ci_i0 heterocycloalkylene)-(CR5R6)q, wherein the Ci_8 alkylene or heterocycloalkylene, is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CU6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, L is Ci_g alkylene optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, L is (CR5R6)p-(Ci_i0 heterocycloalkylene)-(CR5R6)q optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci-6 haloalkyl, CN, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
In some embodiments, L is (CR5R6)pC(O)(CR5R6)q, (CR5R6)pC(O)NRc(CR5R6)q, (CR5R6)pC(O)O(CR5R6)q, (CR5R6)pOC(O)(CR5R6)q, (CR5R6)pOC(O)NRc(CR5R6)q, (CR5R6)pNRc(CR5R6)q, (CR5R6)pNRcC(O)NRd(CR5R6)q, (CR5R6)pS(O)(CR5R6)q, (CR5R6)pS(O)NRc(CR5R6)q, (CR5R6)pS(O)2(CR5R6)q, or (CR5R6)pS(O)2NRc(CR5R6)q.
In some embodiments, Q is H, Cy1, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Q-6 haloalkyl, CN, NO2, 0Ral, or SRal, wherein the Ci_6 alkyl, C2_6 alkenyl, C2_6 or alkynyl, are optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Q-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Q is C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, or S(O)2NRclRdl.
In some embodiments, Q is Cy1, C(O)Rbl, S(O)2Rbl, or 0Ral.
In some embodiments, Cy1 is aryl or cycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cy1 is heteroaryl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)NRclRdl, NRclC(O)ORal, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2R", NRclS(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Ri is H.
In some embodiments, R2 is H.
In some embodiments, R2 is Ci_6 alkyl.
In some embodiments, R2 is methyl.
In some embodiments, R2 is Ci_6 alkoxy.
In some embodiments, R2 is methoxy.
In some embodiments, wherein R3 is H.
In some embodiments, R4 is H.
In some embodiments, R5 is H.
In some embodiments, R^ is H. In some embodiments, the agent is selected from compounds of Formula IXa, IXb, IXc, IXd, IXe, or
IXf:
Figure imgf000177_0001
Figure imgf000177_0002
IXd IXe IXf
and pharmaceutically acceptable salts thereof.
In some embodiments, X is H, halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, CN, SRa, C(O)Rb, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcC(O)NRcRd, C(=NR8)NRcRd, NRcC(=NR8)NRcRd, S(O)Rb, S(O)NRcRd, or S(O)2Rb, In some embodiments, X is NO2, ORa, C(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcS(O)2Rb, or S(O)2NRcRd.
In some embodiments, X is OCH3, OC6H5, NO2, NH2, or N(CH2CH3)2
In some embodiments, X is H.
In some embodiments, Y is Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, or Ci_6 haloalkyl, wherein the Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2R", NRclS(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Y is H, Cy2, halo, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, or S(O)2NRclRdl.
In some embodiments, Y is H.
In some embodiments, Cy2 is aryl, or cycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, Ci_6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRclRdl.
In some embodiments, Cy2 is heteroaryl, or heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, Ci-6 haloalkyl, halosulfanyl, CN, NO2, 0Ral, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)NRclRdl, NRclC(0)0Ral, C(=NR8)NRclRdl, NRclC(=NR8)NRclRdl, S(O)Rbl, S(0)NRclRdl, S(O)2Rbl, NRclS(0)2Rbl, and S(0)2NRclRdl.
In some embodiments, the agent is selected from: 3 -(4-(2-(4-( 1 H-imidazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-( 1 -(2,4- difluorobenzoyl)piperidin-4-yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(4-(piperazin-l-yl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(4-methoxyphenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 4-( 1 -(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 3 -(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-( 1 -(2,4- difluorobenzoyl)piperidin-4-yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(l -methyl- lH-pyrazol-3-ylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(2-(4-phenoxyphenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 2-(4-(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)- 1 -(isoxazole-5- carbonyl)piperidin-4-yl)acetonitrile; 2-(l-(isoxazole-5-carbonyl)-4-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)piperidin-4-yl)acetonitrile; 2-(4-(4-(2-(3-(lH-tetrazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)-l-(isoxazole-5- carbonyl)piperidin-4-yl)acetonitrile; 2-( 1 -(isoxazole-5-carbonyl)-4-(4-(2-(4-(morpholinosulfonyl)phenylamino)pyrimidin-4-yl)- 1 H- pyrazol- 1 -yl)piperidin-4-yl)acetonitrile; 2-( 1 -(isoxazole-5-carbonyl)-4-(4-(2-(6-methoxypyridin-3-ylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)piperidin-4-yl)acetonitrile; 2-(3 -(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)- 1 -
(cyclopropylsulfony^azetidin-S-y^acetonitrile; 2-(l-(cyclopropylsulfonyl)-3-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)azetidin-3-yl)acetonitrile; N-(4-(4-(l -(3-(cyanomethyl)- 1 -(cyclopropylsulfonyl)azetidin-3-yl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)phenyl)acetamide; 2-(l-(cyclopropylsulfonyl)-3-(4-(2-(3-(2-methylpyrimidin-4-yl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)azetidin-3-yl)acetonitrile; 2-(l-(cyclopropylsulfonyl)-3-(4-(2-(4-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)azetidin-3-yl)acetonitrile; 3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(piperidin-4- yl)propanenitrile; 3-(l-(5-fluoropyrimidin-2-yl)piperidin-4-yl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-(l-(methylsulfonyl)piperidin-4-yl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; 3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(l-(phenylsulfonyl)piperidin-
4-yl)propanenitrile; 3-(l-acetylpiperidin-4-yl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-(l-benzoylpiperidin-4-yl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 2-(4-(4-(2-(4-(l H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)- 1 -
(cyclopropylsulfonyl)piperidin-4-yl)acetonitrile; 2-( 1 -(cyclopropylsulfonyl)-4-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)piperidin-4-yl)acetonitrile; 4-(4-(l-(4-(cyanomethyl)-l-(cyclopropylsulfonyl)piperidin-4-yl)-lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzamide ; 4-(4-(l-(4-(cyanomethyl)-l-(cyclopropylsulfonyl)piperidin-4-yl)-lH-pyrazol-4-yl)pyrimidin-2- ylamino)-N-(2-hydroxyethyl)benzamide; 4-(4-(l-(4-(cyanomethyl)-l-(cyclopropylsulfonyl)piperidin-4-yl)-lH-pyrazol-4-yl)pyrimidin-2- ylamino)-N,N-dimethylbenzamide;
4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)benzamide; 3 -(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3 - cyclopentylpropanenitrile;
3-cyclopentyl-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-methoxyphenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; N-(4-(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)acetamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N,N- dimethylbenzamide; 3-cyclopentyl-3-(4-(2-(4-(piperazin- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)propanenitrile; 4-( 1 -(ethylsulfonyl)piperidin-4-yl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)butanenitrile; 3-(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-( 1 -
(ethylsulfonyl)piperidin-4-yl)butanenitrile; 4-(l -(ethylsulfonyl)piperidin-4-yl)-3-(4-(2-(phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)butanenitrile; N-(4-(4-(l -(I -cyano-3-(l-(l -methyl- lH-pyrazol-3-ylsulfonyl)piperidm-4-yl)propan-2-yl)-lH-pyrazol-
4-yl)pyrimidin-2-ylamino)phenyl)acetamide; 4-(4-(l-(l-cyano-3-(l-(ethylsulfonyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4-yl)pyrimidin-2- ylamino)-N,N-dimethylbenzamide; 4-(4-(l-(l-cyano-3-(l -(I -methyl- lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4- yl)pyrimidin-2-ylamino)benzamide; 4-(l-(ethylsulfonyl)piperidin-4-yl)-3-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 3-(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)-5-methylpyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-(l -
(ethylsulfonyl)piperidin-4-yl)butanenitrile; 4-(l-(ethylsulfonyl)piperidin-4-yl)-3-(4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)butanenitrile; N-(4-(4-(l -(I -cyano-3-(l-(l -methyl- lH-pyrazol-3-ylsulfonyl)piperidm-4-yl)propan-2-yl)-lH-pyrazol-
4-yl)-5-methylpyrimidin-2-ylamino)phenyl)acetamide; 4-(4-(l -(I -cyano-3-(l -(ethylsulfonyl)piperidin-4-yi)propan-2-yl)- lH-pyrazol-4-yl)-5- methylpyrimidin-2-ylamino)-N,N-dimethylbenzamide; 4-(4-(l-(l-cyano-3-(l -(I -methyl- lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4- yl)-5-methylpyrimidin-2-ylamino)benzamide; 3-cyclopentyl-3-(4-(2-(4-(4-(methylsulfonyl)piperazin-l-yl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 4-(l-(l-methyl-lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)-3-(4-(2-(4- morpholinophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)butanenitrile; 3 -(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-( 1 -(I -methyl- 1 H- pyrazol-3-ylsulfonyl)piperidin-4-yl)butanenitrile; 4-(l-(l-methyl-lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)-3-(4-(2-(phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 4-(4-(l-(l-cyano-3-(l -(I -methyl- lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)propan-2-yl)- lH-pyrazol-4- yl)pyrimidin-2-ylamino)-N,N-dimethylbenzamide; 4-(4-(l-(l-cyano-3-(l-(2,4-difluorobenzoyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4-yl)pyrimidin-2- ylamino)-N,N-dimethylbenzamide; N-(4-(4-(l-(l-cyano-3-(l-(2,4-difluorobenzoyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4- yl)pyrimidin-2-ylamino)phenyl)acetamide; 4-(l-(l-methyl-lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)-3-(4-(5-methyl-2-(4- morpholinophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4- yl)- 1 H-pyrazol- 1 -yl)butanenitrile; 3-(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)-5-methylpyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-(l -( 1 -methyl- lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)butanenitrile; 3-(4-(2-(4-(lH-pyrazol- 1 -yl)phenylamino)-5-methylpyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-4-(l -(2,4- difluorobenzoyl)piperidin-4-yl)butanenitrile; 4-(l -(I -methyl- lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)-3-(4-(5-methyl-2-(phenylamino)pyrimidin-4- yl)- 1 H-pyrazol- 1 -yl)butanenitrile; 4-(l-(2,4-difluorobenzoyl)piperidin-4-yl)-3-(4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 4-(4-(l-(l-cyano-3-(l -(I -methyl- lH-pyrazol-3-ylsulfonyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4- yl)-5-methylpyrimidin-2-ylamino)-N,N-dimethylbenzamide; 4-(4-(l-(l-cyano-3-(l-(2,4-difluorobenzoyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4-yl)-5- methylpyrimidin-2-ylamino)-N,N-dimethylbenzamide; N-(4-(4-(l-(l-cyano-3-(l-(2,4-difluorobenzoyl)piperidin-4-yl)propan-2-yl)-lH-pyrazol-4-yl)-5- methylpyrimidin-2-ylamino)phenyl)acetamide;
4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)-5-methylpyrimidin-2-ylamino)benzamide; 3-(4-(2-(4-(lH-pyrazol- 1 -yl)phenylamino)-5-methylpyrimidin-4-yl)- lH-pyrazol- 1 -yl)-3- cyclopentylpropanenitrile; 3-cyclopentyl-3-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile;
3-cyclopentyl-3-(4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3-cyclopentyl-3-(4-(5-methyl-2-(4-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-methoxyphenylamino)-5-methylpyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-cyclopentyl-3-(4-(5-methyl-2-(4-(piperazin- 1 -yl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(diethylamino)phenylamino)-5-methylpyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(ethyl(3-hydroxypropyl)amino)phenylamino)-5-methylpyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile;
4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)-5-methylpyrimidin-2-ylamino)benzoic acid; 3-cyclopentyl-3-(4-(5-methyl-2-(4-nitrophenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)-5-methylpyrimidin-2-ylamino)-N-(2- hydroxyethyl)benzamide; 3-cyclopentyl-3-(4-(5-methyl-2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-(4-(2-(4-aminophenylamino)-5-methylpyrimidin-4-yl)-lH-pyrazol-l-yl)-3- cyclopentylpropanenitrile; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)-5-methylpyrimidin-2-ylamino)-N- methylbenzamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)-5-methylpyrimidin-2-ylamino)-N-(l - methoxypropan-2-yl)benzamide; 3-cyclopentyl-3-(4-(2-(4-(4-hydroxypiperidine-l-carbonyl)phenylamino)-5-methylpyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)-5-methylpyrimidin-2- ylamino)phenyl)methanesulfonamide; Methyl 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)-5-methylpyrimidin-2- ylamino)phenylcarbamate; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)-5-methylpyrimidin-2-ylamino)phenyl)-2-
(pyrrolidin- 1 -yl)acetamide; 3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)-4-(piperidin-4- yl)butanenitrile; 2-( 1 -(cyclopropylsulfonyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)azetidin-3-yl)acetonitrile; 2-( 1 -(isoxazole-5-carbonyl)-4-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)piperidin-4-yl)acetonitrile; 4-(l-(methylsulfonyl)piperidin-4-yl)-3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 4-(l-(ethylsulfonyl)piperidin-4-yl)-3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)butanenitrile; 4-(l-(cyclopropylsulfonyl)piperidin-4-yl)-3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4- yl)- 1 H-pyrazol- 1 -yl)butanenitrile; 3-cyclopentyl-3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(3-(2-methylpyrimidin-4-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile;
3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)benzoic acid; 3-cyclopentyl-3-(4-(5-methoxy-2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-(4-(2-(4-(lH-pyrazol-l-yl)phenylamino)-5-methoxypyrimidin-4-yl)-lH-pyrazol-l-yl)-3- cyclopentylpropanenitrile; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)-5-methoxypyrimidin-2- ylamino)phenyl)acetamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)-5-methoxypyrimidin-2-ylamino)-N,N- dimethylbenzamide; 3-cyclopentyl-3-(4-(2-(4-(2-oxopiperidin- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(2-oxo- 1 ,3-oxazinan-3-yl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(2-oxooxazolidin-3-yl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)propanenitrile;
3-(4-(2-(3-aminophenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 -yl^-cyclopentylpropanenitrile; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-methylbenzamide; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N,N- dimethylbenzamide; 3-cyclopentyl-3-(4-(2-(3-(4-hydroxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; 3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(2- hydroxyethyl)benzamide; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(l-methoxypropan-2- yl)benzamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)phenyl)ethanesulfonamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)phenyl)methanesulfonamide; methyl 3 -(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenylcarbamate; N-(3 -(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)acetamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(pyrrolidin-
1 -yl)acetamide;
4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)benzoic acid; 3-cyclopentyl-3-(4-(2-(4-(4-methylpiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(4-(2-hydroxyethyl)piperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(3-oxopiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(4-hydroxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(cyclopropylmethyl)-
N-propylbenzamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-
(cyclopropylmethyl)benzamide; 3-cyclopentyl-3-(4-(2-(4-(3-hydroxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-(4-(2-(4-(azetidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3- cyclopentylpropanenitrile; -cyclopentyl-3-(4-(2-(4-(2-oxopyrrolidin- 1 -yl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(4-(2-oxopyrrolidin-l-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(4-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(3-(2-methylpyrimidin-4-yl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(4-(2-oxopiperidin-l-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; -cyclopentyl-3-(4-(5-methoxy-2-(4-(2-oxooxazolidin-3-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; -cyclopentyl-3-(4-(2-(3-(4-methylpiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; -cyclopentyl-3-(4-(2-(3-(4-(2-hydroxyethyl)piperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; -cyclopentyl-3-(4-(2-(3-(pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; -cyclopentyl-3-(4-(2-(3-(3-oxopiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; -cyclopentyl-3-(4-(2-(3-(3-hydroxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; -(4-(2-(3-(azetidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 -yl)-3- cyclopentylpropanenitrile; -(4-(2-(3-(4-acetylpiperazine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 -yl)-3- cyclopentylpropanenitrile; -cyclopentyl-3-(4-(2-(3-(4-(pyridin-3-ylmethyl)piperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; -(4-(l-(2-cyano-l-cyclopentylethyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(l-(3- methoxyphenyl)ethyl)benzamide; -(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(pyridin-3- ylmethyl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 3-(4-(l-(2-cyano-l-cyclopentylethyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-((5-methylisoxazol-3- yl)methyl)benzamide; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(2-(l - methylpyrrolidin-2-yl)ethyl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(4-hydroxy-4-phenylpiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; 3-(4-(2-(3-(4-benzyl-4-hydroxypiperidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-
3 -cyclopentylpropanenitrile; 3-cyclopentyl-3-(4-(2-(3-(3-(pyridin-2-yl)pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-((tetrahydro-2H- pyran-4-yl)methyl)benzamide; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(l-methylpiperidin-4- yl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(4-phenylpiperidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)propanenitrile; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(l -(pyridin-2- yl)ethyl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(3-(3-fluorophenyl)pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; N-((3R)- 1 -(3-(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidin-3-yl)acetamide; 3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(2-(2- oxoimidazolidin- 1 -yl)ethyl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(2-(pyridin-3- yl)ethyl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(2-(methoxymethyl)pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; 3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(2- methoxybenzyl)benzamide; 3-cyclopentyl-3-(4-(2-(3-(4-phenoxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; 3 -(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-( 1 - (hydroxymethyl)cyclopentyl)benzamide; 4-(4-(3-(4-(l-(2-cyano-l-cyclopentylethyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)benzoyl)piperazin-
1 -yl)benzonitrile; N-(I -benzylpyrrolidin-3-yl)-3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzamide ; 3-cyclopentyl-3-(4-(2-(3-(4-phenylpiperazine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)propanenitrile;
3 -cyclopentyl-3 -(4-(2-(3 -nitrophenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-nitrophenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3-cyclobutyl-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3-(4-(2-(4-aminophenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 -yl)-3-cyclopentylpropanenitrile; 3 -(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3 - cyclobutylpropanenitrile; 3-cyclobutyl-3-(4-(2-(4-(2-oxopiperidin- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)propanenitrile; 3 -cyclobutyl-3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-l H-pyrazol- 1- yl)propanenitrile;
3-cyclobutyl-3-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3-cyclopropyl-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; 3 -(4-(2-(4-( 1 H-pyrazol- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3 - cyclopropylpropanenitrile; 3-cyclopropyl-3-(4-(2-(4-(2-oxopiperidin- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)propanenitrile; 3-cyclopropyl-3-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile;
3-cyclopropyl-3-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)propanenitrile; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2,6-(cis)- dimethylmorpholine-4-sulfonamide;
N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)benzamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)- 1 -
(methylsulfonyl)methanesulfonamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-3,5- difluorobenzamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-N,N- dimethy lsulfamide ; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-5- methylisoxazole-3-carboxamide; N-(4-(4-(l-(2-cyano-l-cyclopentylethyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)isoxazole-5- carboxamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-3,5- dimethylisoxazole-4-carboxamide; N-(4-(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)- 1 -methyl- 1 H- pyrazole-3-sulfonamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2,5- difluorobenzamide; 3-cyclopentyl-3-(4-(2-(4-(l,l-dioxidoisothiazolidin-2-yl)phenyl)aminopyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-5-(2- methylthiazol-4-yl)thiophene-2-sulfonamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-6- methylpyridine-2-sulfonamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-5-(pyridin-2- yl)thiophene-2-sulfonamide; 5-chloro-N-(4-(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)phenyl)thiophene-2-sulfonamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-6- morpholinopyridine-3 -sulfonamide; tetrahydrofuran-3-yl 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)phenylcarbamate; tetrahydrofuran-3-yl 3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)phenylcarbamate; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)- 1 -methyl- 1 H- pyrazole-3-sulfonamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-N,N- dimethy lsulfamide ; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(pyrrolidin-
1 -yl)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(3- hydroxypyrrolidin- 1 -yl)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(4- hydroxypiperidin- 1 -yl)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(3- oxopiperazin- 1 -yl)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2- morpholinoacetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-
((tetrahydro-2H-pyran-4-yl)methylamino)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(2-
(methoxymethyl)pyrrolidin- 1 -yl)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-
(cyclopropylmethylamino)acetamide; N-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(l - methoxypropan-2-ylamino)acetamide; 2-(4-(5-methylisoxazol-3-yloxy)-l-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)cyclohexyl)acetonitrile; 3-cyclopentyl-3-(4-(2-(4-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-((tetrahydro-2H- pyran-4-yl)methyl)benzamide; 3-cyclopentyl-3-(4-(2-(4-((3-endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8- carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(2-oxa-6-azatricyclo[3.3.1.1(3,7)]dec-6-ylcarbonyl)phenyl)aminopyrimidin-
4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(cw-4- hydroxycyclohexyl)-N-methylbenzamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-methyl-N-(tetrahydro-
2H-pyran-4-yl)benzamide; 3-cyclopentyl-3-(4-(2-(4-(S*)-(4,4-dimethyl-2-oxo-l-oxa-3,7-diazaspiro[4.4]nonane-7- carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(4,4-dimethyl-l-oxa-7-azaspiro[4.4]nonane-7- carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(4-methoxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; N-((3S)- 1 -(4-(4-(I -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidin-3-yl)acetamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(cw-4- hydroxycyclohexyl)benzamide; 3-(4-(2-(4-(4-acetylpiperazine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3- cyclopentylpropanenitrile; (3S)- 1 -(4-(4-(I -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidine-3-carbonitrile; 3-cyclopentyl-3-(4-(2-(4-(3-methoxypyrrolidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- IH- pyrazol- 1 -yl)propanenitrile; 4-(4-( 1 -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-( 1 -methylpiperidin-4- yl)benzamide; 3-cyclopentyl-3-(4-(2-(4-(3-oxo-2,8-diazaspiro[4.5]decane-8-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(3-fluoropyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(2-(4-(3-(dimethylamino)pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; Ethyl 4-(4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzamido)piperidine- 1 -carboxylate; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(l -(pyridin-2- yl)pyrrolidin-3-yl)benzamide; 3-cyclopentyl-3-(4-(2-(4-(3-(pyridin-2-yloxy)pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; 1 -(4-(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)benzoyl)-N,N- dimethylpiperidine-4-carboxamide; 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-( 1 -(dimethylamino)-
1 -oxobutan-2-yl)benzamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(4- methylpiperazin- 1 -yl)acetamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(3- hydroxypyrrolidin- 1 -yl)acetamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(3- oxopiperazin- 1 -yl)acetamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(4- hydroxypiperidin- 1 -yl)acetamide; N-(3-(4-(l -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-(4-(2- hydroxyethyl)piperazin- 1 -yl)acetamide; N-(3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-
(cyclopropylmethylamino)acetamide; N-(3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2- morpholinoacetamide; N-(3 -(4-(I -(2-cyano- 1 -cyclopentylethyl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)phenyl)-2-
(ethylamino)acetamide; 2-(4-(5-methylisoxazol-3-yloxy)-l-(4-(2-(4-(3-oxomorpholino)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)cyclohexyl)acetonitrile; -(4-(5-methylisoxazol-3-yloxy)- 1 -(4-(2-(4-(2-oxopiperidin- 1 -yl)phenylamino)pyrimidin-4-yl)- 1 H- pyrazol- 1 -yl)cyclohexyl)acetonitrile; -(l-(4-(2-(4-(lH-pyrazol-l-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l-yl)-4-(5-methylisoxazol-
3-yloxy)cyclohexyl)acetonitrile; -(4-(5-methylisoxazol-3-yloxy)-l-(4-(2-(3-(oxazol-5-yl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)cyclohexyl)acetonitrile; -(cyanomethyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)cyclobutanecarbonitrile; -(4-(l -(3-(cyanomethyl)- 1 -(ethylsulfonyl)azetidin-3-yl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzoic acid; -(4-(l -(2-cyano- 1 -cyclopropylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)benzoic acid; -cyclopropyl-3-(4-(2-(4-(4-hydroxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; -cyclopropyl-3-(4-(2-(4-((3-endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8- carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; -cyclopropyl-3-(4-(2-(4-(pyrrolidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)propanenitrile; -(4-(l -(2-cyano- 1 -cyclopropylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(tetrahydro-2H- pyran-4-yl)benzamide; -(l-(ethylsulfonyl)-3-(4-(2-(4-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)azetidin-3-yl)acetonitrile; -(l-(ethylsulfonyl)-3-(4-(2-(4-(4-hydroxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)azetidin-3-yl)acetonitrile; -(l-(ethylsulfonyl)-3-(4-(2-(4-((3-endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8- carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)azetidin-3 -yl)acetonitrile; -(l -(ethylsulfonyl)-3-(4-(2-(4-(pyrrolidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 - yl)azetidin-3-yl)acetonitrile; -(4-(l -(3-(cyanomethyl)- 1 -(ethylsulfonyl)azetidin-3-yl)- lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-
(tetrahydro-2H-pyran-4-yl)benzamide; -cyclopropyl-3-(4-(2-(4-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)propanenitrile; -(4-(2-(4-(azetidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3- cyclopropylpropanenitrile; -cyclopropyl-3-(4-(2-(4-(2-oxa-6-azatricyclo[3.3.1.1(3,7)]dec-6-ylcarbonyl)phenyl)aminopyrimidin-
4-yl)- 1 H-pyrazol- 1 -yl)propanenitrile; -cyclopropyl-3-(4-(2-(4-(4-methoxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol- 1 -yl)propanenitrile; (3R)- 1 -(4-(4-(I -(2-cyano- 1 -cyclopropylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidine-3-carbonitrile; 3-cyclopropyl-3-(4-(2-(4-(3-methoxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-cyclopropyl-3-(4-(2-(4-(3-hydroxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-cyclopropyl-3-(4-(2-(4-(4-methylpiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; N-((3R)- 1 -(4-(4-(I -(2-cyano- 1 -cyclopropylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidin-3-yl)acetamide; 3-(4-(2-(4-(4-acetylpiperazine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 -yl)-3- cyclopropylpropanenitrile; 3-cyclopropyl-3-(4-(2-(4-(3-(dimethylamino)pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; 3-cyclopropyl-3-(4-(2-(4-(3-fluoropyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-
1 -yl)propanenitrile; Ethyl 4-(4-(4-(l -(2-cyano- 1 -cyclopropylethyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)aminopiperidine- 1 -carboxylate; 2-(3-(4-(2-(4-(azetidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)- 1 -
(ethylsulfonyl)azetidin-3-yl)acetonitrile; l-(ethylsulfonyl)-3-(4-(2-(4-(2-oxa-6-azatricyclo[3.3.1.1(3,7)]dec-6- ylcarbonyl)phenyl)aminopyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)azetidin-3 -ylacetonitrile; (1 -(ethylsulfonyl)-3-4-(2-(4-((4-methoxypiperidin- 1 -yl)carbonyl)phenylamino)pyrimidin-4-yl)- IH- pyrazol- 1 -ylazetidin-3-yl)acetonitrile; 1 -(4-(4-(I -(3-(cyanomethyl)- 1 -(ethylsulfonyl)azetidin-3-yl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidine-3-carbonitrile; 2-(l-(ethylsulfonyl)-3-(4-(2-(4-(3-methoxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)azetidin-3-yl)acetonitrile; 2-(l-(ethylsulfonyl)-3-(4-(2-(4-(3-hydroxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)azetidin-3-yl)acetonitrile; 2-(l-(ethylsulfonyl)-3-(4-(2-(4-(4-methylpiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)azetidin-3-yl)acetonitrile; N-(I -(4-(4-(I -(3-(cyanomethyl)- 1 -(ethylsulfonyl)azetidin-3-yl)- lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidin-3-yl)acetamide; 2-(3-(4-(2-(4-(4-acetylpiperazine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1-yl)- 1 -
(ethylsulfonyl)azetidin-3-yl)acetonitrile; 2-(3-(4-(2-(4-(3-(dimethylamino)pyrrolidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - yl)- 1 -(ethylsulfonyl)azetidin-3-yl)acetonitrile; 2-(l-(ethylsulfonyl)-3-(4-(2-(4-(3-fluoropyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)azetidin-3-yl)acetonitrile; Ethyl 4-(4-(4-(l-(3-(cyanomethyl)-l-(ethylsulfonyl)azetidin-3-yl)-lH-pyrazol-4-yl)pyrimidin-2- ylamino)benzamido)piperidine- 1 -carboxylate;
4-(4-(l-(3-cyano-l-(cyanomethyl)cyclobutyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)benzoic acid; 4-(4-(l-(2-cyano-l-cyclopentylethyl)-lH-pyrazol-4-yl)-5-methoxypyrimidin-2-ylamino)benzoic acid; 3-(cyanomethyl)-3-(4-(2-(4-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-yl)-lH-pyrazol-l- yl)cyclobutanecarbonitrile; 3-(cyanomethyl)-3-(4-(2-(4-(pyrrolidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- lH-pyrazol- 1 - y^cyclobutanecarbonitrile; 4-(4-(l-(3-cyano-l-(cyanomethyl)cyclobutyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-(tetrahydro-
2H-pyran-4-yl)benzamide; 3-(cyanomethyl)-3-(4-(2-(4-(3-hydroxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)cyclobutanecarbonitrile; 4-(4-(l-(3-cyano-l-(cyanomethyl)cyclobutyl)-lH-pyrazol-4-yl)pyrimidin-2-ylamino)-N-((5- methylisoxazol-3-yl)methyl)benzamide; 3-(4-(2-(4-(azetidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3-
(cyanomethyl)cyclobutanecarbonitrile; 3-(cyanomethyl)-3-(4-(2-(4-(4-methylpiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)cyclobutanecarbonitrile; 3-(cyanomethyl)-3-(4-(2-(4-(3-fluoropyrrolidine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- IH- pyrazol- 1 -yl)cyclobutanecarbonitrile; 3-(cyanomethyl)-3-(4-(2-(4-(4-methoxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)cyclobutanecarbonitrile; 3-(cyanomethyl)-3-(4-(2-(4-(3-methoxypyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)cyclobutanecarbonitrile; 1 -(4-(4-( 1 -(3-cyano- 1 -(cyanomethyl)cyclobutyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidine-3-carbonitrile; 3-(4-(2-(4-(4-acetylpiperazine- 1 -carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)-3-
(cyanomethyl)cyclobutanecarbonitrile; N-( 1 -(4-(4-( 1 -(3 -cyano- 1 -(cyanomethyl)cyclobutyl)- 1 H-pyrazol-4-yl)pyrimidin-2- ylamino)benzoyl)pyrrolidin-3-yl)acetamide; 3-(cyanomethyl)-3-(4-(2-(4-((3-endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8- carbonyl)phenylamino)pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl)cyclobutanecarbonitrile; 3-(cyanomethyl)-3-(4-(2-(4-(4-hydroxypiperidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -y^cyclobutanecarbonitrile; 3-cyclopentyl-3-(4-(5-methoxy-2-(4-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(5-methoxy-2-(4-(pyrrolidine-l-carbonyl)phenylamino)pyrimidin-4-yl)-lH- pyrazol- 1 -yl)propanenitrile; 3-cyclopentyl-3-(4-(5-methoxy-2-(4-(4-methylpiperazine-l-carbonyl)phenylamino)pyrimidin-4-yl)-
1 H-pyrazol- 1 -yl)propanenitrile; and 4-(4-(l -(2-cyano- 1 -cyclopentylethyl)- 1 H-pyrazol-4-yl)-5-methoxypyrimidin-2-ylamino)-N-
(tetrahydro-2H-pyran-4-yl)benzamide, or pharmaceutically acceptable salt thereof, and pharmaceutically acceptable salts of any of the aforementioned.
In a tenth aspect, the agent is selected from: 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(3-hydroxycyclopentyl)propanenitrile;
3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(2- hydroxycyclopentyl)propanenitrile; and
3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(3-oxocyclopentyl)propanenitrile; and pharmaceutically acceptable salts of any of the aforementioned.
In a eleventh aspect, the agent is selected from:
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile maleic acid salt;
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile sulfuric acid salt; and
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.
At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "Ci_6 alkyl" is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
At various places in the present specification, linking substituents are described. It is specifically intended that each linking substituent include both the forward and backward forms of the linking substituent. For example, -NR(CR R )n- includes both NR(CR'R")n and -(CR'R")nNR-. Where the structure clearly requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl" then it is understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively.
It is further intended that where a group is depicted in a certain direction or orientation, all other possible orientations are included. For example, it is intended that the defining groups of ring A and ring B are meant to include all orientations, such that when rings A and B are asymmetric they can be combined with the core structure in at least two possible orientations.
It is further intended with respect to the moiety -W1-W2-W3-W4, that the bond(s) connecting each component (e.g., bonds between W1 and W2, between W2 and W3, etc.) can be single, double, or normalized.
The term "n-membered" where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
As used herein, the term "acyl" refers to -C(O)-alkyl.
As used herein, the term "acylamino" refers to an amino group substituted with an acyl group.
As used herein, the term "acyloxy" refers to -OC(O)-alkyl.
As used herein, the term "alkenyl" refers to an alkyl group having one or more double carbon- carbon bonds. Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like. A linking alkenyl group is referred to herein as "alkenylene."
As used herein, the term "alkoxy" refers to an -O-alkyl group. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like.
As used herein, the term "alkyl" is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n- propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms. A linking alkyl group is referred to herein as "alkylene."
As used herein, the term "alkylamino" refers to an amino group substituted by an alkyl group.
As used herein, the term "alkylaminocarbonyl" refers to a carbonyl group substituted by an alkylamino group.
As used herein, the term "alkynyl" refers to an alkyl group having one or more triple carbon- carbon bonds. Example alkynyl groups include ethynyl, propynyl, and the like. A linking alkynyl group is referred to herein as "alkynylene."
As used herein, the term "amino" refers to NH2. As used herein, the term "aminocarbonyl" refers to a carbonyl group substituted by an amino group.
As used herein, the term "aryl" refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms. A linking aryl group is referred to herein as "arylene."
As used herein, the term "arylalkyl" refers to alkyl substituted by aryl and "cycloalkylalkyl" refers to alkyl substituted by cycloalkyl. An example arylalkyl group is benzyl.
As used herein, the term "aryloxy" refers to an -O-aryl group. An example aryloxy group is phenoxy.
As used herein, the term "benzyloxy" refers to -O-benzyl.
As used herein, the term "carbocyclyl" groups are saturated (i.e., containing no double or triple bonds) or unsaturated (i.e., containing one or more double or triple bonds) cyclic hydrocarbon moieties. Carbocyclyl groups can be mono- or polycyclic (e.g., having 2, 3 or 4 fused rings). Example carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl, norbornyl, norpinyl, norcarnyl, adamantyl, phenyl, and the like. Carbocyclyl groups can be aromatic (e.g., "aryl") or non-aromatic (e.g., "cycloalkyl"). In some embodiments, carbocyclyl groups can have from about 3 to about 30 carbon atoms, about 3 to about 20, about 3 to about 10, or about 3 to about 7 carbon atoms.
As used herein, the term "carbocyclylalkyl" refers to an alkyl moiety substituted by a carbocyclyl group. Example carbocyclylalkyl groups include "aralkyl" (alkyl substituted by aryl ("arylalkyl")) and "cycloalkylalkyl" (alkyl substituted by cycloalkyl). In some embodiments, carbocyclylalkyl groups have from 4 to 24 carbon atoms.
As used herein, the term "cyanoalkyl" refers to an alkyl group substituted by cyano. The carbon of the cyano group is typically not counted if a carbon count precedes the term. For example, cyanomethyl is considered herein to be a Ci cyanoalkyl group.
As used herein, the term "cycloalkyl" refers to non-aromatic cyclic hydrocarbons including cyclized alkyl, alkenyl, and alkynyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. In some embodiments, cycloalkyl groups can have from 3 to about 20 carbon atoms, 3 to about 14 carbon atoms, 3 to about 10 carbon atoms, or 3 to 7 carbon atoms. Cycloalkyl groups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2 triple bonds. Ring- forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfide Cycloalkyl groups also include cycloalkylidenes. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of pentane, pentene, hexane, and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. A linking cycloalkyl group is referred to herein as "cycloalkylene."
As used herein, the term "cycloalkylalkyl" refers to an alkyl group substituted by a cycloalkyl group.
As used herein, the term "dialkylamino" refers to an amino group substituted by two alkyl groups.
As used herein, the term "dialkylaminocarbonyl" refers to a carbonyl group substituted by a dialkylamino group.
As used herein, the term "dialkylaminosulfonyl" refers to -Sθ2-N(alkyl)2.
As used herein, the term "halo" or "halogen" includes fluoro, chloro, bromo, and iodo.
As used herein, the term "haloalkoxy" refers to an -O-haloalkyl group. An example haloalkoxy group is OCF3.
As used herein, the term "haloalkyl" refers to an alkyl group having one or more halogen substituents. Example haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, and the like.
As used herein, the term "halosulfanyl" refers to a sulfur group having one or more halogen substituents. Example halosulfanyl groups include pentahalosulfanyl groups such as SF5.
As used herein, the term "heteroaryl" refers to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1 ,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 4 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. A linking heteroaryl group is referred to herein as "heteroarylene."
As used herein, the term "heteroarylalkyl" refers to alkyl substituted by heteroaryl and "heterocycloalkylalkyl" refers to alkyl substituted by heterocycloalkyl.
As used herein, the term "heteroaryloxy" refers to an -O-heteroaryl group. An example heteroaryloxy group is pyridin-2-yloxy or pyridin-3-yloxy.
As used herein, the term "heterocycloalkyl" refers to non-aromatic heterocycles including cyclized alkyl, alkenyl, and alkynyl groups where one or more of the ring- forming carbon atoms is replaced by a heteroatom such as an O, N, or S atom. Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems as well as spirocycles. Example "heterocycloalkyl" groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo- 1 ,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like. Ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally substituted by oxo or sulfide Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles. The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. The heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. In some embodiments, the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heterocycloalkyl group contains 3 to about 14, 4 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double or triple bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double or triple bonds. A linking heterocycloalkyl group is referred to herein as "heterocycloalkylene."
As used herein, the term "heterocycloalkylalkyl" refers to an alkyl group substituted by a heterocycloalkyl group.
As used herein, the term "heterocyclyl" or "heterocycle" refers to a saturated or unsaturated cyclic group wherein one or more of the ring-forming atoms is a heteroatom such as O, S, or N. Heterocyclyl groups include mono- or polycyclic ring systems. Heterocyclyl groups can be aromatic (e.g., "heteroaryl") or non-aromatic (e.g., "heterocycloalkyl"). Heterocyclyl groups can be characterized as having 3-14 ring-forming atoms. In some embodiments, heterocyclyl groups can contain, in addition to at least one heteroatom, from about 1 to about 13, about 2 to about 10, or about 2 to about 7 carbon atoms and can be attached through a carbon atom or heteroatom. In further embodiments, the heteroatom can be oxidized (e.g., have an oxo or sulfido substituent) or a nitrogen atom can be quaternized. Examples of heterocyclyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo- 1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like, as well as any of the groups listed below for "heteroaryl" and "heterocycloalkyl." Further example heterocycles include pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, 3,6-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,2,5,6-tetrahydropyridyl, piperidonyl, 4- piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-l,2,5-thia-diazinyl, 1,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1,2,5- thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1 ,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl, octahydro-isoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5- oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, quinazolinyl, quinolinyl, 4H- quinolizinyl, quinoxalinyl, quinuclidinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzo-thiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, deca-hydroquinolinyl, 2H,6H-l,5,2dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H- indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl and isoxazolyl. Further examples of heterocycles include azetidin- 1 -yl, 2,5-dihydro-lH- pyrrol-1-yl, piperindin-lyl, piperazin- 1 -yl, pyrrolidin- 1 -yl, isoquinol-2-yl, pyridin- 1 -yl, 3,6- dihydropyridin- 1 -yl, 2,3-dihydroindol- 1 -yl, 1 ,3,4,9-tetrahydrocarbolin-2-yl, thieno[2,3-c]pyridin-6-yl, 3 ,4, 10, 1 Oa-tetrahydro- 1 H-pyrazino [ 1 ,2-a]indol-2-yl, 1 ,2,4,4a,5,6-hexahydro-pyrazino [ 1 ,2-a]quinolin- 3-yl, pyrazino[l,2-a]quinolin-3-yl, diazepan-1-yl, l,4,5,6-tetrahydro-2H-benzo[f]isoquinolin-3-yl, l,4,4a,5,6,10b-hexahydro-2H-benzo[f]isoquinolin-3-yl, 3,3a,8,8a-tetrahydro-lH-2-aza- cyclopenta[a]inden-2-yl, and 2,3,4,7-tetrahydro-lH-azepin-l-yl, azepan-1-yl.
As used herein, the term "heterocyclylalkyl" refers to an alkyl moiety substituted by a heterocarbocyclyl group. Example heterocarbocyclylalkyl groups include "heteroarylalkyl" (alkyl substituted by heteroaryl) and "heterocycloalkylalkyl" (alkyl substituted by heterocycloalkyl). In some embodiments, heterocyclylalkyl groups have from 3 to 24 carbon atoms in addition to at least one ring-forming heteroatom.
As used herein, the term "hydrocarbyl" refers to any moiety comprising only hydrogen and carbon atoms. Example "hydrocarbyl" groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl and arylalkenyl groups.
As used herein, the term "hydroxylalkyl" refers to an alkyl group substituted by hydroxyl.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as α-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of α-methyl- benzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1 ,2-diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, IH- and 3H-imidazole, IH-, 2H- and 4H- 1 ,2,4-triazole, IH- and 2H- isoindole, and IH- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention further include hydrates and solvates, as well as anhydrous and non-solvated forms.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium, the term, "compound," as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted. All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.
In some embodiments, the compounds of the invention, and salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which is was formed or detected. Partial separation can include, for example, a composition enriched in the compound of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
The expressions, "ambient temperature" and "room temperature," as used herein, are understood in the art, and refer generally to a temperature, e.g a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 0C to about 30 0C.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non- toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences , 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
The present invention also includes prodrugs of the compounds described herein. As used herein, "prodrugs" refer to any covalently bonded carriers which release the active parent drug when administered to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.
Synthesis
Agents for use in the methods of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
The reactions for preparing the agents can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of the compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T. W. Green and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
Agents for use in the method of the invention can be prepared according to numerous preparatory routes known in the literature. For example, compounds of Formula I, and embodiments thereof, can be prepared by the methods set forth in U.S. Patent Publ. No. US 20070135461, published June 14, 2007 (Appl. Ser. No. 11/637,545, filed December 12, 2006), and in U.S. Patent Appl. Ser. No. 12/137,892, filed June 12, 2008; U.S. Patent Appl. No. 12/138,082, filed June 12, 2008, each of which is incorporated herein by reference in its entirety. Compounds of Formula IV, and embodiments thereof, can be prepared by the methods set forth in U.S. Patent Publ. No. US 20060106020, published May 18, 2006 (Appl. Ser. No. 11/115,702 filed April 27, 2005), which is incorporated herein by reference in its entirety. Compounds of Formulas V and VI, and embodiments thereof, can be prepared by the methods set forth in U.S. Patent Publ. No. US 20060183906, published August 17, 2006 (Appl. Ser. No. 11/313,394, filed December 21, 2005), which is incorporated herein by reference in its entirety. Compounds of Formula VII, and embodiments thereof, can be prepared by the methods set forth in U.S. Patent Publ. No. US 20070149506, published June 28, 2007 (Appl. Ser. No. 11/524,641, filed September 21 , 2006), which is incorporated herein by reference in its entirety. Compounds of Formula VIII, and embodiments thereof, can be prepared by the methods set forth in U.S. Patent Publ. No. US 20080188500, published August 7, 2008 (Appl. Ser. No. 11/961,424, filed December 20, 2007), which is incorporated herein by reference in its entirety.
Compounds of Formulas II and III, and embodiments thereof, can be prepared as set forth in U.S. Prov. Appl. No. 61/035,662, filed March 11, 2008, which is incorporated herein by reference in its entirety, and as detailed below. Compounds of Formula IX, and embodiments thereof, can be prepared as set forth in U.S. Prov. Appl. No. 60/988,606, filed November 16, 2007, which is incorporated herein by reference in its entirety, and as detailed below.
3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(3-hydroxycyclopentyl) propanenitrile, 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(2-hydroxycyclopentyl) propanenitrile, and 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-(3-oxocyclopentyl) propanenitrile, can be prepared as set forth in U.S. Patent Appl. Ser. No. 12/137,883, filed June 12, 2008, which is incorporated herein by reference in its entirety. (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin- 4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile maleic acid salt, (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile sulfuric acid salt, and (R)-3-(4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile phosphoric acid salt can be prepared as set forth in U.S. Patent Appl. Ser. No. 12/137,892, filed June 12, 2008, which is incorporated herein by reference in its entirety. Example synthetic methods for preparing certain agents, for use in the methods of the invention, are provided in the Schemes below.
Kits and Uses
The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of a dry eye disorder comprising a pharmaceutical or ophthalmic composition comprising a therapeutically effective amount of an agent such as those described above; and instructions comprising a direction to administer the composition to a patient in need thereof. The direction may be for a physician to administer the agent to the patient or a direction for self- administration of the agent. The instructions may be in paper form, such as a product label or insert. Alternatively, the instructions may be stored electronically, such as on a website. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit. In a further aspect, the present invention provides use of an agent as described in the embodiments above, for use in the preparation of a medicament for treatment of a dry eye disorder. In another aspect, the present invention provides an agent for use in treatment of a dry eye disorder in an individual.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples have been found to be JAK inhibitors according to at least one assay described herein.
EXAMPLES
Section A: Animal Models and Assay Methods
Example A: Animal Models for the Treatment of Dry Eye, Uveitis, and Conjunctivitis
Agents may be evaluated in one or more preclinical models of dry eye known to those schooled in the art including, but not limited to, the rabbit concanavalin A (ConA) lacrimal gland model, the scopolamine mouse model (subcutaneous or transdermal), the Botulinumn mouse lacrimal gland model, or any of a number of spontaneous rodent auto-immune models that result in ocular gland dysfunction (e.g. NOD-SCID, MRL/lpr, or NZB/NZW) (Barabino et al., Experimental Eye Research 2004, 79, 613-621 and Schrader et al., Developmental Opthalmology, Karger 2008, 41, 298- 312, each of which is incorporated herein by reference in its entirety). Endpoints in these models may include histopathology of the ocular glands and eye (cornea, etc.) and possibly the classic Schirmer test or modified versions thereof (Barabino et al.) which measure tear production. Activity may be assessed by dosing via multiple routes of administration (e.g. systemic or topical) which may begin prior to or after measurable disease exists.
Agents may be evaluated in one or more preclinical models of uveitis known to those schooled in the art. These include, but are not limited to, models of experimental autoimmune uveitis (EAU) and endotoxin induced uveitis (EIU). EAU experiements may be performed in the rabbit, rat, or mouse and may involve passive or activate immunization. For instance, any of a number or retinal antigens may be used to sensitize animals to a relevant immunogen after which animals may be challenged ocuarly with the same antigen. The EIU model is more acute and involves local or systemic administration of lipopolysaccaride at sublethal doses. Endpoints for both the EIU and EAU models may include fundoscopic exam, histopathology amongst others. These models are reviewed by Smith et al. (Immunology and Cell Biology 1998, 76, 497-512, which is incorporated herein by reference in its entirety). Activity is assessed by dosing via multiple routes of administration (e.g. systemic or topical) which may begin prior to or after measurable disease exists. Some models listed above may also develop scleritis/episcleritis, chorioditis, cyclitis, or iritis and are therefore useful in investigating the potential activity of compounds for the therapeutic treatment of these diseases.
Agents may also be evaluated in one or more preclinical models of conjunctivitis known those schooled in the art. These include, but are not limited to, rodent models utilizing guinea-pig, rat, or mouse. The guinea-pig models include those utilizing active or passive immunization and/or immune challenge protocols with antigens such as ovalbumin or ragweed (reviewed in Groneberg, D.A., et al., Allergy 2003, 58, 1101-1113, which is incorporated herein by reference in its entirety). Rat and mouse models are similar in general design to those in the guinea-pig (also reviewed by Groneberg). Activity may be assessed by dosing via multiple routes of administration (e.g. systemic or topical) which may begin prior to or after measurable disease exists. Endpoints for such studies may include, for example, histological, immunological, biochemical, or molecular analysis of ocular tissues such as the conjunctiva.
Example B: In vitro JAK Kinase Assay
Compounds herein are tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et al., Analytical Biochemistry 1999, 269, 94-104. The catalytic domains of human JAKl (a.a. 837-1142), Jak2 (a.a. 828-1132) and Jak3 (a.a. 781-1124) with an N- terminal His tag are expressed using baculovirus in insect cells and purified. The catalytic activity of JAKl, JAK2 or JAK3 is assayed by measuring the phosphorylation of a biotinylated peptide. The phosphorylated peptide is detected by homogenous time resolved fluorescence (HTRF). IC50S of compounds is measured for each kinase in the reactions that contain the enzyme, ATP and 500 nM peptide in 50 mM Tris (pH 7.8) buffer with 100 mM NaCl, 5 mM DTT, and 0.1 mg/mL (0.01%) BSA. The ATP concentration in the reactions is 90 μM for Jakl, 30 μM for Jak2 and 3 μM for Jak3. Reactions are carried out at room temperature for 1 hr and then stopped with 20 μL 45 mM EDTA, 300 nM SA-APC, 6 nM Eu-Py20 in assay buffer (Perkin Elmer, Boston, MA). Binding to the Europium labeled antibody takes place for 40 minutes and HTRF signal is measured on a Fusion plate reader (Perkin Elmer, Boston, MA). Compounds having an IC5O of 10 μM or less for any of the above-mentioned JAK targets are considered active.
Example C: Cellular Assays
One or more compounds herein are tested for inhibitory activity of JAK targets according to at least one of the following cellular assays.
Cancer cell lines dependent on cytokines and hence JAK/STAT signal transduction, for growth, are plated at 6000 cells per well (96 well plate format) in RPMI 1640, 10% FBS, and 1 nG/mL of appropriate cytokine. Compounds are added to the cells in DMSO/media (final concentration 0.2% DMSO) and incubated for 72 hours at 37 0C, 5% CO2. The effect of compound on cell viability is assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) followed by TopCount (Perkin Elmer, Boston, MA) quantitation. Potential off-target effects of compounds are measured in parallel using a non-JAK driven cell line with the same assay readout. Compounds having an IC5O of 10 μM or less with selectivity for JAK driven proliferation are considered active. All experiments are performed in duplicate.
The above cell lines can also be used to examine the effects of compounds on phosphorylation of JAK kinases or potential downstream substrates such as STAT proteins, Akt, Shp2, or Erk. These experiments can be performed following an overnight cytokine starvation, followed by a brief preincubation with compound (2 hours or less) and cytokine stimulation of approximately 1 hour or less. Proteins are then extracted from cells and analyzed by techniques familiar to those schooled in the art including Western blotting or ELISAs using antibodies that can differentiate between phosphorylated and total protein. These experiments can utilize normal or cancer cells to investigate the activity of compounds on tumor cell survival biology or on mediators of inflammatory disease. For example, with regards to the latter, cytokines such as IL-6, IL- 12, IL-23, or IFN can be used to stimulate JAK activation resulting in phosphorylation of STAT protein(s) and potentially in transcriptional profiles (assessed by array or qPCR technology) or production and/or secretion of proteins, such as IL- 17. The ability of compounds to inhibit these cytokine mediated effects can be measured using techniques common to those schooled in the art.
Compounds herein can also be tested in cellular models designed to evaluate their potency and activity against mutant JAKs, for example, the JAK2V617F mutation found in myeloid proliferative disorders. These experiments often utilize cytokine dependent cells of hematological lineage (e.g. BaF/3) into which the wild-type or mutant JAK kinases are ectopically expressed (James, C, et al. Nature 434:1144-1148; Staerk, J., et al. JBC 280:41893-41899). Endpoints include the effects of compounds on cell survival, proliferation, and phosphorylated JAK, STAT, Akt, or Erk proteins.
Certain compounds herein can be evaluated for their activity inhibiting T-cell proliferation. Such as assay can be considered a second cytokine (i.e. JAK) driven proliferation assay and also a simplistic assay of immune suppression or inhibition of immune activation. The following is a brief outline of how such experiments can be performed. Peripheral blood mononuclear cells (PBMCs) are prepared from human whole blood samples using Ficoll Hypaque separation method and T-cells (fraction 2000) can be obtained from PBMCs by elutriation. Freshly isolated human T-cells can be maintained in culture medium (RPMI 1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin) at a density of 2 x 106 cells/ml at 37 0C for up to 2 days. For IL-2 stimulated cell proliferation analysis, T-cells are first treated with Phytohemagglutinin (PHA) at a final concentration of 10 μg/mL for 72h. After washing once with PBS, 6000 cells/well are plated in 96-well plates and treated with compounds at different concentrations in the culture medium in the presence of 100 U/mL human IL-2 (ProSpec-Tany TechnoGene; Rehovot, Israel). The plates are incubated at 37 0C for 72h and the proliferation index is assessed using CellTiter-Glo Luminescent reagents following the manufactory suggested protocol (Promega; Madison, WI).
Example D: Murine Skin Contact Delayed Hypersensitivity Response Test
Compounds herein can also be tested for their efficacies (of inhibiting JAK targets) in the T- cell driven murine delayed hypersensitivity test model. The murine skin contact delayed-type hypersensitivity (DTH) response is considered to be a valid model of clinical contact dermatitis, and other T-lymphocyte mediated immune disorders of the skin, such as psoriasis (Immunol Today. 1998 Jan;19(l):37-44). Murine DTH shares multiple characteristics with psoriasis, including the immune infiltrate, the accompanying increase in inflammatory cytokines, and keratinocyte hyperproliferation. Furthermore, many classes of agents that are efficacious in treating psoriasis in the clinic are also effective inhibitors of the DTH response in mice (Agents Actions. 1993 Jan;38(l-2):116-21).
On Day 0 and 1, Balb/c mice are sensitized with a topical application, to their shaved abdomen with the antigen 2,4,dinitro-fluorobenzene (DNFB). On day 5, ears are measured for thickness using an engineer's micrometer. This measurement is recorded and used as a baseline. Both of the animals' ears are then challenged by a topical application of DNFB in a total of 20 μL (10 μL on the internal pinna and 10 μL on the external pinna) at a concentration of 0.2%. Twenty- four to seventy-two hours after the challenge, ears are measured again. Treatment with the test compounds is given throughout the sensitization and challenge phases (day - 1 to day 7) or prior to and throughout the challenge phase (usually afternoon of day 4 to day 7). Treatment of the test compounds (in different concentration) is administered either systemically or topically (topical application of the treatment to the ears). Efficacies of the test compounds are indicated by a reduction in ear swelling comparing to the situation without the treatment. Compounds causing a reduction of 20% or more are considered efficacious. In some experiments, the mice are challenged but not sensitized (negative control).
The inhibitive effect (inhibiting activation of the JAK-STAT pathways) of the test compounds can be confirmed by immunohistochemical analysis. Activation of the JAK-STAT pathway(s) results in the formation and translocation of functional transcription factors. Further, the influx of immune cells and the increased proliferation of keratinocytes should also provide unique expression profile changes in the ear that can be investigated and quantified. Formalin fixed and paraffin embedded ear sections (harvested after the challenge phase in the DTH model) are subjected to immunohistochemical analysis using an antibody that specifically interacts with phosphorylated STAT3 (clone 58E12, Cell Signaling Technologies). The mouse ears are treated with test compounds, vehicle, or dexamethasone (a clinically efficacious treatment for psoriasis), or without any treatment, in the DTH model for comparisons. Test compounds and the dexamethasone may produce similar transcriptional changes both qualitatively and quantitatively, and both the test compounds and dexamethasone can reduce the number of infiltrating cells. Both systemically and topical administration of the test compounds can produce inhibitive effects, i.e., reduction in the number of infiltrating cells and inhibition of the transcriptional changes.
Example E: In vivo anti-inflammatory activity
Compounds herein can be evaluated in rodent or non-rodent models designed to replicate a single or complex inflammation response. For instance, rodent models of arthritis can be used to evaluate the therapeutic potential of compounds dosed preventatively or therapeutically. These models include but are not limited to mouse or rat collagen-induced arthritis, rat adjuvant-induced arthritis, and collagen antibody-induced arthritis. Autoimmune diseases including, but not limited to, multiple sclerosis, type I-diabetes mellitus, uveoretinitis, thyroditis, myasthenia gravis, immunoglobulin nephropathies, myocarditis, airway sensitization (asthma), lupus, or colitis may also be used to evaluate the therapeutic potential of compounds herein. These models are well established in the research community and are familiar to those schooled in the art (Current Protocols in Immunology, VoI 3., Coligan, J.E. et al, Wiley Press.; Methods in Molecular Biology: Vol. 225, Inflammation Protocols., Winyard, P.G. and Willoughby, D.A., Humana Press, 2003.).
SECTION B. COMPOUND EXAMPLES
Example 67: (3R)- and (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol- l-yl]propanenitrile
Figure imgf000208_0001
Step 1. (2E)- and (2Z)-3-Cyclopentylacrylonitrile
To a solution of 1.0 M potassium tert-butoxide in THF (235 mL) at 0 0C was added dropwise a solution of diethyl cyanomethylphosphonate (39.9 mL, 0.246 mol) in THF (300 mL). The cold bath was removed and the reaction was warmed to room temperature followed by recooling to 0 0C, at which time a solution of cyclopentanecarbaldehyde (22.0 g, 0.224 mol) in THF (60 mL) was added dropwise. The bath was removed and the reaction warmed to ambient temperature and stirred for 64 hours. The mixture was partitioned between diethyl ether and water, the aqueous was extracted with three portions of ether, followed by two portions of ethyl acetate. The combined extracts were washed with brine, then dried over sodium sulfate, filtered and concentrated in vacuo to afford a mixture containing 24.4 g of olefin isomers which was used without further purification (89%). 1H NMR (400 MHz, CDCl3): δ 6.69 (dd, IH, trans olefin), 6.37 (t, IH, cis olefin), 5.29 (dd, IH, trans olefin), 5.20 (d, IH, cis olefin), 3.07-2.95 (m, IH, cis product), 2.64-2.52 (m, IH, trans product), 1.98- 1.26 (m, 16H).
Step 2. (3R)- and (3S)-3-Cyclopentyl-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]- pyrimidin-4-yl)-l H-pyrazol-1 -yl] propanenitrile
To a solution of 4-(lH-pyrazol-4-yl)-7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]- pyrimidine (15.0 g, 0.0476 mol) in ACN (300 mL) was added S-cyclopentylacrylonitrile (15 g, 0.12 mol) (as a mixture of cis and trans isomers), followed by DBU (15 mL, 0.10 mol). The resulting mixture was stirred at room temperature overnight. The ACN was evaporated. The mixture was diluted with ethyl acetate, and the solution was washed with 1.0 N HCl. The aqueous layer was back- extracted with three portions of ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography (gradient of ethyl acetate/hexanes) to yield a viscous clear syrup, which was dissolved in ethanol and evaporated several times to remove ethyl acetate, to afford 19.4 g of racemic adduct (93%). The enantiomers were separated by preparative-HPLC, (OD-H, 15% ethanol/hexanes) and used separately in the next step to generate their corresponding final product. The final products (see Step 3) stemming from each of the separated enantiomers were found to be active JAK inhibitors; however, the final product stemming from the second peak to elute from the preparative-HPLC was more active than its enantiomer.
1H NMR (300 MHz, CDCl3): δ 8.85 (s, IH), 8.32 (s, 2H), 7.39 (d, IH), 6.80 (d, IH), 5.68 (s, 2H), 4.26 (dt, IH), 3.54 (t, 2H), 3.14 (dd, IH), 2.95 (dd, IH), 2.67-2.50 (m, IH), 2.03-1.88 (m, IH), 1.80- 1.15 (m, 7H), 0.92 (t, 2H), -0.06 (s, 9H); MS(ES):437 (M+ 1).
Step 3. (3R)- and (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl] propanenitrile
To a solution of 3-cyclopentyl-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]- pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile (6.5 g, 0.015 mol, R or S enantiomer as isolated above) in DCM (40 mL) was added TFA (16 mL) and this was stirred for 6 hours. The solvent and TFA were removed in vacuo. The residue was dissolved in DCM and concentrated using a rotary evaporator two further times to remove as much as possible of the TFA. Following this, the residue was stirred with ethylenediamine (4 mL, 0.06 mol) in methanol (30 mL) overnight. The solvent was removed in vacuo, water was added and the product was extracted into three portions of ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, decanted and concentrated to afford the crude product which was purified by flash column chromatography (eluting with a gradient of methanol/DCM). The resulting mixture was further purified by preparative-HPLC/MS (C 18 eluting with a gradient of ACN/H20 containing 0.15% NH4OH) to afford product (2.68 g, 58%). 1H NMR (400 MHz, D6-dmso): δ 12.11 (br s, IH), 8.80 (s, IH), 8.67 (s, IH), 8.37 (s, IH), 7.60 (d, IH), 6.98 (d, IH), 4.53 (dt, IH), 3.27 (dd, IH), 3.19 (dd, IH), 2.48-2.36 (m, IH), 1.86-1.76 (m, IH), 1.68-1.13 (m, 7H); MS(ES):307(M+l).
Example 1. {l-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin- 3-yl}acetonitrile trifluoroacetic acid salt
Figure imgf000210_0001
Step 1. tert-butyl 3-(cyanomethylene)azetidine-l-carboxylate
Figure imgf000210_0002
To a suspension of sodium hydride (60% dispersion in mineral oil, 0.257 g, 6.42 mmol) in tetrahydrofuran (32 mL) at 0 0C under a nitrogen atmosphere was added diethyl cyanomethylphosphonate (1.19 g, 6.72 mmol) (purchased from Aldrich). The reaction was then stirred for 45 minutes at room temperature. A solution of tert-butyl 3-oxoazetidine-l-carboxylate (1.00 g, 5.84 mmol) (purchased from Alfa Aesar) in tetrahydrofuran (8.8 mL) was introduced dropwise and the mixture was stirred for 16 hours. Brine and ethyl acetate were added and the layers separated. The aqueous layer was extracted with three portions of ethyl acetate. The combined extracts were dried over sodium sulfate, filtered and concentrated to afford product, used without further purification in Step 2 (1.12 g, 99%). 1H NMR (300 MHz, CDCl3): δ 5.38 (p, IH), 4.73-4.68 (m, 2H), 4.64-4.59 (m, 2H), 1.46 (s, 9H).
Step 2. tert-butyl 3-(cyanomethyl)-3-[4-(7-[2-(tnmethylsιlyl)ethoxy]methyl-7H-pyrrolo[2,3- d]pynmιdιn-4-yl)-l H-pyrazol-1 -ylJazetιdιne-1 -carboxylate
O
_N
N N
'/
Figure imgf000211_0001
To a solution of 4-(lH-pyrazol-4-yl)-7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3- d]pyrimidine (4.61 g, 14.6 mmol) (prepared according to the method of WO 2007/070514 in Example 65, Step 2) and tert-butyl 3 -(cyanomethylene)azetidine- 1 -carboxylate (2.84 g, 14.6 mmol) in acetonitrile (100 mL) was added l,8-diazabicyclo[5.4.0]undec-7-ene (2.19 mL, 14.6 mmol). The reaction was stirred at room temperature for 16 hours. The acetonitrile was removed in vacuo and the residue was dissolved in ethyl acetate. This solution was sequentially washed with IN HCl and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash column chromatography, eluting with 80% ethyl acetate/hexanes to afford desired product (5.36 g, 72%). 1H NMR (300 MHz, CDCl3): δ 8.86 (s, IH), 8.44 (s, IH), 8.34 (s, IH), 7.42 (d, IH), 6.80 (d, IH), 5.68 (s, 2H), 4.54 (d, 2H), 4.29 (d, 2H), 3.59-3.51 (m, 2H), 3.33 (s, 2H), 1.47 (s, 9H), 0.96-0.89 (m, 2H), -0.06 (s, 9H); LCMS (M+H)+: 510.2.
Step 3. 3-[4-(7-[2-(trιmethylsιlyl)ethoxy]methyl-7H-pyrrolo[2,3-d]pynmιdιn-4-yl)-lH-pyrazol-l- yl] azetιdιn-3-ylacetonιtnle
HN s
, N
N H
1V
1V" N ' v To a solution of tert-butyl 3-(cyanomethyl)-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidine-l-carboxylate (5.36 g, 10.5 mmol) in 1,4- dioxane (100 mL) was added 4.00 M of hydrogen chloride in 1,4-dioxane (40 mL, 160 mmol) and the mixture was stirred at room temperature for 16 hours. The reaction was poured into saturated sodium bicarbonate solution sufficient to neutralize. The product was extracted with three portions of ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, filtered and concentrated to afford product which was used without further purification (3.0 g, 69%). 1H NMR (400 MHz, CDCl3): δ 8.85 (s, IH), 8.42 (s, IH), 8.32 (s, IH), 7.41 (d, IH), 6.80 (d, IH), 5.68 (s, 2H), 4.30 (d, 2H), 3.88 (d, 2H), 3.58-3.51 (m, 2H), 3.42 (s, 2H), 0.96-0.89 (m, 2H), -0.06 (s, 9H); LCMS (M+H)+: 410.2.
Step 4. l-(ethylsulfonyl)-3-[4-(7-[2-(trimethylsilyl)ethoxy] methyl- 7H-pyrrolo[2, 3-d]pyrimidin-4-yl)- lH-pyrazol-l-ylJazetidin-3-ylacetonitrile
Figure imgf000212_0001
To a solution of 3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol-l-yl]azetidin-3-ylacetonitrile (0.100 g, 0.244 mmol) in tetrahydrofuran (2 mL) containing N,N-diisopropylethylamine (0.085 mL, 0.49 mmol) was added ethanesulfonyl chloride (0.023 mL, 0.24 mmol). After stirring for 1.5 hours, the reaction mixture was poured into dilute HCl and extracted with three portions of ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, decanted and concentrated to afford product, used without further purification in Step 5 (111 mg, 91%). 1H NMR (300 MHz, CDCl3): δ 8.86 (s, IH), 8.63 (s, IH), 8.35 (s, IH), 7.45 (d, IH), 6.83 (d, IH), 5.68 (s, 2H), 4.63 (d, 2H), 4.26 (d, 2H), 3.54 (t, 2H), 3.42 (s, 2H), 3.09 (q, 2H), 1.41 (t, 3H), 0.92 (t, 2H), -0.06 (s, 9H); LCMS (M+H)+: 502.1.
Step 5. l-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3- ylacetonitrile trifluoroacetate salt
To a solution of l-(ethylsulfonyl)-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-ylacetonitrile (0.111 g, 0.22 mmol) in methylene chloride (3 mL) was added trifluoroacetic acid (2 mL) and the solution was stirred for 1.5 hours. The solvents were removed in vacuo and the residue was dissolved in methanol (3 mL) and ethylenediamine (0.1 mL) was added. After stirring for 3 hours, the volume was reduced in vacuo and the product was purified by preparative-HPLC/MS, (SunFire Cl 8 column, eluting with a gradient of MeCN/H2O containing 0.1% TFA) to afford the product as the trifluoroacetic acid salt (50 mg, 47%). 1H NMR (400 MHz, d6-dmso): δ 9.03 (s, IH), 8.83 (s, IH), 8.56 (s, IH), 7.77 (s, IH), 7.22 (s, IH), 4.59 (d, 2H), 4.26 (d, 2H), 3.71 (s, 2H), 3.25 (q, 2H), 1.24 (t, 3H); LCMS (M+H)+: 372.1.
Alternatively, the deprotection and sulfonylation steps could be performed in the reverse order, as in Example 2.
Example 52. cis and trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol- 1-yl] cyclobutanecarbonitrile
Figure imgf000213_0001
Step 1. i-oxocyclobutanecarbonitrile.
A mixture of water (40 mL, 2 mol) and 1,4-dioxane (100 mL, 1 mol), 3- methylenecyclobutanecarbonitrile (3.30 g, 0.0354 mol) (commercially available from Bepharma Ltd., China), and 0.2 M of osmium tetraoxide in water (0.7 mL) was stirred for 5 min, during which time the mixture became brown. While the temperature was maintained at room temperature, sodium periodate (15.9 g, 0.0744 mol) was added in portions over a period of 30 min. The mixture was stirred for an additional 1.5 h, then extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate and concentrated to give a solid (2.04 g, 60.54%). 1H NMR (300 MHz, CDCl3): δ 3.58 (4H, m), 3.25 (IH, m) ppm.
Step 2. 3-(cyanomethylene)cyclobutanecarbonitrile
To a solution of 1 M of potassium tert-butoxide in THF (67.4 mL) at 0 0C was added dropwise a solution of diethyl cyanomethylphosphonate (11.4 mL, 0.0706 mol) in tetrahydrofuran (100 mL, 1 mol). The reaction mixture was warmed up to room temperature and cooled to 0 0C again. To the resulting mixture, a solution of 3-oxocyclobutanecarbonitrile (6.10 g, 0.0641 mol) in tetrahydrofuran (20 mL, 0.2 mol) was added. The reaction mixture was allowed to warm up to room temperature and stirred for 2 hours. After quenching with water, the mixture was extracted with EtOAc. The combined organic layers were dried and concentrated. The residue was purified by flash silica gel column, eluting with 0-10% MeOH/dichloromethane to give the titled product (5.40 g, 71.26%). LCMS (M+Na) 141.3. 1H NMR (400 MHz, CDCl3): δ 5.30 (IH, m), 3.40 (2H, m), 3.14 (3H, m) ppm.
Step 3. 3-(cyanomethyl)-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol-1 -yl] cyclobutanecarbonitrile
3-(Cyanomethylene)cyclobutanecarbonitrile (120 mg, 0.0010 mol) was combined with 4-(1H- pyrazol-4-yl)-7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]pyrimidine (0.1 g, 0.0003 mol) in acetonitrile (2 mL, 0.04 mol) and l,8-diazabicyclo[5.4.0]undec-7-ene (6 μL, 0.00004 mol) under nitrogen. The mixture was stirred at room temperature over the weekend. After evaporation to dryness, the crude mixture was purified by flash column, eluting with 0 to 10% MeOH in dichloromethane, to give the desired product. LCMS (M+H) 434.4.
Step 4. 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2, 3-d] pyrimidin-4-yl)-l H-pyrazol-1 - yl] cyclobutanecarbonitrile.
A 500 mL round bottom flask fitted with stir bar, condenser, and nitrogen inlet, was charged with acetonitrile (16.3 mL, 0.311 mol), water (1.4 mL, 0.078 mol) and 3-(cyanomethyl)-3-[4-(7-[2- (trimethylsilyl)ethoxy]methyl-7H-pyrrolo [2,3 -d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - yljcyclobutanecarbonitrile (1.00 g, 0.00231 mol). The solution was homogeneous. After adding lithium tetrafluoroborate (2.21 g, 0.0231 mol), the resulting mixture was heated to reflux overnight, then charged with 7.2 M of ammonium hydroxide in water (1.2 mL) in portions over a period of 5 minutes at room temperature to adjust pH to 9-10. The reaction was stirred for 2 h at room temperature. Solid was removed by filtration and the filtrate was diluted with acetonitrile, water, and MeOH. The resultant mixture was purified on Waters XBridge HPLC column (C18, 30x100 mm, 5 μM), with injection volume 5 mL (-50 mg/injection) and flow rate 60 mL/min, at gradient 10-28% B in 12 minutes (A = water with 0.15% NH4OH; B = acetonitrile with 0.15% NH4OH), to give the desired products as free bases. First peak retention time 0.826 min at Waters SunFire HPLC column (C18, 2.1x50 mm, 5 μM) with injection volumn 2 μL and flow rate 3 mL/min, at gradient from 2 to 80% B in 3 minutes (A = water with 0.025% TFA; B = acetonitrile). LCMS calculated for Ci6H14N7(M+H)+: 304.1; Found 304.3. 1H NMR (500 MHz, DMSO-d6): δ 12.1O(1H, br s), 8.82 (IH, s), 8.70 (IH, s), 8.44 (IH, s), 7.61 (IH, d, J = 4.0 Hz), 7.08 (IH, d, J = 4.0 Hz), 3.59 (IH, m), 3.57 (2H, s), 3.19 (2H, m), 2.86 (2H, m) ppm. Second peak retention time 0.864 min at the same SunFire column HPLC condition, LCMS calculated for Ci6H14N7(M+H)+: 304.1; Found 304.3. 1H NMR (400 MHz, CD3OD): δ 8.67 (IH, s), 8.66 (IH, s), 8.40 (IH, s), 7.51 (IH, d, J = 3.6 Hz), 6.99 (IH, d, J = 3.6 Hz), 3.50 (IH, m), 3.42 (2H, s), 3.24 (2H, m), 3.00 (2H, m) ppm.
This application claims the benefit of priority of U.S. Patent Appl. No. 61/102,242, filed October 2, 2008, which is incorporated herein by reference in its entirety.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

What is claimed is:
1. A method of treating a dry eye disorder in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an agent selected from: (a) compounds of Formula I:
Figure imgf000216_0001
I wherein:
A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene,
Figure imgf000216_0002
eye loalkylene)- (CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_i0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12^O(CR11R12),!, (CR11R12^S(CR11R12)^ (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)PNRC(CR11R12)<1, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R1^pS(O)2(CR11R12)^ or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said d_8 alkylene, C2.8 alkenylene, C2_8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, C^ haloalkyl, halosulfanyl, C^ hydroxyalkyl, Ci_4 cyanoalkyl, =C-R, =N-R', Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000216_0003
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(O)NRcRd, NRcC(O)ORa, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci_6 alkyl))Rb, and S(O)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q;
W is Ci_8 alkylenyl, C2-8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(O)NRC', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NR0', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, d_8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said Q_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci-4 haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, 0Ra', SRa', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NRc C(0)0Ra', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, 0Ra ", SRa ", C(0)Rb ", C(O)NRC "Rd ", C(O)OR3 ', 0C(0)Rb ", 0C(0)NRc "Rd ", NRC "Rd ", NRC "C(0)Rb ", NRC "C(O)OR3 ", NRc"S(0)Rb", NRc"S(0)2Rb", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", and S(0)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; R9 and R10 are independently selected from H, d.io alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 alkylcarbonyl, arylcarbonyl, Ci-6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from Ci-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci-6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_g dialkylamino;
D and E are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci-6 alkylene)r-O-( Ci_6 alkylene)s, (Ci-6 alkylene)r-S-(Ci_6 alkylene)s, (Ci-6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-COO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CONRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SONRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReCONRf-(Ci_6 alkylene)s, wherein each of the Ci_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2_8 alkoxyalkyl, d_6 alkoxy, Ci_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D3 and E3 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1 , 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_g dialkylamino;
D4 and E4 are independently selected from H, halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000218_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(O)2NRcRd; Ra is H, Cy1, -(Ci-6 alkyO-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, -(Ci-6 alkyφ-Cy1, Ci-6 alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q-6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, d_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q-6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q-6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci-6 alkyfj-Cy1, Ci_i0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_i0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci.io alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q-6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-β alkyl, Ci_6haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1 ; wherein when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000220_0001
then Y is other than (CR11R12^C(O)NR0CCR11R12)^ (b) compounds of Formula II:
Figure imgf000221_0001
II wherein:
La is SO2 or CO;
Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein said alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R a and R a are independently selected from H, C^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl;
(c) compounds of Formula III:
Figure imgf000221_0002
III wherein:
R5a and R6a are independently selected from H, F, CN, OH, Ci_4 alkyl, benzyloxy, C2_8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1 , 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with C^ alkyl; and pharmaceutically acceptable salts thereof; provided that compound of Formula I is not selected from 4-[5-(2-isopropyl-5- methylcyclohexyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-tert- butylphenoxymethyl)- 1 ,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopentylethyl- 1 ,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(2,6-difluorophenyl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo [2,3 -b]pyridine; 4- [5-( 1 -tert-butyl-3 -methyl- 1 H-pyrazol-5-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo[2,3-b]pyridine; 4-[5-(benzyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-fluorophenyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(phenoxymethyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-methoxybenzyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(phenylthiomethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-methylbutyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-benzyl-l,2-4-oxadiazol-3- yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,2-dimethylpropyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-methyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(formyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(furan-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-(l -methyl- lH-pyrrol-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (sec -butyl)- l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopropyl-l,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; and pharmaceutically acceptable salts of any of the aforementioned.
2. A method according to claim 1, wherein said dry eye disorder is aqueous tear-deficient dry eye.
3. A method according to claim 1, wherein said dry eye disorder is evaporative dry eye.
4. A method according to claim 1, wherein said dry eye disorder is Sjogren syndrome dry eye.
5. A method according to claim 1, wherein said dry eye disorder is non-Sjogren syndrome dry eye.
6. A method according to claim 1, wherein said treating comprises ameliorating a symptom selected from eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface.
7. A method according to any one of claims 1 to 6, wherein said treating comprises administering a pharmaceutical composition to said patient, said composition comprising said agent and a pharmaceutically acceptable carrier.
8. A method according to claim 7, wherein said pharmaceutical composition is an oral dosage form.
9. A method according to any one of claims 1 to 6, wherein said treating comprises administering an ophthalmic composition to said patient, said composition comprising said agent and an ophthalmically acceptable carrier.
10. A method according to claim 9, wherein said ophthalmic composition is a topical composition.
11. A method according to claim 9, wherein said topical composition is an aqueous formulation, an aqueous suspension, an ointment or a gel.
12. A method according to claim 9, wherein said ophthalmic composition is an ophthalmic insert.
13. A method according to claim 12, wherein said ophthalmic insert comprises microspheres.
14. A method according to claim 13, wherein said microspheres are injected to the posterior segment of the eye, in the chroidal space, in the sclera, intravitreally or sub-retinally.
15. A method according to claim 12, wherein said ophthalmic insert comprises collagen, gelatin, or a polymer, wherein said polymer is selected from polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacralate, polyurethane, a nylon, poly(dl-lactide-co- glycolide) (PLGA), or a copolymer of any of the aforementioned.
16. A method according to claim 12, wherein said ophthalmic insert is implanted under the upper eyelid, in the posterior segment of the eye, in the chroidal space, in the sclera, intravitreally or sub- retinally.
17. A method according to any one of claims 1 to 16, further comprising administering at least one additional therapeutic agent.
18. A method according to claim 17, wherein said additional therapeutic agent is fluocinolone acetonide, rimexolone, cyclosporine, riaminolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, civamide, testosterone, ecabet sodium, 15-(s)-hydroxyeicosatetraenoic acid, 2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-m ethyl-oxolane- 2-carboxamide, gefarnate, cevilemine, doxycline, minocycline, oxytetracycline, voclosporin, rivoglitazone, lacritin rebamipide, pilocarpine, tacrolimus, pimecrolimus, loteprednol etabonate, rituximab, diquafosol tetrasodium, dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept, hydroxychloroquine, or thalidomide.
19. A method according to claim 18, wherein said additional therapeutic agent is sodium hyaluronate, hyaluronic acid, polyvinylalcohol, hydroxypropyl methylcellulose, glycerin, polyethylene glycol, or carboxymethyl cellulose.
20. A method according to any one of claims 1 to 19, wherein said agent is selected from compounds of Formula I:
Figure imgf000224_0001
I and pharmaceutically acceptable salts thereof.
21. A method according to claim 20, wherein n is 1 and Y is Ci_g alkylene optionally substituted with 1 , 2, or 3 substituents independently selected from D4.
22. A method according to claim 20, wherein n is 1 and Y is Ci_g alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino, Ci_4 alkylamino, or C2-8 dialkylamino.
23. A method according to claim 20, wherein n is 1 and Y is Ci_g alkylene optionally substituted with cyano.
24. A method according to any one of claims 20 to 23, wherein Z is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Q-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR)NRcRd, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
25. A method according to any one of claims 20 to 23, wherein Z is cyclopentyl, which is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd.
26. A method according to any one of claims 20 to 23, wherein Z is cyclopentyl.
27. A method according to any one of claims 20 to 26, wherein X is N.
28. A method according to any one of claims 20 to 27, wherein A1 is C.
29. A method according to any one of claims 20 to 28, wherein A2 is N.
30. A method according to any one of claims 20 to 29, wherein T is N.
31. A method according to any one of claims 20 to 30, wherein U and V are independently CR5.
32. A method according to any one of claims 20 to 31, wherein R1, R2, R3, and R4 are each H.
33. A method according to any one of claims 20 to 32, wherein the 5-membered ring formed by
A1, A2, U, T, and V is selected from: )n-Z
Figure imgf000225_0001
34. A method according to any one of claims 20 to 32, wherein said agent is selected from compounds having Formula II:
Figure imgf000225_0002
Il and pharmaceutically acceptable salts thereof.
35. A method according to any one of claims 20 to 32, wherein the moiety formed by T, U, V, A1, and A2 is not the following moiety:
Figure imgf000226_0001
36. A method according to claim 20, wherein said agent is selected from 3-cyclopentyl-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile and pharmaceutically acceptable salts thereof.
37. A method according to claim 20, wherein said agent is selected from (3R)-3-cyclopentyl-3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]propanenitrile and pharmaceutically acceptable salts thereof.
38. A method according to any one of claims 1 to 19, wherein said agent is selected from compounds of Formula II:
Figure imgf000226_0002
II and pharmaceutically acceptable salts thereof.
39. A method according to claim 38, wherein La is SO2
40. A method according to claim 38 or 39, wherein Rla is Ci_4 alkyl.
41. A method according to claim 38 or 39, wherein Rla is ethyl.
42. A method according to claim 38, wherein said agent is selected from {l-(Ethylsulfonyl)-3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]azetidin-3-yl} acetonitrile and pharmaceutically acceptable salts thereof.
43. A method according to claim 38, wherein said agent is {l-(Ethylsulfonyl)-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-yl}acetonitrile phosphoric acid salt.
44. A method according to any one of claims 1 to 19, wherein said agent is selected from compounds of Formula III:
Figure imgf000227_0001
III and pharmaceutically acceptable salts thereof.
45. A method according to claim 44, wherein one of R5a and R6a is H and the other is selected from H, F, CN, OH, C^ alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1, 2, or 3 substituents selected from F, OH, CN, and Ci- 4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with Ci_4 alkyl.
46. A method according to claim 44, wherein R5a and R6a are independently selected from H and
CN.
47. A method according to claim 44, wherein said agent is selected from 3-(cyanomethyl)-3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof.
48. A method according to claim 44, wherein said agent is selected from cis-3-(cyanomethyl)-3- [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof.
49. A method according to claim 44, wherein said agent is selected from trans-3-(cyanomethyl)- 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutanecarbonitrile and pharmaceutically acceptable salts thereof.
50. An ophthalmic insert comprising a therapeutically effective amount of an agent selected from: (a) compounds of Formula I:
Figure imgf000228_0001
I wherein:
A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene,
Figure imgf000228_0002
eye loalkylene)- (CR11R1X (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_i0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q,
Figure imgf000228_0003
(CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)PNRC(CR11R12)<1, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q,
Figure imgf000228_0004
or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said Ci-8 alkylene, C2_8 alkenylene, C2_8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, d_4 cyanoalkyl, =C-R, =N-R\ Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(O)ORa, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000228_0005
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl))Rb, and S(O)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q;
W is Ci-8 alkylenyl, C2_8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(O)NRC', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NRC', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said Q_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, C^ haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, 0Ra', SRa', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NRc C(0)0Ra', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, 0Ra ", SRa ", C(0)Rb ", C(O)NRC "Rd ", C(O)OR3 ", 0C(0)Rb ", 0C(0)NRc "Rd ", NRC "Rd ", NRC "C(0)Rb ", NRc"C(0)0Ra", NRc"S(O)Rb", NRc"S(0)2Rb", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", and S(0)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo,
Figure imgf000229_0001
alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci-4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 alkylcarbonyl, arylcarbonyl, d_6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group; R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Q-6 alkyl, Q-6 haloalkyl, C2_8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D2 and E2 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci_6 alkylene)r-O-( Ci_6 alkylene)s, (Ci_6 alkylene)r-S-(Ci_6 alkylene)s, (Ci_6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-C0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-C00-(Ci_6 alkylene)s, (C« alkylene)r-CONRe-(Ci_6 alkylene)s, (Ci_6 alkylene)r-SO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SONRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReCONRf-(Ci_6 alkylene)s, wherein each of the Q_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci_6haloalkyl, C2_8 alkoxyalkyl, Ci_6 alkoxy, Ci_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D and E are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Q_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci_6 alkyl, Ci-6haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D4 and E4 are independently selected from H, halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci-4 hydroxyalkyl, d_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=N0(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl))Rb, and S(O)2NRcRd;
Ra is H, Cy1, -(Ci-6 alkyO-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; Rb is H, Cy1, -(Ci-6 alkyφ-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, d_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci-6 alkyfj-Cy1, Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(d_6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci.io alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; Rc and Rd are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CMO alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 haloalkyl, halosulfanyl, d_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1 ; wherein when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000232_0001
then Y is other than (CR11R12^C(O)NR0CCR11R12)^ (b) compounds of Formula II:
Figure imgf000232_0002
II wherein: La is SO2 or CO;
Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein said alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R2a and R3a are independently selected from H, Q^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl;
(c) compounds of Formula III:
Figure imgf000233_0001
III wherein:
R5a and R6a are independently selected from H, F, CN, OH, Ci_4 alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1 , 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with C^ alkyl; and pharmaceutically acceptable salts thereof; provided that compound of Formula I is not selected from 4-[5-(2-isopropyl-5- methylcyclohexyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-tert- butylphenoxymethyl)- 1 ,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopentylethyl- 1 ,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(2,6-difluorophenyl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo [2,3 -b]pyridine; 4- [5-( 1 -tert-butyl-3 -methyl- 1 H-pyrazol-5-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo[2,3-b]pyridine; 4-[5-(benzyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-fluorophenyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(phenoxymethyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-methoxybenzyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(phenylthiomethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-methylbutyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-benzyl-l,2-4-oxadiazol-3- yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,2-dimethylpropyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-methyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(formyl)- 1,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(furan-2-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 - b]pyridine; 4-[5-(l -methyl- lH-pyrrol-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (sec -butyl)- l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopropyl-l,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; and pharmaceutically acceptable salts of any of the aforementioned.
51. A kit for treatment of dry eye disorder, comprising an ophthalmic or pharmaceutical composition and instructions; wherein said composition comprises a therapeutically effective amount of an agent selected from:
(a) compounds of Formula I:
Figure imgf000234_0001
I wherein:
A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene,
Figure imgf000234_0002
eye loalkylene)- (CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CR11R12V(CM0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CRuR12)pO(CRuR12)q, (CR11R12^S(CR11R12^, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CRuR12)pNRc(CRuR12)q, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R12^S(O)2(CR11R12V or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said Ci-8 alkylene, C2-8 alkenylene, C2_g alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_g alkyl, C2_g alkenyl, C2_g alkynyl, C^ haloalkyl, halosulfanyl, C^ hydroxyalkyl, Ci_4 cyanoalkyl, =C-R, =N-R', Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, alkyl, C2-4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(O)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q;
W is Ci_8 alkylenyl, C2_8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(0)NRc', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NRC', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, d_8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said Q_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Q-4 haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, OR3', SR3', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NRc C(0)0R3', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, OR3", SR3", C(0)Rb", C(0)NRc"Rd ', C(O)OR3", 0C(0)Rb", 0C(0)NRc"Rd ", NRC "Rd ", NRC "C(0)Rb ", NRC 'C(O)OR3 ', NRc"S(0)Rb", NRc"S(0)2Rb", S(O)Rb ', S(O)NRC "Rd ', S(O)2Rb", and S(0)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo,
Figure imgf000235_0001
alkyl, C2_4 alkenyl, C2^ alkynyl, C^ haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; R8 is H, Ci-6 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, d.io alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2-6 alkynyl, Ci-6 alkylcarbonyl, arylcarbonyl, Ci-6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from Ci-6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci-6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D and E are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci-6 alkylene)r-O-( Ci_6 alkylene)s, (Ci-6 alkylene)r-S-(Ci_6 alkylene)s, (Ci-6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-COO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CONRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SONRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReC0NRf-(Ci_6 alkylene)s, wherein each of the Ci_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D3 and E3 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D4 and E4 are independently selected from H, halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(0)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000236_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci_6 alkyl))Rb, and S(O)2NRcRd;
Ra is H, Cy1, -(Ci-6 alkyO-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, -(Ci-6 alkyφ-Cy1, Ci-6 alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, d_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci-6 alkyfj-Cy1, Ci_i0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci.io alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CMO alkyl, d_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1; wherein when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000238_0001
then Y is other than (CR11R12)pC(O)NRc(CR11R12)q; (b) compounds of Formula II:
Figure imgf000239_0001
II wherein:
La is SO2 or CO;
Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein said alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R a and R a are independently selected from H, C^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl;
(c) compounds of Formula III:
Figure imgf000239_0002
III wherein:
R5a and R6a are independently selected from H, F, CN, OH, Ci_4 alkyl, benzyloxy, C2_8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1 , 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with C^ alkyl; and pharmaceutically acceptable salts thereof; provided that compound of Formula I is not selected from 4-[5-(2-isopropyl-5- methylcyclohexyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-tert- butylphenoxymethyl)- 1 ,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopentylethyl- 1 ,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(2,6-difluorophenyl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo [2,3 -b]pyridine; 4- [5-( 1 -tert-butyl-3 -methyl- 1 H-pyrazol-5-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo[2,3-b]pyridine; 4-[5-(benzyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-fluorophenyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(phenoxymethyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-methoxybenzyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(phenylthiomethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-methylbutyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-benzyl-l,2-4-oxadiazol-3- yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,2-dimethylpropyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-methyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(formyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(furan-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-(l -methyl- lH-pyrrol-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (sec -butyl)- l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopropyl-l,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; and pharmaceutically acceptable salts of any of the aforementioned; and wherein said instructions comprise a direction to administer said composition to a patient in need of treatment of said dry eye disorder.
52. Use of an agent for the preparation of a medicament for the treatment of an dry eye disorder; wherein said agent is selected from:
(a) compounds of Formula I:
Figure imgf000240_0001
I wherein:
A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene,
Figure imgf000240_0002
eye loalkylene)- (CR11R1X (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_i0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q,
Figure imgf000240_0003
(CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)PNRC(CR11R12)<1, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q,
Figure imgf000240_0004
or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said Ci-8 alkylene, C2_8 alkenylene, C2-8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, C^ haloalkyl, halosulfanyl, C^ hydroxyalkyl, d_4 cyanoalkyl, =C-R, =N-R1, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, CC=NR)NR0R11, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, CC=NO(CL6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci-8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000241_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(0)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q;
W is Ci_8 alkylenyl, C2_8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(O)NR0', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NR0', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci-8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said Q-8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Q_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo, Q^ alkyl, C2_4 alkenyl, C2_4 alkynyl, Q^ haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, OR3', SR3', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NR0 C(O)OR3', S(O)Rb', S(0)NR° Rd', S(O)2Rb', NR°'S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, OR3 ', SR3 ', C(0)Rb ", C(O)NRC "Rd ", C(O)OR3 ", 0C(0)Rb ", 0C(0)NRc "Rd ", NRC "Rd ", NRC "C(0)Rb ", NRC 'C(O)OR3 ', NRc"S(0)Rb", NRc"S(O)2Rb", S(O)Rb", S(0)NRc"Rd",
S(O)2R" , and S(O)2NR0 Rd ; RR11,, RR22,, RR33,, aanndd RR44 aarree independently selected from H, halo,
Figure imgf000241_0002
alkyl, C2_4 alkenyl, C2^ alkynyl, C^ haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, Ci-4 alkyl, C2_4 alkenyl, C2-4 alkynyl, Ci_4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, ClΛ alkyl, C2.4 alkenyl, C2.4 alkynyl, d_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 alkylcarbonyl, arylcarbonyl, Ci_6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1 , 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D2 and E2 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci-6 alkylene)r-O-( Ci_6 alkylene)s, (Ci-6 alkylene)r-S-(Ci_6 alkylene)s, (Ci-6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-COO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-C0NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0NRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReC0NRf-(Ci_6 alkylene)s, wherein each of the Ci_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2_8 alkoxyalkyl, d_6 alkoxy, Ci_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D3 and E3 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1 , 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci_6 alkyl, Ci-6haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2-8 dialkylamino;
D4 and E4 are independently selected from H, halo, Q_4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci_4 haloalkyl, halosulfanyl, d_4 hydroxyalkyl, Ci-4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, CC=NRONR0R11, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, CC=NO(CL6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci-8 alkyl, C2_8 alkenyl, or C2.8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(O)2NRcRd;
Ra is H, Cy1, -(Ci-6 alkyty-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, -(Ci-6 alkyO-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci-6 alkyfj-Cy1, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci_6 alkyfj-Cy1, OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, -(CL6 alkyfj-Cy1, OH, CN, amino, halo, C^ alkyl, C^haloalkyl, d_6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CMO alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CMO alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1 ; wherein when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000245_0001
then Y is other than (CR11R12)PC(O)NRC(CR1 *R12)q; (b) compounds of Formula II:
II wherein:
La is SO2 or CO;
Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein said alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R2a and R3a are independently selected from H, C^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl;
(c) compounds of Formula III:
Figure imgf000245_0003
III wherein:
R5a and R6a are independently selected from H, F, CN, OH, Q-4 alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1 , 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with C^ alkyl; and pharmaceutically acceptable salts thereof; provided that compound of Formula I is not selected from 4-[5-(2-isopropyl-5- methylcyclohexyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-tert- butylphenoxymethyl)- 1 ,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopentylethyl- 1 ,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(2,6-difluorophenyl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo [2,3 -b]pyridine; 4- [5-( 1 -tert-butyl-3 -methyl- 1 H-pyrazol-5-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo[2,3-b]pyridine; 4-[5-(benzyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-fluorophenyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(phenoxymethyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-methoxybenzyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(phenylthiomethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-methylbutyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-benzyl-l,2-4-oxadiazol-3- yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,2-dimethylpropyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-methyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(formyl)- 1,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(furan-2-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 - b]pyridine; 4-[5-(l -methyl- lH-pyrrol-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (sec -butyl)- l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopropyl-l,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; and pharmaceutically acceptable salts of any of the aforementioned.
53. An agent for use in treatment of a dry eye disorder in an individual; wherein said agent is selected from:
(a) compounds of Formula I:
Figure imgf000246_0001
I wherein:
A1 and A2 are independently selected from C and N; T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic; X is N or CR4; Y is Ci_8 alkylene, C2_8 alkenylene, C2_8 alkynylene, (CR11R1^p-(C340 eye loalkylene)- (CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CRuR12)p-(Ci_i0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12^O(CR11R12),!, (CR11R12^S(CR11R12)^ (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)pNRc(CR11R12)q, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R1^pS(O)2(CR11R12)^ or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said Ci-8 alkylene, C2.8 alkenylene, C2_8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, C^ haloalkyl, halosulfanyl, C^ hydroxyalkyl, Ci_4 cyanoalkyl, =C-R, =N-R', Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000247_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, C(=N0(Ci_6 alkyl))Rb, and S(0)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q;
W is Ci_8 alkylenyl, C2_8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(O)NRC', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NRC', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Q_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, d_8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said Q_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo,
Figure imgf000247_0002
alkyl, C2_4 alkenyl, C2_4 alkynyl, C^ haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, 0Ra', SRa', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(O)Rb', NRc C(0)NRc Rd', NRc C(0)0Ra', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, ORa", SRa", C(O)Rb", C(O)NRc"Rd", C(O)OR3", OC(O)Rb", OC(O)NRc"Rd", NRc"Rd", NRc"C(O)Rb", NRc"C(O)ORa", NRc"S(O)Rb", NRc"S(O)2Rb", S(O)Rb", S(O)NRc"Rd", S(O)2Rb", and S(O)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo, C^ alkyl, C2_4 alkenyl, C2^ alkynyl, d_4 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo,
Figure imgf000248_0001
C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 alkylcarbonyl, arylcarbonyl, Ci_6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci-6 haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_g dialkylamino;
D and E are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci-6 alkylene)r-O-( Ci_6 alkylene)s, (Ci-6 alkylene)r-S-(Ci_6 alkylene)s, (Ci-6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-COO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-C0NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0NRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReC0NRf-(Ci_6 alkylene)s, wherein each of the Ci_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci_6 alkyl, Ci_6haloalkyl, C2_8 alkoxyalkyl, Ci_6 alkoxy, Ci_6haloalkoxy, amino, Ci_6 alkylamino, and C2-8 dialkylamino;
D3 and E3 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1 , 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Q-6 alkyl, Q-6 haloalkyl, C2_8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_g dialkylamino;
D4 and E4 are independently selected from H, halo, Q_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, CC=NR^NR0R11, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000249_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, CC=NR^NR0R11, NR0CC=NR^NR0R11, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=N0(d_6 alkyl))Rb, and S(O)2NRcRd;
Ra is H, Cy1, -(Ci-e alkyO-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, -(CLg alkyFj-Cy1, d_6 alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, d_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci-6 alkyfj-Cy1, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, -(Ci-6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CMO alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q-6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Q-6 haloalkyl, halosulfanyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-6 alkyl, Ci_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is 0 or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is 0 or 1 ; wherein when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000251_0001
then Y is other than (CR11R12)pC(O)NRc(CR11R12)q; (b) compounds of Formula II:
Figure imgf000251_0002
II wherein:
La is SO2 or CO;
Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein said alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R2a and R3a are independently selected from H, C^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl;
(c) compounds of Formula III:
Figure imgf000251_0003
III wherein:
R5a and R6a are independently selected from H, F, CN, OH, Ci_4 alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1 , 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with Q^ alkyl; and pharmaceutically acceptable salts thereof; provided that compound of Formula I is not selected from 4-[5-(2-isopropyl-5- methylcyclohexyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-tert- butylphenoxymethyl)- 1 ,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopentylethyl- 1 ,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(2,6-difluorophenyl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo [2,3 -b]pyridine; 4- [5-( 1 -tert-butyl-3 -methyl- 1 H-pyrazol-5-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H- pyrrolo[2,3-b]pyridine; 4-[5-(benzyloxymethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-fluorophenyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(phenoxymethyl)- 1,2-4- oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(4-methoxybenzyl)-l,2-4-oxadiazol-3-yl]-lH- pyrrolo[2,3-b]pyridine; 4-[5-(phenylthiomethyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4- [5-(3-methylbutyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-benzyl-l,2-4-oxadiazol-3- yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(2,2-dimethylpropyl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3- b]pyridine; 4-[5-methyl-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-(formyl)- 1,2-4- oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 -b]pyridine; 4- [5-(furan-2-yl)- 1 ,2-4-oxadiazol-3 -yl] - 1 H-pyrrolo [2,3 - b]pyridine; 4-[5-(l -methyl- lH-pyrrol-2-yl)-l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5- (sec -butyl)- l,2-4-oxadiazol-3-yl]-lH-pyrrolo[2,3-b]pyridine; 4-[5-cyclopropyl-l,2-4-oxadiazol-3-yl]- lH-pyrrolo[2,3-b]pyridine; and pharmaceutically acceptable salts of any of the aforementioned.
54. A method of treating conjunctivitis, uveitis, chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or iritis; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection related to corneal transplant in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent; wherein said agent is selected from:
(a) compounds of Formula I:
Figure imgf000253_0001
I wherein:
A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6; wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is Ci_8 alkylene, C2-8 alkenylene, C2-8 alkynylene,
Figure imgf000253_0002
eye loalkylene)- (CRuR12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CR11R12V(CM0 heterocycloalkylene)-(CRuR12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR^^pOtCR11^2)^ (CR11R12^S(CR11R12)^ (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)pNRc(CR11R12)q, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R1^pS(O)2(CR11R12)^ or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said Ci_8 alkylene, C2-8 alkenylene, C2_8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Q-4 haloalkyl, halosulfanyl, Q-4 hydroxyalkyl, Ci-4 cyanoalkyl, =C-R, =N-R\ Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR)NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(Ci-6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci-8 alkyl, C2.8 alkenyl, or C2.8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, Ci-4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(O)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, CC=NO(Ci-6 alkyl))Rb, and S(O)2NRcRd; wherein when Z is H, n is 1 ; or the -(Y)n-Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1, A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from -(W)m-Q;
W is Ci_8 alkylenyl, C2_8 alkenylenyl, C2_8 alkynylenyl, O, S, C(O), C(O)NRC', C(O)O, OC(O), 0C(0)NRc', NRC', NRc C(0)NRd', S(O), S(O)NRC', S(O)2, or S(O)2NR0';
Q is H, halo, CN, NO2, Ci_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said Q_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, Ci_8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1 , 2, 3 or 4 substituents independently selected from halo,
Figure imgf000254_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, C^ haloalkyl, halosulfanyl, Cμ hydroxyalkyl, Ci_4 cyanoalkyl, Cy2, CN, NO2, 0Ra', SRa', C(0)Rb', C(0)NRc Rd', C(O)OR3', 0C(0)Rb', 0C(0)NRc Rd', NRc Rd', NRc C(0)Rb', NRc C(0)NRc Rd', NRc C(0)0Ra', S(O)Rb', S(0)NRc Rd', S(O)2Rb', NRc S(0)2Rb', and S(0)2NRc Rd';
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci_4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, CN, NO2, 0Ra ", SRa ", C(0)Rb ", C(O)NRC "Rd ", C(O)OR3 ", 0C(0)Rb ", 0C(0)NRc "Rd ", NRC "Rd ", NRC "C(0)Rb ", NRc"C(0)0Ra", NRc"S(O)Rb", NRc"S(0)2Rb", S(O)Rb", S(0)NRc"Rd", S(O)2Rb", and S(0)2NRc"Rd";
R1, R2, R3, and R4 are independently selected from H, halo,
Figure imgf000254_0002
alkyl, C2_4 alkenyl, C2^ alkynyl, C^ haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7 OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(0)0R7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, Ci-4 alkyl, C2_4 alkenyl, C2^ alkynyl, Ci-4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, Ci-4 alkyl, C2.4 alkenyl, C2.4 alkynyl, Ci-4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, d.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, d_6 alkylcarbonyl, arylcarbonyl, d_6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl; or R9 and R10 together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4; D1 and E1 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Q_6 alkylene, C2_6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1 , 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Q-6 alkyl, Q-6 haloalkyl, C2_8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D2 and E2 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, (Ci_6 alkylene)r-O-( Ci_6 alkylene)s, (Ci_6 alkylene)r-S-(Ci_6 alkylene)s, (Ci_6 alkylene)r-NRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-COO-(Ci_6 alkylene)s, (Ci-6 alkylene)r-CONRe-(Ci_6 alkylene)s, (Ci-6 alkylene)r-S0-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SO2-(Ci_6 alkylene)s, (Ci-6 alkylene)r-SONRe-(Ci_6 alkylene)s, and (Ci-6 alkylene)r- NReC0NRf-(Ci_6 alkylene)s, wherein each of the Q_6 alkylene, C2_6 alkenylene, and C2_6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci-6 alkyl, Ci_6haloalkyl, C2_8 alkoxyalkyl, Ci_6 alkoxy, Ci_6haloalkoxy, amino, Ci_6 alkylamino, and C2_8 dialkylamino;
D3 and E3 are independently absent or independently selected from Ci_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Q_6 alkylene, C2_6 alkenylene, C2_6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1 , 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, Ci_6 alkyl, Ci-6haloalkyl, C2-8 alkoxyalkyl, d_6 alkoxy, d_6haloalkoxy, amino, Ci_6 alkylamino, and C2_g dialkylamino;
D4 and E4 are independently selected from H, halo, Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, d_4 hydroxyalkyl, d_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NR)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=N0H)Rb, C(=NO(Ci_6 alkyl)Rb, and S(O)2NRcRd, wherein said Ci_8 alkyl, C2_8 alkenyl, or C2_8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo,
Figure imgf000255_0001
alkyl, C2_4 alkenyl, C2_4 alkynyl, Ci_4 haloalkyl, halosulfanyl, Ci_4 hydroxyalkyl, Ci_4 cyanoalkyl, Cy1, CN, NO2, 0Ra, SRa, C(O)Rb, C(0)NRcRd, C(O)OR3, OC(O)Rb, 0C(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)NRcRd, NRcC(0)0Ra, C(=NR')NRcRd, NRcC(=NRI)NRcRd, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(0)2Rb, C(=N0H)Rb, C(=N0(d_6 alkyl))Rb, and S(0)2NRcRd;
Ra is H, Cy1, -(Ci-6 alkyty-Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, -(Ci-6 alkyl^Cy1, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra and Ra are independently selected from H, Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci_6 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb and Rb are independently selected from H, d_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Q_6 alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, d_6 haloalkyl, d_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, -(Ci_6 alkyfj-Cy1, Ci_io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, wherein said Ci_io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, or C2_6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(Ci_6 alkyfj-Cy1, OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6haloalkyl,and halosulfanyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(CL6 alkyfj-Cy1, OH, CN, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkyl, and halosulfanyl;
Rc and Rd are independently selected from H, Ci_i0 alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Ci.io alkyl, Ci_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CMO alkyl, d_6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, halosulfanyl, Ci_6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; R1 is H, CN, NO2, or Ci_6 alkyl;
Re and Rf are independently selected from H and Ci_6 alkyl;
R1 Is H1 CN1 OrNO2; m is O or 1 ; n is O or 1 ; p is O, 1, 2, 3, 4, 5, or 6; q is O, 1, 2, 3, 4, 5 or 6; r is O or 1 ; and s is O or 1 ; wherein when X is N, n is 1, and the moiety formed by A1, A2, U, T, V, and -(Y)n-Z has the formula:
Figure imgf000257_0001
then Y is other than (CR11R12)pC(O)NRc(CR11R12)q; (b) compounds of Formula II:
Figure imgf000257_0002
II wherein:
La is SO2 or CO; Rla is Ci_6 alkyl, C3_7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR2aR3a, or OR4a, wherein said alkyl, cycloalkyl, phenyl, or heteroaryl is optionally substituted with 1 , 2, or 3 substituents independently selected from F, CN, and Ci_4 alkyl;
R2a and R3a are independently selected from H, Q^ alkyl, and phenyl; and
R4a is Ci_6 alkyl, phenyl, or benzyl;
(c) compounds of Formula III:
Figure imgf000258_0001
III wherein:
R5a and R6a are independently selected from H, F, CN, OH, Q-4 alkyl, benzyloxy, C2-8 dialkylaminosulfonyl, and 5-membered heteroaryl, wherein said alkyl is optionally substituted by 1 , 2, or 3 substituents selected from F, OH, CN, and Ci_4 alkoxy, and wherein said 5-membered heteroaryl is optionally substituted with C^ alkyl; and pharmaceutically acceptable salts thereof.
55. The method according to claim 54, wherein said agent is administered preoperatively to a patient about to undergo a procedure selected from corneal transplant, LASIK, photorefractive keratectomy, and LASEK.
56. The method according to claim 54, wherein said agent is administered postoperatively to a patient who has undergone a procedure selected from corneal transplant, LASIK, photorefractive keratectomy, and LASEK.
PCT/US2009/059203 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases WO2010039939A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DK09737257.7T DK2349260T3 (en) 2008-10-02 2009-10-01 JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYES AND OTHER EYE-RELATED DISEASES
ES09737257.7T ES2564203T3 (en) 2008-10-02 2009-10-01 Jano kinase inhibitors for the treatment of dry eye and other eye related diseases
PL09737257T PL2349260T3 (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
RS20160064A RS54651B1 (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
EP09737257.7A EP2349260B1 (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
SI200931388A SI2349260T1 (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
JP2011530218A JP2012504639A (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treating dry eye and other eye related diseases
CA2738520A CA2738520C (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
HK12101002.0A HK1160607A1 (en) 2008-10-02 2012-02-02 Janus kinase inhibitors for treatment of dry eye and other eye related diseases janus
SM201600080T SMT201600080B (en) 2008-10-02 2016-03-22 CHINASI JANUS INHIBITORS FOR DRY EYE TREATMENT AND OTHER EYE DISEASES
HRP20160330TT HRP20160330T1 (en) 2008-10-02 2016-04-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10224208P 2008-10-02 2008-10-02
US61/102,242 2008-10-02

Publications (1)

Publication Number Publication Date
WO2010039939A1 true WO2010039939A1 (en) 2010-04-08

Family

ID=41572626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059203 WO2010039939A1 (en) 2008-10-02 2009-10-01 Janus kinase inhibitors for treatment of dry eye and other eye related diseases

Country Status (19)

Country Link
US (4) US20100113416A1 (en)
EP (2) EP3042655A1 (en)
JP (5) JP2012504639A (en)
AR (2) AR073530A1 (en)
CA (2) CA2738520C (en)
CL (1) CL2009001884A1 (en)
CY (1) CY1117317T1 (en)
DK (1) DK2349260T3 (en)
ES (1) ES2564203T3 (en)
HK (1) HK1160607A1 (en)
HR (1) HRP20160330T1 (en)
HU (1) HUE028499T2 (en)
PL (1) PL2349260T3 (en)
PT (1) PT2349260E (en)
RS (1) RS54651B1 (en)
SI (1) SI2349260T1 (en)
SM (1) SMT201600080B (en)
TW (2) TWI591068B (en)
WO (1) WO2010039939A1 (en)

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048082A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011112662A1 (en) * 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011150356A1 (en) * 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
WO2013108644A1 (en) * 2012-01-20 2013-07-25 京都府公立大学法人 Rebamipide therapeutic agent for allergic conjunctivitis
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2013174895A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
WO2015021153A1 (en) * 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN105566332A (en) * 2016-01-29 2016-05-11 上海宣创生物科技有限公司 Baricitinib trifluoroacetate crystal forms A and B and preparation method thereof
CN105601635A (en) * 2016-02-01 2016-05-25 上海宣创生物科技有限公司 Crystal forms A, H and I of barrack gefitinib phosphate and preparation methods thereof
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
CN105924444A (en) * 2015-03-11 2016-09-07 苏州晶云药物科技有限公司 Crystal form of JAK inhibitor and preparation method thereof
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
CN106554363A (en) * 2015-09-28 2017-04-05 正大天晴药业集团股份有限公司 A kind of preparation method of Baricitinib intermediates
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017097224A1 (en) * 2015-12-11 2017-06-15 四川科伦博泰生物医药股份有限公司 Azetidine derivative, preparation method therefor, and use thereof
WO2017114461A1 (en) * 2015-12-31 2017-07-06 正大天晴药业集团股份有限公司 Synthesis process of ruxolitinib
CN107200742A (en) * 2016-03-18 2017-09-26 罗欣生物科技（上海）有限公司 A kind of Ba Ruike is for Buddhist nun's phosphate crystal and preparation method thereof
WO2018113801A1 (en) 2016-12-21 2018-06-28 Zentiva, K.S. Crystalline forms of2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation
WO2018133875A1 (en) * 2017-01-23 2018-07-26 上海长森药业有限公司 Jak kinase inhibitor and preparation method and use thereof
CN108349972A (en) * 2015-11-03 2018-07-31 施万生物制药研发Ip有限责任公司 Jak kinase inhibitor compound for treating respiratory disorder
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018223859A1 (en) * 2017-06-07 2018-12-13 四川科伦博泰生物医药股份有限公司 Solid form of azetidine derivative and preparation method therefor and use thereof
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
CN109867676A (en) * 2017-12-01 2019-06-11 北京普祺医药科技有限公司 Compound derived from a kind of pyrrolopyrimidine, pharmaceutical composition with and application thereof
CN109867675A (en) * 2017-12-01 2019-06-11 北京普祺医药科技有限公司 Compound derived from a kind of pyrrolopyrimidine, pharmaceutical composition with and application thereof
US10561657B2 (en) 2014-12-16 2020-02-18 Centaurus Biophrama Co., Ltd. Pyrrolopyrimidine compound
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
WO2020173364A1 (en) * 2019-02-27 2020-09-03 四川科伦博泰生物医药股份有限公司 Oral pharmaceutical composition with azetidine derivative as active ingredient, and preparation method therefor and use thereof
EA036970B1 (en) * 2010-11-19 2021-01-21 Инсайт Холдингс Корпорейшн USE OF {1-{1-[3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTINOYL]PIPERIDINE-4-YL}-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDINE-4-YL)-1H-PYRAZOL-1-YL]AZETIDINE-3-YL}ACETONITRILE IN TREATING JAK1-ASSOCIATED DISEASES
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN114085224A (en) * 2020-08-25 2022-02-25 北京普祺医药科技有限公司 Preparation method of pyrrolopyrimidine compound
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
CN114907354A (en) * 2021-02-07 2022-08-16 南京知和医药科技有限公司 Sulfonamide polycyclic compound and preparation method and application thereof
CN114957260A (en) * 2021-02-26 2022-08-30 南京知和医药科技有限公司 Baricitinib derivative and preparation method and application thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
DK2049123T4 (en) 2006-08-03 2016-11-28 Horizon Pharma Ag LATE discharge-glucocorticoid treatment of rheumatoid ILLNESS
KR20090082507A (en) 2006-11-20 2009-07-30 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods, compositions, and kits for treating pain and pruritis
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
MY152948A (en) * 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
JOP20190230A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
CA3027255C (en) 2009-07-10 2022-06-21 The General Hospital Corporation Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
JP5946768B2 (en) * 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Hydroxyl, keto and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile
CN103732226B (en) 2011-02-18 2016-01-06 诺瓦提斯药物公司 MTOR/JAK inhibitor combination treatment
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
CA2851801A1 (en) * 2011-10-21 2013-04-25 Glaxosmithkline Llc Compounds and methods for enhancing innate immune responses
MX2015005428A (en) 2012-11-01 2015-07-21 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors.
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
TWI719401B (en) 2013-05-17 2021-02-21 美商英塞特公司 Bipyrazole derivatives as jak inhibitors
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
PL3129021T3 (en) 2014-04-08 2021-05-31 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
JP6833811B2 (en) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ Charged ion channel blockers and how to use
CN107759600A (en) * 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 Crystallization as the Pyrrolopyrimidine compounds of JAK inhibitor
US10098895B2 (en) * 2016-09-07 2018-10-16 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
JP2018048134A (en) * 2016-09-20 2018-03-29 参天製薬株式会社 Eye drop containing JAK inhibitor
JP2018048133A (en) * 2016-09-20 2018-03-29 参天製薬株式会社 Agent for the treatment and/or prevention of inflammatory eye disease
US10759865B2 (en) * 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
US10800775B2 (en) * 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CN111566095B (en) 2017-11-03 2024-09-27 阿克拉瑞斯治疗股份有限公司 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP7565798B2 (en) 2018-03-30 2024-10-11 インサイト・コーポレイション Biomarkers for Inflammatory Skin Disease
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
AU2019317625A1 (en) 2018-08-10 2021-02-18 Aclaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors
CA3117842A1 (en) 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition
JP7431845B2 (en) 2018-10-31 2024-02-15 インサイト・コーポレイション Combination therapy for the treatment of blood disorders
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
CN111320633B (en) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 Pyrrole/imidazo six-membered heteroaromatic ring compound and preparation method and medical application thereof
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3937945A4 (en) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MA55320A (en) 2019-03-11 2022-01-19 Nocion Therapeutics Inc ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS OF USE
EP3962897A4 (en) 2019-05-02 2022-12-14 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as jak inhibitors
CN110028509B (en) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 Pyrrolopyrimidines as selective JAK2 inhibitors, and synthesis method and application thereof
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2021091585A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2021102258A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
AU2021236130A1 (en) 2020-03-11 2022-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
TW202329961A (en) * 2021-11-30 2023-08-01 日商興和股份有限公司 Novel nicotinamide compound and use therefor
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
KR20240069235A (en) 2022-11-11 2024-05-20 주식회사 다운컴퍼니 Digitial agency-based growth hacking testing platform

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026406A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
WO2007062459A1 (en) * 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
WO2007070514A1 (en) * 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007077949A1 (en) * 2005-12-28 2007-07-12 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2009049028A1 (en) * 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009114512A1 (en) * 2008-03-11 2009-09-17 Incyte Corporation Azetidine and cyclobutane derivatives as jak inhibitors

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) * 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
DE3220113A1 (en) * 1982-05-28 1983-12-01 Basf Ag, 6700 Ludwigshafen DIFLUORMETHOXIPHENYLTHIOPHOSPHORSAEUREESTER
US4402832A (en) * 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4498991A (en) * 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
IT1258781B (en) * 1992-01-16 1996-02-29 Zambon Spa OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYLCISTEIN AND POLYVINYL ALCOHOL
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5630943A (en) * 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
US6060038A (en) * 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
JP2001513502A (en) * 1997-08-11 2001-09-04 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 5,6-Heteroaryldipyrido [2,3-b: 3 ', 2'-f] azepines and their use in the prevention and treatment of HIV infection
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
BR9912938B1 (en) 1998-08-11 2011-06-28 isoquinoline derivatives, composition comprising them, process for preparation and use thereof.
US6413419B1 (en) * 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
US6375839B1 (en) * 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
FR2785196B1 (en) * 1998-10-29 2000-12-15 Inst Francais Du Petrole METHOD AND DEVICE FOR SEPARATION WITH VARIABLE LENGTH CHROMATOGRAPHIC AREAS
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
OA12514A (en) * 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2206363T3 (en) * 2000-04-07 2004-05-16 Laboratoire Medidom S.A. OPHTHALMIC FORMULATIONS BASED ON CYCLOSPORINE, Hyaluronic Aid and POLYSORBATE.
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
AU2001274598A1 (en) * 2000-06-23 2002-01-02 Mitsubishi Pharma Corporation Antitumor effect potentiators
WO2002055496A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
CA2446864C (en) * 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
WO2003011285A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES
CN100391958C (en) 2001-09-19 2008-06-04 安万特医药股份有限公司 Chemical compounds
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003048111A1 (en) * 2001-11-30 2003-06-12 Teijin Limited Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7304061B2 (en) * 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
CA2484632C (en) * 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
CA2486183C (en) * 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
AR037647A1 (en) 2002-05-29 2004-12-01 Novartis Ag USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US20060004010A1 (en) * 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
TWI335819B (en) * 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
CA2515132C (en) * 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7183941B2 (en) * 2003-07-30 2007-02-27 Lear Corporation Bus-based appliance remote control
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
CA2543452C (en) * 2003-10-24 2012-03-13 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
MXPA06007076A (en) * 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Thiadiazoles as cxc- and cc- chemokine receptor ligands.
WO2005069865A2 (en) * 2004-01-13 2005-08-04 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
WO2006001463A1 (en) * 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Compound having s1p receptor binding potency and use thereof
DE102004038530B3 (en) * 2004-08-07 2006-01-05 Universität Mannheim Method and device for producing an optical connection between an optoelectronic component and an optical waveguide
ES2308551T3 (en) * 2004-10-13 2008-12-01 F. Hoffmann-La Roche Ag PIRAZOLOBENZODIAZEPINAS DISUSTITUIDES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGENESIS, AND FOR THE TREATMENT OF CANCER OF MAMA, COLON, PULMON AND PROSTATE.
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20060128803A1 (en) * 2004-12-14 2006-06-15 Alcon, Inc. Method of treating dry eye disorders using 13(S)-HODE and its analogs
AR054416A1 (en) * 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
MX2007009429A (en) * 2005-02-03 2008-03-18 Vertex Pharma Pyrrolopyrimidines useful as inhibitors of protein kinase.
EP2354140A1 (en) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2006133426A2 (en) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2621261C (en) * 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
KR20080083680A (en) * 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 Azaindole inhibitors of aurora kinases
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
JP2009525350A (en) * 2006-02-01 2009-07-09 スミスクライン ビーチャム コーポレーション Pyrrolo [2,3, B] pyridine derivatives useful as RAF kinase inhibitors
BRPI0708731A2 (en) * 2006-03-10 2011-06-07 Ono Pharmaceutical Co nitrogenous heterocyclic derivative, and pharmaceutical agent comprising the derivative as an active ingredient
PL2003132T3 (en) * 2006-04-03 2014-10-31 Astellas Pharma Inc Oxadiazole derivatives as S1P1 agonists
CA2648250A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP2044061A2 (en) * 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
WO2008022164A2 (en) * 2006-08-16 2008-02-21 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
AR063141A1 (en) * 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
SG176461A1 (en) * 2006-11-06 2011-12-29 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20080132259A1 (en) * 2006-12-05 2008-06-05 Eric Vin System and method of providing access to instant messaging services via a wireless network
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
AU2007338793B2 (en) * 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
US8513270B2 (en) * 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
CL2008001709A1 (en) * 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
CN101743009A (en) * 2007-07-11 2010-06-16 辉瑞大药厂 Pharmaceutical compositions and methods of treating dry eye disorders
CA2695114A1 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
PL3133080T3 (en) * 2008-01-18 2018-12-31 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Novel cytostatic 7-deazapurine nucleosides
JOP20190230A1 (en) * 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
LT2432472T (en) * 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
BRPI1012159B1 (en) * 2009-05-22 2022-01-25 Incyte Holdings Corporation Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof
AR078012A1 (en) * 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
JP5946768B2 (en) * 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Hydroxyl, keto and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile
CA2790070C (en) * 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
AU2011224484A1 (en) * 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026406A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
WO2007062459A1 (en) * 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
WO2007070514A1 (en) * 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007077949A1 (en) * 2005-12-28 2007-07-12 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2009049028A1 (en) * 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009114512A1 (en) * 2008-03-11 2009-09-17 Incyte Corporation Azetidine and cyclobutane derivatives as jak inhibitors

Cited By (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
WO2011048082A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
JP2018118992A (en) * 2010-03-10 2018-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP4036088A1 (en) * 2010-03-10 2022-08-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
CN102985417B (en) * 2010-03-10 2015-01-28 因塞特公司 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP3050882A1 (en) * 2010-03-10 2016-08-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EA030376B1 (en) * 2010-03-10 2018-07-31 Инсайт Холдингс Корпорейшн Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011112662A1 (en) * 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3354652A1 (en) * 2010-03-10 2018-08-01 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CN102985417A (en) * 2010-03-10 2013-03-20 因塞特公司 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP3715347A1 (en) * 2010-03-10 2020-09-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2013522214A (en) * 2010-03-10 2013-06-13 インサイト・コーポレイション Piperidin-4-ylazetidine derivatives as JAK1 inhibitors
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
WO2011150356A1 (en) * 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EA036970B1 (en) * 2010-11-19 2021-01-21 Инсайт Холдингс Корпорейшн USE OF {1-{1-[3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTINOYL]PIPERIDINE-4-YL}-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDINE-4-YL)-1H-PYRAZOL-1-YL]AZETIDINE-3-YL}ACETONITRILE IN TREATING JAK1-ASSOCIATED DISEASES
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
WO2013108644A1 (en) * 2012-01-20 2013-07-25 京都府公立大学法人 Rebamipide therapeutic agent for allergic conjunctivitis
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2013174895A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
WO2015021153A1 (en) * 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
KR20210076186A (en) * 2013-08-07 2021-06-23 인사이트 코포레이션 Sustained release dosage forms for a jak1 inhibitor
KR102419714B1 (en) 2013-08-07 2022-07-13 인사이트 코포레이션 Sustained release dosage forms for a jak1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
CN105579032A (en) * 2013-08-07 2016-05-11 因赛特公司 Sustained release dosage forms for a JAK1 inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN111018861B (en) * 2014-12-16 2021-11-19 正大天晴药业集团股份有限公司 Pyrrolopyrimidine compounds
US10561657B2 (en) 2014-12-16 2020-02-18 Centaurus Biophrama Co., Ltd. Pyrrolopyrimidine compound
CN111018861A (en) * 2014-12-16 2020-04-17 正大天晴药业集团股份有限公司 Pyrrolopyrimidine compounds
CN105924444A (en) * 2015-03-11 2016-09-07 苏州晶云药物科技有限公司 Crystal form of JAK inhibitor and preparation method thereof
CN106554363A (en) * 2015-09-28 2017-04-05 正大天晴药业集团股份有限公司 A kind of preparation method of Baricitinib intermediates
CN106554363B (en) * 2015-09-28 2019-03-05 正大天晴药业集团股份有限公司 A kind of preparation method of Baricitinib intermediate
US11299492B2 (en) 2015-11-03 2022-04-12 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US11718616B2 (en) 2015-11-03 2023-08-08 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
CN108349972A (en) * 2015-11-03 2018-07-31 施万生物制药研发Ip有限责任公司 Jak kinase inhibitor compound for treating respiratory disorder
CN108349972B (en) * 2015-11-03 2021-06-08 施万生物制药研发Ip有限责任公司 JAK kinase inhibitor compounds for the treatment of respiratory diseases
US10913740B2 (en) 2015-11-03 2021-02-09 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
CN108137603A (en) * 2015-12-11 2018-06-08 四川科伦博泰生物医药股份有限公司 Azetidine derivatives, preparation method and the usage
CN108137603B (en) * 2015-12-11 2019-10-18 四川科伦博泰生物医药股份有限公司 Azetidine derivatives, preparation method and the usage
US11045455B2 (en) 2015-12-11 2021-06-29 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
WO2017097224A1 (en) * 2015-12-11 2017-06-15 四川科伦博泰生物医药股份有限公司 Azetidine derivative, preparation method therefor, and use thereof
US10159662B2 (en) 2015-12-11 2018-12-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
US10245263B2 (en) 2015-12-23 2019-04-02 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10933065B2 (en) 2015-12-23 2021-03-02 Arqule Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020400B2 (en) 2015-12-23 2021-06-01 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN108699063A (en) * 2015-12-31 2018-10-23 正大天晴药业集团股份有限公司 A kind of reed can replace the synthesis technology of Buddhist nun
WO2017114461A1 (en) * 2015-12-31 2017-07-06 正大天晴药业集团股份有限公司 Synthesis process of ruxolitinib
US10562904B2 (en) 2015-12-31 2020-02-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Synthesis process of ruxolitinib
JP2019506379A (en) * 2015-12-31 2019-03-07 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドＣｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． Synthesis process of ruxolitinib
CN108699063B (en) * 2015-12-31 2020-06-26 正大天晴药业集团股份有限公司 Synthesis process of luccotinib
CN105566332A (en) * 2016-01-29 2016-05-11 上海宣创生物科技有限公司 Baricitinib trifluoroacetate crystal forms A and B and preparation method thereof
CN107573348A (en) * 2016-01-29 2018-01-12 上海宣创生物科技有限公司 Ba Ruike is for Buddhist nun's trifluoroacetate B crystal form and preparation method thereof
CN107573349A (en) * 2016-02-01 2018-01-12 上海宣创生物科技有限公司 Ba Ruike is for Buddhist nun's phosphate H crystal form and preparation method thereof
CN105601635A (en) * 2016-02-01 2016-05-25 上海宣创生物科技有限公司 Crystal forms A, H and I of barrack gefitinib phosphate and preparation methods thereof
CN107641125A (en) * 2016-02-01 2018-01-30 上海宣创生物科技有限公司 Ba Ruike is for Buddhist nun's phosphate I crystal and preparation method thereof
CN107200742A (en) * 2016-03-18 2017-09-26 罗欣生物科技（上海）有限公司 A kind of Ba Ruike is for Buddhist nun's phosphate crystal and preparation method thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2018113801A1 (en) 2016-12-21 2018-06-28 Zentiva, K.S. Crystalline forms of2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation
CN108341820A (en) * 2017-01-23 2018-07-31 上海长森药业有限公司 JAK enzyme inhibitors and its preparation method and application
WO2018133875A1 (en) * 2017-01-23 2018-07-26 上海长森药业有限公司 Jak kinase inhibitor and preparation method and use thereof
CN108341820B (en) * 2017-01-23 2020-10-16 上海长森药业有限公司 JAK enzyme inhibitor and preparation method and application thereof
US11524961B2 (en) 2017-01-23 2022-12-13 Shanghai Longwood Biopharmaceuticals Co., Ltd. JAK kinase inhibitor and preparation method and use thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018223859A1 (en) * 2017-06-07 2018-12-13 四川科伦博泰生物医药股份有限公司 Solid form of azetidine derivative and preparation method therefor and use thereof
CN110494435B (en) * 2017-06-07 2022-02-15 四川科伦博泰生物医药股份有限公司 Solid forms of azetidine derivatives, processes for their preparation and their use
CN110494435A (en) * 2017-06-07 2019-11-22 四川科伦博泰生物医药股份有限公司 Solid form of azetidine derivatives and its preparation method and application
US11066403B2 (en) 2017-06-07 2021-07-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of azetidine derivative and preparation method therefor and use thereof
CN113149993A (en) * 2017-12-01 2021-07-23 北京普祺医药科技有限公司 Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof
CN109867675A (en) * 2017-12-01 2019-06-11 北京普祺医药科技有限公司 Compound derived from a kind of pyrrolopyrimidine, pharmaceutical composition with and application thereof
CN109867675B (en) * 2017-12-01 2021-01-19 北京普祺医药科技有限公司 Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof
CN109867676A (en) * 2017-12-01 2019-06-11 北京普祺医药科技有限公司 Compound derived from a kind of pyrrolopyrimidine, pharmaceutical composition with and application thereof
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020173364A1 (en) * 2019-02-27 2020-09-03 四川科伦博泰生物医药股份有限公司 Oral pharmaceutical composition with azetidine derivative as active ingredient, and preparation method therefor and use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
WO2022042577A1 (en) * 2020-08-25 2022-03-03 北京普祺医药科技有限公司 Preparation method for pyrrolopyrimidine compound
CN114085224A (en) * 2020-08-25 2022-02-25 北京普祺医药科技有限公司 Preparation method of pyrrolopyrimidine compound
CN114907354A (en) * 2021-02-07 2022-08-16 南京知和医药科技有限公司 Sulfonamide polycyclic compound and preparation method and application thereof
CN114907354B (en) * 2021-02-07 2024-04-09 南京知和医药科技有限公司 Sulfonamide polycyclic compound and preparation method and application thereof
CN114957260A (en) * 2021-02-26 2022-08-30 南京知和医药科技有限公司 Baricitinib derivative and preparation method and application thereof
CN114957260B (en) * 2021-02-26 2024-04-09 南京知和医药科技有限公司 Barittinib derivative and preparation method and application thereof
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor

Also Published As

Publication number Publication date
JP2012504639A (en) 2012-02-23
ES2564203T3 (en) 2016-03-18
SI2349260T1 (en) 2016-05-31
SMT201600080B (en) 2016-07-01
CA2738520A1 (en) 2010-04-08
CY1117317T1 (en) 2017-04-26
CA2738520C (en) 2020-03-10
PT2349260E (en) 2016-03-07
TW201801731A (en) 2018-01-16
JP2020050682A (en) 2020-04-02
EP2349260B1 (en) 2016-01-06
DK2349260T3 (en) 2016-01-25
JP2017057231A (en) 2017-03-23
CA3064247A1 (en) 2010-04-08
TW201018689A (en) 2010-05-16
TWI591068B (en) 2017-07-11
HK1160607A1 (en) 2012-08-10
US20120301464A1 (en) 2012-11-29
AR112822A2 (en) 2019-12-18
HUE028499T2 (en) 2016-12-28
US20170087158A1 (en) 2017-03-30
HRP20160330T1 (en) 2016-05-06
JP2018044012A (en) 2018-03-22
EP3042655A1 (en) 2016-07-13
US20100113416A1 (en) 2010-05-06
RS54651B1 (en) 2016-08-31
AR073530A1 (en) 2010-11-10
CL2009001884A1 (en) 2010-05-14
EP2349260A1 (en) 2011-08-03
US20200093825A1 (en) 2020-03-26
PL2349260T3 (en) 2016-07-29
JP2015127332A (en) 2015-07-09
TWI643622B (en) 2018-12-11

Similar Documents

Publication Publication Date Title
US20200093825A1 (en) Janus kinase inhibitors for treatment of dry eye and other eye related diseases
DK2288610T3 (en) Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
CN107698569B (en) Bipyrazole derivatives as JAK inhibitors
CN111601593B (en) P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD
US9034311B2 (en) Pyridin-2(1 H)-one derivatives as JAK inhibitors
US20190105312A1 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP2723736B1 (en) 7-Azaindole derivatives suitable for the treatment of cancers
AU2013201219A1 (en) Azetidine and cyclobutane derivatives as jak inhibitors
NZ618904B2 (en) Pyridin-2(1h)-one derivatives as jak inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09737257

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2738520

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011530218

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009737257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2016/0064

Country of ref document: RS